{"title": "PDF", "author": "PDF", "url": "digibug.ugr.es/bitstream/handle/10481/1390/16537853.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": " \nUNIVERSIDAD DE GRANADA \nFACULTAD DE MEDICINA \nDEPARTAMENTO DE FISIOLOGIA \n \n \n \n \nVALORACI\u00d3N DE LAS VITA MINAS DEL GRUPO B EN \nPOBLACI\u00d3N DE RIESGO \n \nTESIS DOCTORAL \nRICARDO SOLA GARC\u00cdA \n \nEditor: Editorial de la Universidad de Granada\nAutor: Ricardo Sola Garc\u00edaD.L.: Gr. 1955- 2006ISBN: 84-338-4115-5 \n \n \n  \n \nDEPARTAMENTO DE FISIOLOGIA \n             Facultad de Medicina     UNIVERSIDAD DE GRANADA \n \n   \nMANUEL J CASTILLO GARZON, CATEDRATIDO DE FISIOLOGIA MEDICA \nDE LA FACULTAD DE MEDICINA DE  LA UNIVERSIDAD DE GRANADA. \n \n \n   CERTIFICA:  \n \nQue Don RICARDO SOLA GARCIA ha realizado bajo mi direcci\u00f3n el trabajo \noriginal de investigaci\u00f3n titulado: \u201cVALORACI\u00d3N DE LAS VITAMINAS DEL \nGRUPO B EN POBLACI\u00d3N DE RIESGO\u201d. \nEl que suscribe ha seguido el desarrollo experimental del trabajo, particularmente \nen lo referente al dise\u00f1o y obtenci\u00f3n de  resultados, considerando dicho trabajo \napto para ser presentado como Tesis Doct oral y sometido a la consideraci\u00f3n del \nTribunal que designe la Universidad de Granada.  \n \n    \n \n   \n      Fdo. Manuel J Castillo Garz\u00f3n \n \n     Granada 1 de Septiembre de 2006 \n  \n \n \n \n  \n \n \nDEPARTAMENTO DE FISIOLOGIA \n             Facultad de Medicina \n    UNIVERSIDAD DE GRANADA \n      \nMARCELA GONZALEZ GROSS, PROF ESORA TITULAR DE UNIVERSIDAD \nDEL DEPARTAMENTO DE FISIOLOGIA DE LA UNIVERSIDAD POLITECNICA DE MADRID.  \n \n \n \n CERTIFICA:   \nQue Don RICARDO SOLA GARCIA ha realizado bajo mi direcci\u00f3n el trabajo \noriginal de investigaci\u00f3n titulado: \u201cVALORACI\u00d3N DE LAS VITAMINAS DEL \nGRUPO B ENPOBLACI\u00d3N DE RIESGO\u201d. \nEl que suscribe ha seguido el desarrollo experimental del trabajo, particularmente \nen lo referente al dise\u00f1o y obtenci\u00f3n de  resultados, considerando dicho trabajo \napto para ser presentado como Tesis Doct oral y sometido a la consideraci\u00f3n del \nTribunal que designe la Universidad de Granada.  \n \n   \n \n  \n      Fdo. Marcela Gonzalez Gross \n      Granada 1 de Septiembre de 2006 \n \n \n \n \nDpt. Pathophysiology of Human Nutrition. \n                Institute of Nutrition.  \n                  University of Bonn.  \n \n \n  \n \nKLAUS PIETRZIK, CATEDRATICO DE FISIOPATOLOGIA DE LA NUTRICION \nDE LA UNIVERSIDAD DE BONN. ALEMANIA.  \n \n  \n \nCERTIFICA:   \nQue Don RICARDO SOLA GARCIA ha realizado bajo mi direcci\u00f3n el trabajo \noriginal de investigaci\u00f3n titulado: \u201cVALORACI\u00d3N DE LAS VITAMINAS DEL \nGRUPO B ENPOBLACI\u00d3N DE RIESGO\u201d. El que suscribe ha seguido el desarrollo experimental del trabajo, particularmente \nen lo referente al dise\u00f1o y obtenci\u00f3n de  resultados, considerando dicho trabajo \napto para ser presentado como Tesis Doct oral y sometido a la consideraci\u00f3n del \nTribunal que designe la Universidad de Granada.\n \n \n \n  \n \n       Fdo. Klaus Pietrzik  \n      Granada 1 de Septiembre de 2006 \n \u00cdNDICE  \n \nI n t r o d u c c i \u00f3 n              1  \n \nHip\u00f3tesis y Objetivos           8  Homociste\u00edna y patolog\u00eda cardiovascular       12 \n I n t r o d u c c i \u00f3 n            1 5  \n Base Bioqu\u00edmica de la hiperhomocisteinemia      16 \n Metabolismo de la homociste\u00edna        16 \n Hiperhomocisteinemia cong\u00e9nita        17  Hiperhomocisteinemia adquirida       19  F o l a t o             1 9   Vitamina B\n1 2            20 \n Vitamina B 6           2 0  \n Vitamina B 2           2 0  \n Hiperhomocisteinemia y envejecimiento      21  Hiperhomocisteinemia relacionada con cambios hormonales   21  Hiperhomocisteinemia ligada a cambios en el estilo de vida    22  Diagn\u00f3stico de la hiperhomocisteinemia      23 \n Indicaciones de la medida de homociste\u00edna      24 \n La hiperhomocisteinemia como factor de riesgo cardiovascular   25 \nFisiopatolog\u00eda de la lesi\u00f3n vascul ar por la hiperhomocisteinemia   26 \nTratamiento de la hiperhomocisteinemia      27 Prevenci\u00f3n de la hiperhomocisteinemia       28 C o n c l u s i o n e s           2 9  \nB i b l i o g r a f \u00ed a            3 1  \n  \nE l  F o l a t o             4 4  \n I n t r o d u c c i \u00f3 n            4 6  \n Folato, folatos y \u00e1cido f\u00f3lico        46  F i s i o l o g \u00ed a  d e l  f o l a t o           4 7  \n B i o q u \u00ed m i c a  d e l  f o l a t o          4 8  \n G e n \u00e9 t i c a            4 8   D \u00e9 f i c i t  c l \u00ed n i c o           4 9   D \u00e9 f i c i t  s u b c l \u00ed n i c o           5 1   Metodolog\u00eda diagn\u00f3stica         57 \n Tratamiento           59 \n P r o f i l a x i s            6 0   Niveles m\u00e1ximos tolerables        62 \n C o n c l u s i o n e s           6 2   B i b l i o g r a f \u00ed a            6 4  \n Vitamina B\n12            7 9  \n I n t r o d u c c i \u00f3 n            8 1  \nAbsorci\u00f3n, transporte, dep\u00f3sitos y excreci\u00f3n      81 D \u00e9 f i c i t  C l \u00ed n i c o           8 2  D \u00e9 f i c i t  s u b c l \u00ed n i c o           8 5  \nD i a g n \u00f3 s t i c o            8 7  \nCuadro hem\u00e1tico          87 B\n12 s \u00e9 r i c a            8 7  \n \u00c1cido metilmal\u00f3nico         89  H o m o c i s t e \u00ed n a           8 9   H o l o t r a n s c o b a l a m i n a  I I          9 1  \n P e p s i n \u00f3 g e n o            9 1  \n G a s t r i n a            9 2   Anticuerpos anti c\u00e9lulas parietales       92  Anticuerpos anti factor intr\u00ednseco       92  M \u00e9 d u l a  \u00f3 s e a            9 2  \n B i o q u \u00ed m i c a            9 3  \n Test de s\u00edntesis de la Timidina        93  Test de Schilling          94  Resonancia magn\u00e9tica         95  D i a g n \u00f3 s t i c o            9 5   Factores que afectan los niveles de B\n12       96 \n Tratamiento           99 \n Prevenci\u00f3n         100  Conclusiones        101 \n Bibliograf\u00eda         107  \nVitamina B\n6           130 \n Introducci\u00f3n         134  Metabolismo         134  Funciones y enzimas dependientes de la vitamina B\n6   136 \n Medida de la vitamina B 6        137 \n Fisiopatolog\u00eda de la vitamina B 6       141 \n Anemia por d\u00e9ficit de vitamina B 6      142 \n Funci\u00f3n Inmune        142  C\u00e1ncer         144 \n Funci\u00f3n cognitiva        147  Enfermedad cardiovascular y homociste\u00edna    150 \n Tratamiento         151 \n Profilaxis         153  Fortificaci\u00f3n alimenticia       154  Toxicidad         155  Bibliograf\u00eda         165   \n \nMaterial y m\u00e9todos         168  Vitaminas B y homociste\u00edna en ancianos institucionalizados  183 \n Introducci\u00f3n         186 \n Material y m\u00e9todos        188 \n Resultados         190 \n Discusi\u00f3n         191  Bibliograf\u00eda         197   \nDiagn\u00f3stico precoz de la deficiencia de B\n12     206 \n Introducci\u00f3n         209 \n Material y m\u00e9todos        210  Resultados         214 \nDiscusi\u00f3n         215 Bibliograf\u00eda         217 \n \nMTHFR          220 \n Introducci\u00f3n         221 \n Objetivos         222  M\u00e9todos         222  An\u00e1lisis estad\u00edstico        223  Resultados         224 \n Conclusiones        225 \n Bibliograf\u00eda         226  \nHomociste\u00edna en adolescentes       241 \n Introducci\u00f3n         244 \n M\u00e9todos         245 \n Resultados         247  Discusi\u00f3n         249 \n Conclusiones        253  Bibliograf\u00eda         254 \n El Estudio AVENA         264 \n Introducci\u00f3n         267 \n M\u00e9todos         268  Resultados         272  Discusi\u00f3n         273 \nBibliograf\u00eda         276 \n \nDiscusi\u00f3n general         284 \n Resumen          288  \nCongresos           291 \n \n  \n \n        \n \n  \nABREVIATURAS: \n \nAD   Alzheimer\u2019s disease (Enfermedd de Alzheimer) \nADE    \u00cdndice de dispersi\u00f3n eritrocitaria \nAGEs  Advanced Glycation end Products (productos finales de la \nglicosilaci\u00f3n) \nAH   Adenosil homociste\u00edna AMM   \u00c1cido Metilmal\u00f3nico AOPPs  Advanced Oxidation Protei n Products (productos proteicos \noxidativos) \nATP   \nAVENA Alimentaci\u00f3n y Valoraci\u00f3n del Estado Nutricional en \nAdolescentes \nB\n2   V i t a m i n a  B 2 \nB6   Vitamina B 6 \nB12   V i t a m i n a  B 12 \nBHMT  Beta\u00edna homociste\u00edna metil transferasa \nBMI   Body mass index  CATCH   Child and Adolescent Tr ial for Cardiovascular Health  \nCbl   Cobalamina \nCBL    Cistationina- \u03b2-liasa \nCBS   Cistationina- \u03b2-sintetasa  \nCEE   Comunidad Econ\u00f3mica Europea CHCM  Concentraci\u00f3n de hemoglobina corpuscular media CNS   Central nervous system (Sistema nervioso central) CPC   Coronariopat\u00eda cr\u00f3nica \nCRP, ESR CI OR vitamina B 6 \nCV   Coeficiente de variaci\u00f3n CVD   Cardiovascular disease (Enermedad cardiovascular) CVF   Cardiovascular fitness  \nDACH vitamina B6  DFE   Dietary folate equivalent \nDiagS    Diagnostic Scheme  \nDNA    DOPA   3,4-dihydroxyphenylalanine (Dihidrofenilalanina) DRI    Dietary Reference Intakes  \ndTMP   Desoxitimidina monofosfato \ndUMP   Desoxiuridina monofosfato  ECV   Enfermedad cardiovascular \nEDTA    EEG   Electroencefalograma \nFAD   Flavin adenin dinucleotido \nFBP   Prote\u00edna fijadora de folato FE   Folato intraeritrocitario FI   Factor intr\u00ednseco de Castle FIT   The Family Intervention Trial fl   Fentolitros \nFRCV   Factores de riesgo cardiovasculares \nFS   Folato s\u00e9rico GABA   convertion of glutamic acid to \u03b3-aminobutyric-acid \n\u03b3GT \nGM   Geometric mean  GOT \nGPT \nHCM    Hemoglobina corpuscular media Hcy   Homocisteine (Homociste\u00edna) HDL cholesterol  HIV   Virus de la inmunodeficiencia humana \nHolo-TC-II  Holotranscobalamina II \nHPLC High-performance liquid chromatography (Cromatograf\u00eda de   \nalta resoluci\u00f3n) \nIL   \u00cdndice de lobularidad IOTF   The International Obesity Task Force  IST   \u00cdndice de saturaci\u00f3n de la transferrina \nLCR   L\u00edquido cefalorraqu\u00eddeo \nLDH   L\u00e1ctico dehidrogenasa LDL-Colesterol  LP(a) LUC   C\u00e9lulas grandes no te\u00f1idas MMA   Methylmalonic Acid (Acido Metilmal\u00f3nico)  \nMMT    Mini Mental Test \nMNA    Mini Nutricional Assessment  MS   Metionina sintetasa MS-GC   5-MTHF  5-Metil-tetrahidrofolato \nMTHFR  Metil-tetrahidrofolato reductasa \nMTRR   Metionina sintetasa reductasa  NDNS  The National Diet and Nutrition Survey  \nNHANES  National Health and Nutrition Examination Survey  \nNTD   Defectos del tubo neural \nNIH    National Institute of Health \nOMS   Organizaci\u00f3n Mundial de la salud ON   Oxido n\u00edtrico PCR   Reacci\u00f3n en cadena de la polimerasa pg   Picogramos PGA   \u00e1cido pteroilmonoglut\u00e1mico \nPL   Pyridoxal (Piridoxal) \nPLP   pyridoxal 5\u00b4-phosphate (Piridoxal fosfato) PM   Pyridoxamine (Piridoxamina)  PMP   pyridoxamin-5\u00b4-phosphate (Piridoxamina 5 fosfato) PN   Pyridoxine (Piridoxina) PNP   pyridoxine 5\u00b4-phosphate (Piridoxina 5 fosfato), and  \nRBC   red blood cell \nRDA    RIA   Radioinmunoan\u00e1lisis RNA RR   Riesgo relativo \nSAH   S-adenosil-homocisteina \nSAM    S-adenosylmethionine (S-adenosil-metionina) SCbl   Serum cobalamin SD   Standard deviations ( SHMT Serine-hydroxymethyltransferase (Serina \nhidroximetiltransferasa) \nSNC   Sistema nervioso central \nsTfR   Receptores solubles de la transferrina TC-II   Transcobalamina II  THF   Tetrahydrofolate (Tetrahidrofolato) tHcy   Homociste\u00edna total VCM   Volumen corpuscular medio \nVLDL-Colesterol  \nVPM   Volumen plaquetario medio XA   Xanthurenic acid (\u00c1cido xantur\u00e9nico) \u03b1-EALT   Alanine aminotransferase () \n\u03b1-EAST   Erythrocyte aspartate aminotransferase ()  \n  \n \n  \n  \n  \n \n     \n \n     \n \n    \n \n     \n \nINTRODUCCI\u00d3N  \n \n  \n2La Organizaci\u00f3n Mundial de la Salud (OMS) define la salud \ncomo un estado de completo bienest ar f\u00edsico, mental y social. Por tanto, \nel mantenimiento de un estado funcional \u00f3ptimo hasta una edad \navanzada es esencial para poder hablar de calidad de vida. De todo esto \nnace la necesidad de valorar el esta do nutricional a trav\u00e9s del d\u00e9ficit \nvitam\u00ednico y en minerales que pueden  influir en el deterioro f\u00edsico y \nmental. \nEn esta tesis confluyen dos te mas de m\u00e1xima actualidad e \ninter\u00e9s: la tercera edad y las vitaminas del grupo B prestando especial \natenci\u00f3n a las vitaminas B 6, B 12 y folato. Estas tres vitaminas intervienen \nde forma directa en el metabolismo de la metionina, provocando en \ncaso de d\u00e9ficit hiperhomocisteinemia, factor de riesgo independiente de \nenfermedades cardiovasculares y degenerativas1, c\u00e1ncer, osteoporosis, \nenfermedad de Alzheimer y otras demencias13, enfermedad de \nParkinson, cataratas, degeneraci\u00f3n macular senil, trastornos g\u00e1stricos y \ncomplicaciones de la diabetes. \nCabe destacar que en cuanto a las vitaminas ha ocurrido un \nfen\u00f3meno curioso. Probablemente en ning\u00fan campo de la nutrici\u00f3n en \nmenos a\u00f1os se adquirieron mayor cantidad de conocimientos. Desde que Casimiro Funk describe la primera en 1912, en s\u00f3lo veinte a\u00f1os, se \nidentifican los compuestos responsables que reciben el nombre de \nvitaminas, se sintetizan todas ellas y se consider\u00f3 que se hab\u00eda llegado al conocimiento completo de su fi siopatolog\u00eda. Sin embargo, en los \n\u00faltimos a\u00f1os, el panorama ha cambiado y las vitaminas vuelven a estar de extraordinaria actualidad. Se de be ello a que se pensaba que las \ndesnutriciones vitam\u00ednicas estaban pr\u00e1cticamente erradicadas y \ncorrespond\u00edan a \u00e9pocas pasadas o en las actuales a grupos \ngeogr\u00e1ficamente muy marginados. Pero los estudios cient\u00edficos han puesto de manifiesto la aparici\u00f3n de casu\u00edsticas de desnutriciones vitam\u00ednicas en individuos pertenecientes a status acomodados del mundo desarrollado, en el cual se segu\u00eda pensando que el problema era la sobrealimentaci\u00f3n.  \nDe todas las vitaminas, una de las que mayor inter\u00e9s despierta es \nla vitamina B\n12, constituye un importante problema de salud p\u00fablica, \nobjeto de renovada y creciente atenci\u00f3n2-5. De hecho, aunque la \nvitamina B 12 no suele ser deficitaria en la poblaci\u00f3n general, s\u00ed lo es en \ndeterminados grupos de riesgo, como son ancianos2,4,6 y  vegetarianos12.  \n \n                                                                                                         Introducci\u00f3n  \n 3Resultados preliminares de nues tro estudio confirman nuestra \nhip\u00f3tesis de que en Espa\u00f1a el problema es similar al de otros pa\u00edses de nuestro entorno, encontr\u00e1ndose un d\u00e9ficit subcl\u00ednico en al menos un \n22% de la poblaci\u00f3n anciana estudiada\n7.  \nLa vitamina B 12 est\u00e1 ausente en los vegetales, encontr\u00e1ndose casi \nexclusivamente en los alimentos de or igen animal. La excepci\u00f3n es la B 12 \nque se produce por microorganismos y est\u00e1 presente en los alimentos. \nComo dato curioso hay que indicar que miembros del presente grupo de investigaci\u00f3n hemos comprobado que en poblaciones desnutridas, \nhabitantes de pa\u00edses con bajo nivel de desarrollo (por ejemplo la India), \nla contaminaci\u00f3n de agua y alimen tos por micro-organismos determina \nun aporte de B\n12 que, a pesar de la extrema desnutrici\u00f3n, evita o aten\u00faa \nlas consecuencias de su d\u00e9ficit. Esto no ocurre, l\u00f3gicamente, en habitantes de pa\u00edses desarrollados donde la contaminaci\u00f3n por micro-\norganismos de los alimentos que se consumen es m\u00ednima, \nespecialmente cuando el preparado y cocinados de los mismos se \nrealiza en condiciones de gran higi ene como ocurre en las residencias \nde ancianos. \nLas necesidades metab\u00f3licas diarias de B\n12 son 5 mcg, de ellos 1-2 \nmcg se absorben al partir de los a limentos y el resto proviene de la B 12 \nalmacenada en el h\u00edgado. Tras la absorci\u00f3n, la B 12 se transfiere a una \nprote\u00edna de transporte, la transcoba lamina II (TC-II). El complejo TC-II-\nB12 es la holotranscobalamina-II (Holo-TC-II), forma biol\u00f3gicamente \nactiva de la vitamina B 12. \nMuchos de estos estados de malnutrici\u00f3n concurren en una \ndeficiencia de vitaminas. En estos momentos, existe un gran consenso \nentre los profesionales de la salud de que el gran problema nutricional \nde los pa\u00edses desarrollados es la desnutrici\u00f3n, en especial a nivel \nsubcl\u00ednico, sobre todo en personas de edad avanzada2-5. \nDe igual modo, el d\u00e9ficit de fola to es tambi\u00e9n un problema de \nsalud publica, numerosos estudios realizados en todo el mundo han puesto de manifiesto la alta prevalen cia de deficiencia de folato en la \npoblaci\u00f3n, especialmente la anciana. La deficiencia de folato es \nprobablemente el d\u00e9ficit vitam\u00ednico m\u00e1s frecuente\n8. Se calcula que \nalrededor de un tercio de la poblaci\u00f3n presenta deficiencia de folato. Datos preliminares de nuestro estudi o indican que alrededor de un 57% \npresenta niveles bajos de folato s\u00e9ri co y un 38% de folato eritrocitario\n7, \neste \u00faltimo indicativo de las reservas de folato en el organismo.  \n \n                                                                                                         Introducci\u00f3n  \n 4La deficiencia subcl\u00ednica de folato se relaciona con alteraciones \ndel sistema nervioso central (defectos del tubo neural, depresi\u00f3n, demencia senil), c\u00e1ncer y aterosclerosis. \nEl metabolismo y funci\u00f3n de la vitamina B\n12 y folato est\u00e1n \n\u00edntimamente relacionados y son imprescindibles para la s\u00edntesis de DNA, maduraci\u00f3n del n\u00facleo, divisi\u00f3n celular y funci\u00f3n neurol\u00f3gica. Esto se traduce en unos ca mbios morfol\u00f3gicos, llamados \nmegalobl\u00e1sticos, que afectan a todas las series medulares: granuloc\u00edtica, plaquetaria y eritroide. El d\u00e9ficit cl\u00ednico de estas vitaminas provoca, en \n\u00faltimo extremo una entidad cl\u00ednica es pec\u00edfica, la anemia megalobl\u00e1stica, \nque en el caso de la deficiencia de vitamina B\n12, a veces se acompa\u00f1a de \nalteraciones neurol\u00f3gicas que llegan a ser irreversibles, de ah\u00ed la \nimportancia de un diagn\u00f3stico precoz. \nEn cuanto a la vitamina B 6, en 1926 se produjo dermatitis en ratas \nalimentadas deficientemente en B 12, pero no fue hasta 1936 cuando \nGy\u00f6rgy distingui\u00f3 entre vitamina B 12 y el factor hidrosoluble cuya \ndeficiencia caus\u00f3 la dermatitis, y la denomin\u00f3 vitamina B 6. Fue en 1939 \ncuando se descubri\u00f3 la estruc tura qu\u00edmica de la vitamina, \ndemostr\u00e1ndose que varios compuest os naturales poseen las mismas \npropiedades biol\u00f3gicas, el piridoxal, piridoxina y piridoxamina. \nLas necesidades diarias de esta vitamina establecidas por la RDA \nson de 2.0 mg/d\u00eda para los hombres y 1.6 mg/d\u00eda para las mujeres. \nEs imprescindible en el metabolismo de las prote\u00ednas. Se \nencuentra tanto en los alimentos de origen animal como vegetal por lo que el estado deficitario es poco frecuente. Su d\u00e9ficit provoca efectos en la piel, dermatitis seborreica periorbitaria y bucal acompa\u00f1adas de \nglositis y estomatitis, efectos sobre el sistema nervioso, crisis \nconvulsivas, neuritis perif\u00e9rica (s\u00edndrome del t\u00fanel carpiano), depresi\u00f3n\n9, demencia10 y por \u00faltimo efectos sobre la eritropoyesis \nprovocando anemia. \nPor tanto, debido a la problem\u00e1tica expuesta, consideramos de \nnotable inter\u00e9s el proyecto de investigaci\u00f3n que se presenta, que no \ntiene equivalente en la bibliograf\u00ed a, con el fin de identificar alg\u00fan \npar\u00e1metro o marcador m\u00e1s temprano para detectar precozmente los niveles bajos de la vitamina B\n12, as\u00ed como la oportunidad de revisar los \nvalores de referencia establecidos para los niveles s\u00e9ricos e intraeritrocitarios de folato, vitaminas B\n12 y B 6 y homociste\u00edna. En estos  \n \n                                                                                                         Introducci\u00f3n  \n 5momentos, en los que se est\u00e1 planteando la necesidad de revisar las \ningestas recomendadas de nutrientes para la poblaci\u00f3n espa\u00f1ola11, los \nresultados de nuestro estudio sin du da contribuir\u00e1n a la informaci\u00f3n \ncient\u00edfica necesaria para  establecer las ingestas recomendas para el \nfolato, vitamina B 12 y B 6. \n   \n \n                                                                                                         Introducci\u00f3n  \n 6Bibliograf\u00eda:  \n \n1.-Boushey CJ, Beresford SAA,  Omenn GS, Motulsky AG. A \nquantitative assessment of plasma ho mocysteine as a risk factor for \ncardiovascular disease. JAMA 1995; 274:1049-1057. \n2.-Chandra RK, Imbach A, Moore C, Skelton D, Woolcott D. Nutrition \nof the elderly. CMAJ 1991;145(11):1475-87 \n3.-Chandra RK. Effect of vitamin an d trace-element supplementation on \ncognitive function in elderly subjects. Nutrition 2001;17(9):709-12. \n4.-Moreiras O, Carbajal A, Perea I & Varela-Moreiras G. The influence \nof dietary intake and sunlight exposu re on the vitamin D status in an \nelderly Spanish group. Int. J. Vit. Nutr. Res 1992; 62: 303-307. \n5.-Rosenberg IH, Miller JW. Nutrit ional factors in physical and \ncognitive functions of elderly people Am J Clin Nutr 1992;55(6 \nSuppl):1237S-1243S. \n6.-WHO (2000). The World Health  Report 2000.  www.who.int/whr. \n7.-M Gonzalez-Gross (1,2), R Sola (1,3) , V Lemmen (1,2), D Janke (2), MJ \nCastillo (1), K Pietrzik (2). Holo-tran scobalamin as an early indicator of \nvitamin b12 deficiency in a group of  institutionalized elderly spanish \npeople. Euromedlab 2003. \n8.-Herbert V, Das KC. Folic acid and vitamin B12. En: ME Shils, JA \nOlson, M Shike, eds. Modern Nutrition in Health and Disease. 8th \nedition. Malvern, PA: Lea & Febiger, pp 402-425, 1994. \n9.-Hvas AM, Juul S, Bech P, Nexo E. Vitamin B6 level is associated with \nsymptoms of depresi\u00f3n. P sychother Psychosom. 2004 Nov-\nDec;73(6):340-3. \n10.-Graban A. Hyperhomocysteinemia in patients with dementia. \nNeurol Neurochir Pol. 2003;37(4):879-87. \n11.-Joyanes M, Gonzalez-Gross M, Marcos A. The need to review the \nSpanish recommended dietary energy an d nutrient intakes. Eur J Clin \nNutr. 2002 Sep;56(9):899-905. \n12.-Krajcovicova-Kudlackova M, Blazicek P, Kopcova J, Bederova A, \nBabinska K. Homocysteine levels in vegetarians versus omnivores. : \nAnn Nutr Metab 2000;44(3):135-8.  \n \n                                                                                                         Introducci\u00f3n  \n 713.-Dominguez RO, Marschoff ER, Guare schi EM, Famulari AL, Pagano \nMA, Serra JA; Collaborative Group for the Study of the Oxidative Stress and Related Abnormalities. Homocysteine, vitamin B 12 and folate in \nAlzheimer \u02b9s and vascular dementias: the paradoxical effect of the \nsuperimposed type II diabetes mellitus  condition. Clin Chim Acta. 2005 \nSep;359(1-2):163-70.   \n   \n \n   \n \n  \n  \n \n     \n \n     \n \n    \n \n     \n \n     \n \n    \nHIP\u00d3TESIS Y OBJETIVOS \n  \n \n                                                                                        Hip\u00f3tesis y Objetivos  \n \n  \n9HIP\u00d3TESIS GENERAL \n \n1. El d\u00e9ficit de B 12 es un importante problema  de salud p\u00fablica que pasa \ninicialmente desapercibido. \n2. Se puede realizar un diagn\u00f3stico (y tratamiento) precoz del d\u00e9ficit de vitamina B\n12 que es altamente coste-efectivo. \n3. Se puede establecer una secuen cia espec\u00edfica de alteraciones \nbioqu\u00edmicas que informan sobre el ni vel evolutivo de un d\u00e9ficit de B 12.  \n  \nHIP\u00d3TESIS ESPEC\u00cdFICAS \n \n1. Ancianos y vegetarianos presentan un d\u00e9ficit subcl\u00ednico de B 12 que \npuede ser desenmascarado.  2. El d\u00e9ficit de B\n12 se asocia a p\u00e9rdidas de memoria, trastornos de la \nsensibilidad perif\u00e9rica, demencias o incluso Alzheimer. A esto \u00faltimo \ncontribuye la hiperhomocisteinemia  (factor independiente de riesgo \nvascular, proaterog\u00e9nico y protrombog\u00e9n ico) que es tambi\u00e9n, en parte, \nconsecuencia del d\u00e9ficit de B 12. \n3. La medida secuencial de B 12 total, polisegmentaci\u00f3n neutr\u00f3fila, MMA, \nhomociste\u00edna, holotranscobalamina perm ite establecer el nivel de d\u00e9ficit \nde B 12. \n5. La medida de holotranscobalamina (forma biol\u00f3gicamente activa de B\n12) permite realizar un diagn\u00f3stico fiable y precoz del d\u00e9ficit de B 12. \n \nHIP\u00d3TESIS NULAS \n \n1. En una poblaci\u00f3n supuestamente en riesgo de padecer d\u00e9ficit de B 12 \nno es posible objetivar tal d\u00e9ficit tras medir los distintos par\u00e1metros bioqu\u00edmicos (B\n12, tHcy, MMA, Holo-TC-II) y hematol\u00f3gicos \n(polisegmentaci\u00f3n de neutr\u00f3filos) susceptibles de estar alterados. \n2. No existe asociaci\u00f3n entre las manifestaciones cl\u00ednicas del d\u00e9ficit de B\n12 y la alteraci\u00f3n de par\u00e1metros biopatol\u00f3gicos. \n3. La Holo-TC-II no permite establecer un diagn\u00f3stico precoz del d\u00e9ficit \nde B 12. \n  \nOBJETIVO GENERAL \n \n- Conocer la relaci\u00f3n entre el d\u00e9ficit de B 12 y las manifestaciones \nespec\u00edficas e inespec\u00edficas que ocasiona.   \n \n                                                                                        Hip\u00f3tesis y Objetivos  \n \n  \n10- Comprobar que existe la posibilidad de detecci\u00f3n y tratamiento precoz \ndel d\u00e9ficit de B 12. \n- Proponer un protocolo de diagn\u00f3stico precoz del d\u00e9ficit de B 12. \n \nOBJETIVOS ESPECIFICOS \n \n1. En poblaciones a riesgo de padecer d\u00e9fict de B 12 (sujetos ancianos \ninstitucionalizados y suje tos vegetarianos) medir: B 12 plasm\u00e1tica total, \ntHcy, folato, B 6, Holo-TC-II, polisegmentaci\u00f3n de neutr\u00f3filos y estudio \ncl\u00ednico ad hoc. \n2. Establecer la secuencia espec\u00edfica de manifestaciones que acompa\u00f1an al d\u00e9ficit de B\n12. \n3. Conocer el nivel de asociaci\u00f3n entre d\u00e9ficit de B 12 y manifestaciones \ninespec\u00edficas del mismo.  3. Determinar (y en su caso proponer) si la Holo-TC-II constituye un \nmarcador muy precoz del d\u00e9ficit de B\n12. \n4. Comprobar la eficiencia de un pr otocolo de diagn\u00f3stico fiable para \ndetectar precozmente el d\u00e9ficit de B 12. \n  \n \n    \n \n \n  \n  \n  \n \n     \n \n     \n \n    \n \n     \n \n     \n \n \n                                       \nHOMOCISTE\u00cdNA \n  \n \n \n  \n12HOMOCISTE\u00cdNA Y PATOLOG\u00cdA CARDIOVASCULAR \n \nMarcela Gonz\u00e1lez-Gross 2,3,4, Ricardo Sola 1,3, Klaus Pietrzik 2, Manuel \nJ. Castillo3 \n \n1 Servicio de Hematolog\u00eda. Hospital Universitario San Cecilio. Granada. \nEspa\u00f1a \n2 Institut fuer Ernaehrungswissensch aft. Abt. Pathophysiologie der \nErnaehrung. Rheinische Friedrich-Wilhelm Universitaet. Bonn. \nAlemania. \n3 Facultad de Medicina y Hospital Cl\u00ednico Universitario. Universidad de \nGranada Granada. Espa\u00f1a. \n4 Instituto de Nutrici\u00f3n y Bromat olog\u00eda CSIC-UCM. Facultad de \nFarmacia. Madrid. Espa\u00f1a. \n \n \n \n           \nDirecci\u00f3n para la correspondencia: \n  \nDra. M Gonzalez-Gross \nInstituto de Nutrici\u00f3n y Bromatolog\u00eda CSIC-UCM Edificio Instituto del Fr\u00edo C/ Ramiro de Maeztu, s/n E-28040 Madrid Tel: +34 91 549 00 38 \nFax: +34 91 549 50 79 \nEmail: mggross@med.ucm.es\n / mggross@canal21.com  \n  \n \n \n  \n13Resumen  \nLas enfermedades cardiovasculares, y en particular la \ncardiopat\u00eda isqu\u00e9mica, constituyen la  principal causa de muerte en los \npa\u00edses occidentales. En la \u00faltima d\u00e9cada se ha reducido notablemente la \nmortalidad cardiovascular. Esto se atribuye, por un lado, a cambios \nsaludables en el estilo de vida (a limentaci\u00f3n, ejercicio f\u00edsico, tabaco) y \npor otro, a los avances en la identificaci\u00f3n, diagn\u00f3stico y tratamiento precoz de diversos factores de riesgo (dislipidemias, hipertensi\u00f3n). A pesar de ello, estas enfermedades segu ir\u00e1n siendo la principal causa de \nmuerte al menos durante los pr\u00f3ximos 20 a\u00f1os. De hecho, los factores \nde riesgo cl\u00e1sicos (dislipidemias, hipertensi\u00f3n, tabaquismo, sedentariedad, stress y obesidad) s\u00f3lo consiguen explicar un 50% de los episodios de cardiopat\u00eda isqu\u00e9mica o lesi\u00f3n cerebrovascular que se \nproducen. \nEs importante identificar y contro lar otros factores de riesgo que \npueden contribuir al desarrollo del proceso ateroscler\u00f3tico. Uno de los \nfactores que parece jugar un importante papel son los niveles plasm\u00e1ticos elevados de homociste\u00edna, la cual se considera como un factor independiente de riesgo. La homociste\u00edna es un amino\u00e1cido no proteico formado en el ciclo metab\u00f3lico de la metionina y que \ninterviene en los procesos de metilaci\u00f3n. En dicho ciclo metab\u00f3lico \nest\u00e1n implicadas cuatro vitaminas: riboflavina, folato, vitamina B\n6 y \nvitamina B 12. La deficiencia absoluta o relativa de alguna o varias de \nestas vitaminas determina la elevaci\u00f3n de los niveles de homociste\u00edna. Diversos estudios epidemiol\u00f3gicos han puesto claramente de manifiesto la relaci\u00f3n entre los nive les de homociste\u00edna, la ingesta de \nestas vitaminas y la incidencia de cardiopat\u00eda isqu\u00e9mica. No obstante, \nexisten aspectos que son objeto de controversia. En el presente art\u00edculo se analiza la evidencia actualmente di sponible relativa a este problema \ny las implicaciones cl\u00ednicas que tiene. \n \n \n \n   Palabras clave: Homociste\u00edna. Folato. Cardiopat\u00eda isqu\u00e9mica. \nSuplementos vitam\u00ednicos.  \n \n \n  \n14Summary  \nCardiovascular disease, and partic ularly ischemic heart disease, \nis the leading cause of death in developed countries. A significant \nreduction in cardiovascular mortality has been observed during the last \ndecade. This is attributed to a healthier life style (nutrition, physical exercise, tobacco) and to the recent ad vances in the identification, early \ndiagnosis and treatment of several  risk factors (dislipidemias, \nhypertension, obesity). Neverthe less, cardiovascular disease will \nremain as the leading cause of death during, at least, the next 20 years. \nIn fact, only 50% of ischemic heart disease episodes and strokes can be \nrelated to classic risk factors (hyp ercholesterolemia, hypertension, lack \nof physical exercise, stress, obesity). Therefore, it is important to identify and control other risk factors that may be important \ncontributors in the atherogenesis process. One of these factor, is the elevated plasma homocysteine levels, which is today considered an \nindependent risk factor. Homocysteine is a non proteinogenic \naminoacid, essential for the methila tion process and formed in the \nmethionine cycle. Four vitamins are implicated in this cycle: riboflavin, folate, B\n6 and B 12. The absolute or relative deficiency of one or more of \nthese vitamins increases the plasma homocysteine levels. Several \nepidemiological studies have shown the relationship between plasma \nhomocysteine levels, vitamin intake and the incidence of ischemic heart \ndisease. Nevertheless, there are some important controversial points. In the present article, the current scientific evidence and its clinical implications are analysed. \n \n \n         \nKey words: homocysteine, folate, cardiovascular disease, supplements \n \n \n  \n \n \n  \n15Introducci\u00f3n: \nLa existencia de alteraciones en el metabolismo de la \nhomociste\u00edna se identific\u00f3 por primera vez en 19621 al analizar la orina \nde ciertos ni\u00f1os con retraso mental. Se comprob\u00f3 que estos ni\u00f1os \npresentaban gran cantidad de homocistina en orina, surgiendo el concepto homocistinuria. Dos a\u00f1os  despu\u00e9s se demostr\u00f3 que el \nproblema radicaba en un d\u00e9ficit cong\u00e9nito de la enzima cistationin-beta-sintetasa, constat\u00e1ndose adem \u00e1s que el proceso cursaba con \nniveles plasm\u00e1ticos elevados de homociste\u00edna y gran incidencia de \nepisodios tromboemb\u00f3licos. De hecho, el 50% de los ni\u00f1os que \npresentaban este cuadro fallec\u00edan  antes de llegar a adultos, por \nenfermedad cardiovascular\n2. En 1969 McCully3 describi\u00f3 la lesi\u00f3n \nanatomopatol\u00f3gica que presentaban es tos pacientes y que inclu\u00eda, entre \notros cambios, proliferaci\u00f3n de c\u00e9lulas musculares lisas, estenosis \narterial y cambios hemost\u00e1ticos.  \nDesde entonces y hasta ahora, pe ro en especial en la \u00faltima \nd\u00e9cada, han sido m\u00faltiples los esfuerzos realizados para profundizar en el conocimiento de la fisiopatolog\u00eda de la hiperhomocisteinemia como factor de riesgo o factor asociado a la enfermedad cardiovascular. Es m\u00e1s, se ha constatado que no s\u00f3 lo los niveles muy elevados de \nhomociste\u00edna se asocian a patolog\u00ed a cardiovascular sino que tambi\u00e9n, \nniveles moderadamente elevados pueden constituir un factor de riesgo independiente para dichas patolog\u00edas. En este sentido, algunos autores \nestablecen el rango de normalidad en las concentraciones plasm\u00e1ticas \nde homociste\u00edna total (tHcy) entre 5 y 15 \u00b5mol/l\n4,5; otros autores cifran la \nnormalidad en valores de hasta 10 \u00b5mol/l6. La hiperhomocisteinemia la \npodemos subdividir en moderada (valores de hasta 30 \u00b5mol/l), \nintermedia (valores de hasta 100 \u00b5mol/l) y severa (valores superiores a \n100 \u00b5mol/l)4. \nAdem\u00e1s de la enfermedad cardiovascular, alteraciones en el \nmetabolismo de la homociste\u00edna se han implicado tambi\u00e9n en otras patolog\u00edas. En la tabla 1 se enumeran algunas de ellas y en la tabla 2 se \npresentan manifestaciones cl\u00ednicas qu e se han visto ligadas a un exceso \nen los niveles circulantes de homocist e\u00edna. En el presente art\u00edculo, se \ndescribe la base bioqu\u00edmico-fisiol\u00f3gic a de la hiperhomocisteinemia y se \nanaliza, de manera espec\u00edfica, la relaci\u00f3n entre hiperhomocisteinemia y patolog\u00eda cardiovascular.  \n  \n \n \n  \n16Base bioqu\u00edmica de la hiperhomocisteinemia \nLa homociste\u00edna es un amino\u00e1cido sulfurado que no forma parte \nde las prote\u00ednas ni est\u00e1 presente en  la dieta de manera significativa. De \nhecho, constituye un producto inte rmediario en el metabolismo de la \nmetionina, interviniendo en las reacci ones de metilaci\u00f3n del organismo \n(figura 1).  \nLos niveles circulantes de homociste\u00edna son el resultado del \nequilibrio entre su tasa de producci\u00f3n y su tasa de degradaci\u00f3n metab\u00f3lica. Un aumento de los nivele s de homociste\u00edna puede ocurrir \npor un aumento de producci\u00f3n o por un defecto de metabolizaci\u00f3n. Es \nprecisamente, una disminuci\u00f3n del catabolismo de la homociste\u00edna el principal determinante de la hiperh omocisteinemia. En el catabolismo \nde la homociste\u00edna intervienen varias enzimas y vitaminas (folato, B\n6, \nB12 y B 2). Estas \u00faltimas act\u00faan como co-factores y/o substratos de las \nreacciones catab\u00f3licas de la homocist e\u00edna. Un ac\u00famulo en los niveles de \nhomociste\u00edna se puede deber a un defecto cong\u00e9nito de algunas de esas \nenzimas ( hiperhomocisteinemia cong\u00e9nita ) o a un d\u00e9ficit de alguno de los \ncofactores (vitaminas) necesarios para la actividad de dichas enzimas (hiperhomocisteinemia adquirida ). Como se ha indicado previamente, al no \nestar presente en la dieta, no cabe hablar de una hiperhomocisteinemia \nligada a un exceso de aporte nutricional. No obstante, la ingesta de \nprote\u00ednas con alto contenido en meti onina podr\u00eda dar lugar en algunas \npersonas a un aumento pasajero en lo s niveles de homocisteina, al ser la \nmetionina un precursor de \u00e9sta. Hay que indicar, por \u00faltimo, que los niveles de homociste\u00edna se modifican en diversas situaciones fisiol\u00f3gicas (edad, embarazo) y se alteran tambi\u00e9n ante modificaciones \nen el estilo de vida. \n Metabolismo de la homociste\u00edna \nLa homociste\u00edna es el producto que se forma al ceder la S-\nadenosil-metionina (forma activa de la metionina) un grupo metilo. Una vez formada, la homociste\u00edna pu ede ser metabolizada por dos v\u00edas \ndiferentes: la remetilaci\u00f3n a metionin a o la degradaci\u00f3n a ciste\u00edna en la \nv\u00eda de la transulfuraci\u00f3n (figura 1). En caso de fallo de una o ambas \nv\u00edas, la homociste\u00edna se acumula en  exceso, pasa a homocistina y se \nelimina por orina (homocistinuria).  \n \n \n  \n17Remetilaci\u00f3n a metionina . En la mayor\u00eda de los tejidos, la \nhomociste\u00edna es remetilada a meti onina por medio de la metionina \nsintetasa (MS), cuyo cofactor es la vitamina B 12 (figura 1). El 5-metil-\ntetrahidrofolato (5-MTHF) es el sustrato de esta reacci\u00f3n, que por \nmedio de la MS pasa a tetrahidrofolato (THF). El 5-MTHF proviene de la reacci\u00f3n que convierte el 5,10- metilen-tetrahidrofolato en metil-\ntetrahidrofolato. Esta otra reacci\u00f3n es catalizada por la metilen-tetrahidrof\u00f3lico-reductasa (MTHFR), cuyo coenzima es la vitamina B\n2 \nen su forma activa, el flavin adenin  dinucleotido (FAD). De este modo, \ny como puede apreciarse  en la figura 1, se completa el ciclo del folato. \nEn h\u00edgado y, en menor medida, en ri\u00f1ones, la enzima betaina \nhomocisteina metil-transferasa (BHMT) es la encargada de la remetilaci\u00f3n de la homocisteina  para transformarse en metionina \n(figura 1). Esta segunda ruta no necesita de B\n12 ni de folato, utilizando la \nbeta\u00edna como dadora de grupos metilo. \nDegradaci\u00f3n a ciste\u00edna . La v\u00eda de la transulfuraci\u00f3n supone la \ndegradaci\u00f3n irreversible de homocist eina a cisteina (figura 1). En esta \nv\u00eda est\u00e1n implicadas dos enzimas: la cistationina- \u03b2-sintetasa (CBS) y la \ncistationina- \u03b2-liasa (CBL). La vitamina B 6, en su forma activa, el \npiridoxal fosfato (PLP) act\u00faa como coenzima de ambas enzimas. En \ncaso de seguir una dieta normal, la v\u00ed a de la transulfuraci\u00f3n y la v\u00eda de \nla metilaci\u00f3n est\u00e1n implicadas al 50% en el metabolismo de la homociste\u00edna\n4,7. Cuando se ingiere un exceso de metionina, la \nhomociste\u00edna se dirige fundamentalment e a la v\u00eda de la transulfuraci\u00f3n. \nEn condiciones de balance negativo, la homocisteina se dirige principalmente a la v\u00eda de la metila ci\u00f3n, para conservar as\u00ed los niveles \nde metionina\n8.  \n Hiperhomocisteinemia cong\u00e9nita \nEn el metabolismo de la homocisteina se han descrito diversos \ndefectos gen\u00e9ticos, que cursan con di ferentes repercusiones cl\u00ednicas, que \nno s\u00f3lo afectan a las v\u00edas de t ransulfuraci\u00f3n y remetilaci\u00f3n, sino \ntambi\u00e9n a la remetilaci\u00f3n v\u00eda beta\u00edna, que es vitamin-independiente. \nLos defectos enzim\u00e1ticos cong\u00e9nitos (tabla 3) que se han descrito como determinantes de hiperhomocis teinemia son los siguientes: \na) D e f e c t o  d e  l a  C B S .  E s t e  d e f e c t o es el m\u00e1s grave y conduce a \nconcentraciones mayores de 100 \u00b5mol/l, dando lugar a  \n \n \n  \n18homocistinuria. Se han identificado 92 mutaciones diferentes en \nel gen CBS. Las m\u00e1s frecuentes son la I278T, cuyos homocigotos responden al tratamiento con piri doxina, y la G307S, que no lo \nhacen\n9. La incidencia var\u00eda de unas  regiones a otras. As\u00ed, en \nIrlanda es de 1/50.000 personas. En otros pa\u00edses es de 1/250.000 - 300.000, pero var\u00eda en  funci\u00f3n del grupo \u00e9tnico.  \nb) Polimorfismo C677T de la MTHFR.  Esta mutaci\u00f3n se describi\u00f3 \npor Kang en 1988\n10. Los homocigotos para este defecto expresan \nuna variante termol\u00e1bil de la enzima. La actividad enzim\u00e1tica \nest\u00e1 reducida comparada con la normalidad. Los niveles \nplasm\u00e1ticos de homociste\u00edna est\u00e1n ligeramente elevados (15-20 \u00b5mol/l). Afecta alrededor de un 10 - 15% de la poblaci\u00f3n, y en la \nactualidad existen datos insuficientes sobre su relevancia cl\u00ednica. Los heterocigotos, por el contrario, son frecuentes, apareciendo en el 40-45% de la poblaci\u00f3n. Seg\u00fan el estado actual del \nconocimiento, la variante heterocig\u00f3tica carece de relevancia \ncl\u00ednica \n11,12. Esto es debido a que los de fectos enzim\u00e1ticos de la v\u00eda \nde la remetilaci\u00f3n de la homoci ste\u00edna no provocan incrementos \nen los niveles de homociste\u00edna en ayunas pero s\u00ed tras una sobrecarga importante de la mism a. Esto es necesario tenerlo en \ncuenta a la hora de hacer el te st de sobrecarga con metionina, \nque es el m\u00e9todo empleado para identificar el defecto.  \nc) Polimorfismo A1298 C de la MT HFR. Esta mutaci\u00f3n, menos \nconocida hasta la fecha, se describi\u00f3 en 1998 por van der Put y col\n13; y da lugar a una menor acti vidad de la MTHFR. Tanto \nhomocigotos como heterocigotos no presentan mayores niveles \nde homociste\u00edna, pero parece haber una interacci\u00f3n entre esta \nmutaci\u00f3n y el polimorfismo C677T antes descrito. La heterocigocidad combinada se ha observado en un estudio en el 20% de la poblaci\u00f3n y s\u00ed se asoc ia a aumento de los niveles de \nhomociste\u00edna\n13. \nd) Polimorfismo A2756G de la MS. Fue descrito por Leclerc y col. \nen 199614. El genotipo 2756AA se asocia con un incremento \nmoderado, pero significativo, de los niveles de homociste\u00edna. Este trastorno \u00fanicamente se ha descrito en casos aislados. \ne) Recientemente se ha descrito el polimorfismo A66G de la \nmetionina sintetasa reductasa (MTRR) por Gaughan y col.\n15. Esta \nenzima es la encargado de restaurar la actividad de la MS en  \n \n \n  \n19determinadas circunstancias. Los homocigoticos presentan unos \nniveles plasm\u00e1ticos m\u00e1s elevados de homociste\u00edna. Por ser reciente, no se tienen datos sobre su frecuencia y relevancia \ncl\u00ednica. \nf) Beta\u00edna homociste\u00edna metil transferasa (BHMT). La \nsecuenciaci\u00f3n gen\u00f3mica de esta enzima es muy reciente, y se han descrito tres mutaciones para  esta enzima, G199S, Q406H, \nQ239R, las dos \u00faltimas \u00fanicamente en heterocigotos\n16. En el \nestudio de Heil y col.16, ninguna de estas mutaciones curs\u00f3 con \nniveles elevados de homociste\u00edna. \n \nHiperhomocisteinemia adquirida  \nLos factores nutricionales son los principales determinantes de la \nhiperhomocisteinemia adquirida. Existe escasa evidencia de que la ingesta de prote\u00ednas o metionina en cantidades fisiol\u00f3gicas induzca modificaci\u00f3n alguna en los niveles de homociste\u00edna\n17. En cambio, la \ndeficiencia tanto cl\u00ednica como subcl\u00ednica de cualquiera de las 4 \nvitaminas del grupo B (folato, cianocobalamina, piridoxina y riboflavina) implicadas da lugar a un a alteraci\u00f3n en el ciclo metab\u00f3lico \ny a elevaci\u00f3n de la homociste\u00edna, aunque no de la misma intensidad. \n \nFolato \nE l  f o l a t o  e s  l a  v i t a m i n a  q u e  d e  f o r m a  i n d i v i d u a l  p r e s e n t a  u n  \nmayor grado de asociaci\u00f3n inversa con los niveles de homociste\u00edna\n18-20. \nAdem\u00e1s, tanto su ingesta como su s concentraciones plasm\u00e1ticas y \neritrocitarias, se asocian de forma inversa con el riesgo de enfermedad coronaria\n21-23. Esto est\u00e1 suficientemente comprobado. As\u00ed, los datos m\u00e1s \nrecientes confirman los publicados en estudios anteriores. En el estudio \nde Koehler y col.20, la ingesta de folato procedente de alimentos se \nasoci\u00f3 de forma negativa a los niveles de homociste\u00edna. En la vig\u00e9sima anal\u00edtica bianual de la cohorte del \u201cFramingham Heart Study\u201d \n19, se \nobtuvo una fuerte asociaci\u00f3n inversa entre los niveles de tHcy y folato, \nsiendo esta asociaci\u00f3n m\u00e1s d\u00e9bil para las vitaminas B 12 y B 6. La \nprevalencia de niveles elevados (> 14 \u00b5mol/l) fue del 29.3%, siendo \nmayor en los sujetos con peor estado  en folato. En este estudio, las \nconcentraciones plasm\u00e1ticas inadecuadas de una o varias de las vitaminas del grupo B contribuyeron, en un 67% de los casos, a  \n \n \n  \n20determinar niveles elevados de homociste\u00edna. Asimismo, en el estudio \nde la cohorte del Framingham Offspring24, las concentraciones de folato \nplasm\u00e1tico fueron las principales determinantes de los niveles de \nhomociste\u00edna. Entre los sujetos que se encontraban en los quintiles \nsuperior e inferior de nivel de folato plasm\u00e1tico, la diferencia en los niveles de tHcy fue del 49%. \n Vitamina B\n12 \nE n  e l  c a s o  d e  l a  v i t a m i n a  B 12, los resultados obtenidos en \ndiferentes estudios apuntan haci a una correlaci\u00f3n inversa con los \nniveles de homociste\u00edna20,25,26 , si bien es m\u00e1s d\u00e9bil que la observada para \nel folato. De hecho, en la mayor\u00eda de estos estudios, se suele encontrar \ncorrelaci\u00f3n con los niveles plasm\u00e1ticos de esta vitamina20, pero no con \nla ingesta24. \u00danicamente en ancianos y en vegetarianos se han \nencontrado correlaciones m\u00e1s signific ativas, tal y como se indica m\u00e1s \nadelante. \n Vitamina B\n6 \nLa relaci\u00f3n entre la vitamina B 6 y la homociste\u00edna plasm\u00e1tica \ntodav\u00eda no est\u00e1 del todo esclarecida y necesita de estudios posteriores. \nNo obstante, son varios los estudios que han encontrado una \ncorrelaci\u00f3n significativa inversa entr e los niveles de homociste\u00edna y el \nestado en B 6, entre ellos se encuentra el estudio de Selhub y col26. En \ncambio, est\u00e1 bien fundamentada en la bibliograf\u00eda la relaci\u00f3n entre la deficiencia subcl\u00ednica de B\n6 y patolog\u00eda cardiovascular27, aunque no se \nsabe si esto es debido a la implicaci\u00f3n directa que la B 6 tiene sobre \nplaquetas, tejido conectivo y trombog\u00e9nesis y/o a una acci\u00f3n indirecta \nv\u00eda hiperhomocisteinemia28. \n Vitamina B\n2 \nDe las vitaminas implicadas en el metabolismo de la \nhomocisteina, la vitamina B 2 ha sido la que menos atenci\u00f3n ha recibido \nen estudios sobre humanos. Recientemente, Hustad y col.29 han puesto \nde manifiesto que la riboflavina plasm\u00e1tica es un indicador independiente del nivel de homociste\u00edna. Jacques y col.\n24 han observado \nuna asociaci\u00f3n modesta entre la inge sta de riboflavina y los niveles de  \n \n \n  \n21homociste\u00edna en casi 2000 personas pertenecientes a la cohorte del \nestudio \u201cFramingham Offspring\u201d. Se necesitan m\u00e1s estudios para poder evaluar la utilidad de la suplementaci\u00f3n con riboflavina en la \nhiperhomocisteinemia. \n Niveles de homociste\u00edna en sit uaciones fisiol\u00f3gicas espec\u00edficas \nHiperhomocisteinemia y envejecimiento  \nSe ha observado una relaci\u00f3n inversa entre los niveles de \nhomociste\u00edna y los niveles de folato, B\n6 y B 12 en ancianos. La inadecuada \nnutrici\u00f3n de estos pacientes podr\u00eda explicar los aumentos de los niveles \nde homociste\u00edna con la edad, si bien  las enfermedades digestivas, como \nla gastritis atr\u00f3fica o la malabsorci\u00f3n  intestinal, debido a la p\u00e9rdida de \nfactor intr\u00ednseco, pueden jugar tamb i\u00e9n un papel interfiriendo con la \nabsorci\u00f3n de vitaminas. Van Asselt30 estudi\u00f3 105 pacientes con edades \ncomprendidas entre los 74 y 80 a\u00f1os y demostr\u00f3 que a pesar de que los \ncambios gastrointestinales eran subcl\u00ednicos, un 28% de los pacientes \npresentaba d\u00e9ficit de B 12, bien por dieta inadecuada o por gastritis \natr\u00f3fica. Por otra parte, la funci\u00f3n renal disminuye con la edad y por \ntanto aumentan los niveles de homociste\u00edna, lo que se produce por la disminuci\u00f3n del aclaramiento plasm\u00e1tico  de la misma. Se ha observado \ntambi\u00e9n una correlaci\u00f3n negativa entre la edad y la actividad de la \nCBS\n7. \n \nHiperhomocisteinemia relacionada con cambios hormonales  \nLos niveles de homociste\u00edna se van incrementando despu\u00e9s de la \nmenopausia, aumentando los nivele s de la misma tanto en ayunas \ncomo tras sobrecarga de metionina. De hecho, la homociste\u00edna aumenta \nm\u00e1s con la edad en la mujer que en el hombre. Se ha descrito la existencia de una correlaci\u00f3n negativa entre el estradiol y la homociste\u00edna en mujeres postmenopa\u00fasicas\n31. Diversos estudios han \ndemostrado que las terapias sustitutivas con estr\u00f3genos-progesterona o s\u00f3lo estr\u00f3genos provocan cambios en la tasa de homociste\u00edna, en \ngeneral disminuy\u00e9ndola. La disminuci\u00f3n es mayor si la homociste\u00edna \nestaba previamente muy alta\n32. Se ha demostrado que la \nsuplementaci\u00f3n vitam\u00ednica en mu jeres postmenop\u00e1usicas baja los \nniveles de homociste\u00edna.   \n \n \n  \n22Hiperhomocisteinemia ligada a ca mbios en el estilo de vida \nDieta vegetariana . La vitamina B 12 s\u00f3lo se encuentra en \nalimentos de origen animal, por tant o en los sujetos vegetarianos, se \nobservan niveles plasm\u00e1ticos reducidos de vitamina B 12, tanto m\u00e1s \ncuanto m\u00e1s estricto es el vegetarianismo33-35. En diversos estudios \nrealizados comparando vegetarianos con controles omn\u00edvoros, los primeros presentaron niveles plasm\u00e1ticos de homociste\u00edna significativamente superiores a los segundos (p<0.05)\n33,34,36 . En estos \nestudios, los omn\u00edvoros presentaron niveles significativamente menores \nde folato s\u00e9rico. En las dietas vegetarianas tambi\u00e9n es menor la ingesta \nde metionina, un amino\u00e1cido presente en mayor cantidad en los alimentos de origen animal. Como ya se ha indicado anteriormente, en \ncondiciones de menor disponibilidad de metionina, predomina el paso de remetilaci\u00f3n en el ciclo metab\u00f3lico (figura 1), por lo que es dependiente de B\n12 y folato. Por tanto, en el caso de los vegetarianos, la \nhiperhomocisteinemia es consecuencia  de la deficiencia de vitamina B 12. \nEstos niveles elevados de homociste\u00edna podr\u00edan contrarrestar los beneficios conocidos de las dietas vegetarianas en relaci\u00f3n con la \npatolog\u00eda cardiovascular, en especial las dietas vegetarianas estrictas. Aqu\u00ed tambi\u00e9n se puede constatar que resulta m\u00e1s beneficiosa una dieta \nequilibrada omn\u00edvora como la di eta mediterr\u00e1nea que las dietas \nrestrictivas, que desequilibran la re laci\u00f3n existente en el organismo \nentre los diversos nutrientes. \nAlcohol\n. Un consumo moderado de alcohol se relaciona con \nniveles bajos de homociste\u00edna37, mientras que un consumo elevado \npresenta una asociaci\u00f3n directa, aume ntando los niveles. Esto puede ser \ndebido a varios factores: un el evado consumo de alcohol puede \nprovocar trastornos gastrointestinales, con la consiguiente menor absorci\u00f3n de vitaminas. Asimismo, disminuye los niveles de vitamina \nB\n6, folato s\u00e9rico y eritrocitario38. Tambi\u00e9n se ha observado que el alcohol \ninhibe la MS20. En cambio, un consumo moderado de cerveza se ha \nasociado a una reducci\u00f3n de los nive les de homociste\u00edna, debido a su \ncontenido en vitamina B 6 39 y folato38. \nCaf\u00e9 . El consumo de caf\u00e9 afecta a los niveles de homociste\u00edna. El \nmecanismo es desconocido. En el Hordaland Homocysteine Study, los \npacientes mayores de 40 a\u00f1os que cons um\u00edan m\u00e1s de 9 tazas de caf\u00e9 al \nd\u00eda presentaron un aumento de la ho mociste\u00edna de m\u00e1s del 19% frente a \nlos que no ten\u00edan ese h\u00e1bito40. En este mismo estudio el consumo de t\u00e9  \n \n \n  \n23se asoci\u00f3 con niveles menores de ho mociste\u00edna, probablemente debido a \nla presencia de cantidades moderadas de folato en el t\u00e941 que \ncontrarrestan el efecto de la cafe\u00edna. \nTabaco . E n  d i v e r s o s  e s t u d i o s  s e  h a  p u e s t o  d e  m a n i f i e s t o  l a  \nrelacion directa entre el tabaco y los niveles de homocisteina34,40. El \nn\u00famero de cigarrillos est\u00e1 directamente relacionado con los niveles de homociste\u00edna. En el estudio de Nakazawa y col\n42, el incremento en los \nniveles de tHcy en las mujeres fue  del 1% por cigarillo fumado. Las \ncausas que se han propuesto son vari as. Al parecer, la nicotina provoca \nun incremento del catabolismo de los folatos42. Varios estudios han \nobservado niveles bajos de B 643,44, B 12 y folato45 en fumadores. Se habla \nde una posible interacci\u00f3n entre lo s componentes nitrosos encontrados \nen los fumadores y la MS, lo cual explicar\u00eda la hiperhomocisteinemia24. \nParece que la v\u00eda de la metilaci\u00f3n es t\u00e1 tambi\u00e9n influida por la nicotina.  \n \nDiagn\u00f3stico de la hiperhomocisteinemia \nExisten diferentes m\u00e9todos para la determinaci\u00f3n de \nhomociste\u00edna en plasma. La medida de la tHcy, bien en suero o en \nplasma, representa la suma de toda s las formas que aparecen \u201cin vivo\u201d, \ncomo son la homociste\u00edna libre, la homociste\u00edna unida a prote\u00edna y los \nproductos oxidados de la misma (homocistina y cisteina-homocisteina). \nEn pacientes con hiperhomocisteinemia, a los tres compuestos anteriores, hay que a\u00f1adir la homociste\u00edna-tiolactona. Tal y como se ha descrito anteriormente, son m\u00faltiples los factores que pueden influir en \nlos niveles plasm\u00e1ticos de homociste\u00edna, y por tanto, los valores anal\u00edticos s\u00f3lo se pueden interpretar correctamente conociendo y \nvalorando estos otros factores\n37,46. A menos que se especifique otra cosa \nlos niveles de homociste\u00edna en plasma se refieren a la homociste\u00edna total \npor ser esta la que com\u00fanmente se analiza. \nUno de los m\u00e9todos de referencia para la medida de \nhomociste\u00edna es el desarrollado por Araki y Sato47 mediante HPLC. \nPosteriormente, Schipchandler y col.48 desarrollaron un m\u00e9todo \ntotalmente automatizado de inmu noan\u00e1lisis de fluorescencia \npolarizada, a partir de un anticuerpo monoclonal que reconoce la S-adenosil-homocisteina. Para cualquiera de los m\u00e9todos citados, el manejo de la muestra es de importancia cr\u00edtica, ya que una manipulaci\u00f3n incorrecta puede aumentar artificialmente los niveles de  \n \n \n  \n24homociste\u00edna. La toma de muestra debe  ser realizada tras un periodo de \n12 horas de ayuno. Una dieta previa rica en prote\u00ednas puede aumentar de manera circunstancial los niveles de homociste\u00edna. La determinaci\u00f3n \nde la homocisteina se puede realizar tanto en plasma como en suero. En \nambos casos, una vez realizada la extracci\u00f3n, la muestra debe ser colocada inmediatamente en ba\u00f1o  d e  h i e l o .  S i  s e  u t i l i z a  c o m o  \nanticoagulante el EDTA, la muestra se puede centrifugar \ninmediatamente despu\u00e9s de extra\u00edda la sangre. Una vez centrifugada la \nmuestra y separado el plasma, \u00e9ste  puede permanecer a temperatura \nambiente durante 3 d\u00edas y congelad o durante meses. Seg\u00fan Willens y \ncol\n49, el anticoagulante id\u00f3neo es el \u00e1cido c\u00edtrico, ya que la sangre \npermanece estable durante 4 a 6 horas.   \nLa homociste\u00edna libre es la fracci\u00f3n no unida a prote\u00edna. Para su \ndeterminaci\u00f3n, una fracci\u00f3n del plasma anticoagulado con EDTA es \ninmediatamente mezclado con buffer borato hipercl\u00f3rico y \nrecentrifugado. El sobrenadante se  guarda congelado a \u201320\u00b0C. Cuando \nse vaya a realizar el an\u00e1lisis y una vez descongelada la muestra anterior, se a\u00f1ade sobre ella tri-n-butil-fosfina, mezclado e incubado durante 30 minutos en la oscuridad y a 4\u00b0C\n47,50, los siguientes \nprocedimientos son iguales a los descritos anteriormente para la \nhomociste\u00edna total. \nLa determinaci\u00f3n de la homociste\u00edna tras una sobrecarga de \nmetionina se realiza para distinguir entre defectos que involucran a la \nv\u00eda de la remetilaci\u00f3n o de la transulfuraci\u00f3n. Asimismo tambi\u00e9n se emplea para diagnosticar a pacientes co n niveles de homociste\u00edna en el \nl\u00edmite de la normalidad, que pueden llegar a ser susceptibles de tener \nriesgo de enfermedad cardiovascular\n51.  \n Indicaciones de la medida de homociste\u00edna \nNo hay datos precisos de la incidencia de hiperhomocisteinemia \nen la poblaci\u00f3n. Aquellos casos cl\u00ednicos en los que est\u00e1 indicada la medida de la homociste\u00edna en el la boratorio se presentan en la Tabla 4.  \n \n \n  \n25La hiperhomocisteinemia como factor de riesgo cardiovascular \nSon m\u00faltiples los estudios epidemi\u00f3logicos que han puesto de \nmanifiesto la relaci\u00f3n entre la hiperhomocisteinemia y la enfermedad \ncardiovascular. En el ya mencionado metan\u00e1lisis realizado por Boushey \ny col.21, se analizaban los datos de 27 estudios realizados entre 1988 y \n1994. Por cada incremento de 5 \u00b5mol/l tHcy, el riesgo relativo (RR) de \nenfermedad coronaria aumentaba 1.6 (95% de intervalo de confianza, \n1.4 a 1.7), estableciendo los autores que la elevaci\u00f3n en los niveles de homociste\u00edna se pueden considerar un factor de riesgo independiente. \nDesde entonces y hasta ahora, se ha realizado un mayor n\u00famero \nde estudios con resultados diferent es. En tres estudios prospectivos \ncaso-control, se observ\u00f3 una asociaci \u00f3n lineal entre las concentraciones \nde homociste\u00edna y la patolog\u00eda cardiovascular\n52-54. Otros estudios han \nencontrado un mayor RR co mparando los percentiles m\u00e1s elevados de \nhomociste\u00edna con el resto55,56. En cambio, en otros estudios no se ha \npodido identificar esta asociaci\u00f3n57-60.  \nBas\u00e1ndose en estos resultados contradictorios, algunos grupos de \ntrabajo punteros en el campo de  la homociste\u00edna han puesto \nrecientemente en duda esta teor\u00eda56,61, alegando que los datos de los que \nse dispone apuntan m\u00e1s hacia una consecuencia que a una causa de \naterosclerosis, sugiriendo que se t rata \u00fanicamente de un marcador de \nriesgo de patolog\u00eda vascular. Aqu\u00ed hay que diferenciar entre las personas sanas y las que ya padecen alg\u00fan tipo de enfermedad cardiovascular. En un estudio caso-control reciente, Knekt y col.\n56 \ndurante el seguimiento al cabo de  13 a\u00f1os, observaron que los niveles \nelevados de homociste\u00edna no constituyen un factor de riesgo en \npersonas sin patolog\u00eda cardiaca manifiesta o aparente. En cambio, \nproponen, que en pacientes con enfe rmedad coronaria diagnosticada, la \nhiperhomocisteinemia moderada pued e ser predictiva de un segundo \nevento. De hecho, se puede afirmar que pr\u00e1cticamente todos los estudios retrospectivos y la mayor\u00ed a de los prospectivos han encontrado \nelevaciones de homociste\u00edna de ligeras a moderadas en pacientes con \naterosclerosis comparando con controles. Sin embargo otros estudios \npublicados recientemente, confirman la relaci\u00f3n entre la hiperhomocisteinemia y la disfunci\u00f3n endotelial\n62 y/o la enfermedad \ncardiovascular63,64 en personas aparentemente sanas. Por tanto, hace \nfalta mayor n\u00famero de estudios prospectivos para demostrar de  \n \n \n  \n26manera inequ\u00edvoca la existencia de una relaci\u00f3n causal entre  \nhiperhomocisteinemia y enfermedad cardiovascular. \nContrastando con aquellos autores que ponen en duda el papel \nde la homociste\u00edna, Vollset y col.65, en un estudio prospectivo de 4766 \npersonas con edades comprendidas  entre los 65 y 67 a\u00f1os, observaron \nun aumento de la mortalidad total asociado a niveles elevados de homociste\u00edna, aportando un nueva perspectiva en el papel de la homociste\u00edna cual ser\u00eda su implicaci\u00f3n no s\u00f3lo en la enfermedad cardiovascular sino tambi\u00e9n en otras patolog\u00edas que directa o \nindirectamente contribuyen a aument ar la mortalidad. Esto se escapa \ndel \u00e1mbito del presente trabajo y se r\u00e1 objeto de revisi\u00f3n posterior. \n \nFisiopatolog\u00eda de la lesi\u00f3n vascular ligada a la hiperhomocisteinemia \nEl mecanismo fisiopatol\u00f3gico por el que la hiperhomocisteinemia \ncondiciona la lesi\u00f3n cardiovascular no est\u00e1 del todo esclarecido. La \nevidencia indica que interact\u00faa dire cta y/o indirectamente sobre el \nproceso aterog\u00e9nico, contribuyendo por una parte a la disfunci\u00f3n endotelial y por otra facilitando la trombog\u00e9nesis. Varios son los mecanismos por los que puede ocurrir esta interacci\u00f3n. \nHomociste\u00edna y stress oxidativo \nSe sabe que la homociste\u00edna  se autooxida r\u00e1pidamente, \nform\u00e1ndose homocistina, homocisteina tiolactona y mezcla de disulfuros. Durante el proceso de au tooxidaci\u00f3n se forma super\u00f3xido y \nper\u00f3xido de hidr\u00f3geno que, como se ha comprobado in vitro, act\u00faan lesionando las membranas de las c\u00e9lulas endoteliales\n66,67, iniciado la \nperoxidaci\u00f3n lip\u00eddica y la oxidac i\u00f3n del LDL-colesterol. Asimismo, \nHarker y col.68 le confieren al per\u00f3xido de hidr\u00f3geno una acci\u00f3n de \naumento de proliferaci\u00f3n de c\u00e9 lulas musculares que activan las \nplaquetas y los leucocitos.  \nHomociste\u00edna y trombog\u00e9nesis \nLa acumulaci\u00f3n de homociste\u00edna altera el mecanismo \nantitromb\u00f3tico del endotelio, ya que aumenta la actividad del Factor \nXII69 y del factor V70, y disminuye la actividad de la proteina C71. \nTambi\u00e9n inhibe la trombomodulina72, dando lugar al aumento del \nfactor tisular73 y suprimiendo la expres i\u00f3n del heparinin-sulfato74 por el  \n \n \n  \n27endotelio vascular. Todos estos efectos favorecen la formaci\u00f3n de \ntrombina y crean un medio pretromb\u00f3g\u00e9nico (Tabla 4). \nHomociste\u00edna y \u00f3xido n\u00edtrico \nLa identificaci\u00f3n del \u00f3xido n\u00edtric o (ON) como el factor relajante \ndel endotelio75, por lo cual Furchgott, Ig narro y Murad obtuvieron el \nPremio Nobel de Medicina en 1998, le ha conferido una nueva dimensi\u00f3n al estudio del proceso ater oscler\u00f3tico. La menor presencia de \nON est\u00e1 considerada como un marc ador temprano de la patolog\u00eda \ncardiovascular y los avances en la investigaci\u00f3n ponen de manifiesto \nque la mayor\u00eda de los factores de riesgo est\u00e1n asociados a ella. De \nhecho, Tawakol y col.\n18 en un estudio realizado in vivo observaron que \nla vasodilataci\u00f3n endotelia l mediada por el ON estaba \nsignificativamente reducida en los casos de hiperhomocisteinemia de aterescler\u00f3ticos frente a controles.  Como posible mecanismo proponen \nque la homociste\u00edna disminuye la biodisponibilidad del ON, bien \nreduciendo su s\u00edntesis o aumentando  su degradaci\u00f3n. Recientemente, \nChao y col.\n76 han confirmado que la disfunci\u00f3n endotelial causada por \nla hiperhomocisteinemia va ligada a una menor actividad del ON y llegan incluso a cuestionanar la hip\u00f3 tesis de la v\u00eda del mecanismo del \nstress oxidativo. Upchurch y col.\n77 en un estudio in vitro observaron \nuna reducci\u00f3n dosis-dependiente de ON, sugiriendo que la \nhomociste\u00edna reduce su biodisponibilidad al reducir la actividad de la glutation peroxidasa, no pudiendo la c\u00e9lula inactivar el H\n2O2 y \naumentando por tanto la susceptibilidad del ON frente a la inactivaci\u00f3n oxidativa. Esto enlaza con la hi p\u00f3tesis expresada recientemente por \nalgunos autores, que consideran que el  papel de la homociste\u00edna es el \nde potenciar otros factores de riesgo que participan en la etiolog\u00eda de la \naterosclerosis\n78. \n \nTratamiento de la hiperhomocisteinemia \nLa suplementaci\u00f3n con las vitaminas implicadas en el \nm e t a b o l i s m o  d e  l a  h o m o c i s t e \u00ed n a  s e  h a  d e m o s t r a d o  e f i c a z  e n  l a  \nreducci\u00f3n de sus niveles plasm\u00e1ticos. En sujetos omn\u00edvoros, la vitamina \nque, ingerida de manera aislada, re sulta m\u00e1s eficaz en reducir los \nniveles de homociste\u00edna es el fola to. No obstante, la combinaci\u00f3n de \nfolato, B 12 y B 6 resulta m\u00e1s efectiva79. Tanto en estudios in vivo80,81 como \nin vitro81,82, la suplementaci\u00f3n con \u00e1cido f\u00f3lico mejor\u00f3 la funci\u00f3n  \n \n \n  \n28endotelial, probablemente mejorando la biodisponibilidad del ON. La \nsuplementaci\u00f3n con vitamina B 12 redujo significativamente los niveles \nplasm\u00e1ticos de homocisteina (12.4 \u00b1 4.7 a 7.9 \u00b1 3.1 \u00b5mol/l; p<0.001) en \nvegetarianos36. Seg\u00fan estos autores, hay que seguir investigando si esta \nsuplementaci\u00f3n mejora la menor morbi-mortalidad cardiovascular asociada a las dietas vegetarianas. \nHay que tener en cuenta, que en las personas mayores con \ngastritis atr\u00f3fica, se consigue una mayor reducci\u00f3n de los niveles de tHcy con la suplementaci\u00f3n de vitamina B\n12. \nEn la actualidad hay diversos estudios de intervenci\u00f3n en \nmarcha (SEARCH, WACS, CHAOS II, NORVIT, VITATOPS, VISP), con el fin de investigar si la suplementaci\u00f3n con f\u00f3lico, B\n6 y B 12 no reduce \n\u00fanicamente los niveles plasm\u00e1ticos de tHcy, sino tambi\u00e9n la frecuencia de enfermedades ateroscler\u00f3ticas. Algunos de estos estudios pueden \ntener menor significancia de la es perada debido al enriquecimiento \nobligatorio de harinas y cereales qu e desde el 1 de enero de 1998 se \nviene realizando en EEUU y Canad\u00e1, tal y como expresan algunos autores\n83,84.  \n \nPrevenci\u00f3n de la hiperhomocisteinemia \nLa prevenci\u00f3n de la hiperhomocisteinemia va ligada al \nmantenimiento de un \u00f3ptimo esta do vitam\u00ednico. Este se puede \nconseguir adoptando las siguientes medidas: \na) Mayor ingesta de alimentos ricos en folato , como verduras de hoja \nverde, pl\u00e1tanos, mangos, pistachos. No se debe olvidar la labilidad de la vitamina que requiere un almacenamiento, cocinado y \nmantenimiento correcto de los alimentos, ya que se puede perder hasta \nel 100% de su contenido\n85. \nb) Enriquecimiento de alimentos . Como ya se ha indicado, desde el \n1 de enero de 1998, en EEUU se enriqu ecen los cereales y derivados con \n140 \u00b5g de \u00e1cido f\u00f3lico/100 g. Los primeros  datos publicados al respecto, \nindican que con esta medida se increm entan los niveles de folato en un \n30%, pero que s\u00f3lo se reducen los de  homociste\u00edna en un 3 a 7%. En \ncambio, los cereales enriquecidos con 400 \u00b5g de \u00e1cido f\u00f3lico/100 g \nreducen los niveles de homociste\u00edna en un 11%86. Esto sugiere que el \nenriquecimiento con mayores niveles puede ser recomendado como \u00f3ptimo. En la cohorte del F ramingham Offspring estudiada  \n \n \n  \n29recientemente por Jacques y col.24 despu\u00e9s del enriquecimiento \nobligatorio citado, se ha observad o una reducci\u00f3n significativa (p< \n0.001) de la prevalencia de niveles elevados de homociste\u00edna, \ndisminuyendo \u00e9stos a la mitad. \nc) Suplementaci\u00f3n vitam\u00ednica . Diversos estudios han puesto de \nmanifiesto, que las personas que co nsumen regularmente suplementos \nde vitaminas del grupo B presentan menores concentraciones de homociste\u00edna que las personas qu e no consumen ning\u00fan suplemento\n24. \nPrestigiosos investigadores87 han propuesto que debido a la elevada \nprevalencia (al menos un tercio) de  deficiencia vitam\u00ednica en las \npersonas mayores, este grupo de poblaci\u00f3n deber\u00eda suplementarse de \nrutina. Por tanto, en relaci\u00f3n con esta patolog\u00eda que comparte factores \nde riesgo con los accidentes cerebrovasculares, tambi\u00e9n hay que considerar la oportunidad de esta medida. Un potencial riesgo de la suplementaci\u00f3n s\u00f3lo con \u00e1cido f\u00f3lico es el da\u00f1o neurol\u00f3gico progresivo \nen pacientes con d\u00e9ficits subcl\u00ednicos de B\n12, donde el tratamiento con \n\u00e1cido f\u00f3lico puede enmascarar el desarrollo de las manifestaciones hematol\u00f3gicas de la misma. Una de las l\u00edneas de investigaci\u00f3n \nactualmente en desarrollo por parte de nuestro grupo trata, precisamente, de dilucidar esta problem\u00e1tica. \n Conclusiones \nLa investigaci\u00f3n en torno a la implicaci\u00f3n de la homociste\u00edna en \nla etiolog\u00eda de la enfermedad c ardiovascular atraviesa un momento \nimportante ya que, a pesar de las numerosas evidencias epidemiol\u00f3gicas que apuntan en es te sentido, no se ha podido \ndemostrar hasta la fecha una relaci\u00f3n inequ\u00edvoca de causalidad \nmediante estudios de intervenci\u00f3n bien controlados. Igualmente, es \nnecesario profundizar en el estudio de los mecanismos mediante los cuales la hiperhomocisteinemia cont ribuye a la disfunci\u00f3n endotelial. \nNo obstante, los datos de los que se dispone actualmente parecen indicar que los niveles elevados de homociste\u00edna son algo m\u00e1s que un \nmarcador de la enfermedad cardiovascular estando per se  implicados, \nde alguna forma, en el desarrollo de l proceso aterog\u00e9nico. Se sabe que \nniveles elevados de homociste\u00edna se producen como consecuencia de d\u00e9ficits subcl\u00ednicos de las diversas vitaminas que intervienen en su metabolismo (folato, vitamina B\n12 y vitamina B 6). La administraci\u00f3n de \nestas vitaminas consigue reducir la hiperhomocisteinemia. Debido al  \n \n \n  \n30progresivo envejecimiento de la poblaci\u00f3n en los pa\u00edses occidentales y a \nla elevada prevalencia de deficiencias subcl\u00ednicas de vitaminas en la poblaci\u00f3n anciana, parece indicado su plementar de rutina a este grupo \nde poblaci\u00f3n. No obstante, habr\u00e1 que esperar los resultados de los \nestudios prospectivos de intervenci\u00f3n actualmente en curso, tanto en Europa como en EEUU y Canad\u00e1, para poder adoptar medidas basadas en una s\u00f3lida evidencia. \n  \n \n \n  \n31Bibliograf\u00eda  \n \n1.-Gerritsenn T, Vaughan JG, Waisman HA. The identification of \nhomocysteine in the urine. Bi ochem BioPhys Res Commun. 1962;9:493-\n496. \n2.-Mudd SH, Finkelstein JD, Irreverre F, Laster L. Homocystinuria: an \nenzymatic defect. Science 1964;143:1443-1445. \n3.-Mc Cully KS. Vascular pathology of homocysteinemia: implications \nfor the pathogenesis of arterio sclerosis. Am J Pathol 1969; 56:111-28. \n4.-Kang SS, Wong PW, Malinow MR. Hyperhomocysteinemia as a risk \nfactor for occlusive vascular disease. Ann Rev Nutr 1992;12:279-98. \n5.-Jacobsen DW, Gatautis VJ, Green R,  Robinson K, Savon SR, Secic M, \nJi J, Otto JM, Taylor LM Jr. Rapid HPLC determination of total homocysteine and other thiols in se rum and plasma: sex differences and \ncorrelation with cobalamin and folate concentrations in healthy subjects. Clin Chem. 1994 Jun;40(6):873-81.  \n6.-Pietrzik K, Br\u00f6nstrup A. Folate in preventive medicine: a new role in \ncardiovascular disease, neural tube  defects, and cancer. Ann Nutr \nMetab 1997;41:331-343. \n7.-Mudd SH, Skovby F, Levy HL, Pettigrew KD, Wilcken B, Pyeritz RE, \nAndria G, Boers GHJ, Bromberg IL, Cerone R, Fowler B, Gr\u00f6be H, \nSchmidt H, Schweitzer L. The natural history of homocystinuria due to \ncystathionine beta-synthase de ficiency. Am J Hum Genet 1985;37:1-31. \n8.-Finkelstein JD. Methionine metabolism in mammals. J Nutr Biochem \n1990;1:228-37. \n9.-Kraus JP, Janosik M, Kozich V, y col. Cystathionine beta-synthase \nmutations in homocystinuria. Hum Mutat 1999;13(5):362-375. \n10.-Kang SS, Zhou J, Wong PWK,  Kowalisyn J, Strokosch G. \nIntermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate re ductase. Am J Hum Genet 1988;43:414-421. \n11.-Blom HJ, Kleinveld HA, Boers GH , et al. Lipid peroxidation and \nsusceptibility of low density lipopr otein to in vitro oxidation in \nhiperhomocysteinaemia.. Eur J Clin Invest 1995;25:149-54. \n12.-Welch GN, Loscalzo J. Homocysteine and atherothrombosis. New \nEngl J Med 1998;338:1042-1050.  \n \n \n  \n3213.-Van der Put NMJ, Gabre\u00ebls F, Stevens EMB, Smeitink JAM, Trijbels \nFJM, Eskes TKAB, van den Heuvel LP, Blom HJ. A second common mutation in the methylentetrahydrofolate reductase gene: an additional \nrisk factor for neural tube defects?. Am J Hum Genet 1998;62:1044-1051. \n14.-Leclerc D, Campeau E, Goyette P, y col. Human methionine \nsynthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. Hum Mol Genet 1996;5(12):1867-74. \n15.-Gaughan DJ, Kluijtmans LAJ, B arbaux S, McMaster D, Young IS, \nYarnell JWG, Evans A, Whitehead AS. The methionine synthase \nreductase (MTRR) A66G polymorphism  is a novel genetic determinant \nof plasma homocysteine conc entrations. Atherosclerosis 2001;157:451-\n456. \n16.-Heil SG, Lievers KJ, Boers GH, Verhoe f P, den Heijer M, Trijbels FJ, \nBlom HJ. Betaine-homocysteine methyltransferase (BHMT): genomic \nsequencing and relevance to hy perhomocysteinemia and vascular \ndisease in humans. Mol Genet Metab 2000;71(3):511-9. \n17.-Guttormsen AB, Solheim E, Ueland PM and Refsum H. Quantitation \nof total homocysteine, total cyst eine and cystathionine in human \nplasma and serum by gas chromatography-mass spectrometry (GC-\nMS). Neth J Med 1998;52:539-540. \n18.-Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA. \nHyperhomocysteinemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997;95:1119-1121. \n19.-Selhub J, Jacques PF,Bostom AG, Wilson PW, Rosenberg IH. \nRelationship between plasma homocy steine and vitamin status in the \nFramingham study population. Impact of  folic acid fortification. Public \nHealth Rev 2000;28(1-4):117-45. \n20.-Koehler KM, Baumgartner RN, G arry PJ, Allen RH, Stabler SP, \nRimm EB. Association of folate intake and serum homocysteine in elderly persons according to vitami n supplementation and alcohol use. \nAm J Clin Nutr 2001;73:628-637. \n21.-Boushey CJ, Beresford SAA,  Omenn GS, Motulsky AG. A \nquantitative assessment of plasma homocysteine as a risk factor for \ncardiovascular disease. JAMA 1995;274:1049-1057.  \n \n \n  \n3322.-Morrison HI, Schaubel D, Desmeu les M, Wigle DT. Serum folate \nand risk of fatal coronary he art disease. JAMA. 1996;275(24):1893-6. \n23.-Verhoef P, Stampfer MJ, Rimm EB. Folate and coronary heart \ndisease. Curr Opin Lipidol 1998;9(1):17-22.  \n24.-Jacques PF, Bostom AG, Wilson PWF, Rich S, Rosenberg IH, Selhub \nJ. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am J Clin Nutr 2001;73:613-621. \n25.-Israelsson B, Brattstrom LE, Hultberg BL. Homocysteine and \nmyocardial infaction. Atherosclerosis 1988;71:227-233. \n26.-Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin \nstatus and intake as primary determ inants of homocysteinemia in an \nelderly population. JAMA 1993;270:2693-8. \n27.-Verhoef  P, Stampfer MJ, Buring JE, Gaziano JM, Allen RH, Stabler \nSP, Reynolds RD, Kok FJ, Hennekens CH, Willet WC. Homocysteine metabolism and risk of myocardial infarction \u2013 relation with vitamin \nB6, vitamin B\n12, and folate. Am J Epidemiol 1996;143:845-859. \n28.-McKinley MC. Nutritional aspe cts and possible pathological \nmechanisms of hyperhomocysteinemi a: an independent risk factor for \nvascular disease. Proc Nutr Soc 2000;59:221-237. \n29.-Hustad S, Ueland PM, Vollset SE, Zhang Y, Bjorke-Monsen AL, \nSchneede J. Riboflavin as a determin ant of plasma total homocysteine: \neffect modification by the methyl enetetrahydrofolate reductase C677T \npolymorphism. Clinical Chem 2000;46:1065-1071. \n30.-Van Asselt DZ, de Groot LC, van Staveren WA, Blom HJ, Wevers \nRA, Biemond I, Hoefnagels WH. Role of cobalamin intake and atrophic gastritis in mild cobalamin deficiency  in older Dutch su bjects. Am J Clin \nNutr 1998;68(2):328-34. \n31.-Ventura P, Cagnacci A, Malmusi S, Panini R, Baldassari F, Arangino \nS, Volpe A, Salvioli G. Continuo us combined hormone replacement \ntherapy with oral 17beta-estradiol an d norethisterone acetate improves \nhomocysteine metabolism in postmenopausal women. Menopause 2001;8(4):252-8. \n32.-Morris MS, Jacques PF, Selhub J, Rosenberg IH. Total homocysteine \nand estrogen status indicators in  the Third National Health and \nNutrition Examination Survey. Am J Epidemiol 2000;152(2):140-8.  \n \n \n  \n3433.-Mann NJ, Li D, Sinclair AJ, et al . The effect of diet on plasma \nhomocysteine concentrations in heal thy male subjects. Eur J Clin Nutr \n1999; 53(11):895-9. \n34.-Krajcovicova-Kudlackova M, Blazicek P, Kopcova J, Bederova A, \nBabinska K. Homocysteine levels in  vegetarians versus omnivores. Ann \nNutr Metab 2000;44(3):135-8. \n35.-Refsum H, Yajnik CS, Gadkari M, Schneede J, Vollset SE, Orning L, \nGuttormsen AB, Joglekar A, Sayyad MG, Ulvik A, Ueland PM. Hyperhomocysteinemia and elevated methylmalonic acid indicate a \nhigh prevalence of cobalamin deficiency in Asian Indians. Am J Clin \nNutr 2001;74(2):233-41. \n36.-Mezzano D, Munoz X, Martinez C, et al. Vegetarians and \ncardiovascular risk factors: hemostasis, inflammatory markers and plasma homocysteine. Thromb Haemost 1999;81(6):913-7. \n37.-Halsted CH. Lifestyle effects on  homocysteine and an alcohol \nparadox. Am J Clin Nutr 2001;73:501-2. \n38.-Cravo ML, Gloria LM, Selhub J,  Nadeau MR, Camilo ME, Resende \nMP, Cardoso JN, Leitao CN, Mira FC. Hiperhomocisteinemia in chronic alcoholism: correlation with folate, vitamin B\n12 and vitamin B 6 status. \nAm J Clin Nutr 1996;63:220-224. \n39.-van der Gag MS, Ubbink JB, Sillanaukee P, Nikkari S, Hendriks HF. \n2000Effect of consumption of red wi ne, spirits, and beer on serum \nhomocysteine. Lancet. 2000;355(9214):1522.  \n40.-Nygard O, Nordrehaug JE, Refs um H, Ueland PM, Farstad M, \nVollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997;337:230-236.  \n41.-Chen TS, Lui CKF, Smith CH. Folacin content of tea. J Am Diet \nAssoc 1983;82:627-32. \n42.-Nakazawa Y, Chiba K, Imatoh N, Kotorii T, Sakamoto T, Ishizaki T. \nSerum folic acid levels and antipyri ne clearance rates in smokers and \nnon-smokers. Drug Alcohol Depend 1983;11:201-207. \n43.-Ubbink JB, van der Merwc A, De lport A, et al. The effect of \nsubnormal B\n6 status on homocysteine metabolism. J Clin Invest \n1996;98:177-84.   \n \n \n  \n3544.-Vermaak WJ, Ubbink JB, Barnard HC, Potgieter GM, Jaarsveld H, \nGroenewald AJ. Vitamin B 6 nutrition status and cigarette smoking. Am \nJ Clin Nutr 1990;51:1058-61. \n45.-Ortega RM, Marzana I, Gonzal ez-Gross M, Redondo R, L\u00f3pez-\nSobaler A, Andr\u00e9s P, Zamora MJ. Influence of Smoking on Folate Intake and Blood Folate Concentrations in  a Group of Elderly Spanish Men. \nAm Coll Nutr 1994,13(1):68-72. \n46.-Vollset SE, Refsum H, Ueland PM. Population determinants of \nhomocysteine. Am J Clin Nutr 2001a;73:499-500. \n47.-Araki A, Sako Y. Determination of free and total homocysteine in \nhuman plasma by high performance liquid cromatography with fluorescence detection. J Cromatogr 1987;422:43-52. \n48.-Shipchandler MT, Moore EG. Rapi d, fully automated measurament \nof plasma homocysteine with th e Abbot Imx analyzer. Clin Chem \n1995;41:991-4. \n49.-Willens HP, Bos GM, Gerrits WB, den Heijer M, Vloet S, Blom HJ. \nAcidic citrate stabilizes blood sample s for assay of total homocysteine, \nClin Chem 1998;44:342-5. \n50.-Vester B, Rasmussen K. High performance liquid cromatography \nmethod for rapid and accurate determination of homocysteine in \nplasma and serum. Eur J Clin Chem. Clin Biochem 1991;29:549-554. \n51.-Bolander-Gouaille C. Focus on homocysteine. Springer-Verlag \nFrance. Paris. 2001. \n52.-Arnesen E, Refsum H, Bonaa KH, Ueland PM, Forde OH, \nNordrehaug JE. Serum total homocysteine and coronary heart disease. Int J Epidemiol 1995;24:704-9. \n53.-Wald NJ, Watt HC, Law MR, Weir DG, McPartlin J, Scott JM. \nHomocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch Intern Med 1998;158:862-867. \n54.-Bots ML, Launer LJ, Lindemans J, Hoes AW, Hofman A, Witteman \nJCM, Koudstaal PJ, Grobbe DE. Homocysteine and short-term risk of \nmyocardial infarction and stroke in the eldery. Arch Intern Med \n1999;159:38-44.  \n \n \n  \n3655.-Whincup PH, Refsum H, Perry IJ, Morris R, Walker M, Lennon L, \nThomson A, Ueland PM, Ebrahim SB. Serum total homocysteine and coronary heart disease: prospectiv e study in middle aged men. Heart. \n1999;82(4):448-54.  \n56.-Knet P, Reunanen A, Alfthan G, Heliovaara M, Rissanen H, \nMarniemi J, Aromaa A. Hyperhomoc ysteinemia: a risk factor or a \nconsequence of coronary heart  disease? Arch Intern Med \n2001;161(13):1589-94. \n57.-Folsom AR, Nieto J, McGovern PG , Tsai MY, Malinow MR, Eckfeldt \nJH, Hess DL, Davis CE. Prospective study of coronary heart disease \nincidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: The atherosclerosis risk in communitie (ARIC) study. Circulation 1998;98:204-210. \n58.-Evans RW, Shaten J, Hempel JD, Cutler JA, Kuller LH. \nHomocysteine and risk of cardiovascu lar disease in the multiple risk \nfactor intervention trial. Arteriol Thromb Vasc Biol 1997;17:1947-1953. \n59.-Ubbink JB, Fehily AM, Picker ing J, Elwood PC, Vermaak WJ. \nHomocysteine and ischaemic heart disease in the Caerphilly cohort. Atherosclerosis 1998;140(2):349-56.  \n60.-Fallon UB, Ben-Shlomo Y, Elwood  P, Ubbink JB, Davey Smith G. \nHomocysteine and coronary heart disease in the Caerphilly cohort: a 10 \nyear follow up. Heart 2001; 85:153-158. \n61.-Brattstrom L, Wilcken DE. Homocysteine and cardiovascular \ndisease: cause or effect ? Am J Clin Nutr 2000;72(2):315-23. \n62.-Mujumdar VS, Hayden MR, Tyagi SC. Homocyst(e)ine induces \ncalcium second messenger in va scular smooth muscle cells. J Cell \nPhysiol. 2000 Apr;183(1):28-36. \n63.-Voutilainen S, Alfthan G, Nyssonen K, Salonen R, Salonen JT. \nAssociation between elevated plasma  total homocysteine and increased \ncommon carotid artery wall thickness. Ann Med 1998;30:300-306. \n64.-Aronow WS, Ahn C. Increased plasma homocysteine is an \nindependent predictor of new coron ary events in older persons. Am J \nCardiol 2000;86:346-347.  \n \n \n  \n3765.-Vollset SE, Refsum H, Tverdal A, Nygard O, Nordrehaug JE, Tell \nGS, Ueland PM. Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Ho rdaland Study. Am J Clin Nutr \n2001b;74(1): 130-136. \n66.-Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced \nendothelial cell injury in vitro: a mo del for the study of vascular injury. \nThromb Res 1980;18:113-121. \n67.-Starkebaum G, Harlan JM. Endoth elial cell injury due to copper-\ncatalyzed hydrogen peroxide gene ration from homocysteine. J Clin \nInvest 1986;77:1370-6. \n68.-Harker LA, Sliclner SJ, Scott CR, Ross R. Homocysteine: vascular \ninjury and arterial thombosis. N Engl J Med 1974;291:537-43. \n69.-Ratnoff OD. Activation of Hageman factor by L-homocysteine, \nScience 1968;162:1007-9. \n70.-Rodgers GM, Kane WH. Activation of endogenous factor V by a \nhomocysteine induced vascular endoth elial cell activator: J Clin Invest \n1986;77:1909-16. \n71.-Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, \nreduces protein C activation by art erial and venous endothelial cells. \nBlood 1990;75:895-901. \n72.-Lentz SR, Sadler JE. Inhibition of thrombomodulin surface \nexpression and protein C activati on by the thrombogenic agent \nhomocysteine. J Clin Invest 1991;88:1906-14. \n73.-Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM, \nHomocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor  activity in endothelial cells. \nArterioscler Thromb 1993;13:1327-33. \n74.-Nissinaga 1993 Nishinaga M, Ozawa T, Shintada K. Homocysteine, \na thrombogenic agent, suppresses anticoagulant heparan sulfate expression in cultured porcinic aortic endothelial cells. J Clin Invest 1993:92:1381-6. \n75.-Chao CL, Kuo TL, Lee YT. Effects of methionine-induced \nhyperhomocysteinemia on endothelium-dependent vasodilation and \noxidative status in healthy adults. Circulation 2000;101(5):485-90.  \n \n \n  \n3876.-Upchurch GR Jr, Welch GN, Fabian AJ, et al. Homocysteine \ndecreases bioavailable nitric oxide by a mechanism involving glutatione peroxidase. J Biol Chem 1997;272:17012-7. \n77.-Ueland PM, Refsum H, Beresford SAA, Vollset SE. The controversy \nover homocysteine and cardiova scular risk. Am J Clin Nutr 2000;72:324-\n32. \n78.-Br\u00f6nstrup A, Hages M, Pietrzi k K. Lowering of homocysteine \nconcentrations in elderly men and women. Int J Vitam Nutr Res 1999;69(3):187-193. \n79.-Title LM, Cummings PM, Giddens K, Genest JJ Jr, Nassar BA. Effect \nof folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. J Am Coll Cardiol 2000;36(3):758-\n65. \n80.-Verhaar MC, Wever RMF, Kastelein JJP, van Dam T, Koomans HA, \nRabelink TJ. 5-methyltetrahydrofolte, the active form of folic acid, \nrestores endothelial function in familial hypercholesterolemia. \nCirculation 1998;97:237-241. \n81.-Zhang X, Li H, Jin H, Ebin Z, Brodsky S, Goligorsky MS. Effects of \nhomocysteine on endothelial nitr ic oxide production. Am J Physiol \nRenal Physiol 2000;279(4):F671-8. \n82.-Bostom AG, Selhub J, Jacques PF, Rosenberg IH. Power shortage: \nclinical trials testing the \u201chom ocysteine hypothesis\u201d against a \nbackground of folic acid-fortified cereal grain flour. Ann Intern Med \n2001;135(2):133-7. \n83.-Blacher J, Safar ME. Homocystei ne, folic acid, B vitamins and \ncardiovascular risk. J Nutr Health Aging 2001;5(3):196-199. \n84.-B\u00e4ssler KH, Golly I, Loew K, Pietrzik K. Vitamin-Lexikon. \nFrankfurt-Main: Govi Verlag, 1997. \n85.-Malinow MR, Duell PB, Hess DL, Anderson PH, Kruger WD, \nPhillipson BE, Gluckman RA, Block PC, Upson BM. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary  heart disease. N Engl J Med \n1998;338(15):1009-1015. \n86.-Chandra RK. Nutrition and immunity in the elderly. Nutr Rev \n1992;50(12):367-71.  \n \n \n  \n39 \nFigura 1 . Metabolismo de la homociste\u00edna \n \n        Prote\u00ednas de la dieta        Prote\u00ednas end\u00f3genas \n \n                               \n     \nC\u03b2S.  Cistationina Beta Sintetasa \n     M S .   M e t i o n i n a  S i n t e t a s a  \n     B H M T .   B e t a \u00ed n a  H o m o c i s t e \u00ed n a  Metiltransferasa      5,10 MTHFR 5,10 Metil Tetrahidrofolato Reductasa      Metil THF Metil Tetrahidrofolato      5,10 MTHF 5,10 Metilentetrahidrofolato \n     A H   A d e n o s i l  H o m o c i s t e i n a s a  \n     C \u03b2L  Cistationina Beta Liasa METIONINA \ns-adenosil-metionina \ns-adenosil-homocisteina \nHOMOCISTEINA ATP \nB12 \nMSGrupo metilo \nadenosina \ncistationina \nciste\u00edna B6 \nC\u03b2S serina \nB6 \n\u03b1-cetobutirato \nV\u00eda de la transulfuraci\u00f3n   BHMT Beta\u00edna \nV\u00eda de la remetilaci\u00f3n Tetrahidrofolato \nMetil THF 5,10 MTHF \n5,10 MTHFR AH\nC\u03b2LB \n \n \n  \n40 \n \n  \n \n  \n \n   \nTabla 1 . Patolog\u00edas ligadas a hiperhomocisteinemia \n  \nEnfermedad gastrointestinal: \nGastrectomizados, resecciones intestinales Gastritis atr\u00f3fica \nEnteropat\u00eda inducida por gluten \nEnfermedad de Crohn \nNutrici\u00f3n Inadecuada: \nVegetarianos estrictos \nOvolactovegetarianos \nEnfermedades autoinmunes: \nArtritis reumatoide \nLupus eritematoso \nDiabetes \nHipotiroidismo Psoriasis \nInsuficiencia renal Enfermedades cardiovasculares \n  \n \n \n  \n41 \n   \n \n \n \nTabla 2 . Manifestaciones cl\u00ednicas que pueden estar ligadas a hiperhomocisteinemia \n \n \n \n \nAstenia P\u00e9rdida de peso  S\u00edntomas neurol\u00f3gicos  y psiqui\u00e1tricos: \nV\u00e9rtigos P\u00e9rdida de memoria \nParestesias de miembros \nAtaxia Disminuci\u00f3n de reflejos Confusi\u00f3n Irritabilidad Dificultad de concentraci\u00f3n \nDisminuci\u00f3n de la memoria \nDemencia Depresi\u00f3n S\u00edndrome de fatiga cr\u00f3nica Fibromialgia \nAstenia P\u00e9rdida de peso \nS\u00edntomas de anemia \nApat\u00eda Disnea de esfuerzo Cansancio \nLuxaci\u00f3n del cristalino Reacciones adversas a la anestesia: \u00f3xido nitroso  \nTrombosis espont\u00e1nea \nComplicaciones en embarazos \n  \n \n \n  \n42 \n \n  \n \n \n \n \nTabla 3.  Hiperhomocisteinemia cong\u00e9nita \n \n \n \nALTERACI\u00d3N \nENZIM\u00c1TICA REACCI\u00d3N ENZIM\u00c1TICA \nAFECTADA ALTERACI\u00d3N \nANAL\u00cdTICA \nC\u03b2S Homociste\u00edna \u2192Cistationina \u2191 Homociste\u00edna \n\u2191 Metionina \nMTHFR Metilen THF \u2192Metil THF \u2191 Homociste\u00edna \n\u2191Metionina \n\u2193Folato \nMTHFR Termol\u00e1bil Metilen THF \u2192Metil THF \u2191 Homociste\u00edna \n\u2193 Folato \nFactor Intr\u00ednseco Absorci\u00f3n de B 12 \u2191Homociste\u00edna \n\u2193 B12 \nTranscobalamina II Transporte de B 12 \u2191 Homociste\u00edna \n\u2193 Folato \nCb1 C y D Cb1(II) \u2192Cb1(III) \u2193 B12 \n\u2191Homociste\u00edna \n\u2193 Folato \nCb1 F Salida de Cb1 de los lisosomas  \nCb1 E y G Homociste\u00edna \u2192Metionina \u2191Homociste\u00edna \n \n \n \n  \n \n \n  \n43Tabla 4 . Indicaciones para la anal\u00edtica de la homociste\u00edna plasm\u00e1tica \nFACTORES GEN\u00c9TICOS Homociste\u00edna* \nHomocigotos para la CBS \nHeterocigotos para la CBS \nHomocigotos para la MTHFR \nHeterocigotos para la MTHFR Mutaciones C, D, E, F y G de la Cobalamina MTHFR Termol\u00e1bil \u2191\u2191\u2191 \n\u2191 \n\u2191\u2191\u2191 \n\u2191 \n\u2191\u2191\u2191 \n\u2191 \nFACTORES FISIOL\u00d3GICOS  \nEdad \nSexo. Mujeres postmenop\u00e1usicas  \nDisminuci\u00f3n de la funci\u00f3n renal \nObesidad \u2191 \n\u2191 \n\u2191 \n\u2191 \nESTILO DE VIDA  \nTabaco \nCaf\u00e9 Alcohol \u2191 \n\u2191 \n\u2191 \nFACTORES CL\u00cdNICOS  \nD\u00e9ficit de folatos \nD\u00e9ficit de B 12 \nD\u00e9ficit de B 6 \nFallo renal S\u00edndromes linfoproliferativos Hipotiroidismo Enfermedad cardiovascular \u2191\u2191 \n\u2191\u2191\u2191 \n\u2191 \n\u2191\u2191 \n\u2191 \n\u2191 \n\u2191\u2191 \nINGESTA DE MEDICAMENTOS  \nAntagonistas del folato: \nMetotrexato Fenotiazinas Antidepresivos tric\u00edclicos Anticonceptivos orales Tuberculost\u00e1ticos Trimetropin \nAntiepil\u00e9pticos:  \n(Fenitiona, fenobarbital, primidona,  carbamazepina, \u00e1cido valproico) \nAntagonistas de la B\n12: \nOxido nitroso Antagonistas de la B\n6: \nAzarabina Isoniazida \nCicloserina \nCarbamazepina Teofilina \u2191 \n \n \n      \n\u2191\u2191 \n \n\u2191 \n*\u2191 Aumento leve  \u2191\u2191 Moderado y \u2191\u2191\u2191 grave  de homociste\u00edna, \nCBS= Cistationina-beta-sintetasa MTHFR= Mutilen-tetrahidrofolato reductasa \n \n \n  \n \n \n  \n \n    \n \n     \n \n     \n \n    \n \n     \n \n \n  \n \nEL FOLATO \n  \n \n 45 \nEL FOLATO: UNA VITAMINA EN CONSTANTE EVOLUCI\u00d3N \nMarcela Gonz\u00e1lez-Gross 1,2,4, Ricardo Sola 3, Manuel J. Castillo 4 \nmggross@canal21.com \n1 Institut fuer Ernaehrungswissensch aft. Abt. Pathophysiologie der \nErn\u00e4hrung. Rheinische Friedrich-Wilhelms Universit\u00e4t. D-53115 Bonn. \nAlemania. \n2 Instituto de Nutrici\u00f3n y Brom atolog\u00eda. Consejo Superior de \nInvestigaciones Cient\u00edficas (CSIC). E-28040 Madrid. Espa\u00f1a. \n3 Servicio de Hematolog\u00eda. Hospital Cl\u00ednico Universitario San Cecilio de \nGranada. Espa\u00f1a. \n4 Departamento de Fisiolog\u00eda. Facultad de Medicina. Universidad de \nGranada E-18071 Granada. Espa\u00f1a. \n \n \n \n    \n \nAgradecimientos:\n Los autores agradecemos al Prof. Klaus Pietrzik su \ngenerosa ayuda en la preparaci\u00f3n del manuscrito.  Direcci\u00f3n para la correspondencia\n: \n \nDra. Marcela Gonz\u00e1lez-Gross \nInstituto de Nutrici\u00f3n y Bromatolog\u00eda  Consejo Superior de Investigaciones Cient\u00edficas Edificio Instituto del Fr\u00edo C/ Ramiro de Maeztu, s/n E-28040 Madrid \nTel: +34 91 549 00 38 \nFax: +34 91 549 50 79 Email: mggross@canal21.com\n \n  \n \n 46Introducci\u00f3n: \nLa publicaci\u00f3n de las nuevas ingestas recomendadas de energ\u00eda y \nnutrientes para la poblaci\u00f3n de EEUU y Canad\u00e1, engobladas en el \nnuevo concepto de Dietary Reference Intakes  (DRI)1, ha dado lugar a uno \nde los movimientos cient\u00edficos m\u00e1s im portantes de los \u00faltimos a\u00f1os en \nmateria de nutrici\u00f3n. Por primera ve z, estas recomendaciones no se han \nplanteado \u00fanicamente con el fin de cubrir las necesidades de la poblaci\u00f3n y evitar las carencias cl\u00ednic amente evidentes, sino que se ha \nevaluado para cada nutriente el posible potencial de beneficio que una \ndeterminada ingesta puede suponer para la salud. En el caso del folato, \nuna vitamina hidrosoluble englobada dentro del grupo de vitaminas B, las investigaciones realizadas en lo s \u00faltimos a\u00f1os en distintos pa\u00edses, \nhan llevado (tabla 1) a duplicar las ingestas recomendadas para los adultos, pasando de 200 a 400 \u00b5g/d\u00eda\n1. A la espera de actualizar las \ningestas recomendadas de energ\u00eda y nutrientes para la poblaci\u00f3n \nespa\u00f1ola2,3 , parece oportuno revisar las novedades que se han \nproducido recientemente en torno a esta vitamina.  \n \nFolato, folatos y \u00e1cido f\u00f3lico \nEn las nuevas DRI1 se diferencian por primera vez de forma \nexpl\u00edcita los t\u00e9rminos folato ( folate ), folatos alimentarios ( food folate ) y \n\u00e1cido f\u00f3lico ( folic acid ), con el fin de aclarar conceptos y evitar diferentes \ninterpretaciones. El folato  se propone como t\u00e9rmino gen\u00e9rico para esta \nvitamina hidrosoluble, que comprende un grupo de compuestos de estructura qu\u00edmica similar. Estos diferentes folatos pueden estar \npresentes en concentraci\u00f3n variable en los alimentos ( folatos \nalimentarios ). El \u00e1cido f\u00f3lico  (\u00e1cido pteroilmonoglut\u00e1mico, PGA) es la \nforma sint\u00e9tica farmac\u00e9utica de la vitamina, y es la forma que se \nencuentra en los suplementos vi tam\u00ednicos y se emplea en el \nenriquecimiento de alimentos. \nLa mol\u00e9cula de \u00e1cido f\u00f3lico se compone de un anillo de pteridina \nunida por la mitad por medio de un puente de metileno a un \u00e1cido p-aminobenzoico (fig. 1). Al extremo c arboxilo de este radical \u00e1cido se \npueden unir de uno a siete restos de glutamato\n4. Si el compuesto posee \nmas de dos restos glutamato, se trat a de un poliglutamato, si solo posee \nuno se habla de monoglutamato. En los alimentos se encuentran los folatos preferentemente en forma de poliglutamatos. Tambi\u00e9n como mezcla de mono y poliglutamatos, siendo mayor la biodisponibilidad  \n \n 47de los primeros. Adem\u00e1s, los folatos naturales presentan diferentes \ngrados de hidrogenaci\u00f3n del anillo de pteridina (por ejemplo, dehidro y tetrahidrofolato). A esto hay que a\u00f1adir que los \u00e1tomos de nitr\u00f3geno N-\n5 y N-10 pueden captar unidades de \u00e1tomos de carbono (por ejemplo, \nrestos metilo, metileno, formilo y formimino). En consecuencia, el \nt\u00e9rmino folatos engloba una amp lia variedad de compuestos \nemparentados. \nLa biodisponibilidad media de los folatos alimentarios se \nencuentra en torno al 50%, debido  a la necesaria conversi\u00f3n a \nmonoglutamatos previa a su absorci\u00f3n. La del \u00e1cido f\u00f3lico, en cambio, \nes casi del 100%. Con el fin de establecer la biodisponibilidad real de los diversos compuestos, se ha defini do el t\u00e9rmino de \u201cequivalente \ndiet\u00e9tico de folato\u201d ( Dietary folate equivalent , DFE)\n1. El National Institute \nof Health (NIH) americano establece, adem\u00e1s, una diferencia entre la biodisponibilidad del folato seg\u00fan que se est\u00e9 o no en ayunas\n1. Por ser \nel ayuno un factor que determina un a peque\u00f1a influencia (en torno al \n10%), las Sociedades de Nutrici\u00f3n de Alemania, Austria y Suiza proponen en sus ingestas recomendadas conjuntas\n5 no establecer esta \ndiferencia. En base a lo anterior, p arece razonable adoptar los siguientes \nDFE: \n1 \u00b5g DFE = 1 \u00b5g folato alimentario = 0.5 \u00b5g \u00e1cido f\u00f3lico (PGA) \nLos alimentos ricos en folato se citan en la tabla 2.  Algunos \nestudios han puesto de manifiesto que las prote\u00ednas de la leche \u2013 que \ntienen la capacidad de combinarse co n el folato \u2013 aceleran en gran \nmedida la absorci\u00f3n de la vitamina6. \nFisiolog\u00eda del folato en el organismo \nLos folatos de los alimentos, antes de ser absorbidos, son \nhidrolizados de poliglutamatos a monoglutamatos por medio de una conjugasa intestinal, la \u03b3-glutamil-carboxi-peptidasa. El transporte \nactivo de los monoglutamatos a trav\u00e9s de las c\u00e9lulas de la mucosa intestinal a nivel del yeyuno proxim al es pH-dependiente y sigue una \ncin\u00e9tica de saturaci\u00f3n, vi\u00e9ndose esti mulado por la presencia de glucosa \ny Na\n+ con las que se absorbe mediante un mecanismo de co-transporte7. \nAlrededor de un 20-30% del folato se  absorbe mediante difusi\u00f3n pasiva \n(mecanismo no saturable), siendo \u00e9s ta la v\u00eda que act\u00faa preferentemente \ncuando se administran dosis farmacol \u00f3gicas de la vitamina. En sangre, \nse encuentra preferentemente en form a de 5-metil-tetrahidrofolato (5- \n \n 48MTHF), que se une de forma inespec\u00edfica a alb\u00famina, alfa-\nmacroglobulina y transferrina. \nAntes de ser depositados en los tejidos, los monoglutamatos se \nconjugan a poliglutamatos por medio de la enzima folilpoliglutamato-\nsintetasa. Estos poliglutamatos, o bien se almacenan intracelularmente (en mayor proporci\u00f3n en h\u00ed gado), o pasan a \u00e1cido 5,6,7,8 - \ntetrahidrof\u00f3lico (THF), que es la forma activa coenzim\u00e1tica. La homeostasis del folato viene regulada por un ciclo entero-hep\u00e1tico. El adulto sano posee alrededor de 22 mg de folato. La eliminaci\u00f3n urinaria \nes del 10 al 20% del folato absorbido, la eliminaci\u00f3n v\u00eda fecal es \ndespreciable\n7-9. \n \nBioqu\u00edmica del folato en la c\u00e9lula \nEl THF funciona como transporta dor intermediario de unidades \nde un carbono (C 1) en cierto n\u00famero de reacciones enzim\u00e1ticas, \ncaptando los grupos hidroxi-metilo, metileno y formilo y volvi\u00e9ndolos a \nceder. Los distintos compuestos THF-C 1 se diferencian por su grado de \noxidaci\u00f3n. Participan en la s\u00edntesis del DNA y en el metabolismo de los amino\u00e1cidos. En este \u00faltimo caso, su participaci\u00f3n en el ciclo metab\u00f3lico de la metionina le confiere un papel importante en el \nfuncionamiento del sistema nervioso, ya que la S-adenosil-metionina \n(SAM), la forma activa de la metionin a, es el principal dador de grupos \nmetilo para la s\u00edntesis de la colina (fig. 2). Para el \u00f3ptimo funcionamiento de este ciclo metab\u00f3lic o, la homociste\u00edna (tHcy), que es \nun producto intermedio, capta el grupo metilo del folato para pasar de nuevo a metionina (fig. 2). En la s\u00edntes is del DNA, el folato participa en \nvarios pasos. En la s\u00edntesis de pirimidinas, el 5,10-metilen-THF metila el \nd-urilato a timidilato. En la s\u00edntesis de purinas, el 10-formil-THF cede dos \u00e1tomos de carbono en las posiciones C\n2 y C 8 a la estructura anular. \nEl folato, adem\u00e1s, participa en el catabolismo de histidina a \u00e1cido glut\u00e1mico y en la interconversi\u00f3n de serina y glicina. \n \nGen\u00e9tica \nEl estudio de la influencia de los factores gen\u00e9ticos sobre las \nnecesidades nutricionales es un aspe cto muy novedoso, que en el caso \ndel folato adquiere cierta relevanci a. De las enzimas que participan en \nlos diferentes aspectos bioqu\u00edmicos y metab\u00f3licos descritos con  \n \n 49anterioridad, la metil-tetrahidrof\u00f3lico-reductasa (MTHFR) que participa \nen el ciclo metab\u00f3lico de la metionina, presenta dos mutaciones que interfieren en el metabolismo, y por tanto en los niveles de folato. Estas \nmutaciones son las siguientes:  \ng) Polimorfismo C677T de la MTHFR.  Esta mutaci\u00f3n se describi\u00f3 \npor Kang et al en 1988\n10. Los homocigotos para este defecto \nexpresan una variante termol\u00e1bil de esta enzima. La actividad enzim\u00e1tica est\u00e1 reducida comparada con la normalidad. Los niveles plasm\u00e1ticos de folato est\u00e1n ligeramente disminuidos y \npor tanto los de homociste\u00edna elevados (15-20 \u00b5mol/l). Afecta \nalrededor de un 10 - 15% de la poblaci\u00f3n, y en la actualidad existen datos insuficientes sobre su relevancia cl\u00ednica. Los heterocigotos, por el contrario, son m\u00e1s  frecuentes, apareciendo en el 40-45% de la poblaci\u00f3n. Seg\u00fan el estado actual del conocimiento, la variante heterocig\u00f3tica carece de relevancia \ncl\u00ednica\n11,12. Esto es debido a que los de fectos enzim\u00e1ticos de la v\u00eda \nde la remetilaci\u00f3n de la homoci ste\u00edna no provocan incrementos \nen los niveles de homociste\u00edna en ayunas pero s\u00ed tras una sobrecarga importante de la mism a. Esto es necesario tenerlo en \ncuenta a la hora de hacer el te st de sobrecarga con metionina, \nque es el m\u00e9todo empleado para identificar el defecto.  \nh) Polimorfismo A1298 C de la MT HFR. Esta mutaci\u00f3n, menos \nconocida hasta la fecha, se describ i\u00f3 en 1998 por van der Put et al \n13, y da lugar a una menor actividad de la MTHFR. Tanto \nhomocigotos como heterocigotos no presentan mayores niveles de homociste\u00edna, pero parece haber una interacci\u00f3n entre esta \nmutaci\u00f3n y el polimorfismo C677T antes descrito. La \nheterocigocidad  combinada se ha observado en el 20% de la \npoblaci\u00f3n y s\u00ed se asocia a aumento de los niveles de homociste\u00edna\n13. \n \nConsecuencias del d\u00e9ficit cl\u00ednico \nLa deficiencia de folato es probablemente el d\u00e9ficit vitam\u00ednico \nm\u00e1s frecuente7. Puede deberse a un aporte inadecuado, a trastornos en \nla absorci\u00f3n, a factores gen\u00e9ticos, a interacciones con medicamentos o a necesidades aumentadas, tal y como se muestra en la tabla 3. A todo \nello se unen las limitadas reservas en el organismo. La deficiencia mantenida de folato provoca en \u00faltimo extremo anemia megalobl\u00e1stica ,  \n \n 50que se hace manifiesta al cabo de 4 \u00f3 5 meses, debido a una alteraci\u00f3n \nen la maduraci\u00f3n de las c\u00e9lulas de la m\u00e9dula \u00f3sea. Esto se traduce en unos cambios morfol\u00f3gicos, llamados megalobl\u00e1sticos, que afectan a \ntodas las series medulares: granuloc\u00edticas, plaquetaria y eritroide. Es en \nesta \u00faltima donde los cambios se hace n m\u00e1s evidentes. En la deficiencia \nde folato, el fallo est\u00e1 en una s\u00ednt esis inadecuada de ADN, que carece \nde timidilato, que se forma gracias a la enzima timidilato-sintetasa. Esta \nrequiere de la forma bimetilada del folato, el N-5,10-metilen-THF, encargado de convertir el deoxiuridilato-monofosfato en timidilato. \nCuando la forma bimetilada del folato es escasa, el deoxiuridilato-\nmonofosfato y trifosfato se acumulan y se incorporan al ADN por medio de la ADN-polimerasa, que es incapaz de distinguir entre timidilato y deoxiuridilato. El  ADN tendr\u00e1 gran cantidad de \ndeoxiuridilato y esto le impedir\u00e1 funcionar adecuadamente, mostrando \nuna fase de s\u00edntesis mucho m\u00e1s prolongada que en condiciones de \nsuficiencia de folato. Otro mecanism o responsable de la anemia es la \nhem\u00f3lisis intramedular, que se prod uce por la imposibilidad de los \nmacrocitos de abandonar la m\u00e9dula. Estos macrocitos tienen una vida \nmedia muy inferior a los hemat\u00edes normales. Las alteraciones madurativas se traducen en un asincronismo madurativo n\u00facleo-\ncitoplasma, esto es, una maduraci\u00f3n adecuada del citoplasma con \nsuficiente cantidad de hemoglobin a y un retraso en la maduraci\u00f3n \nnuclear. Esto se traduce en una divi si\u00f3n celular lenta, por lo que el \ntama\u00f1o se hace mayor (megalobl\u00e1stico) ocasionando la salida a sangre perif\u00e9rica de gl\u00f3bulos rojos inmaduros con un volumen corpuscular medio (VCM) superior a 100 fl. \nLa serie granuloc\u00edtica tambi\u00e9n se afecta, pudi\u00e9ndose observar en \nla m\u00e9dula \u00f3sea metamielocitos y neutr\u00f3filos en banda gigantes y en sangre perif\u00e9rica neutr\u00f3filos muy segmentados. Los megacariocitos tambi\u00e9n se afectan, apareciendo m\u00e1s inmaduros y segmentados, pudi\u00e9ndose contar 8, 10 o m\u00e1s l\u00f3bulos. Por tanto, en la anemia megalobl\u00e1stica, en sangre perif\u00e9rica observaremos macrocitosis con \npoiquilocitosis, punteado bas\u00f3filo, anillos de Cabot y disminuci\u00f3n del \nn\u00famero de reticulocitos. Respecto a la serie granuloc\u00edtica en sangre \nperif\u00e9rica observamos leucopenia y polisegmentaci\u00f3n neutr\u00f3fila. Puede \nexistir tambi\u00e9n trombopenia moderada\n14. \nDebido a la estrecha interrelaci\u00f3n que existe entre el metabolismo \ndel folato y el de la vitamina B 12, la anemia megalobl\u00e1stica aparece \ncuando existe deficiencia de una o de ambas vitaminas. A veces es  \n \n 51dif\u00edcil la distinci\u00f3n cl\u00ednica entre los dos estados carenciales, siendo \nimprescindible realizar un diagn\u00f3stico preciso de la carencia que se padece antes de administrar una u otra vitamina. De hecho, el \ntratamiento con \u00e1cido f\u00f3lico a pacien tes con d\u00e9ficit de cianocobalamina \nenmascara muchas de las manifestacione s hematol\u00f3gicas de este d\u00e9ficit, \nmanteni\u00e9ndose as\u00ed el deterioro del sistema nervioso lo que puede llegar a ser peligroso \n15  por la irreversibilidad de las lesiones.  \n \nConsecuencias del d\u00e9ficit subcl\u00ednico  \n \nAlteraciones del sistema nervioso central: \nEl THF se encuentra tambi\u00e9n pres ente en el cerebro y en el \nl\u00edquido cefalorraqu\u00eddeo (LCR), donde participa en m\u00faltiples reacciones. Los niveles de folato all\u00ed se regulan por homeostasis mediante la barrera hemato-encef\u00e1lica. La concentraci\u00f3n de  folato en el LCR es de 2 a 3 \nveces superior a la del plasma. La SA M es el principal dador de grupos \nde metilo en 35 reacciones de transmetilaci\u00f3n, entre ellas, la s\u00edntesis de \ncolina y de adrenalina. La colina a su vez participa en la s\u00edntesis de \nacetilcolina, fosfol\u00edpidos y esfingom ielina. La implicaci\u00f3n de las bajas \nconcentraciones de folato en el de terioro cognitivo puede ser debida \ntanto a un mecanismo vascular como a otros de origen no vascular. En el cerebro, est\u00e1 pr\u00e1cticamente inhibi da la transulfuraci\u00f3n que es la v\u00eda \nde eliminaci\u00f3n de tHcy cuando est\u00e1n aumentados sus niveles. Por \ntanto, es m\u00e1s f\u00e1cil la acumulaci\u00f3n de tHcy en el cerebro que en otros tejidos. La homociste\u00edna, adem\u00e1s de  su efecto vascular, compite con los \nreceptores del glutamato, presen tando una afinidad mucho mayor. \nComo es sabido, la sobreexcitaci\u00f3n de  estos receptores tiene un efecto \nneurot\u00f3xico \n \nDefectos del tubo neural\n \nEl d\u00e9ficit de folato en la gestante no produce en ella \nmanifestaciones cl\u00ednicas, pero puede tener graves consecuencias sobre el feto ocasion\u00e1ndole defectos del cierre del tubo neural. Los defectos del tubo neural (NTD) son las prin cipales malformaciones cong\u00e9nitas \ndel sistema nervioso central. Su incidencia en Europa es de 1,47 por \ncada 1000 nacimientos\n13. Son debidos a un fallo total o parcial del cierre \ndel tubo neural. Este cierre comienza alrededor del vig\u00e9simo d\u00eda de  \n \n 52gestaci\u00f3n en al menos tres localizac iones distintas: cerebro posterior, \npros-mesenc\u00e9falo y rostral del prosen c\u00e9falo, y se va extendiendo hasta \ncompletarse. En funci\u00f3n de la localizaci\u00f3n del cierre defectuoso, \ndiferenciamos entre anencefalia, meningomielocele, meningocele y \ncraniorraquisquisis1. La deficiencia de folato ocasiona un doble \nperjuicio sobre este proceso. Por v\u00eda directa, al no poder desarrollarse con normalidad la divisi\u00f3n celular, y por v\u00eda indirecta, v\u00eda homociste\u00edna (tHcy). Diversos estudios han relacionado niveles bajos, pero no deficitarios, de folato s\u00e9rico o plasm\u00e1tico con una mayor prevalencia de \nNTD. El riesgo de NTD disminuye de  una forma casi linear conforme se \naumenta la ingesta de folato de la madre durante la fase periconcepcional (de 100 a 400 \u00b5g/d\u00eda)\n16, tanto de folatos alimentarios 17 \ncomo de suplementos vitam\u00ednicos18. Asimismo, aunque los datos son \nescasos, hay diversos estudios de casos y controles que han encontrado niveles de tHcy superiores en caso de abortos repetidos\n19 y NTD20,21 que \nen controles. \nEn el estudio de Vollset et al.22 realizado en mujeres noruegas, los \nniveles elevados de tHcy se rela cionaron con complicaciones en el \nembarazo y parto. Aunque el mecanism o de acci\u00f3n de la tHcy no est\u00e1 \ndel todo esclarecido23, parece ser que adem\u00e1s de citot\u00f3xico es \nneurot\u00f3xico. Asimismo, las mutaciones gen\u00e9ticas mencionadas \nanteriormente parecen constituir un factor de riesgo adicional. La homocigosidad para la mutaci\u00f3n 677(C \u2192T) de la MTHFR es un factor \nde riesgo para los NTD\n24. Otro estudio realizad o en ni\u00f1os con NTD y \nsus padres demostr\u00f3 que la heterocigosidad combinada para las dos mutaciones de la MTHFR tiene un riesgo similar a la homocigosidad \npara la mutaci\u00f3n 677(C \u2192T) de la MTHFR, y por tanto es un factor de \nriesgo adicional para NTD; en dicho estudio, el riesgo relativo se duplicaba respecto a los controles\n13. \n \nDepresi\u00f3n  \nLa hip\u00f3tesis de la relaci\u00f3n entr e la deficiencia de folato y la \ndepresi\u00f3n tiene sus or\u00edgenes en los estudios cl\u00e1sicos de Herbert14, que \nexperiment\u00f3 personalmente los efecto s de una dieta pobre en folato, \napareciendo al cabo de los 4 mese s modificaciones en las funciones \nmentales y en la conducta. Posteriormente, en el estudio realizado por Shorvon et al.\n25 se observ\u00f3 que el 56% de los pacientes que padec\u00edan \nanemia megalobl\u00e1stica tambi\u00e9n presentaba s\u00edntomas maniaco- \n \n 53depresivos. Estos datos han sido confirmados tanto en pacientes \npsiqui\u00e1tricos26 como no psiqui\u00e1tricos27. Adem\u00e1s del efecto neurot\u00f3xico \nproducido por los niveles elevados de tHcy, la deficiencia de SAM \nenlentece las reacciones de transmetila ci\u00f3n en el SNC, por lo que no se \nsintetizan los neurotransmisores. En pacientes depresivos se han encontrado niveles reducidos de SAM\n28, parece ser debido a que existe \nrelaci\u00f3n entre el metabolismo del folato y el metabolismo de la serotonina. Una de las hip\u00f3tesis apun ta a la tetrahidrobiopterina como \nenlace entre los dos metabolismos\n28. \n \nDemencia senil  \nLa demencia es la principal causa de deterioro cognitivo en el \nanciano. Diversos estudios han puesto de manifiesto, que tanto \npacientes que padecen enfermedad de  Alzheimer como los que padecen \ndemencia vascular, presentan niveles plasm\u00e1ticos bajos de folato y \nvitamina B 12, lo que conduce a niveles elevados de tHcy. Los niveles \nelevados de tHcy han sido propue stos como un factor de riesgo \nindependiente en la demencia vascular29,30, y tambi\u00e9n parecen \nimplicados en la fisiopatolog\u00eda de la demencia tipo Alzheimer31-33. En el \nestudio realizado por Snowdon et al32 en monjas norteamericanas, los \nindicadores neuropatol\u00f3gicos de enfermedad de Alzheimer post-mortem  \nfueron correlacionados con los niveles s\u00e9ricos de folato obtenidos en vida antes del diagn\u00f3stico de la enfermedad, obteni\u00e9ndose correlaciones significativas. En su estudio, Clarke et al.\n31 encontraron \nuna fuerte asociaci\u00f3n negativa entre los niveles de folato s\u00e9rico y el riesgo de padecer la demencia tipo Alzheimer. Esto ha sido confirmado \nrecientemente por el estu dio de Seshadri et al.\n34, en el que los niveles \nelevados de tHcy fueron un factor de  riesgo para el desarrollo posterior \nde la demencia tipo Alzheimer. La re laci\u00f3n de homociste\u00edna con folato \n(tambi\u00e9n con las vitaminas B 6 y B 12) se aproxima al concepto definido \npor Rosenberg y Miller35 de deficiencia subcl\u00ednica de vitaminas y \nfunci\u00f3n neurocognitiva en el ancian o. En la revisi\u00f3n bibliogr\u00e1fica \nrealizada por nosotros36, ya proponemos que los niveles elevados de \ntHcy pueden ser un marcador temprano y sensible de deterioro cognitivo; resultados preliminares de nuestro grupo as\u00ed lo sugieren.  \n  \n \n 54C\u00e1ncer: \nVarias son las hip\u00f3tesis que relaci onan la deficiencia de folato \ncon la carcinog\u00e9nesis. El folato es es encial para la s\u00edntesis, metilaci\u00f3n y \nreparaci\u00f3n del ADN, por lo que se ha sugerido que la metilaci\u00f3n del \nADN es uno de los principales mecanismos que intervienen en la expresi\u00f3n gen\u00e9tica, estabilidad del ADN y sensibilidad a las mutaciones\n37,38. De hecho, se ha observado una modificaci\u00f3n en el \npatr\u00f3n de metilaci\u00f3n del ADN en las c\u00e9lulas tumorales. La hipometilaci\u00f3n, tanto global como localizada, es una de las \ncaracter\u00edsticas observadas en la carcinog\u00e9nesis en humanos\n39,40. Se han \ndescrito asociaciones entre el estado global de metilaci\u00f3n y las etapas \npremalignas en algunos tumores, como son de h\u00edgado, estomago41, \novario42 y cuello uterino43,44. \nLa alteraci\u00f3n en la expresi\u00f3n gen\u00e9tica se ha comprobado por el \naumento del ARNm en algunos protoo ncogenes, c-fos, c-HA-ras, etc. \nSiendo observado como un efecto concomitante de la hipometilaci\u00f3n \ndel ADN45. En ratas, se ha observado una hipometilaci\u00f3n localizada \ndentro del gen supresor del p 53, debi do a la disminuci\u00f3n de los niveles \nplasm\u00e1ticos de folato46. Otra de las hip\u00f3tesis, aunque todav\u00eda menos \nestudiada, es que el 5-10 metilen-THF, por metilaci\u00f3n de un residuo de \nuracilo de la desoxiuridina monofosfato (dUMP) da lugar a dTMP \n(desoxitimidina monofosfato). La de ficiencia de folato conduce a una \nmenor s\u00edntesis de timidina, aumentan do el pool de desoxiuridilato. La \ndisminuci\u00f3n de folato da lugar a un aumento del uracilo en las c\u00e9lulas de la m\u00e9dula \u00f3sea y en los leucocitos perif\u00e9ricos\n38.  \nEl c\u00e1ncer es una enfermedad mu ltifactorial sobre un sustrato \ngen\u00e9tico. Muchos son los estudios epidemiol\u00f3gicos realizados sobre \neste tema; en relaci\u00f3n con el folato , merecen especial consideraci\u00f3n los \nsiguientes: \nC\u00e1ncer de colon y recto :  \nLa primera vez que se relacionaron los niveles de folato con el \nc\u00e1ncer o displasia colorrectal, fue en pacientes con colitis ulcerosa. \nVarios son los mecanismos que prov ocan esta mayor incidencia: la \ndisminuci\u00f3n de la ingesta, la disminuci\u00f3n de la absorci\u00f3n y por el propio tratamiento de la enfermedad  con sulfasalazina, inhibidor de la \nabsorci\u00f3n del folato. Algunos autore s afirman que la suplementaci\u00f3n \ncon folato en enfermos con colitis ulce rosa, reduce el riesgo de displasia  \n \n 55colorrectal45. Otros estudios relacionan los niveles de folato con los \nadenomas colorrectales, se\u00f1alando una disminuci\u00f3n de la concentraci\u00f3n del folato intraeritrocitario en pacientes con adenomas rectales\n47. El \nefecto terap\u00e9utico del folato, tambi\u00e9n ha sido estudiado. En el estudio \nde Cravo et al48, la suplementaci\u00f3n con \u00e1cido f\u00f3lico provoc\u00f3 una mejor\u00eda \nen la metilaci\u00f3n de las c\u00e9lulas del epitelio colorrectal en pacientes diagnosticados de c\u00e1ncer de colon. En cambio, otros autores\n49 \ndesaconsejan la suplementaci\u00f3n con \u00e1cido f\u00f3lico por provocar el crecimiento tumoral.  \nC\u00e1ncer de mama\n:  \nLas dietas ricas en vegetales y fr utas parecen disminuir el riesgo, \nmientras que la ingesta baja de vegetales y el consumo alto de alcohol aumentan el riesgo de padecer la enfermedad\n50,51. Sin embargo, otros \nautores no confirman esta relaci\u00f3n52,53. \nDisplasia y c\u00e1ncer de \u00fatero :  \nAlgunos autores sugieren que la displasia cervical est\u00e1 \nrelacionada con niveles bajos de folato y que esta displasia podr\u00eda ser reversible, pues responde a dosi s altas de folato (10 mg/d\u00eda)\n53. \nAsimismo, varios estudios sugieren que el aumento de la ingesta de \nfolatos, puede disminuir el riesgo de padecer c\u00e1ncer de \u00fatero37,54. \nC\u00e1ncer de pulm\u00f3n, c\u00e1ncer de es\u00f3fago y est\u00f3mago :  \nNo parecen existir datos suficiente s para relacionar estos tipos de \nc\u00e1nceres con los niveles de folatos55. \n Aterosclerosis \nLa implicaci\u00f3n del folato en la fisiopatolog\u00eda de la aterosclerosis \nes a trav\u00e9s de la tHcy. El mecanismo fisiopatol\u00f3gico por el que la \nhiperhomocisteinemia condiciona la lesi\u00f3n cardiovascular no est\u00e1 del \ntodo esclarecido. La evidencia indica que interact\u00faa directa y/o indirectamente sobre el proceso at erog\u00e9nico, contribuyendo por una \nparte a la disfunci\u00f3n endotelial y po r otra facilitando la trombog\u00e9nesis. \nAdem\u00e1s del folato, otras 3 vitaminas del grupo B est\u00e1n \nimplicadas en el ciclo me tab\u00f3lico de la metionina (B\n2, B 6, B 12). La \ndeficiencia de una o varias de estas vitaminas es capaz de inducir a una \nhiperhomocisteinemia, aunque el fola to parece ser el m\u00e1s importante a \nla hora de determinar los niveles de homocisteina (tHcy)56,57.  \n \n 56La hiperhomocisteinemia est\u00e1 considerada hoy como un factor \nde riesgo independiente de las enfermedades cardiovasculares, \nincluyendo las enfermedades coronarias y la patolog\u00eda \ncerebrovascular29. Aunque en la \u00faltima d\u00e9cada se ha reducido la \nmortalidad debido a la difusi\u00f3n de medidas de salud p\u00fablica, las \nmejoras nutricionales y la promoci\u00f3n de la actividad f\u00edsica, para el a\u00f1o \n2020 esta patolog\u00eda seguir\u00e1 ocupando el primer lugar como causa de \nmuerte en los pa\u00edses occidentales. \nAlteraciones en el metabolismo de la homociste\u00edna fueron \nidentificadas por primera vez en 196258 al analizar la orina de ni\u00f1os con \nretraso mental, surgiendo entonces el concepto homocistinuria. Dos a\u00f1os despu\u00e9s se pudo atribuir es ta homocistinuria a un defecto \ncong\u00e9nito en la enzima cistationin a\u2013beta-sintetasa, que cursaba adem\u00e1s \ncon niveles plasm\u00e1ticos muy elevados de homociste\u00edna y episodios tromboemb\u00f3licos. De hecho, el 50% de los ni\u00f1os que presentaban este \ncuadro cl\u00ednico fallec\u00edan por enfermedad cardiovascular\n59. En 1969 \nMcCully60 en un trabajo ya cl\u00e1sico, describi\u00f3 la patolog\u00eda vascular en \nestos pacientes que inclu\u00eda, entre otros cambios, proliferaci\u00f3n de las c\u00e9lulas musculares lisas, estenosis arterial y cambios hemost\u00e1ticos. Desde entonces hasta ahora, pero en especial en la \u00faltima d\u00e9cada, han \nsido m\u00faltiples los esfuerzos rea lizados para profundizar en el \nconocimiento de la fisiopatolog\u00eda de la hiperhomocisteinemia como factor de riesgo independiente o asociado a la enfermedad cardiovascular.  \nSon m\u00faltiples los estudios epidemiol\u00f3gicos que han puesto de \nmanifiesto la relaci\u00f3n entre la hiperhomocisteinemia y la enfermedad \ncardiovascular. En el metan\u00e1lisis  realizado por Boushey et al\n29, se \nanalizaban los datos de 27 estudi os realizados entre 1988 y 1994. Por \ncada incremento de 5 \u00b5mol/l tHcy, el riesgo relativo (RR) de \nenfermedad coronaria aumentaba 1,6 (intervalo de confianza 95%: 1.4-\n1.7), estableciendo los autores que la elevaci\u00f3n en los niveles de homociste\u00edna se puede considerar un factor de riesgo independiente. \nEstudios m\u00e1s recientes corroboran estos resultados\n61-63, aunque \ntambi\u00e9n hay en la actualidad algunos grupos que cuestionan este aspecto\n64,65, ya que no ha sido demostrada una relaci\u00f3n inequ\u00edvoca de \ncausalidad (para profundizar en este  tema, se puede consultar la \nrevisi\u00f3n reciente realizada por Gonz\u00e1lez-Gross et al66). En cualquier \ncaso, en pacientes diagnosticados ap arecen niveles de tHcy elevados y  \n \n 57bajos los de folato57. La importancia del folato en este proceso tambi\u00e9n \nse ve confirmada por los datos obtenidos en el Canadian Nutrition \nSurvey67, donde a medida que aumentan los niveles plasm\u00e1ticos de \nfolato se produce una disminuci\u00f3n del riesgo de mortalidad por \nenfermedad coronaria. \n \nMetodolog\u00eda diagn\u00f3stica \nTal y como se indica en la tabla 4, el diagn\u00f3stico biopatol\u00f3gico de \nuna deficiencia en folato se puede hacer por m\u00e9todos morfol\u00f3gicos y/o \nbioqu\u00edmicos. \n M\u00e9todos morfol\u00f3gicos: \nTal y como se ha descrito anterior mente, la deficiencia de folato \nconduce a una hipersegmentaci\u00f3n de neutr\u00f3filos y finalmente a anemia megalobl\u00e1stica. En t\u00e9rminos pr\u00e1cti cos y como regla nemot\u00e9cnica, se \naplica la llamada \u201cregla del 5\u201d: tras contar 100 neutr\u00f3filos, la presencia \nde m\u00e1s de un 5% que contengan 5 o m\u00e1s l\u00f3bulos (media de l\u00f3bulos superior a 3,6) es indicativa de hipersegmentaci\u00f3n\n14 (tabla 5). El \nrecuento normal de l\u00f3bulos da una media inferior a 3,2.  \nM\u00e9todos bioqu\u00edmicos: \nRadioinmunoan\u00e1lisis.  Es el m\u00e9todo de referencia. Se trata de un \nan\u00e1lisis competitivo entre ligandos, en  e l  c u a l  e l  f o l a t o  p l a s m \u00e1 t i c o  d e l  \npaciente se mezcla con cantidades constantes de I125 f\u00f3lico y ambos \ncompiten por unirse a la prote\u00edna fijadora de folato (FBP) que tambi\u00e9n \nse encuentra en cantidad constante.  Cuanto mayor sea la cantidad de \nfolato en la muestra hem\u00e1tica menor ser\u00e1 la uni\u00f3n del f\u00f3lico marcado a \nla FBP y viceversa. Previamente, es pr eciso liberar el folato end\u00f3geno de \nsu uni\u00f3n con las distintas prote\u00ednas transportadoras presentes en plasma. En este radioinmunoan\u00e1lisis, la separaci\u00f3n de la  radioactividad fijada de la no fijada se realiza mediante separaci\u00f3n magn\u00e9tica y decantaci\u00f3n del sobrenadante.  \nAn\u00e1lisis mediante captaci\u00f3n i\u00f3nica. En este m\u00e9todo, la matriz de \nfibra de vidrio de la celdilla de reacci\u00f3n se ha recubierto de un \ncompuesto de amonio cuaternario de  elevado peso molecular, que le \nconfiere una carga positiva y la capacidad de capturar compuestos de carga negativa. Durante el an\u00e1lisis, se forman complejos cargados  \n \n 58negativamente, utilizando un reactivo de afinidad soluble compuesto \nde una prote\u00edna folato-ligante un ida a anticuerpos monoclonales y \nligados a su vez a carboxi-met il-celulosa. Existe un m\u00e9todo \nautomatizado de inmunoan\u00e1lisis  de fluorescencia polarizada \ncomercializado por IMX Abbott. \nMuestras :  \nSe pueden utilizar muestras de sa ngre total, suero o plasma, en \ncualquier caso deben ser obtenidas en ayunas y una vez extra\u00edda la \nsangre, la muestra debe preservarse de la luz. \nFolato en suero o plasma : \nLa t\u00e9cnica del folato s\u00e9rico se  puede hacer con suero o plasma, \neste \u00faltimo obtenido por sangre anticoagulada con EDTA tripot\u00e1sico, \ncitrato s\u00f3dico u oxalato pot\u00e1sico. El suero o plasma debe ser separado de los hemat\u00edes lo antes posible, y siempre antes de las 24 horas. El suero se puede almacenar durante una semana entre 2 y 8\u00b0 C, o \ncongelado a \u201320 \u00b0 C durante un mes. Las muestras de plasma no se \ndeben almacenar m\u00e1s de una semana en ning\u00fan caso. \nFolato intraeritrocitario\n: \nLa muestra de sangre total para esta t\u00e9cnica anticoagulada con \nlos anticoagulantes citados anteri ormente, se puede almacenar a \ntemperaturas de entre 2 y 8 \u00b0 C pero s\u00f3lo durante 24 horas.  \nNiveles circulantes de folato \nLos niveles de folato s\u00e9rico son muy variables y dependen de la \ningesta diaria. Personas sin deficiencia pueden presentar niveles plasm\u00e1ticos bajos y personas con defi ciencia los pueden tener normales. \nNo obstante, unos niveles s\u00e9ricos ba jos suelen representar la primera \netapa del balance negativo en folatos y preceder al d\u00e9ficit tisular. El \nfolato intraeritrocitario es mucho m\u00e1s estable, s\u00f3lo est\u00e1 disminuido cuando hay una ingesta baja por malabsorci\u00f3n, aumento de necesidades o interacci\u00f3n medicamentosa mantenida durante meses.  \nEsta determinaci\u00f3n representa la segunda etapa en el d\u00e9ficit de \nfolato y en el caso de estar dism inuido, guarda una estrecha relaci\u00f3n \ncon los niveles tisulares de folato. \n   \n \n 59Valores de referencia \nLos niveles plasm\u00e1ticos de folato son considerados indicadores \nde la ingesta reciente de folato. Seg\u00fan diversos autores68,69, se \nconsideran normales valores superior es a 6 ng/ml; un d\u00e9ficit moderado \nse corresponde con valores entre 3 y 6 ng/ml y un d\u00e9ficit importante \ncon valores inferiores a 3 ng/ml (tabla 5). \nLos niveles de folato eritrocitari o se consideran indicadores de \nlas reservas de la vitamina en el organismo, ya que el gl\u00f3bulo rojo capta el folato durante su formaci\u00f3n en  la m\u00e9dula \u00f3sea y mantiene la \nconcentraci\u00f3n constante durante los 120 d\u00edas de vida media del \nhemat\u00ede. La concentraci\u00f3n eritrocitari a en folato se correlaciona con los \nniveles hep\u00e1ticos de reserva, y disminuye al cabo de unos meses de deficiencia mantenida\n70. Se consideran nive les normales aquellos \nsuperiores a 150 ng/ml15, aunque algunos autores rebajan esta cifra a \n125 ng/ml71. \nEn relaci\u00f3n con la prevenci\u00f3n de los defectos del tubo neural, \nDaly et al.16 e s t a b l e c e n  u n o s  v a l o r e s  d e  r e f e r e n c i a  e n  f u n c i \u00f3 n  d e  l a  \nprobabilidad de una gestaci\u00f3n con al g\u00fan defecto cong\u00e9nito (tabla 6), \nconsiderando estos autores que el me nor riesgo va asociado a niveles \neritrocitarios de folato superiores a 400 ng/ml. \n Tratamiento del d\u00e9ficit cl\u00ednico \nConsiste en la administraci\u00f3n por v\u00eda oral o parenteral de dosis \nfarmacol\u00f3gicas de la vitamina. La cantidad que se administra habitualmente es de 5 mg/d\u00eda de \u00e1cido f\u00f3lico. Las consecuencias del d\u00e9ficit cl\u00ednico han sido expuesta s previamente y es, l\u00f3gicamente, \ncuando \u00e9stas consecuencias se han puesto de manifiesto cuando es \nineludible recurrir a este tratamiento.  Los procesos y circunstancias que \npueden conducir a un d\u00e9ficit de fola tos se relacionan en la tabla 3\u00aa, \ndestacar aqu\u00ed solamente las anemias hemol\u00edticas y las dermatitis exfoliativas, en las que se pierde gran cantidad de folato, debido a la destrucci\u00f3n celular y descamaci\u00f3n. La p\u00e9rdida en folato se ve agravada \nal asociar como tratamiento el meto trexate, potente inhibidor de la \ns\u00edntesis de esta vitamina.   \n \n 60Tratamiento preventivo del d\u00e9ficit subcl\u00ednico: suplementaci\u00f3n con \n\u00e1cido f\u00f3lico \nEn base a los datos obtenidos en diversos estudios recientes72-75 y \nlas conclusiones de diversas revisi ones bibliograficas y metan\u00e1lisis \npublicados recientemente36,76, la prevalencia de deficiencia de folato \nentre la poblaci\u00f3n anciana es frecuente en los pa\u00edses desarrollados. Debido a la implicaci\u00f3n de esta vitamina en los m\u00faltiples procesos descritos, parece indicada su suplemen taci\u00f3n. En el reciente estudio de \nRydlewicz et al.\n77, en el que suplementaron con distintas dosis de \u00e1cido \nf\u00f3lico a personas entre 65 y 75 a\u00f1os durante 6 semanas, aquellos que \ntomaron 400 y 600 \u00b5g/d\u00eda presentaron niveles significativamente \nmenores de tHcy que los controles. Los autores concluyen que ser\u00eda necesaria una ingesta de 926 \u00b5g/d\u00eda para garantizar que el 95% de la \npoblaci\u00f3n anciana no tuviera riesgo cardiovascular debido a deficiencia \nde folato, algo s\u00f3lo alcanzable medi ante la suplementaci\u00f3n. Debido al \nestado de malnutrici\u00f3n que puede presentar este colectivo, algunos \nautores indican que puede estar m\u00e1s indicada la administraci\u00f3n de un \nsuplemento polivitam\u00ednico\n78. \nEl tratamiento preventivo m\u00e1s co nocido es el que se administra \ndurante el embarazo, en el cual las recomendaciones de folato \naumentan hasta 5 \u2013 10 veces respecto a las condiciones normales  (tabla \n1). No se debe olvidar que est\u00e1n relacionados con la deficiencia en folato, adem\u00e1s de los defectos en el  cierre del tubo neural, el parto \nprematuro, la toxemia del embarazo y el desprendimiento prematuro de la placenta. Por tanto, para toda s las mujeres que est\u00e9n planeando un \nembarazo, diversos organismos  re comiendan un suplemento de 400 \n\u00b5g/d\u00eda de \u00e1cido f\u00f3lico al menos desde 4 semanas antes de la \nfecundaci\u00f3n\n1,5. Esto es debido, a que el cierre del tubo neural se produce \nalrededor del d\u00eda 28 de gestaci\u00f3n,  cuando todav\u00eda se desconoce el \nembarazo. Esta suplementaci\u00f3n debe ma ntenerse a lo largo de todo el \nembarazo por los efectos adversos citados anteriormente. \nEl alcohol, el tabaco y el caf\u00e973,79,80  son determinantes de los \nniveles de folato s\u00e9rico, por lo que puede estar indicada una \nsuplementaci\u00f3n en aquellas pers onas que presentan un consumo \nelevado de los mismos. \n  \n \n 61Prevenci\u00f3n del d\u00e9ficit subcl\u00ednico \nNuevas ingestas recomendadas \nLas nuevas ingestas recomendadas o ingestas de referencia \n(DRI)1 promulgadas por algunos organismos internacionales \nrepresentan una nueva aproximaci\u00f3n para aportar estimaciones cuantitativas de la ingesta optima de nutrientes. Estas nuevas recomendaciones incluyen criterios novedosos. Para su formulaci\u00f3n, adem\u00e1s de los factores cl\u00e1sicos, como son los fisiol\u00f3gicos (edad, sexo, gestaci\u00f3n o lactancia, etc), se tienen en cuenta otros, como son factores \nmedioambientales y de estilo de vida, as\u00ed como la descripci\u00f3n de \nnuevas funciones de ciertos componentes alimenticios tal y como ha sido revisado recientemente por Joyanes et al.\n2. Entre estas nuevas \nfunciones cabe destacar el potencial preventivo que conlleva cada nutriente. En el caso del folato, varios estudios sugieren que el aumento en la ingesta de folatos puede dism inuir el riesgo de padecer ciertos \ntipos de c\u00e1ncer, como la neoplasia cervical\n55 y los defectos del tubo \nneural. Otros aspectos, como la relaci\u00f3n con enfermedades cardiovasculares, depresi\u00f3n y demencia, aunque se mencionan no han sido objeto de consideraci\u00f3n espec\u00edfi ca dado que se necesita disponer \nde mayor evidencia cient\u00edfica\n1.  \nEspec\u00edficamente para el folato, las ingestas recomendadas se han \nduplicado con respecto a las anteriores pasando de 200 a 400 \u00b5g/d\u00eda. La ingesta cl\u00e1sicamente recomendada para adultos (200 \u00b5g/d\u00eda\n81) se \nconsidera que s\u00f3lo consegu\u00eda evitar la  deficiencia cl\u00ednica pero no la \ndeficiencia subcl\u00ednica, con el consigui ente riesgo para la poblaci\u00f3n que \nesto pod\u00eda tener. Una ingesta \u00f3ptima de folato se incluye en los \nobjetivos nutricionales para la poblaci\u00f3n espa\u00f1ola propuestos \nrecientemente3. Hay que instar, pues, a la poblaci\u00f3n a cubrir sus \ningestas de folato (tabla 1) medi ante una selecci\u00f3n y manipulaci\u00f3n \nadecuada de alimentos (tabla 2). En caso de no ser esto factible, se deben tomar en consideraci\u00f3n otras medidas, como la recomendaci\u00f3n \ndel enriquecimiento de alimentos por parte de las autoridades \nsanitarias. \nEnriquecimiento de alimentos  \nDesde el 1 de enero de 1998, en EE. UU. es obligatorio enriquecer \nlos cereales y derivados con 140 \u00b5g de \u00e1cido f\u00f3lico/100 g \n82. En Chile se \nha iniciado esta medida el 1 de enero de 2.00083. Otros pa\u00edses, como  \n \n 62Hungr\u00eda, a\u00f1aden adem\u00e1s de 160 \u00b5g de \u00e1cido f\u00f3lico, 0,8 \u00b5g de vitamina \nB12 y 880 \u00b5g vitamina B 6 / 100 g de harina desde agosto de 199884 y otros, \ncomo Suiza, Sud\u00e1frica o Australia, est\u00e1n evaluando tomar esta medida. \nLos datos publicados en este contexto85-87 parecen indicar que la medida \ntomada en EE.UU. est\u00e1 resultando be neficiosa, sobre todo en relaci\u00f3n \ncon los NTD, aunque son necesari os mayor n\u00famero de estudios. \nAlgunos de ellos est\u00e1n actualmente en curso y habr\u00e1 que estar \natentos a sus resultados para valorar la implementaci\u00f3n de estas medidas en los pa\u00edses que todav\u00eda no lo han hecho. Cabe cuestionarse la \noportunidad de a\u00f1adir B\n12 debido a la problem\u00e1tica referida \nanteriormente del enmascaramiento en la anemia megalobl\u00e1stica, y a la \nelevada prevalencia de la deficiencia de B 12 entre la poblaci\u00f3n anciana, \ntal y como han indicado algunos autores83. En la lactancia, la leche \nmaterna contiene de 50 a 100 \u00b5g de folato por 100 ml, lo que \ncorresponde al requerimiento diario del reci\u00e9n nacido. Durante el \ncrecimiento aumenta la s\u00edntesis de DNA, lo que requiere mayor aporte \nde folato. Estas cantidades deben te nerse en cuenta en las leches de \nf\u00f3rmula y alimentos infantiles. \n \nToxicidad - Niveles m\u00e1ximos tolerables \nLos niveles de ingesta m\u00e1xima tolerables establecidos por el NIH \namericano1 se resumen en la tabla 7. Los niveles m\u00e1ximos tolerables se \nrefieren \u00fanicamente a la ingest a de \u00e1cido f\u00f3lico de alimentos \nenriquecidos o de suplementos, siendo para los adultos de 1000 \u00b5g/d\u00eda, \nno estableci\u00e9ndose ingestas m\u00e1ximas para los folatos naturales de los alimentos. Este valor ha sido establecido como norma de seguridad \ndado que se han encontrado niveles de toxicidad para la ingesta de 5 \nmg al d\u00eda de \u00e1cido f\u00f3lico. \n Conclusi\u00f3n \nEl folato es una vitamina implicada en importantes reacciones \nmetab\u00f3licas. La carencia de folato se manifiesta cl\u00ednicamente por la \naparici\u00f3n de anemia megalob\u00e1stica y en el caso de la mujer embarazada \npor la aparici\u00f3n de defectos del tubo  neural en el feto. Investigaciones \nrecientes han puesto de manifiesto que un d\u00e9ficit subcl\u00ednico de folato puede estar implicado en diversos procesos de gran incidencia y gravedad como son depresi\u00f3n, demencia senil (vascular y Alzheimer),  \n \n 63aterosclerosis y ciertos tipos de c\u00e1 ncer. Estos hallazgos han llevado a \ndiversos organismos de salud intern acionales a incrementar las ingestas \nrecomendadas de folato, pasando de los 200 \u00b5g/d\u00eda que se \nrecomendaban para prevenir un esta do carencial a los 400 \u00b5g/d\u00eda que \nactualmente se recomiendan como ingesta de referencia. Para garantizar este aporte puede ser nece sario recurrir a la suplementaci\u00f3n \nvitam\u00ednica especialmente en personas ancianas donde el estado carencial subcl\u00ednico tiene mayor in cidencia. En algunos pa\u00edses se \nrecomienda incluso el enriquecimiento con folato de ciertos alimentos. \n  \n \n 64Bibliograf\u00eda \n \n1. Dietary reference intakes for thia min, riboflavin, niacin, vitamin B 6, \nfolate, vitamin B 12, pantothenic acid, biotin, and choline/ a report of the \nStanding Committee on the Scientific  Evaluation of Dietary Reference \nIntakes and its Panel on Folate, Other B Vitamins, and Choline and Subcommittee on Upper Levels on Nutrients, Food and Nutrition Board. Institute of Medicine. Was hington, DC: National Academy \nPress. 1998. \n2. Joyanes M, Gonz\u00e1lez-Gross M, M arcos A. The need to review the \nSpanish recommended dietary energy an d nutrient intakes [en prensa]. \nEur J Clin Nutr. \n3. Serra-Majem L, Aranceta J; SENC  Working Group on Nutritional \nObjectives for the Spanish Popula tion. Spanish Society of Community \nNutrition. Nutritional objectives fo r the Spanish population. Consensus \nfrom the Spanish Society of Communi ty Nutrition. Public Health Nutr \n2001;4:1409-13. \n4. Wagner C. Symposium on the subc elular compartmentation of folate \nmetabolism. J Nutr 1996;126:1228S-1234S. \n5. DACH. Referenzwerte f\u00fcr die N\u00e4hr stoffzufuhr. 1. Auflage. Frankfurt \nam Main: Umschau/Braus GmbH, Verlagsgesellschaft. 2000. \n6. Crawley HF. The role of breakfast cereals in the diets of 16-17-year \nold teenagers in Britain. J Hum Nutr Diet 1993;6:295-216. \n7. B\u00e4ssler KH, Golly I, Loew K, Pi etrzik K. Vitamin-Lexikon. Govi \nVerlag, Frankfurt-Main. 2002. \n8. Whitehead VM. Polygammaglutamyl metabolites of folic acid in \nhuman liver. Lancet 1973;1:743-745. \n9. Hoppner K, Lampi B. Folate levels  en human liver frem autopsies in \nCanada. Am J Clin Nutr 1989;33:862-864. \n10. Kang Kang SS, Zhou J, Wong PW K, Kowalisyn J, Strokosch G. \nIntermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate re ductase. Am J Hum Genet 1988;43:414-421. \n11. Blom HJ, Kleinveld HA, Boers GH, et al. Lipid peroxidation and \nsusceptibility of low density lipopr otein to in vitro oxidation in \nhiperhomocysteinaemia.. Eur J Clin Invest 1995;25:149-54.  \n \n 6512. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. New \nEngl J Med 1998;338:1042-1050. \n13. Van der Put NMJ, Gabre\u00ebls F, Stevens EMB, Smeitink JAM, Trijbels \nFJM, Eskes TKAB, van den Heuvel LP, Blom HJ. A second common \nmutation in the methylentetrahydrofolate reductase gene: an additional risk factor for neural tube defects?. Am J Hum Genet 1998;62:1044-1051. \n14. Herbert V, Das KC. Folic acid and vitamin B12. En: ME Shils, JA \nOlson, M Shike, eds. Modern Nutrition in Health and Disease. 8\nth \nedition. Malvern, PA: Lea & Febiger, 1994, pp 402-425. \n15. Zittoun J. Acide folique: une carence sans consequences? En: \nL\u2019alimentation des persones agees. Paris: Cidil eds. 1985. \n16. Daly LE, Kirke PN, Molloy A, Weir DG, Scott JM. Folate levels and \nneural tube defects. Implicatio ns for prevention. J Am Med Assoc \n1995;274:1698-1702. \n17. Werler MM, Shapiro S, Mitchell AA. Periconceptional folic acid \nexposure and risk of occurrent ne ural tube defects. J Am Med Assoc \n1993:269:1257-1261. \n18. Shaw GM, Schaffer D, Velie EM, Morland K, Harris JA. \nPericonceptional vitamin use, diet ary folate, and the occurence of \nneural tube defects. Epidemiology 1995;6:219-226. \n19. Steegers-Theunissen RP, Boers GH, Blom HJ, Trijbels FJ, Eskes TK. \nHyperhomocysteinemia and recurrent spontaneous abortion or abruptio placentae. Lancet 1992;339:1122-1123. \n20. Steegers-Theunissen RP, Boers GH, Trijbels FJ, Finkelstein JD, Blom \nHJ, Thomas CM, et al. Maternal hy perhomocysteinemia: a risk factor \nfor neural tube defects? Metabolism 1994;43:1475-1480. \n21. Mills JL, McPartliin JM, Kirke PN, Lee YJ, Conley MR, Weir DG, et \nal.. Homocysteine metabolism in pregnancies complicated by neura-tube defects. Lancet 1995;345:149-151. \n22. Vollset SE, Refsum H, Irgens LM,  Emblem BM, Tverdal A, Gjessing \nHK, et al. Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland homocysteine study. Am J \nClin Nutr 2000;71:962-8.  \n \n 6623. Pietrzik K, Br\u00f6nstrup A. Folate in preventive medicine: a new role in \ncardiovascular disease, neural tube  defects, and cancer. Ann Nutr \nMetab 1997;41:331-343. \n24. van der Put NM, Steegers-Theunissen RP, Frosst P, Trijbels FJ, Eskes \nTK, van den Heuvel LP, et al. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 1995;346:1070-1. \n25. Shorvon SD, Carney MW, Chanarin I, Reynolds EH. The \nneuropsychiatry of megaloblastic anaemia. Br Med J 1980;281:1036-8. \n26. Bottiglieri T, Laundy M, Crellin R, Toone BK, Carney MW, Reynolds \nEH Homocysteine, folate, methylatio n, and monoamine metabolism in \ndepression. : J Neurol Neurosurg Psychiatry 2000;69:228-32.  \n27. Lindeman RD, Romero LJ, Ko ehler KM, Liang HC, LaRue A, \nBaumgartner RN, et al. Serum vitamin B12, C and folate concentrations in the New Mexico elder health survey: correlations with cognitive and affective functions. J Am Coll Nutr 2000;19:68-76. \n28. Bottiglieri T, Hyland K, Laundy  M, Godfrey P, Carney MW, Toone \nBK, et al. Folate deficiency, biopterin and monoamine metabolism in depression. Psychol Med 1992;22:871-6. \n29. Boushey CJ, Beresford SAA,  Omenn GS, Motulsky AG. A \nquantitative assessment of plasma ho mocysteine as a risk factor for \ncardiovascular disease. JAMA 1995;274:1049-1057. \n30. Fassbender K, Mielke O, Bertsch T, Nafe B, Fr\u00f6schen S, Hennerici M. \nHomocysteine in cerebral macroangiography and microangiopathy. Lancet 1999;353:1586-1587. \n31. Clarke R, Smith AD, Jobst KA, Refsum H, Sutton L, Ueland PM. \nFolic acid, vitamin B\n12, and serum homocysteine levels in confirmed \nAlzheimer\u00b4s disease. Arch Neurol  1998;55:1449-1455. \n32. Snowdon DA, Tully CL, Smith CD, Perez Riley K, Markesberry WR. \nSerum folate and the severity of atro phy of the neocortex in Alzheimer \ndisease: findings form the Nu n Study. Am J Clin Nutr 2000;71,993-998. \n33. Nilsson K, Gustafson L, Faldt R, Andersson A, Brattstrom L, \nLindgren A, et al. Hyperhomocyste inaemia - a common finding in a \npsychogeriatric population. Eur J Clin Invest 1996;26,853-859.  \n \n 6734. Seshadri S, Beiser A, Selhub  J, Jacques PF, Rosenberg IH, D \u02b9Agostino \nRB, et al. Plasma Homocysteine as  a Risk Factor for Dementia and \nAlzheimer \u02b9s Disease. N Engl J Med 2002;346:476-483. \n35. Rosenberg IH, Miller JW. Nutritional factors in physical and \ncognitive functions of elderly people. Am J Clin Nutr 1992;55(6 Suppl):1237S-1243S. \n36. Gonzalez-Gross M, Marcos A, Pietrzik K. Nutrition and cognitive \nimpairment in the elderly. Br J Nutr 2001;86:313-321. \n37. Ziegler RG, Brinton LA, Hamman RF, Lehman HF, Levine RS, \nMallin K, et al. Diet and risk of in  situ cercical cancer among white \nwomen in the United States. Cancer Causes Control 1990;2:17-29. \n38. Blount BC, Mack MM, Werh GM, MacGregor JT, Hiatt RA, Wang G, \net al. Folate deficiency causes u racil misincorporation into human DNA \nand chromosome breakage: implications for cancer and neuronal damage. Proc Natl Acad Sci 1997;94:3290-3295. \n39. Halsted CH, Gandhi G, Tamura T. Sulfalazine inhibits the \nabsorption of folates in ulce rative colitis. N Engl J Med 1981;305:1513-\n1517. \n40. Jones PA(1996) DNA methylation errors and cancer. Cancer Res \n56:2463-2467. \n41. Cravo M, Pinto R, Fidalgo P, Chaves P, Gloria L, Nobre-leitao C, et \nal. Global DNA hipomethylation occurs in the early stages of intestinal \ntype gastric carcinoma. Gut 1996;39:434-438. \n42. Cheng P, Schumutte C, Cofer KF, Felix JC, Yu MC, Dubeau L. \nAlterations in DNA Methylation are early, but not initial, events in ovarian tumorigenesis. Br J Cancer 1997;75:396-402. \n43. Kin YI, Giuliano A, Hatch KD, Sc heneider A, Nour MA, Dallal GE, \net al. Global DNA hipomethylation in creases progressively in cervical \ndysplasia and carcinoma. Cancer 1994;74:893-899. \n44. Fowler BM, Giuliano A, Plyathilake C, Nour M, Hatch K. \nHipomethylation in cervical tissue: is there a correlation with folate \nstatus? Cancer Epidemiol 1998;7:901-906. \n45. Fang JY, Xiao SD. Alteration of DN A methylation in gastrointestinal \ncarcinogenesis. J Gastroenterol Hepatol 2001;16:960-8.  \n \n 6846. Kim YI, Pogrbny IP, Basnakian AG, M iller JW, Selhub J, James SJ, et \nal. Folate deficiency in rats induces DNA strand breaks and hipomethylation within the p53 tumo r suppressor gene. Am J Clin Nutr \n1995;65:46-52. \n47. Paspatis GA, Kalafatis E, Oros L, Xourgias V, Koutsioumpa P, \nKaramanolis DG.  Folate status and adenomatous colonic polyps. A \ncolonoscopically controlled study. Dis Colon Rectum 1995;38:64-67. \n48. Cravo M, Fidalgo P, Pereira AD, Gouveira-Oliveira A, Chaves P, \nSelhub J, et al. DNA methylation as an intermediate biomarker in \ncolorectal cancer: modulation by folic acid supplementation. Eur J \nCancer Prev 1994;3:473-479. \n49. Ryan BM, Weir DG. Relevance of folate metabolism in the \npathogenesis of colorectal cancer. : J Lab Clin Med 2001;138:164-76. \n50. Graham S, Hellmann R, Marshall J, Freudenheim J, Vena J, Swanson \nM, et al. Nutritional epidemiology of postmenopausal breast cancer in \nwestern New York. Am J Epidemiol 1991;134:552-566. \n51. Freudenheim JL, Marshall JR, Vena JE, Laughlin R, Brasure JR, \nSwanson MK, et al. Premenopausal breast cancer risk and intake of vetetables, fruits, and related nutr ients. J Natl Cancer Inst 1996;88:340-\n348. \n52. Zhang S, Hunter DJ, Hankinson SE, Giovannucci EL, Rosner BA, \nColditz GA, et al. A prospective study of folate intake and the risk of breast cancer. JAMA 1999;281:1632-1637. \n53. Terry P, Suzuki R, Hu FB, Wolk A. A prospective study of major \ndietary patterns and the risk of breast cancer. Cancer Epidemiol \nBiomarkers Prev 2001;10:1281-5. \n54. Potischman N, Brinton LA, Laim ing VA, Reeves WC, Brenes MM, \nHerrero R, et al. A case-control study of serum folate levels and \ninvasive cervical cancer. Cancer Res 1991;51:4785-4789. \n55. Prinz-Langenohl R, Fohr I, Pietrzik K. Beneficial role for folate in the \nprevention of colorectal and br east cancer. Eur J Nutr 2001;40:98-105. \n56. Pietrzik K, Bronstrup A. Vitamins B12, B6 and folate as \ndeterminants of homocysteine concentration in the healthy population. \nEur J Pediatr 1998;157 Suppl 2:S135-8.  \n \n 6957. Fern\u00e1ndez-Miranda C, Aranda JL,  G\u00f3mez Gonz\u00e1lez P,  D\u00edaz-Rubio \nP, Estenoz J, G\u00f3mez de la C\u00e1mara A.  La hiperhomocisteinemia es frecuente en pacientes con enfe rmedad coronaria. Estudio de 202 \nenfermos. Med Clin (Barc) 1999; 113:407-410. \n58. Gerritsenn T, Vaughan JG, Waisman HA. The identification of \nhomocysteine in the urine. Biochem BioPhys Res Commun 1962;9:493-496. \n59. Mudd SH, Finkelstein JD, Irreverre F, Laster L. Homocystinuria: an \nenzymatic defect. Science 1964;143:1443-1445. \n60. Mc Cully KS. Vascular pathology of homocysteinemia: implications \nfor the pathogenesis of arterio sclerosis. Am J Pathol 1969; 56:111-28. \n61. Aronow WS, Ahn C. Increased plasma homocysteine is an \nindependent predictor of new coron ary events in older persons. Am J \nCardiol 2000;86:346-347. \n62. Vollset SE, Refsum H, Tverdal A,  Nygard O, Nordrehaug JE, Tell \nGS, et al. Plasma total homocy steine and cardiovascular and \nnoncardiovascular mortality: the Ho rdaland Study. Am J Clin Nutr \n2001;74:130-136. \n63. \u00c1lvarez Sab\u00edn J ,Tur\u00f3n J, Montaner J, Malinow R, Codina \nA. Homociste\u00edna plasm\u00e1tica en pacientes con ataques isqu\u00e9micos \ntransitorios. Med Clin (Barc) 1999;113:531-532. \n64. Brattstrom L, Wilcken DE. Homocysteine and cardiovascular \ndisease: cause or effect? Am J Clin Nutr 2000;72:315-23. \n65. Knet P, Reunanen A, Alfthan G, Heliovaara M, Rissanen H, \nMarniemi J, et al. Hyperhomocysteinemia: a risk factor or a consequence of coronary heart disease? Arch Intern Med 2001;161:1589-\n94. \n66. Gonzalez-Gross M, Sola R, Castillo MJ, Pietrzik K. Homociste\u00edna y \nriesgo cardiovascular [en prensa]. Investigaci\u00f3n Cl\u00ednica.  \n67. Morrison HI, , Schaubel D, Desm eules M, Wigle DT. Serum folate \nand risk of fatal coronary heart disease. JAMA. 1996;275:1893-1896. \n68. Roe DA. Nutritional assessment of the elderly. World Rev Nutr Diet \n1986;48:85-113. \n69. Keller HE, Salkeld RM. Bereichswerte von Analysenparametern fuer \nden Vitaminstatus. GCR 1988; 106:334.  \n \n 7070. Pietrzik K. Concept of borderline vitamin deficiencies. Int J Vitam \nNutr Res Suppl 1985;27:61-73. \n71. Kuebler W. Vitaminmangel und seine Folgen. Bibl Nutr Dieta \n1988;42:2-6. \n72. Serra Majem L, Ribas Barba L, Armas Navarro A, Alvarez Leon E, \nSierra A; Equipo de investigacion de ENCA. Ingesta de energ\u00eda y nutrientes y riesgo de ingesta inad ecuada en las Islas Canarias (1997-\n98). Arch Latinoam Nutr 2000;50(1 Suppl 1):7-22. \n73. Christodoulakos G, Panoulis C, Ri zos D, Moustakarias T, Phocas I, \nCreatsas G. Homocysteine and folate levels in postmenopausal women \nMaturitas 2001;39:161-7. \n74. Marshall TA, Stumbo PJ, Warren JJ,  Xie XJ. Inadequate nutrient \nintakes are common and are associated with low diet variety in rural, community-dwelling elderly. J Nutr 2001;131:2192-6. \n75. Ventura P, Panini R, Verlato C, Scarpetta G, Salvioli G. \nHyperhomocysteinemia and related fa ctors in 600 hospitalized elderly \nsubjects. Metabolism 2001;50:1466-71. \n76. Aranceta J, Serra Majem L, Ortega RM, Entrala A, Gil A. Las \nvitaminas en la alimentaci\u00f3n de los espa\u00f1oles. Estudio EVE Libro Blanco. Laboratorios Roche. 2000. \n77. Rydlewicz A, Simpson JA, Taylor  RJ, Bond CM, Golden MH The \ne f f e c t  o f  f o l i c  a c i d  s u p p l e m e n t a t i o n  o n  p l a s m a  h o m o c y s t e i n e  i n  a n  elderly population. QJM 2002;95:27-35. \n78. Chandra RK. Effect of vitamin and trace-element supplementation \non cognitive function in elderly subjects. Nutrition 2001;17:709-12. \n79. Ortega RM, Lopez-Sobaler AM, Gonzalez-Gross MM, Redondo RM, \nMarzana I, Zamora MJ, et al. Influence of smoking on folate intake and \nblood folate concentrations in a gr oup of elderly Spanish men. J Am \nColl Nutr 1994;13:68-72. \n80. Brussaard JH, Lowik MR, van den Berg H, Brants HA, Goldbohm \nRA. Folate intake and status among adults in the Netherlands. Eur J Clin Nutr 1997;51 Suppl 3:S46-50. \n \n  \n \n 7181. NRC (National Research Council). Recommended Dietary \nAllowances. 10th edition. Report of the Subcommittee on the tenth \nedition of the RDAs, Food and Nu trition Board, Commission on Life \nSciences. Washington, DC: Na tional Academy Press. 1989. \n82. FDA (Food and Drug administratio n). Folic acid to fortify food \nproducts to prevent birth defects.  \nwww.cfsan.fda.gov/~lrd/hhsfolic.html. 1996. 83. Hirsch S, de la Maza P, Barrera G, Gattas V, Petermann M, Bunout \nD. The Chilean flour folic acid fo rtification program reduces serum \nhomocysteine levels and masks vitamin B-12 deficiency in elderly \npeople. J Nutr 2002;132:289-91. \n84. Czeisel AE, Merhala Z. Bread fortification with folic acid, vitamin \nB12, and vitamin B6 in Hungary. Lancet 1998;352:1225. \n85. Boushey CJ, Edmonds JW, Welshimer KJ. Estimates of the effects of \nfolic-acid fortification and folic -acid bioavailability for women. \nNutrition 2001;17:873-9. \n86. Choumenkovitch SF, Jacques PF, Nadeau MR, Wilson PW, \nRosenberg IH, Selhub J. Folic Acid  Fortification Increases Red Blood \nCell Folate Concentrations in the Framingham Study. J Nutr 2001;131:3277-3280. \n87. Honein MA, Paulozzi LJ, Math ews TJ, Erickson JD, Wong LY. \nImpact of folic acid fortification of the US food supply on the occurrence of neural tube  defects. JAMA 2001;285:2981-6. \n88. Moreiras O, Carbajal A, Cabrera L, Cuadrado C. Tablas de \ncomposici\u00f3n de alimentos. Madrid: Editorial Pir\u00e1mide. 1995. \n \n \n   \n  \n \n  \n \n 72 \n  \n \nTABLAS:  \nTabla 1 . Ingestas recomendadas de folato\n1 \n \nFolato* (\u00b5g/d\u00eda) Edad \n Varones Mujeres \n0 \u2013 6 meses 65 65 \n7 \u2013 12 meses 80 80 \n1 \u2013 3 a\u00f1os 150 150 \n4 \u2013 8 a\u00f1os 200 200 \n9 \u2013 13 a\u00f1os 300 300 \n14 \u2013 18 a\u00f1os 400 400\u00aa \n19 \u2013 30 a\u00f1os 400 400\u00aa \n31 \u2013 50 a\u00f1os 400 400\u00aa \n51 \u2013 70 a\u00f1os 400 400 \n> 70 a\u00f1os 400 400 \nEmbarazo  600b \nLactancia  500 \n \n a = en mujeres que est\u00e9n planificando un embarazo, se recomienda una \ningesta adicional diaria de 400 \u00b5g en forma de suplementos o alimentos \nenriquecidos  b = se asume que las mujeres segu ir\u00e1n tomando la ingesta adicional \ndiaria de 400 \u00b5g en forma de suplementos o alimentos enriquecidos al \nmenos durante las primeras 8 semanas de gestaci\u00f3n \n \n* 1 \u00b5g FE = 1 \u00b5g folatos alimentarios = 0.5 \u00b5g \u00e1cido \npteroilmonoglut\u00e1mico (\u00e1cido f\u00f3lico) \n  \n \n 73 \nTabla 2.  Alimentos ricos en folato \n \n \nAlimento \u00b5g/100 g alimento (porci\u00f3n comestible) \nVerduras y hortalizas \n- grelos \n- coles \n- jud\u00edas verdes \n- espinacas, acelgas \n- tomate,  \n- remolacha  \n110 79 \n60 \n140 28 90 \nFruta \n- pl\u00e1tano \n- naranja \n- mel\u00f3n \n- fresa, frambuesa y fres\u00f3n  \n22 37 \n30 \n20 \nFrutos secos \n- pistachos \n- cacahuetes \n- almendras  \n58 110 96 \nLegumbres  \n- garbanzos \n- lentejas  \n180 35 \nLeche y productos l\u00e1cteos \n- queso brie, camembert, \nroquefort, cabrales  \n50 \nCarnes y v\u00edsceras \n- H\u00edgado \n- Ri\u00f1ones \n- Carne vacuno y pollo  \n192 \n77 \n10 \nPescado \n- Salm\u00f3n \n- pez espada, bonito y at\u00fan  \n26 15 \n* Fuente: 88      \n \n 74Tabla 3 . Causas de deficiencia de folato \nAporte deficitario : \nElecci\u00f3n incorrecta de alimentos  \nP\u00e9rdidas debidas a almacenamiento y cocinado incorrectos  \nRestricciones diet\u00e9ticas frecuentes y mal planteadas \nConsumo elevado de alcohol \nTrastornos en la absorci\u00f3n: \nEnfermedad celiaca \nEsprue tropical Enfermedad de Wipple Esclerodermia \nAmiloidosis \nDiverticulosis intestinal Consumo cr\u00f3nico de alcohol \nNecesidades aumentadas : \nEmbarazo \nLactancia \nPrematuridad \nCrecimiento Hem\u00f3lisis cr\u00f3nica Dermatitis exfoliativa cr\u00f3nica Situaciones hiper-catab\u00f3licas (postoperatorio, quemaduras) \nHemodi\u00e1lisis \nTrastornos cong\u00e9nitos del metabolismo : \nHomocistinuria \nInteracciones con f\u00e1rmacos : \nMetrotrexate \nPirimetamina Trimetropin Procuanil Sulfasalazina \nTriamterene \n5-Fluoracilo \n6-Azauridina \nZidovudina \nArabinoso de citosina Hidroxiurea \nFenobarbital \nDifenil hidantoina Primidona \nFenitoina \nAnticonceptivos orales \nCicloserina \nGlutetimida \nOxido nitroso Mecanismos de la interacci\u00f3n : \nImpiden la reducci\u00f3n del dihidrofolato a tetrahidrofolato, esta acci\u00f3n se puede evitar si junto a estos medicamentos se asocia \u00e1cido f\u00f3lico.  \n \nInhibidores de la s\u00edntesis   Inhiben la reducci\u00f3n de los ribonucle\u00f3tidos   \n \n   Destruye la metil-cobalamina, la cual impide la acci\u00f3n de la metil-transferasa y se produce un atrapamiento de la forma metilada del folato, \nprovocando una anemia megalobl\u00e1stica aguda. \n \n 75 \n \nTabla 4 . Modificaciones bioqu\u00edmicas y morfol\u00f3gicas caracter\u00edsticas de la \ndeficiencia de folato14 \n \n- Disminuci\u00f3n de la concentrac i\u00f3n de folato en plasma  \n- Elevaci\u00f3n de los niveles de  homociste\u00edna en plasma \n- Aumento de la tasa de segmentaci\u00f3n de los neutr\u00f3filos \n- Aumento en la excreci\u00f3n urinaria de \u00e1cido forminoglut\u00e1mico \n- Disminuci\u00f3n de la concentraci\u00f3n de f\u00f3lico eritrocitario \n- Macroovalocitosis en sangre perif\u00e9rica y megaloblastia en la m\u00e9dula \nespinal \n- Anemia megalobl\u00e1stica \n \n \nTabla 5.  Valores de referencia para el diagn\u00f3stico de deficiencia en \nfolato 68,69 \n \nVariable Valor \n- Concentraci\u00f3n de folato plasm\u00e1tico \n- Niveles plasm\u00e1ticos de homociste\u00edna \n- Concentraci\u00f3n de folato eritrocitario \n- Tasa de segmentaci\u00f3n de neutr\u00f3filos  < 3 ng/ml (< 6.8 nmol/l) \n> 8 ng/ml (18.1 nmol/l) \n< 140 ng/ml (317 nmol/l) \n\u2265 3.5 \n \n \n \nTabla 6 . Intervalos de niveles de folato eritrocitario y riesgo de defectos \ndel tubo neural (NTD)* \n \nFolato eritrocitario ( \u00b5g/L) Riesgo de NTD \n0 \u2013 149 8,25 \n150 \u2013 199 4,00 \n200 \u2013 299 2,88 \n300 \u2013 399 2,00 \n\u2265 400 1,00 \n* modificado de Daly et al. 16 \n     \n \n 76 \n      \n \nTabla 7. Niveles m\u00e1ximos tolerables de ingesta de \u00e1cido f\u00f3lico \n1 \n \n     \n\u00c1cido f\u00f3lico \n(\u00b5g/d\u00eda) Edad \n \nVarones Mujeres \n0 \u2013 6 meses * * \n7 \u2013 12 meses * * \n1 \u2013 3 a\u00f1os 300 300 \n4 \u2013 8 a\u00f1os 400 400 \n9 \u2013 13 a\u00f1os 600 600 \n14 \u2013 18 a\u00f1os 800 800 \n19 \u2013 30 a\u00f1os 1000 1000 \n31 \u2013 50 a\u00f1os 1000 1000 \n51 \u2013 70 a\u00f1os 1000 1000 \n> 70 a\u00f1os 1000 1000 \nEmbarazo \n14 \u2013 18 a\u00f1os > 19 a\u00f1os   \n800 1000 \nLactancia \n14 \u2013 18 a\u00f1os \n> 19 a\u00f1os   \n800 \n1000 \n \n* No se han establecido los niveles m\u00e1ximos tolerables. \n \n \n        \n \n 77O \n \nC \nC OH H2 \nC \nC H\n2 O \n \nC \nOH OH \nH2N  \n            \nFIGURAS: \n \n \nFigura 1.  Estructura del \u00e1cido f\u00f3lico \n \n                 \n \n  \n \n     \npteridina               \u00e1cido p-aminobenzoico   \u00e1cido glut\u00e1mico H \nN H2 \nC \nN H C \n\u00e1cido pteroico \n\u00e1cido pteroil mono glut\u00e1mico  \n \n 78Figura 2 . Relaciones metab\u00f3licas del folato. \n \n \n \n \n     \n \n    \n \n    \n \n     \n \n    \n \n     \n \n    \nMS: Metionina-sintetasa \n5-MTHF: 5-metil-tetrahidrof\u00f3lico THF: tetrahidrof\u00f3lico SAM: S-adenosil-metionina  MS \nB12 METIONINA HOMOCISTEINA\nTHF 5\u00b4MTHF \n10 Formilo THF 5,10 Metenil THF \n5,10 Metileno THF DNA \nS\u00edntesis de \npurina SAM Metilaci\u00f3 n\nDNAEtanolamina Colina \nGlicina \nB6 \nSerina Dihidro folato \ndUMP dTMP Pirimidina DN \n \n  \n \n \n     \n \n     \n \n    \n \n     \n \n    \nVITAMINA B\n12  \n \n 80\u00bfEXISTE LA NECESIDAD DE UNA DETECCI\u00d3N PRECOZ DEL \nD\u00c9FICIT DE VITAMINA B 12? \nRicardo Sola1,2.Marcela Gonz\u00e1lez-Gross2,3. Klaus Pietrzik4. Manuel J \nCastillo2 \n1Servicio de Hematolog\u00eda, Hospital Cl\u00ednico Universitario San Cecilio de \nGranada. Espa\u00f1a. \n2Grupo EFFECTS-262, Departamento de Fisiolog\u00eda M\u00e9dica, Facultad de \nMedicina de Granada. Espa\u00f1a. \n3Facultad de Ciencias de la Actividad F\u00edsica y del Deporte. Universidad \nPolit\u00e9cnica de Madrid. Espa\u00f1a. \n(4) Institut f\u00fcr Ern\u00e4hrungs-und Lebensmittelwissenschaften. \nPathophysiologie. Rheinische Friedrich-Wilhelms-Universit\u00e4t. Bonn. \nGermany. \n \nResumen \nEl ser humano es incapaz de sintetizar vitamina B 12 por s\u00ed mismo, \ntoda la que necesita debe ser apor tada casi exclusivamente por los \nalimentos de origen animal. La vitamina B 12 es imprescindible para la \ncorrecta funci\u00f3n neurol\u00f3gica y la formaci\u00f3n de elemento formes de la sangre. Su d\u00e9ficit, de gran preval encia, sobre todo en la poblaci\u00f3n \nanciana\n1 y en vegetarianos, provoca a largo plazo anemia \nmegalobl\u00e1stica y todo su cortejo de  alteraciones neurol\u00f3gicas. Especial \nimportancia se atribuye al d\u00e9fici t subcl\u00ednico que implica alteraciones \ninespec\u00edficas del sistema nervioso central y perif\u00e9rico, sin que existan todav\u00eda alteraciones hematol\u00f3gicas que permitan sospechar la deficiencia, por esto es muy import ante el diagn\u00f3stico precoz y el \ntratamiento adecuado antes de que estas alteraciones neurol\u00f3gicas se \nhagan irreversibles. En este art\u00edculo se revisan las t\u00e9cnicas anal\u00edticas \ndisponibles en la actualidad que permiten el diagn\u00f3stico precoz de la deficiencia de B\n12 y donde el coste-beneficio debe ser valorado.  \n \n 81Introducci\u00f3n \nEn la literatura m\u00e9dica y en este art\u00edculo, los t\u00e9rminos \ncianocobalamina, cobalamina (Cbl) y vitamina B 12 se utilizan \nindistintamente2. Aunque, en sentido estricto, la vitamina B 12 es la \ncianocobalamina, otras cobalaminas tambi\u00e9n han demostrado similares \npropiedades nutricionales. \nLa cobalamina metab\u00f3licamente activa se encuentra bajo dos \nformas, la 5\u00b4deoxiadenosilcobalamin a y la metilcobalamina. Bajo el \npunto de vista farmacol\u00f3gico, se emplea la hidroxicobalamina y la \ncianocobalamina aunque esta tiene menor capacidad de uni\u00f3n a las \nprote\u00ednas s\u00e9ricas y se excreta m\u00e1s r\u00e1pidamente3. \nLa vitamina B 12 pertenece a la familia de las corrinas y est\u00e1 \nformada por un nucle\u00f3tido, el 5,6-dimetil-benziminazol y por un anillo corr\u00ednico (fig 1). El 40-50% de las corrinas s\u00e9ricas est\u00e1n en forma de an\u00e1logos de la vitamina B\n12, fisiol\u00f3gicamente inactivos, pero compiten \ncon la vitamina B 12 para ocupar su transportador s\u00e9rico.  \nLa vitamina B 12 act\u00faa como cofactor para convertir el \nMetilmalonil CoA en Succinil CoA, adem \u00e1s es necesaria para la s\u00edntesis \nde Metionina a partir de la Homocist e\u00edna, participa en la s\u00edntesis de \nmielina y junto con el folato en la s\u00edntesis de DNA, lo que explica las \nconsecuencias comunes de ambas deficiencias. \n \nAbsorci\u00f3n, transporte, dep\u00f3sitos y excreci\u00f3n \nToda la vitamina B 12 que necesita el organismo es de origen \nexterno, solo se encuentra en los alimentos de origen animal. \nRecientemente se ha publicado la biodisponibilidad en vitamina B 12 que \nposee un tipo de alga4 y un T\u00e9 negro japon\u00e9s5. \nLa absorci\u00f3n se produce en el ileon terminal, pero para que esta \nsea posible, se necesita: un estomago intacto que segregue una glicoprote\u00edna espec\u00edfica, el factor intr\u00ednseco de Castle (FI) y el \u00e1cido clorh\u00eddrico, a prop\u00f3sito se ha demostrado una disminuci\u00f3n en los niveles plasm\u00e1ticos de vitamina B\n12, durante el tratamiento con \nomeprazol6. El medio \u00e1cido del est\u00f3mago y la pepsina, facilitan la \nseparaci\u00f3n de la B 12 de las prote\u00ednas de los alimentos a los que se \nencuentra unida. Tambi\u00e9n pacientes con insuficiencia pancre\u00e1tica,  \n \n 82pueden tener disminuida la absorc i\u00f3n de Cbl, aunque rara vez llegan a \ntener deficiencia7. \nEn la luz gastro-intestinal, la B 12, ya disociada de las prote\u00ednas, se \nune a las haptocorrinas, prote\u00ednas segregadas por las gl\u00e1ndulas \nsalivares y la mucosa g\u00e1strica. En el  intestino delgado, las proteasas \npancre\u00e1ticas, degradan las haptocorrinas, liber\u00e1ndose la B 12 que se une \nal FI, el complejo resultante, B 12-FI, se une a los receptores de la mucosa \nileal. Aproximadamente 3-4 horas despu\u00e9s de la ingesta, la B 12 es \nabsorbida ingresando en circulaci\u00f3n. La  falta de FI da lugar a la anemia \nperniciosa. \nEn plasma, la vitamina B 12 se une para su transporte a unas \nprote\u00ednas plasm\u00e1ticas espec\u00edficas, la transcobalamina I, II y III. Solo la \nB12 unida a la Transcobalamina II pued e ser internalizada por las c\u00e9lulas \nmediante un receptor espec\u00edfico que permite dicha internalizaci\u00f3n8,9. \nSolo el 6-20% de la cobalamina ci rculante, se encuentra unida a la \ntranscobalamina II. La uni\u00f3n B 12-transcobalamina II constituye la \nllamada Holotranscobalamina II, la determinaci\u00f3n de este complejo parece ser importante en el diagn\u00f3stico precoz del d\u00e9ficit vitam\u00ednico que nos ocupa, aunque se necesitan m\u00e1s estudios para determinar el valor de esta prueba en el diagn\u00f3stico precoz de dicho d\u00e9ficit\n8. La \ndeficiencia de transcobalamina II da  lugar a una anemia megalobl\u00e1stica \nmuy severa en la infancia10, la deficiencia de transcobalamina I y III \nparece ser benigna11. \nLa cianocobalamina se acumula en ciertos tejidos que hacen la \nfunci\u00f3n de dep\u00f3sitos de reserva, entre ellos destaca el h\u00edgado. El contenido de B\n12 almacenada en el h\u00edgado de adultos es \naproximadamente de 1 \u00b5g/g de tejido12,13. \nLa cantidad de B 12 total almacenada en el organismo va desde los \n0.6 mg14 a los 3.9 mg15, otros autores estiman esta cantidad entre los 2 y \n3mg16-19. La excreci\u00f3n de B 12, es proporcional a los dep\u00f3sitos y ocurre \nprincipalmente a trav\u00e9s de las heces20, tambi\u00e9n en menor cantidad por \nla orina17,18,21 . Se pierde vitamina B 12, de forma diaria, en una cantidad \nque oscila entre el 0.1-0.2 %22,23. \n \nD\u00c9FICIT CL\u00cdNICO DE VITAMINA B 12: \nYa sea por d\u00e9ficit nutricional, disminuci\u00f3n de la absorci\u00f3n por \ncausa g\u00e1strica o intestinal, alteraciones en el transporte s\u00e9rico de la  \n \n 83vitamina B 12, o alteraciones metab\u00f3licas cong\u00e9nitas, el estadio final del \nd\u00e9ficit, es la anemia megalobl\u00e1stica.  \nDe comienzo insidioso, suele pasar inadvertido, el enfermo \nacude al m\u00e9dico por cansancio, disnea de esfuerzo, palpitaciones, \ndolores angoroides, s\u00edntomas es tos comunes a cualquier anemia \nestablecida.  \nSe afectan las tres series medu lares, dando lugar a leucopenia, \nanemia y trombopenia, en ocasiones de origen autoinmune24. La \nanemia, es macroc\u00edtica, con un volumen corpuscular medio (VCM) \nsuperior a 100 fl, debi\u00e9ndose hacer el diagnostico diferencial con otras \ncausas de macrocitosis, que cursan  con niveles de vitaminas normales2.  \nLa serie mielopoy\u00e9tica tambi\u00e9n se afecta, apareciendo \nleucopenia, gigantismo y el signo m\u00e1s patognom\u00f3nico la polisegmentaci\u00f3n neutr\u00f3fila\n25, hallazgo t\u00edpico de  la anemia \nmegalobl\u00e1stica establecida. Tambi\u00e9n puede haber trombopenia. \nMenci\u00f3n especial por su incidencia merece la anemia perniciosa \nde Addison-Biermer. Propia de la presenilidad y vejez fu\u00e9 descrita por \nAddisson en 1855 y completada cl\u00ednicamente por Biermer en 1872. Esta enfermedad se produce por una disminuci\u00f3n de la absorci\u00f3n intestinal de vitamina B\n12.  \nEtiopatol\u00f3gicamente el estomago de estos enfermos deja de \nsegregar FI. Hoy en d\u00eda, se cono ce el mecanismo inmunol\u00f3gico \nautoinmune responsable de las alterac iones g\u00e1stricas y la malabsorci\u00f3n \nde vitamina B 12. Por un lado, las c\u00e9lulas parietales del estomago van \ndesapareciendo progresivamente, se va configurando la gastritis atr\u00f3fica que puede llegar a la atrofia g\u00e1strica cuando desaparecen todas \nlas c\u00e9lulas parietales. En estos enferm os se demuestran anticuerpos anti \nc\u00e9lulas parietales y anti Factor intr\u00ednseco de tipo bloqueante, que impide la uni\u00f3n del FI a los receptores espec\u00edficos de la mucosa ileal. Por otro lado, la etiolog\u00eda autoinmune , se apoya en la asociaci\u00f3n de la \nenfermedad con otras enfermedades autoinmunes como tireotoxicosis, hipotiroidismo, enfermedad de Hashimoto, etc. Se ha descrito alg\u00fan \ncaso de la enfermedad durante tratamientos con interfer\u00f3n\n26, tambi\u00e9n es \nfrecuente la asociaci\u00f3n a c\u00e1ncer g\u00e1strico. \nHay una predisposici\u00f3n gen\u00e9tica y racial a padecer la \nenfermedad.  \n \n 84Las manifestaciones cl\u00ednicas  caracter\u00edsticas de la anemia \nperniciosa son la lengua ardiente,  dolorosa y agrietada, apareciendo \ndepapilada y roja por la glositis atr\u00f3fica27. Pueden aparecer tambi\u00e9n \ns\u00edntomas digestivos como dolor epig\u00e1strico, flatulencia y diarrea. \nPueden aparecer parestesias en miembros superiores o inferiores y otros s\u00edntomas neurol\u00f3gicos dependientes de la mielosis funicular\n28 que \nacompa\u00f1a a la enfermedad. En la exploraci\u00f3n se observa un tinte \nict\u00e9rico, amarillo lim\u00f3n. No suele haber hepato-esplenomegalia. \nSe han descrito algunos casos de esta enfermedad sin anemia, \nestos casos se manifestaron por macrocitosis y glositis. La enfermedad \nse diagnostica por niveles de B 12 bajos, anticuerpos anti-Factor \nIntr\u00ednseco y excreci\u00f3n aumentada por la orina de grandes cantidades de \n\u00e1cido metilmal\u00f3nico con valores superiores a 4 mg/24 horas29. La \nexcreci\u00f3n aumentada de metilmal\u00f3nico, es patognom\u00f3nica del d\u00e9ficit de B\n12, permaneciendo normal si se trata solo de un d\u00e9ficit de folato.  \nDado que esa megaloblastosis suele ser uno de los primeros \nindicios que hacen sospechar la existencia de un d\u00e9ficit de B 12, cualquier \ncircunstancia que enmascare dicha megaloblastosis puede determinar \nque el d\u00e9ficit de B 12 pase desapercibido y, por tanto, el enfermo quede \nsin diagn\u00f3stico y oportuno tratamiento con lo que las manifestaciones \nneurol\u00f3gicas espec\u00edficas del d\u00e9ficit de vitamina B 12 contin\u00faan su \nevoluci\u00f3n llegando a ser irreversibles30. Uno de los factores \nnutricionales que se sabe enmascara la megaloblastosis por d\u00e9ficit de B 12 \nes la administraci\u00f3n de suplemento s con folato. Este problema debe \ntenerse en cuenta cuando se instau ra dicha suplementaci\u00f3n con folato \nen personas con riesgo de padecer d\u00e9ficit de B 12 (ancianos y \nvegetarianos).  \nOtras causas de d\u00e9ficit de B 12: \nLas enfermedades g\u00e1stricas y la gastrectom\u00eda total o parcial \npueden dar lugar a una anemia megalobl\u00e1stica, por ausencia o disminuci\u00f3n de Factor Intr\u00ednseco y como consecuencia d\u00e9ficit de vitamina B\n12. \nLa vagotom\u00eda y la medicaci\u00f3n con receptores anti H 2, inhibidores \nde la bomba de protones, reducen la absorci\u00f3n de B 12 y puede provocar \ntambi\u00e9n d\u00e9ficit de vitamina B 12 por lo que algunos autores recomiendan \nla suplementaci\u00f3n vitam\u00ednica cuan do se inicia el tratamiento con \nanti\u00e1cidos31.  \n \n 85Enfermedades intestinales : Resecciones de \u00edleon, ile\u00edtis, esprue, \nceliaqu\u00eda o parasitaciones por Botrioc\u00e9falo. El motivo es la falta de receptores ileales para el complejo B\n12-FI, que limita su absorci\u00f3n.  \nTambi\u00e9n se produce en la enfermedad pancre\u00e1tica  severa. La falta \nde enzimas pancre\u00e1ticas impide la ruptura de la uni\u00f3n haptocortina-B 12, \nla vitamina B 12 no se puede transferir y unir se al FI, esto ocurre en el \ns\u00edndrome de Zollinger-Ellison, tumor generalmente pancre\u00e1tico, en el \nque se producen grandes cantidades de gastrina. Esto da lugar a grandes cantidades de ClH, lo que puede provocar malabsorci\u00f3n de la \nB\n12 dado que se impide la transferencia desde la haptocortina al FI. \nD\u00e9ficit de B 12 por aporte insuficiente en la dieta , son raros en \nnuestro medio, no as\u00ed en pa\u00edses cu ya dieta en muy pobre en alimentos \nde origen animal. Los vegetarianos y lactantes de madres vegetarianas, \ntambi\u00e9n pueden sufrir este d\u00e9ficit. En caso de malnutriciones severas, \npueden coexistir junto al d\u00e9ficit de vitamina B 12, d\u00e9ficit de hierro y \nfolatos. \n \nD\u00c9FICIT SUBCL\u00cdNICO DE VITAMINA B 12 \nSe puede decir que existe un d\u00e9 ficit subcl\u00ednico de vitamina B 12 \ncuando existe tal d\u00e9ficit pero no hay manifestaciones hematol\u00f3gicas que \nnos hagan pensar en el mismo. Este d\u00e9 ficit ocurre pues sin anemia y sin \nalteraciones hematol\u00f3gicas t\u00edpicas: macrocitosis y polisegmentaci\u00f3n neutr\u00f3fila. \nA veces, algunos pacientes, presentan alteraciones solo \ndemostrables electrofisiol\u00f3gicamente, lo que demuestra cambios neurol\u00f3gicos escondidos tras la apariencia de asintom\u00e1ticos\n32,33. \nLa principal y m\u00e1s grave caracter\u00edstica de la deficiencia \nsubcl\u00ednica de B 12 son las alteraciones. La sintomatolog\u00eda neurol\u00f3gica \n(tabla 2) es inespec\u00edfica, muy variad a y frecuente, pudiendo ir desde la \nneuropat\u00eda perif\u00e9rica, con disminuci\u00f3n de la sensibilidad superficial a la \nm\u00e1s grave, la degeneraci\u00f3n de lo s cordones espinales (mielosis \nfunicular), t\u00edpica de la anemia Perniciosa28. Las alteraciones \nneurol\u00f3gicas perif\u00e9ricas, son muy frecuentes y preceden a veces a las \nanomal\u00edas hematol\u00f3gicas, empiezan de forma insidiosa y son principalmente de tipo sensitivo, parestesias o debilidad muscular.  \n \n 86Los desordenes mentales ligados al d\u00e9ficit de B 12 son frecuentes y \npueden ser de tipo paranoide, esquizoide o depresivo. Se ha relacionado el d\u00e9ficit de vitamina B\n12 con la enfermedad de Alzheimer. \nCon frecuencia no se piensa en esta  causa que, l\u00f3gicamente es preciso \ntomar en consideraci\u00f3n. As\u00ed, el d\u00e9ficit de vitamina B 12, esta relacionado \ncon un mayor riesgo de padecer de presi\u00f3n severa, y otros trastornos \nneuropsiqui\u00e1tricos como agitaci\u00f3n y estados paranoicos,34-37. Mujeres \ncon niveles bajos de B 12 est\u00e1n particularmente inclinadas a la depresi\u00f3n. \nHay autores que consideran que el d\u00e9ficit de B 12 multiplica por \ndos el riesgo de depresi\u00f3n severa38. Sin embargo, otros autores han \nestudiado la depresi\u00f3n y su relaci\u00f3n con la alimentaci\u00f3n vegetariana u omn\u00edvora, y aunque la prevalencia de d\u00e9ficit de vitamina B\n12 es mayor \nentre la poblaci\u00f3n vegetariana, estos autores encuentran una menor tasa \nde depresi\u00f3n en esta poblaci\u00f3n39, por tanto, otros factores deben estar \ntambi\u00e9n implicados. Tambi\u00e9n se ha relacionado el d\u00e9ficit de vitamina \nB12 con la enfermedad de Alzheimer que constituye la demencia senil \nm\u00e1s frecuente en la poblaci\u00f3n occidental40. \nLa deficiencia de B 12 se ha relacionado con la aterosclerosis. La \nimplicaci\u00f3n de la vitamina B 12 en la fisiopatolog\u00eda de la aterosclerosis es \na trav\u00e9s de la homociste\u00edna41. El mecanismo fisiopatol\u00f3gico por el que la \nhiperhomocisteinemia condiciona la lesi\u00f3n cardiovascular no est\u00e1 del \ntodo esclarecido. Parece que interact\u00fa a directa y/o indirectamente sobre \nel proceso aterog\u00e9nico, contribuye ndo por una parte a la disfunci\u00f3n \nendotelial y por otra facilitando la  trombog\u00e9nesis. Adem\u00e1s de la \nvitamina B 12, otras vitaminas del grupo B (Folato, B 2, B 6) pueden ser \ndeterminantes de hiperhomocisteinem ia. La hiperhomocisteinemia est\u00e1 \nconsiderada hoy d\u00eda como un factor de riesgo independiente de las \nenfermedades cardiovasculares, incluyendo las enfermedades \ncoronarias y la patolog\u00eda cerebrovascular. Aunque en la \u00faltima d\u00e9cada se han reducido el n\u00famero de muertes en n\u00fameros absolutos, debido a las medidas de salud p\u00fablica, incluyendo aspectos nutricionales y promoci\u00f3n de la actividad f\u00edsica, para el a\u00f1o 2020 estas enfermedades \nseguir\u00e1n ocupando el primer lugar de causa de muerte en los pa\u00edses \noccidentales. Una revisi\u00f3n sobre el  papel de la homociste\u00edna como \nfactor de riesgo cardiovascular ha  sido recientemente publicada por \nnuestro grupo\n42. \n   \n \n 87Metodolog\u00eda diagn\u00f3stica \nEl diagn\u00f3stico de la deficiencia de vitamina B 12 est\u00e1 basado en \ncriterios cl\u00ednicos, morfol\u00f3gicos y bioqu\u00edmicos. Es muy importante el \ndiagn\u00f3stico precoz, antes que las alteraciones neurol\u00f3gicas se hagan \nirreversibles, por eso en los \u00faltimo s a\u00f1os se han ido desarrollando una \nserie de t\u00e9cnicas encaminadas al diagn\u00f3stico precoz. Entre ellas cabe destacar la holotranscobalamina II (holoTC-II), el \u00e1cido metilmal\u00f3nico (AMM) y la homociste\u00edna total (tHcy). \nEl diagn\u00f3stico de la deficiencia de B\n12 permite ahora un mejor \ndiagn\u00f3stico incluso en casos at\u00edp icos, una mayor confianza en el \nrechazo de casos en que no existe de ficiencia y m\u00e1s f\u00e1cil diagn\u00f3stico en \ncasos de deficiencia subcl\u00ednica43. \nEl desarrollo del d\u00e9ficit de B 12 e s  l e n t o ,  v a  a c o m p a \u00f1 a d o  d e  \nastenia, perdida de memoria y polineuropat\u00eda36,37,44-47 . Pero hay que \ntener en cuenta que los s\u00edntomas neurol\u00f3gicos m\u00e1s o menos severos, \npueden ocurrir en ausencia de anemia en una considerable proporci\u00f3n \nde pacientes38. \nLos s\u00edntomas inespec\u00edficos con lo s que comienza el proceso, la \nposible ausencia de anemia y los da\u00f1os en el sistema nervioso que pueden llegar a ser irreversibles cuando el diagn\u00f3stico es tard\u00edo\n48,49, son \nun fuerte incentivo para establecer un adecuado diagn\u00f3stico. \n \nCuadro hem\u00e1tico perif\u00e9rico \nLa Hematimetr\u00eda completa, y el examen morfol\u00f3gico de la sangre \nperif\u00e9rica, nos pueden ayudar mucho al diagn\u00f3stico de sospecha. El \nVCM se eleva, pero esto ocurre cuando la vitamina B 12 est\u00e1 por debajo \nde 200 pg/ml. Algunos autores como Chanarin y Metz50, atribuyen la \ninsensibilidad del VCM a los rangos de normalidad de la mayor\u00eda de \nlos laboratorios, y recomiendan que vol\u00famenes de 94 fl y superiores, sean sospechosos de d\u00e9ficit de B\n12. \n \nNiveles de B 12 \nMuchos autores han hablado sobre las limitaciones en la \ndosificaci\u00f3n de la vitamina B 122,51,52.  \n \n 88Es el test m\u00e1s familiar, el de  m\u00e1s bajo coste y m\u00e1s amplia \ndisponibilidad, lo que ha contribuido a favorecer el papel de este test en \nel diagn\u00f3stico del d\u00e9ficit de Cobala mina, a pesar de las limitaciones en \nsu especificidad51. y de la controversia en cuanto a su sensibilidad que \nes del 97% solo en caso de d\u00e9ficit cl\u00ednico51. Tabla III. \nMuchas son las t\u00e9cnicas que se han ido utilizando para medir los \nniveles de vitamina B 12, son m\u00e9todos microbiol\u00f3gicos, isot\u00f3picos y \nt\u00e9cnicas de enzimoinmunoensayo.  \nDependiendo de la t\u00e9cnica utilizada y del laboratorio que realice \nla prueba, el limite bajo de la normalidad para la vitamina B 12, es muy \nvariable51,53,54 . Hoy utilizamos el corte tradicional de 200 pg/ml como \nvalor de normalidad, basado en m\u00faltiples estudios en los cuales se estudian pacientes cobalamino defici entes diagnosticados por criterios \ncl\u00ednicos y hematol\u00f3gicos y comparados con sujetos sanos\n55. El uso para \nel diagn\u00f3stico de la deficiencia de la holoTC-II, del \u00e1cido \nmetilmal\u00f3nico50,56 y homociste\u00edna, ha mejorado las expectativas del \ndiagn\u00f3stico precoz, encontrandose valores patol\u00f3gicos incluso con niveles normales de la vitamina, se postula que la deficiencia tisular es \nmayor y m\u00e1s  frecuente que la deficiencia s\u00e9rica\n57 de Cobalamina. \nSe ha demostrado, la elevaci\u00f3n de los metabolitos incluso con \nnivel normal de la vitamina. La deficiencia tisular es responsable entre \notros de los desordenes neuropsiqui\u00e1tricos y enfermedad tromboemb\u00f3lica, por lo que se recomienda la suplementaci\u00f3n vitam\u00ednica en poblaciones de riesgo  como ancianos, incluso con niveles \ns\u00e9ricos normales de las vitaminas correspondientes. \nRecordar que una B\n12 normal no excluye la  deficiencia funcional \nde Cobalamina, por tanto, es m\u00e1s importante la dosificaci\u00f3n de los \nmetabolitos dependientes de la vitamina B 12, el \u00e1cido Metilmal\u00f3nico y la \nHomociste\u00edna. \nFalsas elevaciones se han observado en los s\u00edndromes \nmieloproliferativos, por el contrari o, valores falsamente bajos se \nobservan en la deficiencia de folato58, embarazo, mielomatosis y en la \ndeficiencias de Transcobalamina. En la disbacteriosis intestinal, puede \nhaber niveles de B 12 normal, por la producci\u00f3n por parte de las bacterias \nde Cobalamina biol\u00f3gicamente inactiva59. \n \n  \n \n 89Niveles de folato s\u00e9rico y eritrocitario \nSe deben medir los niveles de folato, tanto s\u00e9rico como \nintraeritrocitario, ya que pueden coexistir el d\u00e9ficit de folato junto a la \ndeficiencia de vitamina B 12. \n\u00c1cido metilmal\u00f3nico (AMM) \nAunque las elevaciones del AMM son muy espec\u00edficas60 del \nd\u00e9ficit de vitamina B 12, tambi\u00e9n puede aparecer elevado en la \ninsuficiencia renal cr\u00f3nica61,62, hipovolemia y algunos defectos \nmetab\u00f3licos cong\u00e9nitos (Tabla A).  \nLa determinaci\u00f3n del AMM63-65 en suero, ha recibido una especial \natenci\u00f3n, debido a la estabilidad del AMM en sangre y la peque\u00f1a muestra necesaria\n66 , pero el coste elevado y la complejidad del m\u00e9todo \nimpiden su uso rutinario. Otros autore s analizan la utilidad diagn\u00f3stica \ny el coste beneficio de dicha prueba67. \nLa medida del AMM urinario puede estar indicado en pacientes \ncon insuficiencia renal, para distinguir la elevaci\u00f3n del AMM s\u00e9rico \npropia de la insuficiencia renal de un d\u00e9ficit real de B 1267. \nHomociste\u00edna \nEs un muy buen test para el  diagn\u00f3stico del d\u00e9ficit de \nCobalamina51,60. Su elevaci\u00f3n aparece temprano y precede en el tiempo \na los s\u00edntomas, aumenta cuando aume nta la deficiencia y no decrece \nhasta que se establece el tratamiento. \nPero tiene poca especificidad, la minor\u00eda de las elevaciones de la \nHomociste\u00edna se deben al d\u00e9ficit de Cobalamina y en su mayor\u00eda a d\u00e9ficit de folato o el abuso de alcohol\n68,69, o reflejan caracter\u00edsticas \npersonales o de h\u00e1bito de vida ta mbi\u00e9n en enfermedades sist\u00e9micas \ncomo el Lupus, donde parece no estar recomendado el tratamiento70 \n(Tabla A). Los intervalos de referencia no son universalmente aceptados\n71. \nTanto el AMM como la Homociste\u00edna, se elevan con la edad, lo \npuede indicar el d\u00e9ficit subcl\u00ednico de estas vitaminas en ancianos 72. \nAMM y la Homociste\u00edna se han mostrado muy eficaces en el \ndiagn\u00f3stico del d\u00e9ficit de vitamina B 12, en el estudio de Stabler73, usando \nla respuesta al tratamiento con B 12 como evidencia del diagn\u00f3stico, \ntienen elevado al menos un metabolito un 94 % de los pacientes.  \n \n 90En algunos pacientes, con d\u00e9ficit \u00fan ico de folato en el estudio de \nSavage 60, se evidencio una elevaci\u00f3n del AMM en 15 de 123 pacientes, \n11 de ellos ten\u00edan Insuficiencia renal y 3 Hipovolemia. \nLa utilidad del an\u00e1lisis de los metabolitos en las deficiencias \nmoderadas es incierta, aunque es sa bido que las elevaciones del AMM y \nHomociste\u00edna preceden a los cambio s hematol\u00f3gicos, neurol\u00f3gicos y a \nlos niveles s\u00e9ricos bajos de B 12 74. \nLos metabolitos, pueden dar elevaciones falsas como se ha visto \nen una tabla anterior, particularmen te en los ancianos en que la \nprevalencia de niveles altos de A MM y Homociste\u00edna es mucho mayor \nque los niveles bajos de B 12 o evidencia cl\u00ednica de deficiencia54,75 . Esto es \nas\u00ed por que los test no son espec\u00edficos y por la deficiencia subcl\u00ednica de B\n12, folato o B 6. Por todo esto hay que tomar con precauci\u00f3n las \nelevaciones de los metabolitos sin evidencia cl\u00ednica de la deficiencia50,56. \nDespu\u00e9s del tratamiento de la  deficiencia, los metabolitos \ntienden a normalizarse al cabo de 7-14 d\u00edas74. \nEn pacientes con deficiencia de Cobalamina, tratados con folato \ninapropiadamente, el AMM permanecer\u00e1 alto92. En otros trabajos76,77 se \nsugiere que la normalizaci\u00f3n de los metabolitos despu\u00e9s del tratamiento es una respuesta inespec\u00edfica. \nDada la importancia que est\u00e1 adquiriendo la determinaci\u00f3n de la \nHomociste\u00edna, se ha pensado en los posibles efectos de la fase preanal\u00edtica, sobre la determinaci\u00f3n,  parece que el \u00e9xtasis venoso \nprolongado provocado por el torniquete, puede provocar diferencias en los niveles de Homociste\u00edna\n78. Lo mismo cabe pensar de la postura del \nenfermo durante la venopunci\u00f3n79, algunos autores han recomendado \nhacer la venopunci\u00f3n sin tornique te y despu\u00e9s de 15 minutos de \nreposo109, esto no es posible en muchos laboratorios.  \nInmediatamente despu\u00e9s de tomada la muestra ya sea de suero o \nanticoagulada preferiblemente con EDTA80, las c\u00e9lulas rojas empiezan a \nceder homociste\u00edna al plasma81,82, causando un incremento artificial de \nesta, la homociste\u00edna aumenta un 10%  por hora hasta la centrifugaci\u00f3n, \npor ello para inhibir este efecto81,82 y tener unos resultados fiables, las \nmuestras deben ser colocadas inmediat amente despu\u00e9s de la extracci\u00f3n \nen un ba\u00f1o de hielo y centrifug ar antes de una hora y por \u00faltimo \nrealizar la determinaci\u00f3n o congelar a -20\u00baC hasta la realizaci\u00f3n de la  \n \n 91prueba. A\u00f1adiendo Fluoruro84 o \u00e1cido c\u00edtrico85, a las muestras de \nsangre, tambi\u00e9n se controla el problema. \nLas causas que alteran las determinaciones de Cobalamina y sus \nmetabolitos la homociste\u00edna y el AMM. Las podemos consultar en la tabla V  \n Holotranscobalamina II \nLa mayor\u00eda de la Cobalamina circula en la sangre unida a la \nTranscobalamina I, llamada Haptocorrina que no libera Cobalamina a \nlos tejidos, es de m\u00e1s inter\u00e9s una peque\u00f1a fracci\u00f3n de Cobalamina que \nse une a la Transcobalamina II, es la llamada Holotranscobalamina II que s\u00ed libera Cobalamina para su uso a los tejidos. Recientes estudios \nhan demostrado que el descenso de la Holotranscobalamina II es un \nmarcador temprano del d\u00e9ficit\n86,87, mientras que otros88, en estudios \nsobre ancianos, dicen lo contrario. Todo esto debe ser m\u00e1s \ndocumentado. La especificidad de los niveles bajos puede ser limitada, \npuede estar baja en el d\u00e9ficit de vitamina B 12 y cuando hay un \nincremento de utilizaci\u00f3n de la Ho lo-TC II, como ocurre cuando hay \nhiperplasia eritroide89. \nHay m\u00e9todos radioisot\u00f3picos y los nuevos de inmunoan\u00e1lisis82,90, \nalguno comercializado90, considerando como valores normales los \nsuperiores a 50 pmol/L91. Es pronto para determinar si el uso de la \nHolotranscobalamina II tiene ventajas en el diagn\u00f3stico del d\u00e9ficit de Cobalamina\n92, aunque parece que la Holotranscobalamina II baja, es un \nsigno temprano del balance negativo de B 126, frecuentemente no \nasociado a alteraciones hematol\u00f3gicas8. \nValores normales o altos de B 12 y bajos de Holo-TC cursan con \nanemia megalobl\u00e1stica y alteraciones neurol\u00f3gicas, es la deficiencia hereditaria de Transcobalamina II\n93. \n \nPepsin\u00f3geno A y C s\u00e9rico: \nJunto con la gastrina, son in dicadores de atrofia g\u00e1strica  2,,94,95 .  \n \n 92Gastrina s\u00e9rica:  \nNiveles altos est\u00e1n presentes en el 80-90 % de los pacientes de \nAnemia perniciosa55,96, puede elevarse en pacientes con diferentes \ngrados de gastritis atr\u00f3fica que pueden tener malabsorci\u00f3n de B 12 unida \na prote\u00ednas, el test limita su especificidad y sensibilidad para detectar anormalidades g\u00e1stricas subcl\u00ednicas \n97,98. \n \nAnticuerpos anti-c\u00e9lulas parietales: \nPueden tener un papel importante en la etiopatogenia de la \ngastritis autoinmune de la Anemia Perniciosa99. Est\u00e1n presentes en el 85 \n% de los pacientes con anemia perniciosa55,100, pero no son espec\u00edficos, \npues pueden estar presentes en otro s procesos autoinmunes y en un 3-\n10 % de personas sanas, dependiendo de la edad101. \n \nAnticuerpos anti-Factor Intr\u00ednseco: \nSon menos espec\u00edficos que los anteriores, solo est\u00e1n presentes en \nla mitad de los caso de Anemia Perniciosa 55,102. Es raro encontrarlos en \npacientes sanos o con otras enfermedades autoinmunes103, se han visto \nen algunos pacientes con enfermedad de Graves, en tales casos se encuentra una gastritis atr\u00f3fica con producci\u00f3n normal de FI \n104. \n \nM\u00e9dula \u00f3sea \nGeneralmente no es necesario es te examen para el diagn\u00f3stico44, \npero en alg\u00fan estudio se ha hecho para identificar la enfermedad en pacientes con alteraciones neurol\u00f3gicas sin anemia \n38. \nEl aspirado de m\u00e9dula \u00f3sea, es muy rico en pulpa medular, \nobserv\u00e1ndose un predominio de la serie roja, que puede representar el \n40-60% de los elementos nucleados de la m\u00e9dula. Es t\u00edpica la presencia de megaloblastos, eritroblastos de gran tama\u00f1o de citoplasma a menudo muy bas\u00f3filo y n\u00facleo inmaduro, son frecuentes las mitosis, muchas veces se observa asincronismo madurativo n\u00facleo-citoplasma. La hemopoyesis megalobl\u00e1stica es la responsable de la eritropoyesis \nineficaz y de la hem\u00f3lisis perif\u00e9rica.  \n \n 93Se han publicado casos en que la  m\u00e9dula se pod\u00eda confundir con \nuna leucemia aguda, que regres\u00f3 inmediatamente tras tratamiento con vitamina B\n1251. \nLa serie mielopoy\u00e9tica, tambi\u00e9n muestra un gigantismo celular. \nLos megacariocitos son muy grandes y segmentados. Es muy valida para el diagn\u00f3stico \n2,105. \n \nCuadro bioqu\u00edmico \nLa hem\u00f3lisis acelerada de los hemat\u00edes macroc\u00edticos da lugar a \nuna hiperbilirrubinemia indirecta y a un incremento de la LDH, sobre \ntodo la isoenzima LDH 1. No es infrecuente la Hipersideremia. \nLa eritropoyesis ineficaz est\u00e1 provocada por: un tiempo de \ns\u00edntesis del DNA prolongado y por el aborto eritrobl\u00e1stico \nintramedular, con un aumento de la fagocitosis por los histiocitos de los eritroblastos patol\u00f3gicos. \n \nTest de s\u00edntesis de la Timidina: \nLa prueba mide la incorporaci\u00f3n de la timidina radiactiva al \nDNA celular, la preincubaci\u00f3n de las c\u00e9lulas con deoxiuridina suprime dicha incorporaci\u00f3n. En la  deficiencia de folatos se  impide la conversi\u00f3n \ndel deoxiuridilato en deoxitimidilato, con lo que la prueba saldr\u00e1 \nalterada. La deficiencia de vitamina B\n12 provoca una disminuci\u00f3n del \nmetiltetrahidrofolato, con lo que la pr ueba se altera de forma similar. La \nadici\u00f3n de vitaminas in vitro y el estudio de si corrigen o no la prueba, permiten diferenciar ambos procesos, es un test muy sensible en el \ndiagn\u00f3stico de la anemia megalobl\u00e1stica, por d\u00e9ficit de folato o de \nvitamina B\n12106. Utiliza m\u00e9dula \u00f3sea y es dif\u00edcil de estandarizar por lo \nque es raramente usado 50,106. \nLas determinaciones del \u00e1cido 2-Metilc\u00edtrico I y II148 y \nCistationina s\u00e9rica 107 pueden utilizarse en el diagn\u00f3stico, aunque son \nt\u00e9cnicas no utilizadas de rutina.  \nUna vez identificado el d\u00e9ficit en B 12, hay que identificar la causa \ndel d\u00e9ficit, obviar este paso puede si gnificar un error diagn\u00f3stico grave, \nno olvidemos que en algunos casos el d\u00e9ficit puede ir acompa\u00f1ado de un c\u00e1ncer g\u00e1strico.  \n \n 94Estudio de Absorci\u00f3n de B 12: Test de Schilling:110 \nSe administra Cobalamina marcada con cobalto radiactivo, si se \ndemuestra carencia de absorci\u00f3n, se repite la prueba administrando \nCobalamina y Factor intr\u00ednseco, si se corrige la malabsorci\u00f3n, el \nproblema est\u00e1 en el F.I. y estamos an te una anemia perniciosa, si no se \ncorrige el problema es de origen intestinal. \nPaso 1 : \nSe da una dosis de B 12 cristalina por boca va marcada con cobalto \nradioactivo y se mide la cantidad de  Cobalamina eliminada en orina de \n24 horas. Si el resultado es anormal se pasa a: \nPaso 2 : \nSe realiza una semana despu\u00e9s y se da Cbl marcada con cobalto y \nFI. \nLa interpretaci\u00f3n del test la vemos en la tabla IV La elevaci\u00f3n de los niveles de Cobalamina tras tratamiento oral, \ndiagnostica la ausencia de malabsorci \u00f3n y el d\u00e9ficit de Transcobalamina \nI, que es responsable del 15% de las deficiencias de Cobalamina \n111. \nEstudio de la patolog\u00eda g\u00e1strica: \u0083 Aclorhidria resistente a la estimulaci\u00f3n con histamina \n\u0083 Ausencia de Factor Intr\u00ednseco en el jugo g\u00e1strico \n\u0083 Anticuerpos anti-F.I \n\u0083 Anticuerpos anti c\u00e9lulas parietales \n \nPrueba terap\u00e9utica : \nAlgunas veces, a pesar de estas determinaciones, el diagn\u00f3stico \nes dudoso y se recurre a la prueba terap\u00e9utica con B\n12 parenteral. \nDespu\u00e9s de iniciado el tratamiento, el VCM tiende a aumentar en los \nprimeros 3-4 d\u00edas, presumiblemente por causa de la reticulocitosis, \ndespu\u00e9s decrece hasta alcanzar los rangos de normalidad en 25-78 d\u00edas\n81. \n  \n  \n \n 95Hay que tener varias cosas en cuenta: \n1.- La respuesta al tratamiento puede ser escasa o nula si se \nasocia un d\u00e9ficit de hierro o a otra enfermedad cr\u00f3nica que \ndisminuya la respuesta reticulocitaria. \n2.-Los resultados pueden ser ambi guos en pacientes con anemia \nmedia, no hay que olvidar que la respuesta es proporcional al \ngrado de anemia 55. \n3.-El tratamiento con folato en pacientes con d\u00e9ficit de \nCobalamina, puede mejorar los par\u00e1metros hematol\u00f3gicos, pero \nel da\u00f1o neurol\u00f3gico sigue y por el contrario tratamiento con B 12 \nen pacientes con d\u00e9ficit de folato  no causa mejor\u00eda hematol\u00f3gica \nalguna 112. \n \nResonancia Magn\u00e9tica: \nEn los \u00faltimos tiempos, se utiliza esta t\u00e9cnica para el diagn\u00f3stico \ndel d\u00e9ficit de Cobalamina113. La imagen puede identificar pacientes con \ndeficiencia de Cobalamina con s\u00edntomas neurol\u00f3gicos y par\u00e1metros hematol\u00f3gicos normales y puede ser utilizado para constatar la mejor\u00eda \nde las alteraciones neurol\u00f3gicas tras tratamiento espec\u00edfico\n114. \n \nEstrategia diagn\u00f3stica del paciente: \nNaturalmente no todos los test hay que hacerlos a todos los \npacientes, aunque no existe un diag n\u00f3stico est\u00e1ndar en cada paciente y \nseg\u00fan el contexto cl\u00ednico hay que se guir una estrategia determinada, se \nrequieren resultados anormales en un m\u00ednimo de dos test, estos no deben ser subsidiarios de dar falso negativo por los mismos motivos, \npor ejemplo la Homociste\u00edna y el AMM que se elevan en la insuficiencia \nrenal, lo mismo ocurre con la Cobalamina y la Holotranscobalamina II que hablan de la Cobalamina circul ante, una combinaci\u00f3n aceptable es \nholoTC-II y homociste\u00edna, podemos ve r las estrategias en varios casos \ntipo: \nEn pacientes con s\u00edntomas y signos t\u00edpicos de la enfermedad, \ncomo son la anemia megalobl\u00e1stica y la neuropat\u00eda, est\u00e1 indicada la \nCobalamina s\u00e9rica, donde la posibilidad de un nivel normal falso es de un 2,9% de los casos\n51 de pacientes con deficiencia cl\u00ednica manifiesta.   \n \n 96Los niveles de Cobalamina pueden ser falsamente bajos en la \ndeficiencia de folato55, esclerosis m\u00faltiple115 y en la infecci\u00f3n por HIV y \nel d\u00e9ficit real debe ser diagnosticado por el aumento del AMM o de la \ntHcy o descenso de la holoTC-II. Po r otro lado en estos enfermos los \nniveles bajos de Cobalamina son un signo de mal pron\u00f3stico116  \natribuidos al bajo contaje de c\u00e9lulas blancas factor asociado a la enfermedad avanzada\n117. \nUna vez hecho el diagn\u00f3stico hay que buscar la causa, la \nmalabsorci\u00f3n explica el 90% de los casos de deficiencia cl\u00ednica55,118. Se ha \npublicado malabsorci\u00f3n de B 12 unida a prote\u00ednas procedente de los \nalimentos y absorci\u00f3n normal de la Cobalamina libre.  \nEn pacientes con anemia o problemas neurol\u00f3gicos de naturaleza \nincierta. El dilema principal se presenta cuando los niveles de \ncobalamina son normales83, en estos casos hay que hacer test \nmetab\u00f3licos (AMM y Homociste\u00edna). \nEn pacientes con causa conocida para d\u00e9ficit de Cobalamina, \nenfermedad ileal, enfermedad g\u00e1strica, infecci\u00f3n por el Helicobacter pylori\n165 y vegetarianos. Hay que hacer test metab\u00f3licos porque la \nanormalidad de estos preceden a los niveles de Cobalamina bajos y a los signos y s\u00edntomas de la enfermedad\n51,120,121 . \nEn pacientes asintom\u00e1ticos en qu e se encuentra accidentalmente \nunos niveles de Cobalamina bajos u otras anormalidades bioqu\u00edmicas, \nse realiza de elecci\u00f3n el AMM que estar\u00e1 elevado precediendo incluso al aumento de Homociste\u00edna\n54.  \n \nFactores que afectan los niveles de vitamina B 12: \n \nEnvejecimiento: \nCon el aumento de la edad, las concentraciones de vitamina B 12, \nvan disminuyendo, mientras que las del AMM, van aumentando. Los factores que contribuyen a estos cambios, son la disminuci\u00f3n de la acidez g\u00e1strica, la presencia de gastritis atr\u00f3fica y la perdida de \nvitamina B\n12 de los dep\u00f3sitos hep\u00e1ticos122.  \nEn un reciente estudio se ha publicado que la incidencia de \nd\u00e9ficit de B 12 en ancianos es del 5-15%, diagnosticados por elevaci\u00f3n del \nAMM y baja o normal vitamina B 1225,54, la Homociste\u00edna suele estar  \n \n 97elevada y ambos AMM y Homociste\u00edna bajan cuando se inicia el \ntratamiento con B 12123. \nDesde el inicio de la fortificaci\u00f3 n con folato un gran problema se \nha presentado y es que aunque el folato s\u00e9rico ha aumentado en la \npoblaci\u00f3n124,125  y los niveles de Homocist e\u00edna tienden a disminuir125 con \nel consiguiente potencial beneficio en la prevenci\u00f3n de la enfermedad vascular\n126, tambi\u00e9n se enmascara el d\u00e9ficit cl\u00ednico y subcl\u00ednico del \nd\u00e9ficit de vitamina B 12127,128 . \n \nTabaco: \nSe ha demostrado, un aumento de la excreci\u00f3n urinaria de \nvitamina B 12 en fumadores129, otros autores no encuentran diferencias \nsignificativas en los niveles de vitamina B 12, entre fumadores y no \nfumadores. \n Sexo: \nAlgunos autores, demuestran niveles de B\n12, mayores en hombres \nque en mujeres130-132 , mientras que otros no encuentran diferencias \nsignificativas entre los dos g\u00e9neros 133,134 . \n Vitamina C: \nLas dosis elevadas de vitamina C,  parecen afectar la dosificaci\u00f3n \nde vitamina B\n12 por radioinmunoensayo135, aunque parece que la \nabsorci\u00f3n nutricional no se afecta. \n \nFibra: \nLa fibra no afecta la absorci\u00f3n de vitamina B 12136. \n  \n \n 98Dieta vegetariana: \nEs conocida la gran prevalencia del d\u00e9ficit de vitamina B 12, entre \nla poblaci\u00f3n vegetariana, mientras que en esta la ingesta de folato \nsupera en mucho la recomendada (RDA), la ingesta de B 12, es \ninadecuada o ausente137,138 . Ya hemos comentado que solo los alimentos \nde origen animal139, son capaces de aportar vitamina B 12 al organismo.  \nLa deficiencia de Cobalamina de origen nutricional se puede \ndesarrollar en vegetarianos estrictos139,140 , ovolactovegetarianos141-143 y en \nhijos de madres vegetarianas140,144-147 , en estos ni\u00f1os se han observado \nalteraciones neurol\u00f3gicas148. \nRecientes estudios, han demost rado el d\u00e9ficit funcional de \nCobalamina con niveles normales de B 12 en suero y sin alteraciones \nmorfol\u00f3gicas149. \nTrastornos neuropsiqui\u00e1tricos, pueden desarrollarse en ausencia \nde macrocitosis y/o anemia56, a menudo la macroc itosis puede estar \nenmascarada por coexistir junto al d\u00e9ficit de vitamina B 12, ferropenia, \npor otro lado frecuente entre individuos vegetarianos 56,149. \nLa noci\u00f3n de que los vegetarianos, est\u00e1n protegidos de la \nenfermedad cardiovascular est\u00e1 mu y extendida. La dieta vegetariana, \nmodifica favorablemente varios factores de riesgo150-153 , disminuyendo \nlos riesgos y la mortalidad por enfermedad coronaria154-156 . Sin embargo, \ninsuficiencia o ausencia de alimentos de origen animal, origina una alteraci\u00f3n en el balance de la salud.  La disminuci\u00f3n en la ingesta de \ncarne, pollo, pescado, origina una deficiencia de vitamina B\n12. La \ntemprana manifestaci\u00f3n de la deficiencia de Cobalamina, es el incremento de la Homociste\u00edna\n157 conocido como un factor de riesgo \nindependiente de la enfermedad cardiovascular158, por otro lado la \nautoxidaci\u00f3n de la Homociste\u00edna estimula la peroxidaci\u00f3n lip\u00eddica, la formaci\u00f3n de productos proteicos oxidativos (AOPPs Advanced Oxidation Protein Products)\n159 y productos finales de la glicosilaci\u00f3n \n(AGEs Advanced Glycation end Products)160,161 , que est\u00e1n implicados en \nla patog\u00e9nesis de algunas enfermedades degenerativas e inflamatorias \nincluyendo a la arteriosclerosis137, la Homociste\u00edna se eleva antes que \ndisminuya la hemoglobina o el hematocrito. \nLa hiperhomocisteinemia se ha demostrado en ni\u00f1os que se \nalimentan de dietas macrobi\u00f3tica s y en ni\u00f1os nacidos de madres \nvegetarianas162 y en adultos vegetarianos163.  \n \n 99En segundo lugar, la exclusi\u00f3n de la dieta del pescado da lugar a \nuna disminuci\u00f3n de \u00e1cidos grasos n- 3 que induce a un aumento en el \nriesgo de enfermedad cardiaca, se ha demostrado que la ingesta regular \nde pescado est\u00e1 asociada a una disminuci\u00f3n en el riesgo de enfermedad \ncoronaria164,165 , los \u00e1cidos grasos n-3 y el aceite de pescado EPA (20:5, n-\n3) y DHA (22:6, n-3), parecen los responsables de este efecto \nbeneficioso166,167 . Su deficiencia incrementa la agregaci\u00f3n plaquetaria y \nconsecuentemente el riesgo de trombosis. Por lo que la dieta vegetariana, puede considerarse un factor de riesgo de enfermedad\n168. \n \nTratamiento: \nTradicionalmente, se recomienda el tratamiento con vitamina B 12 \nintramuscular169,170 , pero desde hace tiempo, se ha visto que el \ntratamiento oral es tambi\u00e9n efectivo20-22. Entre 1950 y 1960, varios \ninvestigadores171-174 , demuestran una v\u00eda adicional que no requiere de \nFactor Intr\u00ednseco o de un Ile\u00f3n intacto171,174-176  y si de grandes cantidades \nde cianocobalamina, del orden de 100 a 100.000 \u00b5g. De estas dosis que \nse dan a los pacientes por v\u00eda oral, aproximadamente el 1% se absorbe, lo que excede el requerimiento diari o de la vitamina. Otros autores, \ndemuestran unos resultados hematol\u00f3 gicos excelentes en pacientes con \nanemia perniciosa con dosis de 300 a 2000 \u00b5g de cianocobalamina \noral\n171,174 . Estos pacientes con dosis de mantenimiento de 1000 \u00b5g/d\u00eda, no \npadecen reca\u00eddas neurol\u00f3gicas ni hematol\u00f3gicas y las concentraciones de Cobalamina permanecen normales\n173,174,177 .  \nEn estudios m\u00e1s recientes178,179 , pacientes con deficiencia de \nCobalamina, se seleccionan en dos grupos de tratamiento, con \ncianocobalamina intramuscular y o ral respectivamente, viendo los \ncambios neurol\u00f3gicos, hematol\u00f3gicos y los cambios en los niveles de Cobalamina, Metilmal\u00f3nico y Homociste\u00edna, indicadores m\u00e1s sensibles de la deficiencia de Cobalamina\n41,60,180 . En este estudio, se demostr\u00f3 \nnuevamente la eficacia del tratam iento oral, tan efectivo como el \nintramuscular. Las grandes dosis de Cobalamina oral, no parece ser \nt\u00f3xicas181.   \n \n 100El tratamiento intramuscular es m\u00e1s caro, por necesitar \nenfermer\u00eda182, menos agradable para el enfermo y presenta algunas \ncomplicaciones como la alergia al medicamento e hiperpigmentaci\u00f3n183. \nPor otro lado el tratamiento int ramuscular de mantenimiento, es \ninterrumpido por el paciente, mientras  que el oral es m\u00e1s f\u00e1cilmente \nmantenible184. \n\u00daltimamente se ha descrito tambi\u00e9n como efectiva la v\u00eda oral \nsublingual185 e intranasal \nNosotros utilizamos la Cobalamina intramuscular, sobre todo si \nhay alteraciones neurol\u00f3gicas o anemia grave, en dosis de 1mg en d\u00edas \nalternos durante 10 dias, seguido de 1mg a la semana durante 10 \nsemanas y terminamos con una dosis de mantenimiento de 1mg al mes. \n \nPrevenci\u00f3n: \nEsta indicada la suplementaci\u00f3n  alimenticia, especialmente en \npoblaciones de riesgo; ancianos, vegetarianos y ni\u00f1os nacidos de \nmadres vegetarianas57. \n \nNuevas ingestas recomendadas: \nComo medicina preventiva en la salud p\u00fablica, nacen una serie \nde recomendaciones encaminadas a esta consecuci\u00f3n, son las nuevas \ningestas de referencia (DRI)186 promulgadas por algunos organismos \noficiales. Para elaborar estas recomendaciones, se tienen en cuenta factores fisiol\u00f3gicos como la edad , sexo, gestaci\u00f3n y lactancia, adem\u00e1s \nde otros factores medioambientales y del estilo de vida, en esto \u00faltimo, tiene especial relevancia las dietas ovolactovegetarianas y las \nvegetarianas estrictas. \n \nEnriquecimiento de alimentos: \nDesde la introducci\u00f3n de la fortificaci\u00f3n con folato en USA en \n1998, ha habido una dr\u00e1stica disminuci\u00f3n de la deficiencia de folato e hiperhomocisteinemia\n266. Esto ha contribuido a un sustancial cambio en \nel riesgo proporcional atribuible al folato o a la vitamina B 12 como \ncausas de hiperhomocisteinemia116,123 .  \n \n 101Hay que vigilar especialmente entr e los ancianos la deficiencia \nde B 12, ya que esta puede verse enmascarada236, sobre todo sus \nmanifestaciones hematol\u00f3gicas con la fortificaci\u00f3n generalizada entre la \npoblaci\u00f3n con folato237 l o  q u e  d a  l u g a r  a  u n  a u m e n t o  e n  e l  d a \u00f1 o  \nneurol\u00f3gico por deficiencia de Coba lamina no diagnosticada a tiempo \n237,238 . \nLa gran prevalencia del d\u00e9ficit de vitamina B 12, sobre todo entre \nla poblaci\u00f3n de ancianos y los vege tarianos, hace muy importante el \ndiagn\u00f3stico precoz por m\u00e9todos bioqu\u00edmicos, cl\u00ednicos o por las \nanormalidades hematol\u00f3gicas. Co mo m\u00e9todos m\u00e1s \u00fatiles en el \ndiagn\u00f3stico precoz de este d\u00e9ficit, cabe destacar las determinaciones de tHcy, AMM y HoloTC-II. \nValoramos positivamente el costo-beneficio que suponen estas \nnuevas t\u00e9cnicas, teniendo en cuenta que s\u00ed el diagn\u00f3stico es tard\u00edo, las \nalteraciones neurol\u00f3gicas ser\u00e1n irre versibles, aunque las alteraciones \nhematol\u00f3gicas remitan. Por \u00faltimo recomendar a poblaciones de riesgo, \nel aumento de la ingesta de vitamina B\n12 utilizando productos \nalimenticios fortificados o suplementaci\u00f3n vitam\u00ednica. \n \nConclusiones: \nEl diagn\u00f3stico temprano y preciso del d\u00e9ficit de vitamina B 12 es \nimprescindible en la poblaci\u00f3n gene ral, pero cobra especial importancia \nen poblaciones de riesgo; ancianos, vegetarianos y ni\u00f1os nacidos de madres vegetarianas. \nComo m\u00e9todo diagn\u00f3stico, la vitamina B\n12, se muestra como un \npar\u00e1metro poco eficaz, siendo recomendadas las determinaciones de \nHoloTC-II y tHcy. \nNo hay que olvidar la frecuente asociaci\u00f3n a deficiencia de \u00e1cido \nf\u00f3lico y vitamina B 6. \nEl mejor tratamiento es el preven tivo, la fortificaci\u00f3n alimenticia \ndeber\u00eda estar regulada como en otros paises.  \n \n 102CH 2O\nO\nOOP\nCH 3 CH\nCH 2 \nNH\nCO\nCH 2 \nCH 2 \nCH 3 CH 2 CH 2 \nCH 2\nCH 3 CH 3 \nCCH 3 \nCH 3 CH  \nCH 3 CH\nCH 3 C CH 2 \nCH 2 CH 2 CONH 2 \n\uf8e6\uf8e6\uf8e6 Cianocobalamina  \nO Hidroxicobalamina  \nAcuacobalamina  \nCH 3 Metilcobalamina  COBALAMINAS  CH 2 CH 2 \nTABLAS Y FIGURAS: \n Figura I: Vitamina B 12 \n      \n \n     \n \n   \n \n      \n \n     \n \n    \n \n. H \nH2O H H CONH 2 H \nCONH 2 CH 2 CH 3 CONH 2 CH 2 H CH 2OH H \nH \nH O H \nN \nCoCONH 2 N \nN \nN \nN N \nN C \u2295 CONH 2  \n \n 103  \n  \n \n \nTabla I: Contenido en B\n12 de los alimentos en microgramos  \n \nLeche fluida de vaca 0.86 \nLeche en polvo entera reconstituida 0.65 \nLeche evaporada reconstituida 0.19 \nYogour 1.34 \nHuevo de gallina 0.65 \nCarne de ternera 8.28 \nCarne de ave 1.38 \nCarne de carnero 10.17 \nCarne de cerdo 3.68 \nH\u00edgado de ternera 60.95 \nH\u00edgado de pollo 22.31 \nCoraz\u00f3n de cerdo 4.37 \nCoraz\u00f3n de res 14.95 \nCoraz\u00f3n de pollo 8.40 \nRi\u00f1\u00f3n de ternera 21.85 \nRi\u00f1\u00f3n de cerdo 8.05 \nMolleja de pollo 2.19 \nPescado 0.96 \nCarne picada 2.48 \nMasa c\u00e1rnica 0.69 \n \n  \n: \n \n \n \n \n  \n \n 104 \n \n \n    \nTabla II: Trastornos neurol\u00f3gicos asociados a la deficiencia de B\n12. \n \nDegeneraci\u00f3n combinada de los cordones espinales. Mielosis funicular \nCordones posteriores C. Laterales Tracto espinotal\u00e1mico \nAcroparesias Debilidad o Paraplej\u00eda Calambres \nIncoordinaci\u00f3n motora Marcha esp\u00e1 ctica Crisis abdominales tipo \ntab\u00e9tico \nS\u00edndrome de \nL\u00b4Hermitte \u2191 Reflejos tendinosos  \n\u2193 Sensibilidad vibratoria Babinski positivo  \nAtaxia sensitiva   \n\u2193 Reflejos tendinosos   \nAlteraciones cerebrales : \nDemencia \nDesorietaci\u00f3n \nApat\u00eda \nIrritabilidad \nDepresi\u00f3n \nPsicosis  \nAlteraciones de los nervios craneales: \nDisminuci\u00f3n de la visi\u00f3n ( nervio \u00f3ptico) \nAlteraciones del olfato y el gusto  \nNeuropat\u00eda perif\u00e9rica: \nPerdida de la sensibilidad superficial \nAcroparesias \nPerdida de la sensibilidad vibratoria \nDisminuci\u00f3n de los reflejos tendinosos  \n \n \n     \n \n 105 \nTabla III: Causas de deficiencia de B 12. \n \nAlimentarias (Disminuci\u00f3n del aporte) Vegetarianos. Nacidos de madres \nvegetarianas \nDisminuci\u00f3n de la Absorci\u00f3n \nCausa G\u00e1strica Causa intestinal \nAnemia perniciosa del adulto              Defecto cong\u00e9nito de absorci\u00f3n ileal de \nB12 \nAnemia perniciosa cong\u00e9nita infantil Anemia perniciosa infantil con \nalbuminuria \nGastrectom\u00eda total o parcial                             Infestaciones por Botrioc\u00e9falo \nGastritis atr\u00f3fica      Diverticulosis intestinal \nFactor Intr\u00ednseco anormal      F\u00edstulas intestinales \n     S\u00edndrome del asa ciega \n     Estenosis intestinal \n     Esclerodermia \n     Resecci\u00f3n ileal \n     Enfermedad de Crohn \n     Enfermedad pancre\u00e1tica severa \n     Ile\u00edtis \n     Enfermedad cel\u00edaca \n     Esp\u00fae tropical \n     S\u00edndrome de Zollinger-Ellison \n     Tratamientos con colchicina \n     Tratamientos con PAS \n     Tratamientos con neomicina \n     Tratamientos con cloruro pot\u00e1sico \nDefectos en la Transcobalamina II \nMetabolismo y utilizaci\u00f3n celular anormales \nAnestesia con \u00f3xido nitroso \nDefectos metab\u00f3licos cong\u00e9nitos \nAnticonceptivos orales \nDi\u00e1lisis renal \nSIDA \nDeficiencia severa de hierro \nAltas dosis de \u00e1cido Asc\u00f3rbico \nNeoplasias \n \n \n   \n \n 106 \n  \nTabla IV: Interpretaci\u00f3n del test de Schilling \n \nPaso I Normal Paso I anormal II Normal I y II anormales \nDeficiencia \ndiet\u00e9tica Anemia Perniciosa Anemia Perniciosa, recogida de \nmuestra inadecuada en paso II \nHipoclorhidria Gastrectom \u00eda Insuficiencia renal132,133 \nGastrectom\u00eda \nparcial By-pass g\u00e1strico Recogida inadecuada de la orina en \nambos pasos \n Ausencia cong\u00e9nita o \ndisfunci\u00f3n del FI Crecimiento bacteriano exagerado \n Recogida de orina inadecuada \nen el paso 131 Infecci\u00f3n por la tenia del pescado \n  Insuficiencia pancre\u00e1tica. \nPAS, Colchicina, Neomicina, \nanticonvulsivantes 201 \nS\u00edndrome de Zollinger-Ellison \n \nTabla V : causas que alteran los niveles de B 12, AMM y tHcy \n \nCausas a parte del d\u00e9ficit de Cobalamina que pueden alterar las \ndeterminaciones de Cobalamina AMM y Homociste\u00edna \nCOBALAMINA AMM HOMOCISTEINA \n\u2022 Idiop\u00e1tica \n\u2022 Embarazo \n\u2022 D\u00e9ficit de TC-I \n\u2022 Enf asociadas \n(infecci\u00f3n, HIV, \nMieloma) \n\u2022 D\u00e9ficit folato \u2022 IRC \n\u2022 Deshidrataci\u00f3n \n\u2022 Infancia \n\u2022 Defectos \nenzim\u00e1ticos \ndeficiencia en \nmutasa) \u2022 Muestra incorrecta \n\u2022 Procesamiento \nincorrecto \n\u2022 D\u00e9ficit de folato \n\u2022 Edad, sexo, estilo \nde vida \n\u2022 D\u00e9ficit de B6  \n \n 107\u2022 Medicamentos \n(anticonvulsivante\ns, anticonceptivos \norales) \n\u2022 Error laboratorio \n \u2022 Contaminaci\u00f3n \nbacteriana \n\u2022 Error laboratorio  \u2022 Hipotiroidismo \n\u2022 IRC \n\u2022 Medicamentos \n(isoniacida) \n\u2022 Enfermedades \n(leucemia) \n\u2022 Errores metab\u00f3licos \n\u2022 Error laboratorio  \n  \n \n 108Bibliograf\u00eda:  \n1.-Stabler SP, Lindenbaum J, Allen RH. Vitamin B-12 deficiency in the \nelderly: current dilemmas. Am J Clin Nutr 1997;66:739-40. \n2.-Snow CF. Laboratory di agnosis of vitamin B 12 and folate deficiency. \nArch Intern Med 1999;159:1289-1298. \n3.-Tudhope GR, Swan HT, Spray GH. Patient variation in pernicious \nanaemia, as shown in a clinical trial of cyanocobalamin, hydroxicobalamin and cyanocobalamin-zinc tannate. Br J Haematol 1967;13:216-228. \n4.-Watanabe F, Takenaka S, Kittaka-katsura H, Ebara S, Miyamoto E. \nCharacterization and bioavailability of vitamin B12-compounds from edible algae. J Nutr Sci Vitaminol 2002;48:325-31. \n5.-Kittuka-Katsura H, Ebara S, Watanab e F, Nakano Y. Characterization \nof corrinoid compounds from a Ja panese black tea (Batabata-Cha) \nfermented by bacteria. J Agric Food Chem 2004;52:909-11. \n6.- Koop H. Review article: meta bolic consequences of long-term \ninhibition of acid secretion by omeprazole. Aliment Pharmacci Ther \n1992;6:399-406. \n7.-Schilling RF. The role of the pancreas in vitamin B-12 absorption. Am \nJ Hematol 1983;14:197-199. \n8.-Herzlich B, Herbert V. Depletion of  serum holotranscobalamin II. An \nearly sign of negative vitamin B\n12 balance. Lab Investig 1988;58:332-337. \n9.-Gimsing P, Nex\u00f8 E. Cobalamin-binding capacity of haptocorrin and \ntranscobalamin: age-correlated reference intervals and values from patients. Clin Chem 1989;35:1447-1451. \n10.-Hamaka N, Nieman P, Canellos G, Lazerson J. Neonatal \nmegaloblastic anemia due to inheri ted transcobalamin II deficiency in \ntwo sibling. N Engl J Med 1971;285:1163. \n11.-Carmel R, Herbert V. Deficiency of vitamin B\n12 binding alpha \nglobulin in two brothers. Blood 1969;33:1. \n12.-Kato N, Narita Y, Kamohara S. Liver vitamin B12 levels in chronic \nliver diseases. J Vitamin 1959;5:134-140.  \n \n 10913.-Stahlberg KG, Radner S, Norden A. Liver B 12 in subjects with and \nwithout vitamin B 12 deficiency. A quantitative and qualitative study. \nScand J Haematol 1967;4:312-330. \n14.-Adams JF, Boddy K, Douglas AS. Interrelation of serum vitamin B 12, \ntotal body vitamin B 12, peripheral blood morphology and the nature of \nerythropoiesis. Br J Haematol 1972;23:297-305. \n15.-Grasbeck T, Nyberg W, Reizenstei n P. Biliary and fecal vitamin B 12 \nexcrection in man. An isotope study. Proc Soc Exp Biol Med 1958;97:780-784. \n16.-Adams JF. The measurement of the total assayable vitamin B\n12 in the \nbody. In: Heinrich HC, ed. Vitamin B 12 und Intrinsic Factor. Stuttgart, \nGermany: Ferdinand Enke. Pp. 397-403. \n17.-Adams JF. Correlation of serum and urine vitamin B 12. Br Med J \n1970;1:138-139. \n18.-Heinrich HC. Metabolic basis of  the diagnosis and therapy of \nvitamin B 12 deficiency. Semin Hematol 1964;1:199-249.  \n19.-Reizensteins P, Ek G, Matthews CM. Vitamin B 12 kinetics in man. \nImplications on total-body B 12 determinations, human requeriments, \nand normal and pathological cellular B 12 uptake. Phys Med Biol \n1966;11:295-306. \n20.-Reizensteins P. Excretion of non-labeled vitamin B 12 in man. Acta \nMed Scand 1959;165:313-320. \n21.-Mollin DL, Ross GI. The vitamin B 12 concentrations of serum and \nurine of normal and patients with megaloblastic anaemias and other diseases. J Clin Pathol 1952;5:129-139. \n22.-Amin S, Spinks T, Ranicar A, Short MD, Hoffbrand AV. Long-term \nclearance of (57 Co) cyanocobalamin in vegan and pernicious anaemia. \nClin Sci 1980;58:101-103. \n23.-Boddy K, Adams JF. The long-t erm relationship between serum \nvitamin B\n12 and total body vitamin B 12. Am J Clin Nutr 1972;25:395-400. \n24.-Rabinowitz AP, Sacks Y, Carmel R. Autoimmune cytopenias in \npernicious anemia: a report of four  cases and review of the literature. \nEur J Haematol 1990;44:18-23.  \n \n 11025.-A Metz J, Bell AH, Flicker L, Bottigl ieri T, Ibrahim J, Seal E, Schultz \nD. The significance of subnormal serum vitamin B 12, concentration in \nolder people: a case control study. J Am Geriatr Soc 1996;44:1355-61. \n26.-Borgia  G, Raynaud L, Gentile J, Borrelli F, Cerini R, Ciampi R, \nPiazza M. Pernicious anemia during IFN-alpha treatment for chronic hepatitis C. J Interferon  Cytokine Res 2003;23(1):11-2. \n27.-Petavy-Catala C, Fontes V, Giro net N, Huttenberger B, Lorette G, \nVaillant L. Clinical manifestations of the mouth reveling Vitamin B12 deficiency before the onset of anemia. Ann Dermatol Venereol \n2003;130:191-4. \n28.-Bottiglieri T. Folate, vitamin B\n12, and neuropsyquiatric disorders. \nNutr Rev 1996;54:382-90. \n29.-Gompertz D, Hoffbrand AV. Methym alonic aciduria. Br J Haematol \n1970;18(4):377-81. \n30.-Carmel R. Prevalence of undiag nosed pernicious anemia in the \nelderly. Arc Intern Med. 1996;156:1097-100. \n31.-Force RW, Mecker AD, Cady PS, Culbertson VL, Force WS, Kelley \nCM. Ambulatory care increased vita min B12 requirement associated \nwith chronic acid suppression therapy. Ann Pharmacother 2003;37:1730. \n32.-Karnaze DS, Carmel R. Neurol ogical and evoked potential \nabnormalities in subtle cobalamin deficiency states, including those \nwithout anemia and with normal abso rption of free cobalamin. Arch \nNeurol. 1990;47:1008\u20131012.  \n33.-Carmel R, Gott PS, Waters CH, et al. The frequently low cobalamin \nlevels in dementia usually signify treatable metabolic, neurologic and \nelectrophysiologic abnormalities. Eur J Haematol. 1995;54:245\u2013253. \n34.-Hector M, Burton JR. What are the psychiatric manifestations of \nvitamin B\n12 deficiency?. J Am Geriatr Soc 1988;36:1105-1112. \n35.-Beck WS. Neuropsychiatric consequences of cobalamin deficiency. \nAdv Intern Med 1991;36:33-56. \n36.-Lindenbaum J, Healton EB, Sa vage DG, Brust JCM, Garrett TJ, \nPodell ER. Neuropsychiatric disorders caused by cobalamin deficiency \nin the absence of anemia or macrocytosis. N Engl J Med 1988;318:1720-1728.  \n \n 11137.-Zucker DK, Livingston RL, Nakra R, Clayton P. B 12 deficiency and \npsychiatric disorders case-report and literature review. Biol Psychiatry 1981;16:197-205. \n38.-Pennix BW, Geralnik JM, Ferrucci L, Fre\u00edd LP, Allen RH, Stable SP. \nVitamin B(12) deficiency and depressi on in physically disabled older \nvomen: epidemiologic evidence fr om the Women\u00b4s Health and aging \nstudy. Am J Psychiatry 2000;157(5):715-21. \n39.- Rodriguez Jimenez J, Rodriguez JR, Gonzalez MJ. Indicators of \nanxiety and depression in subjects  with different kinds of diet: \nvegetarians and omnivores] Bol Asoc Med P R 1998;90(4-6):58-68. \n40.-Mens W, Muller-Thomsen T, Me ier-Baumgartner HP. Subnormal \nserum vitamin B12 and behavioural and psychological symptoms in \nAlzheimer\u00b4s disease. Int J Ge riatr Psychiatry 2000;15(5):415-8. \n41.-Green R, Miller JW. Folate defici ency beyond megaloblastic anemia: \nhiperhomocysteinemia and other manife stations of dysfunctional folate \nstatus. Semin hematol 1999;36:47-64. \n42.- Marcela Gonz\u00e1lez-Gross , Ricardo Sola, Klaus Pietrzik, Manuel J. \nCastillo. Homociste\u00edna y patolog\u00eda cardiovascular. \n43.- .-Carmel R. Current concepts in cobalamin deficiency. Annu Rev \nMed. 2000;51:357\u2013375.[CrossRef][Medline]  \n44.-Long ER. Thomas Addison and his discovery of idiopathic anemia. \nAnn Med 1935;7:130-132.  \n45.-Lindenbaum J, Pezzimenti JF, Shea  N. Small-intestinal function in \nvitamin B 12 deficiency. Ann Intern Med 1974;80:326-331. \n46.-Levitt AJ, Karlinsky H. Folate, vitamin B 12 and cognitive impairment \nin patients with Alzheimer \u02b9s disease. Acta Psychiatr Scand 1992;86:301-\n305. \n47.-Regland B, Gottfries C. Vitamin B 12-brist \u2013 inte minst ett \nneuropsykiatrisk problem. L\u00e4kartidningen 1992;89:2736-2740. \n48.-Healton EB, Savage DG, Brust JCM, Garrett TJ, Lindenbaum J. \nNeurologic aspects of cobalamin deficiency. Medicine 1991;70:229-245. \n49.-Martin DC, Francis J, Protetch J,  Jacob Huff F. Time dependency of \ncognitive recovery with cobalamin repl acement: report of a pilot study. \nJ Am Geriatr Soc 1992;40:168-172.  \n \n 11250.-Chanarin I, Metz J. Diagnosis of  cobalamin deficiency: the old and \nthe new. Br J Haematol 1997;97:695-700. \n51.-Lindenbaum J, Savage DG, Stabler SP, Allen RH. Diagnosis of \ncobalamin deficiency: II. Relative sensitivities of serum cobalamin, \nmethylmalonic acid, and total ho mocysteine concentrations. Am J \nHematol. 1990;34:99\u2013107. \n52.-Amos RJ, Dawson DW, Fish DI[, Leeming RJ, Linnell JC. Guidelines \non the investigation and diagnosis of  cobalamin and folate deficiencies. \nClin Lab Haematol 1994;46:101-15. \n53.-Norman EJ, Morrison JA. Screening elderly populations for \ncobalamin (vitamin B12) deficiency  using the urinary methylmalonic \nacid assay by gas chromatography mass spectrometry. Am J Med 1993;94:589-594. \n54.-Pennypacker LC. Allen RH, Kelly JP, et al. High prevalence of \ncobalamin deficiency in elderly out-patients. J Am Geriatr Soc \n1992;40:1197-1204. \n55.-Chanarin I. The Megaloblastic Anaemias . 2nd ed. Oxford, England. \nBlackwell Scientific Publishers:1979. \n56.-Green R. Screening for vitamin B1 2 deficiency: caveat emptor. Ann \nIntern Med 1996;124:509-511. \n57.-Hans J Naurath, Etienne Joosten,  Reiner Riezler, Sally P Stabler, \nRobert H Allen, John Lindenbaum. Effects of vitamin B12, folate, and vitamin B6 supplements in elderly people with normal serum vitamin concentrations. Lancet 1995; 85-89. \n58.-Lindenbaum J, Allen RH. Clinical Spectrum and diagnosis of folate \ndeficiency. In: Bailey LB. Ed. Folate in Health and Disease. New York. \nNY: Marcel Dekker Inc 1995;43-73. \n59.-Murphy MF, Sourial Na, Burman JF, et al. Megaloblastic anaemia \ndue to vitamin B12 deficiency caus ed by small intestinal bacterial \novergrowth: possible role of vitamin B12 analogues. Br J Haematol 1986;52:7-12. \n60.-Savage DG, Lindenbaum J, Stab ler SP, Allen RH. Sensitivity of \nserum methylmalonic acid and total homocysteine determinations for \ndiagnosis of cobalamin and folate deficiencies. Am J Med. 1994;96:239\u2013246.   \n \n 11361.- Rasmussen K, Vyberg B, Ped ersen KO, Br\u00f8chner-Mortensen J. \nMethylmalonic acid in renal insuffi ciency: evidence of accumulation \nand implications for diagnosis of cobalamin deficiency. Clin Chem \n1990;36:1523-1524.  \n62.- Hvas AM, Juul S, Gerdes LU, Nexo E. The marker of cobalamin \ndeficiency, plasma methylmalonic acid , correlates to plasma creatinine. \nJ Intern Med 2000;247:507-12. \n63.-Schneede J, Ueland PM. Applicat ion of capillary electrophoresis \nwith laser-induced fluorescence dete ction for routine determination of \nmethylmalonic acid in human serum. Anal Chem 1995;67:812-819. \n64.-Scheneede J, Ueland PM. Automated assay for methylmalonic acid \nin serum and urine by derivatizat ion with 1-pyrenyldiazomethane, \nliquid chromatography and fluorescence detection. Clin Chem 1993;39:392-399. \n65.-Schneede J, Ueland PM. The formation in an aqueous matrix, \nproperties and chromatographic behavior of 1\u2014pyrenyldiazomethane derivatives of methylmalonic acid and other short chain dicarboxylic \nacids. Anal Chem 1992;64:315-319. \n66.-Nex\u00f8 E, Hansen M, Rasmussen K, Lindgren A, Grasbeck R. How to \ndiagnose cobalamin deficiency. Scand J Clin Lab Investig 1994;54(Suppl 219):61-76. \n67.-H\u00f8lleland G, Schneede\n J, Ueland PK, Lund  PK, Refsum H, Sandberg  \nS. Cobalamin Deficiency in Gene ral Practice. Assessment of the \nDiagnostic Utility and Cost-Benefit Analysis of Methylmalonic Acid \nDetermination in Relation to Curren t Diagnostic Strategies Clin Chem \n1999;45:189-98. \n68.-Carmel R, James SJ. Alcohol abus e: an important cause of severe \nhyperhomocysteinemia. Nutr Rev. 2002;60:215\u2013221.  \n69.-Ganji V, Kafai MR. Demographic, health, lifestyle, and blood \nvitamin determinants of serum total homocysteine concentrations in the \nthird National Health and Nutrition Examination Survey, 1988\u20131994. Am J Clin Nutr. 2003;77:826\u2013833. \n70.-Martinez-Berriotxoa A, Ruiz-I rastorza G, Egurbide Arberas MV, \nRueda Gutierrez M, Aguirre Erraste C.  Plasma homocysteine levels in \nsystemic lupus erythematos us. Med Clin 2003;120(18):681-5.  \n \n 11471.-Rasmussen K, Moller J. Methodologies of testing. In: Carmel R, \nJacobsen DW, eds. Homocysteine in  health and disease. Cambridge, \nUK: Cambridge University Press; 2001:199\u2013211.  \n72.-Joosten E, Lesattrer,R Reizler R. Are different reference intervals for \nmethylmalonic acid and total homocysteine necessary in elderly people? Eur J Haematol 1996;57:222-226. \n73.-Stabler SP, Allen RH, Savage DG , et al. Clinical spectrum and \ndiagnosis of cobalamin deficiency. Blood 1990;76:871-881. \n74.-Green R. Metabolite assays in cobalamin and folate deficiency. \nBaillieres Clin Haematol 1995;8:533-566. \n75.-Joosten E, van der Berg A, Reizler R. Metabolic evidence that \ndeficiencies of vitamin B-12 (cobalam in), folate, and vitamin B-6 occur \ncommonly in elderly people. Am J Clin Nutr 1993;58:468-476. \n76.-Brattsron LE, Hulberg BL, Hardebo JE. Folic acid responsive \npostmenopausal homocysteinemia. Metabolism 1985;34:1073-1077. \n77.-Rasmussen K, Moller J, Ostergaard K, ET al. Methylmalonic acid \nconcentrations in serum of normal su bject: biologic variability and efect \nof oral L-isoleucine loads before and after intramuscular administration \nof cobalamin. Clin Chem 1990;36:1295-1299. \n78.-Rasmussen K, Moller J, Lyngbak M. Within-person variation of \nplasma Homocisteine and effects of posture and tourniquet application. \nClin Chem 1999;45:1850-55. \n79.-Thirup P, Ekelund S. Day-to-day , orthostatic variation of plasma \nhomocysteine [Abstract]. Scand J Clin Lab Investig 1998;58:94-95.  \n80.-Stranger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, \nWeger M. DACH-LIGA Homocystein (German, Austrian and Swiss \nHomocysteine Society): Consensus Pa per on the Rational Clinical Use \nof Homocysteine, Folic Acid and B-Vitamins in Cardiovascular and \nThrombotic Diseases: Guidelines and Recommendations. Clin Chem Lab Med 2003;41:1392-1403. \n81.-Vester B, Rasmussen K. High performance liquid chromatography \nmethod for rapid and accurate determination of homocysteine in \nplasma and serum. Eur J Clin Chem Clin Biochem 1991;29:549-554.  \n \n 11582.-Andersson A, Isaksson A, Hultberg  B. Homocysteine export from \nerythrocytes and its implication fo r plasma sampling. Clin Chem \n1992;38:1311-1315. \n83.-Allen RH, Stabler SP, Savage DG , et al. Diagnosis of cobalamin \ndeficiency. I: usefulness of seru m methylmalonic acid and total \nhomocysteine concentrations. Am J Hematol 1990;34:90-9 \n84.-M\u00f8ller J, Rasmussen K. Homocysteine in plasma: stabilization of \nblood samples with fluoride. Clin Chem 1995;41:758-759. \n85.-Willems HP, Bos GM, Gerrits WB, den Heijer M, Vloet S, Blom HJ. \nAcidic citrate stabilizes blood sample s for assay of total homocysteine. \nClin Chem 1998;44:342-345. \n86.-Refsum H, Smith AD. Low vitamin B-12 status in confirmed \nAlzheimer\u00b4s disease as revealed by serum holotranscobalamin. J Neurol \nNeurosurg Psychiatry 2003;74(7):959-61. \n87.-Herrmann W, Obeid R, Schorr H, Geisel J. Functional citamin B12 \ndeficiency and determination of holo transcobalamin in populations at \nrisk. Clin Chem Lab Med 2003;41:1478-88. \n88.-Van Asselt, Thomas CM, Sege rs MF, Blom HJ, Wevers RA, \nHoefnagels WH. Cobalamin-binding proteins in normal-deficient older subjects. Ann Clin Biochem 2003;40:65-9. \n89.-Wickramasinghe SN, Ratnayaka ID. Limited value of serum holo-\ntranscobalamin II measurements in the differential diagnosis of macrocitosis. Clin Pathol 1996;49:755-8. \n90.-Ulleland M, Eilertsen I, Quadros EV, et al. Direct assay for \ncobalamin bound to transcobalamin (holo-transcobalamin) in serum. Clin Chem. 2002;48:526\u2013532. \n91.-Wright ZL, Hvas AM, Moller J, Sanders TAB, Nexo E. \nHolotranscobalamin as an indicator of dietary vitamin B\n12 deficiency. \nClin Chem 2003;49:2076-8. \n92.-Carmel R. Measuring and interp reting holo-transcobalamin (holo-\ntranscobalamin II). Clin Chem. 2002;48:407\u2013409.   \n \n 11693.-Teplitsky V, Huniner D, Zoldan J, Pitlik S, Shohat M, Mittelman M. \nHereditary partial Transcobalamin II de ficiency with neurologic, mental \nand hematologic abnormalities in ch ildren and adults. Isr Med assoc J \n2003;5:868-72. \n94.-Toh BH, van Driel IR, Gleeson PA. Mechanisms of disease: \npernicious anemia (review). N Engl J Med 1997;337:1441-8. \n95.-Lindgren A, Lindstedt G, Kila nder AF. Advantages of serum \npesinogen A combined with gastri n or pepsinogen C as first line \nanalytes in the evaluation of suspec ted cobalamin deficiency: a study in \npatients previously not subjected to gastrointestinal surgery. J Intern \nMed 1998;244:341-9. \n96.-Carmel R. Pepsinogens and other serum markers in pernicious \nanemia. Am J Clin Pathol 1988;90:442-445. \n97.-Scarlett JD, Read H, O\u00b4Dea K, et al. Protein-bound cobalamin \nabsorption declines in the elderly. Am J Hematol 1992;39:79-83. \n98.-Kekki M, Samloff IM, Varis K, et  al. Serum pepsinogen I and serum \ngastrin in the screening of severe atrophic corpus gastritis. Scand J Gastroenterol suppl 1991;186:109. \n99.-DeAizpurua HJ, Cosgrove LJ, Ungar B, et al. Autoantibodies \ncytotoxic to gastric parietal cells in  serum  of patiens with pernicious \nanemia. N Eng J Med 1983;309:625-629. \n100.-TeVelde K, Abels J, Anders GJPA, et al. A family study of \npernicious anemia by an inmunologic method. J Lab Clin Med 1964;64;177-187. \n101.-Strickland RG, Hooper B. The parietal cell heteroantibody in \nhuman sera: prevalence in a normal population and relationnship to \nparietal cell autoantibody. Pathology 1972;4:259-263.  \n102.-Fairbanks VF, Lennon VA, Kokmen E, et al. Tests to pernicious \nanemia: serum intrinsic factor bloc king antibody. Mayo Clin Proc \n1983;58:203-204. \n103.-Lee GR. Megaloblastic and nonmeg aloblastic macrocytic anemias. \nIn: Lee GR. Ed Clinical Hematology. Philadelphia, Pa: Lea & Febiger \n1993;745-790.  \n \n 117104.-Rose MS, Chanarin I, Doniach D, et  al. Intrinsic factor antibodies in \nabsence of pernicious anemia: 3-7 year follow-up. Lancet 1970;2:9-12. \n105.-Nexo E, Hansen M, Rasmussen K,  Lindgren A, Gasbeck R. How to \ndiagnose cobalamin deficiency. Sc and J Clin lab Investig Suppl \n1994;219:61-76. \n106.-Carmel R, Rasmunssen K, Jacobssen DW, Green R. Comparison of \nthe deoxyuridine suppression test with serum levels of methylmalonic acid and homocysteine in mild cobalamin deficiency. Br J Haematol 1996;93:311-8. \n107.-Stabler SP, Lindenbaum DG, Sava ge DG, Allen RH. Elevation of \nserum cystationine levels in patients with cobalamin and folate deficiency. Bood 1993;81(12):3404-413. \n108.-Patel A, Chanarin I. Restoratio n of normal red cell size after \ntreatment in megaloblastic anemia. Br J Haematol 1975;30:57-63. \n109.-Alstrom T, Grasbeck R, Lindbl ad B, Solberg HE, Winkel P, \nViinikka L. Establishing reference values from adults: recommendation \non procedures for the preparation of  individuals, collection of blood, \nand handling and storage of sp ecimens. Committee on Reference \nValues of the Scandinavian Society for Clinical Chemistry. Scand J Clin Lab Investig 1993;53:649-652. \n110.-Fairbank VF. Test for pernicious anemia: The \u201cSchilling test\u201d. \nMayo Clin Proc 1983;58:541-544.151.- \n111.-Carmel R, Green R, Rosenblatt DS and Watkins D. Update on \nCobalamin, Folate, and Homocysteine. American Society of Hematology \n112.-Savage DG, Lindenbaum J. Folate-cobalamin interactions in: \nBailey. Ed. Folate in Health and disease. New York, NY:Marcel Dekker \nInc;1995:237-285. \n113.Yu MK, Rodgers GM. Detection of occult cobalamin deficiency by \nmagnetic resonance imaging. Am J Hematol 2000;65:83-4. \n114.-Morita S, Miwa H, Kihira T, Kondo T. Cerebellar ataxia and \nleukoencephalopathy associated with  cobalamin deficiency. J Neurol \nSci 2003;216:183-4.  \n \n 118115.-Burkes RL, Cohen H, Krailo M,  Sinow RM, Carmel R. Low serum \ncobalamin levels occur frequently in  the acquired immune deficiency \nsyndrome and related disorders. Eur J Haematol. 1987;38:141\u2013147.  \n116.-Liaugaudas G, Jacques PF, Selh ub J, Rosenberg IH, Bostom AG. \nRenal insufficiency, vitamin B(12) status, and population attributable risk for mild hyperhomocysteinemia among coronary artery disease patients in the era of folic acid-forti fied cereal grain flour. Arterioscler \nThromb Vasc Biol. 2001;21:849\u2013851. \n117.-Baum MK, Shor-Posner G, Lu Y et al. Micronutrients and HIV-1 \ndisease progression. AIDS 1995;9:1051-6. \n118.-Lindenbaum J. Aspects of vitamin B\n12 and folate metabolism in \nmalabsorption syndromes. Am J Med. 1979;67:1037\u20131048. \n119.-Carmel R, Aurangzeb I, Qian D.  Associations of food-cobalamin \nmalabsorption with ethnic origin, age, Helicobacter Pylori infection, and serum markers of gastriti s. Am J Gastroenterol 2001;96:63-70. \n120.-Refsum H, Yajnik CS, Gadkari M, et al. Hyperhomocysteinemia \nand elevated methylmalonic acid indicate a high prevalence of cobalamin deficiency in Asia n Indians. Am J Clin Nutr. 2001;74:233\u2013\n241. \n121.-Carmel R, Mallidi PV, Vinars kiy S, Brar S, Frouhar Z. \nHyperhomocysteinemia and cobalamin deficiency in young Asian \nIndians in the United States. Am J Hematol. 2002;70:107\u2013114. \n122.-van Asselt DZ, van den Broek WJ, Lamers CB, Corstens FH, \nHoefnagels WH. Free and protein-bound cobalamin absorption in healthy middle-aged and older subjects. J Am Geriatr Soc 1966;44:949-\n953. \n123.- Johnson MA Hawthorne NA, Brak ett WR, Fischer JG, Gunter EW, \nAllen RH and Stabler SP. Hyperh omocysteinemia and vitamin B-12 \ndeficiency in elderly using Title IIIc nutrition services. Am J Clin Nutr 2003;77:211-20. \n124.-Lawrence JM, Petitti DB,Watki ns M, Umekubo MA. Trends in \nserum folate after food fo rtification. Lancet 1999;354:915\u20136. \n125.-Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The \neffect of folic acid fortification on plasma folate and total homocysteineconcentrations. N Engl J Med 1999;340:1449\u201354.  \n \n 119126.-Boushey CJ, Beresford SAA, Om enn GS, et al. A quantitative \nassessment of plasma homocysteine as  a risk factor for vascular disease: \nprobable benefits of increasing folic acid intakes. JAMA 1995;274:1049\u2013\n57. \n127.-Herbert V, Bigaouette J. Call for endorsement of a petition to the \nFood and Drug Administration to always add vitamin B-12 to any folate fortification. Am J Clin Nutr 1997;65:572\u20133. \n128.-Mills JL, Von Koborn J, Conley MR, Zeller JA, Cox C, Williamson \nRE, Dufour DR. Low vitamin B-12 co ncentrations y patients without \nanemia: the effect of folic acid fort ification of grain. Am J Clin Nutr \n2003;77(6):1474-7. \n129.- Linnell JC, Smith AD, Smith CL, Wilson J, Matthews DM. Effects \nof smoking on metabolism and excretion of vitamin B\n12. Br Med J \n1968;2:215-216. \n130.-Fernandes-Costa F, van Tonder S, Metz J. A sex difference in serum \ncobalamin and transcobalamin levels. Am J Clin Nutr 1985;41:784-786. \n131.-Low-Beer TS, McCarthy CF, Aust ad WI, Brzechwa-Ajdukiewicz A, \nRead AE. Serum vitamin B 12 levels and vitamin B 12 binding capacity in \npregnant and non pregnant Europeans and West Indians. Br Med J 1968;4:160-161. \n132.-Metz J, Hard D, Harpending HC. Iron, folate, and vitamin B\n12 \nnutrition in a hunter-gatherer peop le: A study of the Kung Bushmen. \nAm J Clin Nutr 1971;24:229-242. \n133.-Rosner F, Schreiber ZA. Serum vitamin B12 and vitamin B12 \nbinding capacity in chronic myelogen ous leukemia and other disorders. \nAm J Med Sci 1972;263:473-480. \n134.-Scott JM, Bloomfield FJ, Stebbins R, Herbert V. Studies on \nderivation of transcobalamin 3 from granulocytes. Enhancement by lithium and elimination by fluoride of in vitro increments in vitamin \nB12 binding capacity. J Clin Invest 1974;53:228-239. \n135.-Herbert V, Jacob E, Wong KT, Scott J, Pfeffer RD. Low serum \nvitamin B\n12 levels in patients receiving ascorbic acid in megadoses: \nStudies concerning the effect of ascorbate on radioisotope vitamin B 12 \nassay. Am J Clin Nutr 1978;31:253-258.  \n \n 120136.-Doi K, Matsuura M, Kawara A, Tanaka T, Baba S. Influence of \ndietary fiber(Konjac Mannan) on absorption of vitamin B 12 and vitamin \nE. Tohoku J Exp Med 1983;141:677-681. \n137.-Sebekova K, Krajcovicov\u00e1-Kudl\u00e1ckov\u00e1 M, Blaz\u00edcek P, Parr\u00e1k V, \nSchinzel R, Heidland A. Functional  hyperhomocysteinemia in healthy \nvegetarians: No association with advanced glycation end products, \nmarkers of protein oxidation, or lipi d peroxidation after correction with \nvitamin B 12. Clin Chem 2003;49:963-6. \n138.-Herbert V. Vitamin B 12, plant sources, requirements and assay. Am \nJ Clin Nutr 1998;48:852-8. \n139.-Davis RE. Clinical chemistry of vitamin B12. Adv Cli Chem \n1985;24:163-216. \n140.-Miller DR, Specker BL, Ho ML, Norman EJ. Vitamin B-12 status in \na macobiotic  community. Am J Cli Nutr 1991;53:524-29. \n141.-Alexander D, Ball MJ, Mann J. Nu trient intake and haematological \nstatus of vegetarians and age-sex ma tched omnivores. Eur J Clin Nutr \n1994;48:538-46. \n142.-Rauma AL, T\u00f6rr\u00f6nen R, H\u00e4nninen O, Mykk\u00e4nen H. Vitamin B-12 \nstatus of long.term adherents of stri c uncooked vegan diet (\u201cliving food \ndiet\u201d) is compromised. J Nutr 1995;125:2511-5. \n143.-Bevan DH, Butler T. Cyanocobalamin ( vitamin B-12) status in \nSeventh-day Adventist ministers in Australia. Am J Clin Nutr 1999;70(S):576S-578S. \n144.-Higginbottom MC, Sweetman L,  Nyhan WL. A syndrome of \nmethylmalonic aciduria, homocystinuria, megalobl\u00e1stic anemia an neurological abnormalities in a vitamin B12 deficient breastfed infant of \nstrict vegetarian. N Engl J Med 1978;299:317-323. \n145.-Sklar R. Nutritional vitamin B12 defi ciency  in a breast-fed infant of \na vegan-diet mother. Clin Pediatr 1986;25:219-221. \n146.-Specker BL, Miller D, Norman EJ, Greene H, Hayes KC. Increased \nurinary methylmalonic acid excretion in brease-fed infants of vegetarian mothers and an identifica tion of an acceptable source of \nvitamin B12. Am J Clin Nutr 1988;47:89-92.  \n \n 121147.-Dagnelie PC, van Staveren WA, Vergote FJVRA, Dingjan PG, van \nder Berg H, Hautvast JGAJ. Increa sed risk of vitamin B-12 and iron \ndeficiency in infants on macrob iotic diets. Am J Clin Nutr 1989;50:818-\n824. \n148.-Kuhne T, Bubl R, Baumgartner R. Maternal vegan diet causing a \nserious infantile neurological disorder due to vitamin-B12 deficiency. Eur J Pediatr 1991;150:205-208. \n149.-Carmel R, Sinow RM, Karnaze DS. Atypical cobalamin deficiency \nsubtle biochemical evidence of defi ciency is commonly demonstrated in \npatients without megaloblastic anemia and is often associated with \nprotein-bound cobalamin malabsorption. J Lab Clin Med 1987;109:454-463. \n150.-Thorogood M, Roe L, McPherson K, Mann JI. Dietary intake and \nplasma lipid levels:lessons from a st udy on the diet of health conscious \ngroups. BMJ 1990;300:1271-1301. \n151.-Margetts BM, Armstrong BK, Bekin LJ, Vamdongen R. Vegetarian \ndiet in mild hypertension: a randomised controled trial. BMJ \n1986;293:1468-71. \n152.-Thorogood M, Carter R, Benfield L, McPherson K, Mann JI. Plasma \nlipids and lipoprotein cholesterol conc entration in people with different \ndiets in Britain. BMJ 1987;295:351-3. \n153.-Hostmark AT, Lystad E, Vellar OD, Hovi K, Berg JE. Reduced \nplasma fibrinogen, serum peroxides, lipids and apolipoprotein after a three week vegetarian diet. Plant Food Hum Nutr 1993;43:55-61. \n154.- M. Dietary determinants of i schaemic heart disease in health \nconscious Mann JI, Appleby PN, Key TJ, Thorogood individuals. Heart \n1997;78:450-5. \n155.-Fraser GE, Shavlik DJ. Risk factor s for all cause and coronary heart \ndisease mortality in the older-old. Th e Adventist Health Study. Arch Int \nMed 1997;157:2249-58. \n156.-Key TJA, Thorogood M, Appleby PN, Burr ML. Dietary habits and \nmortality in 11.000 vegetarians and heal th conscious people: results of a \n17 year follow up. BMJ 1996;313:775-9. \n157.-Herbert V. Staging vitamin B-12 (c obalamin) status in vegetarians. \nAm J Clin Nutr 1994;59(5):1213S-1222S.  \n \n 122158.-Eikelboom JW, Lonn E, Genest  J Jr, Hankey G, Yusuf S. \nHomocyst(e)ine and cardiovalcular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999;131:363-75. \n159.-Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-\nKhoa T, Nguyen AT, Zingraff J, et al. Advanced oxidation Products as a new marker of oxidative stress in uremia. Kidney int 1996;49:1304-13. \n160.-M\u00fcnch G, Keis R, Wessels A, Riederer P, Bahner Y, Heidland A, et \nal. Determination of advanced glyc ation end products in serum by \nfluorescence spectroscopy and comp etitive ELISA. Eur J Clin Chem \n1997;35:669-77. \n161.-Mellinghoff AC, Reininger AJ, Wu erth JP, Founds HW, Landgraf \nR, Hepp KD. Formation of plasma advanced glycosilytion end products (AGEs) has no influence on plasma viscosity. Diabet Med 1997;14:832-6. \n162.-Schneede J, Dagnaelie PC, van Stav eren WA, Vollset SE, Refsum H, \nUeland PM. Methylmalonic acid an d homocysteine in plasma as \nindicators of functional cobalamin de ficiency in infants on macrobiotic \ndiets. Pediat Res 1994;36:194-201. \n163.-Mezzano D, Mu\u00f1oz X, Martinez C, Cuevas A, Panes O, Aranda E, \nGuasch V, Strobel P, Mu\u00f1oz B, Rodriguez S, Pereira J, Leighton F. Vegetarians and cardiovascular risk factors: hemostasis, inflammatory \nmarkers and plasma homocysteine. Thromb Haemostas 1999;81:913-7. \n164.-Kromhout D, Bosschieter EB, De Lezenne, Coulander C. The \ninverse relation between fish com\u00e7nsumption and 20-year mortality from coronary heart disease. N Engl J Med 1985;312:1205-9. \n165.-Shekelle R, Missell L, Paul O, MacMillan-Schryock A, Stamler J. \nFish consumption and mortality from coronary heart disease. N Engl J \nMed 1985;313:820. \n166.-Dyerberg J, Bang HO. Haemostatic function and platelet \npolyunsaturated fatty acids in Eskimos. Lancet 1979;2:433-5. \n167.-Simopoulos AP. Essential fatty acid s in health and chronic disease. \nAm J Clin Nutr 1999;70(S):560S-569S.  \n \n 123168.-Mezzano D, Kosiel K, Martinez C, Cuevas A, Panes O, Aranda E, \nStrobel P, P\u00e9rez DD, Pereira J, Rozo wki J, Leighton F. Cardovascular \nRisk Factors in vegetarians: Norm alization of Hiperhomocisteinemia \nwith Vitamin B12 and Reduction of Pl atelet Aggregation with n-3 Fatty \nAcids. Thrombosis Research 2000. \n169.-Verhaeverbeke I, Mets T, Mulkens K, Vandewonde M. \nNormalization of low vitamin B12 se rum levels by oral treatment. \nJournal of the American geriatrics society 1997;45:124-5. \n170.-Elia M. Oral or parenteral th erapy for B12 deficiency. Lancet \n1998;352:1721-22. \n171.-Ross GIM, Mollin DL, Cox EV, Un gley CC. Hematologic responses \nand concentration of vitamin B12 in serum and urine following and oral \nadministration of vitamin B12 wi thout intrinsic factor. Blood 1954;9:473. \n172.-Heinrich HC, Gabbe EE. Experimental basis of oral and parenteral \ntherapy with cyano-and aquacobalamin, in Linnell JC, Bhatt HR (eds) \nBiomedicine and Physiology of vitamin B12. London. UK. The \nChildren\u00b4s Medical Charity. 1990.p51. \n173.-Berlin H, Berlin R, Brante G. O ral treatment of pernicious anemia \nwith high doses of vitamin B12  without intrinsic factor. Acta Med \nScand 1968;184:247. \n174.-Waife SO, Jansen CJ, Crabtree RE, Grinnan EL, Fouts PJ. Oral \nvitamin B12 without intrinsic factor in the treatment of pernicious anemia. Ann Intern Med 1963;58:810. \n175.-McIntyre PA, Hahn R, Masters JM, Krevans JR. Treatment of \npernicious anemia with orally administered cyanocobalamin (vitamin B12). Arch Intern Med 1960;106:280. \n176.-Unglaub WG, Goldsmith GA. Oral vitamin B12 in the treatment of \nmacrocytic anemias. Southern Med J 1955;48:261. \n177.-Magnus EM. Cobalamin and unsaturated transcobalamin values in \npernicious anaemia: Relation to treatment. Scand J Haematol 1986;36:457. \n178.-Kuzminski AM, Del Giacco EJ, A llen RH, Stabler SP, Lindembaum \nJ. Effective treatment of cobalamin deficiency with oral cobalamin. \nBlood 1998;92:1191-1198.  \n \n 124179.-Takasaki Y, Moriuchi Y, Tsushima H, Ikeda E, Koura S, Taguchi J, \nFukushima T, Tomonaga M, Ikeda S. Rinsho Ketsueki 2002;43(3)165-9. \n180.-Lindenbaum J, Rosenberg IH, W ilson PWF, Stabler SP, Allen RH. \nPrevalence of cobalamin deficien cy in the Framingham elderly \npopulation. Am J Clin Nutr 1994;60:2. \n181.-Hathcock JN, Troendle GJ. Oral cobalamin for treatment of \npernicious anemia ? J Am Med Assoc 1991;265:96. \n182.-Middleton J, Wells W. Vitamin B12 injections: Considerable source \nof work for the district nurse. Br Med J 1985;290:1254. \n183.-Hoffman CF, Palmer DM, Papadopolulos D. Vitamin B12  \ndeficiency: a case report of ongo ing cutaneous hyperpigmentation. \nCutis 2003;71:127-30. \n184.-Savage D, Lindenbaum J. Relapses after interruption of \ncyanocobalamin therapy in patients  with pernicious anemia. Am J Med \n1983;74:765. \n185.-Sharabi A, Cohen E, Sulkes J, Garty M. Replacement therapy for \nvitamin B12 deficiency: comparison between the sublingual and oral route. Br J Clin Pharmacol 2003;56:635-8. \n186.- Dietary reference intakes for thiamin, riboflavin, niacin, vitamin \nB6, folate, vitamin B12, pantothenic acid, biotin, and choline/ a report of \nthe Standing Committee on the Sc ientific Evaluation of Dietary \nReference Intakes and its Panel on Folate, Other B Vitamins, and Choline and Subcommittee on Upper Levels on Nutrients, Food and Nutrition Board. Institute of Medi cine. Washington, DC: National \nAcademy Press. 1998. \n187.-Rampersaud GC, Kauwell GP, Bailey LB. Folate: a key to \noptimizing health and reducing dise ase risk in the elderly. J Am Coll \nNutr 2003;22(1):1-8. \n188.-Food and Nutrition Board\u2014Ins titute of Medicine. Dietary \nreference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline. Washington, DC: National Academy Press; 1998. \n \n  \n \n 124 Workout B12 deficiency \nSerum folate \u2264 7 or \nRBC folate \u2264 175Serum folate > 7 + RBC folate >175 \nB12 \nB12 \u2264 200 \nOutcome 1 B12>200 B12 \nB12 \u2264 200 \nOutcome 8B12>200 \nHOMOCYSTEIN HOMOCYSTEIN \ntHcy <12 tHcy \u226512 tHcy <12 tHcy \u226512 \nHOLO-TC HOLO-TC HOLO-TC HOLO-TC \nHolo-tc \u226445 \nOutcome 2 Holo-TC >45 Holo-tc \u226445 \nOutcome 5Holo-TC >45 Holo-tc \u226445 \nOutcome 9 Holo-TC >45 Holo-tc \u226445 \nOutcome 12Holo-TC >45 \nAMM AMM AMM AMM \nAMM \u2265300 \nOutcome 3AMM <300 \nOutcome 4 AMM \u2265300 \nOutoc me 6AMM <300 \nOutcome 7AMM \u2265300 \nOutcome 10AMM <300 \nOutcome 11AMM \u2265300 \nOutcome 13AMM <300 \nOutcome14  \n \n 125 Figura 2. En amarillo deficiencia de B 12 \n \n \n                            \n   \nWorkout B12 \ndeficienc y\nSerum folate \u22647 or RBC folate  \u2264 \n175 Serum folate >7 + RBC folate >175\nHomocystein <12  Homocystein \u2265 \n12Homocystein <12 Homocystein \u2265 \n12\nHolo TC Holo TC Holo TC Holo TC \nHolo TC \u226445 \nOutcome 7Holo TC >45 Holo TC \u226445 \nOutcome 10Holo TC >45 Holo TC \u226445 \nOutcome 1Holo TC >45 Holo TC \u226445 \nOutcome 4Holo TC >45 \nAMM AMM AMM AMM \nAMM \u2265300 \nOutcome 8AMM<300 \nOutcome 9 AMM \u2265300 \nOutcome 11AMM<300 \nOutcome 12AMM \u2265300 \nOutcome 2AMM<300 \nOutcome 3AMM \u2265300 \nOutcome 5AMM<300 \nOutcome 6 \n \n 126 Figura 3. En amarillo deficiencia de B 12 \n \n                            \n    \nWorkout B12 deficiency \nSerum folate \u22647 or RBC folate  \u2264 175 Serum folate >7 + RBC folate >175 \nHolo TC Holo TC \nHolo TC \u226445 \nOutcome 4 Holo TC >45 Holo TC \u226445 \nOutcome 1Holo TC >45 \nAMM AMM \nAMM \u2265300 \nOutcome 5AMM<300 \nOutcome 6AMM \u2265300 \nOutcome 2AMM<300 \nOutcome 3 \n \n 127 Figura 4. En amarillo deficiencia de B 12 \n \nWorkout B12 deficiency \nSerum folate \u22647 or RBC folate  \u2264 175 Serum folate >7 + RBC folate >175 \nHolo TC <40 \nOutcome 5 Holo TC \u226540 y <50 \n Holo TC < 40 \nOutcome 1 Holo TC \u226540 y <50 \n \nAMM AMM \nAMM \u2265300 \nOutcome 6 AMM<300 \nOutcome 7AMM \u2265300 \nOutcome 2AMM<300 \nOutcome 3Holo TC \u226550 \nOutcome 8 Holo TC \u2265 50 \nOutco me 4 \n \n 128\n Figure 5. Standardized variab les in Diagnostic Scheme 3 \n \na) Vitamin B12 deficiency   b) Combined Deficiency \n \nb12_max holo_max amm_max folser_max folint_max tHcy_max0,000,200,400,600,801,00\n174116\n141867183179\n29182\n183182\nb12_max holo_max amm_max folser_max folint_max tHcy_max0,000,200,400,600,801,00\n9455\n101987674\n61449310711337\n97\n96884740\n11262\n \n \nc) Isolated Folate deficiency   d) Normal \n \nb12_max holo_max amm_max folser_max folint_max tHcy_max0,000,200,400,600,801,00\n132118133\n120\n117145122119121128\n131119128118\nb12_max holo_max amm_max folser_max folint_max tHcy_max0,000,200,400,600,801,00\n191217\n207191206202\n \n \n   \n \n 129\n  \nFigure 6. Standardized variab les in Diagnostic Scheme 4 \n \na) Vitamin B12 deficiency    b) Combined. Deficiency \n \nb12_max holo_max amm_max folser_max folint_max tHcy_max0,000,200,400,600,801,00\n6\n142528\n29\n1272527\nb12_max holo_max amm_max folser_max folint_max tHcy_max0,000,200,400,600,801,00\n5047\n61447637\n40\n62\n \n \n \nc) Folate deficiency    d) Normal \n \nb12_max holo_max amm_max folser_max folint_max tHcy_max0,000,200,400,600,801,00\n207184218183217179 182\n191182206\n180202\n \n \n b12_max holo_max amm_max folser_max folint_max tHcy_max0,000,200,400,600,801,00\n97120\n11211188\n11711297122119121113\n132118133128\n131119128118\n108 \n \n 130\n Figure 7. Mean value of the index in the 4 outcome groups of Diagnostic Scheme 3 \n \n \n \n \nFigure 8. Mean value of the index in the 4 outcome groups of Diagnostic Scheme 4 \n \n \n \n \n  \n \n   \n \n    \n \n     \n \n    \n \n \n    \n \n    \n \nVITAMINA B 6  \n \n 132VITAMIN B 6 STATUS, DEFICIENCY AND ITS CONSEQUENCES \u2013 \nAN OVERVIEW \nSpinneker A.3, Sola R. 1,2, Lemmen V.,2,3, Gonzalez-Gross M.2,3,4,  \nCastillo MJ.2, Pietrzik K.3 \n1 Servicio de Hematolog\u00eda. Hospital Universitario San Cecilio. Granada. \nSpain. \n2 Grupo Effects 262. Facultad de Medicina. Universidad de Granada. \nSpain. \n3 Institut f\u00fcr Ern\u00e4hrungs-und Lebensmittelwissenschaften, Rheinische \nFriedrichs-Wilhelms Universit\u00e4t Bonn, Germany  \n4 Facultad de Ciencias de la Actividad F\u00edsica y del Deporte. Universidad \nPolit\u00e9cnica de Madrid. Spain.  \n   \n \n    \n \n Address for correspondence: Prof. Dr. Marcela Gonzalez-Gross Facultad de CC de la Actividad F\u00edsica y del Deporte \nUniversidad Polit\u00e9cnica de Madrid \nc/ Mart\u00edn Fierro s/n \nE-28040 Madrid \nTel.: +34 91 336 4006 \nFax: +34 91 5497307 \ne-mail: marcela.gonzalez.gross@upm.es\n  \n \n 133Abstract: \nVitamin B 6 is thought to be a most versatile coenzyme that \nparticipates in more than 100 bioche mical reactions. It is involved in \namino acid and homocysteine metabolism, glucose and lipid \nmetabolism, neurotransmitter production and DNA/RNA synthesis. Vitamin B\n6 can also be a modulator of gene expression. Nowadays, \nclinically evident vitamin B 6 deficiency is not a common disorder, at \nleast in the general population. Nevertheless, a subclinical, undiagnosed deficiency may be presen t in some subjects, particularly in \nthe elderly. \nIn fact, it has been proposed that suboptimal vitamin B\n6 status is \nassociated with certain diseases th at particularly afflict the elderly \npopulation: impaired cognitive function, Alzheimer\u2019s disease, cardiovascular disease, and differen t types of cancer. Some of these \nproblems may be related to the elev ated homocysteine concentrations \nassociated to vitamin B\n6 deficiency, but there is also evidence for other \nmechanisms independent of homocysteine by which a suboptimal vitamin B\n6 status could increase the risk for these chronic diseases. \n  \n \n     \n \n    \nKey words : Vitamin B\n6 - coenzyme \u2013 elderly \u2013 homocysteine \u2013 vitamin \nB6 deficiency  \n \n 134Introduction \nVitamin B 6 sufficiency is required for optimal health. This is due \nto the participation in many differe nt biochemical reactions. Vitamin B 6 \nand its derivatives are needed, especi ally in there coenzyme function, \nfor the main metabolic pathways in the human body. For that reason, it \nis clear that a vitamin B 6 deficiency, even in mild forms, has affects on \nthe human metabolism. Several diseas es and impairments of health are \nconnected to the wide variety of B 6 functions in suboptimal status. This \ncan also be worsening through ageing.  \nThis article gives a brief overview about vitamin B 6 in general, its \nfunctions, requirements and meas urement. Further, we will discuss \ndetailed associated diseases as possible effects of vitamin B 6 deficiency \nand talk about prevention potentials. \n \nVitamin B 6 \u2013 Chemistry, metabolism and bioavailability  \nVitamin B 6 comprises a group of three related 3-hydroxy-2-\nmethyl-pyrimidine derivatives. The derivative pyridoxine (PN) is an alcohol, pyridoxal (PL) is an aldehyde and pyridoxamine (PM) contains an amino group. Their respective 5 \u00b4-phosphate esters: pyridoxine 5\u00b4-\nphosphate (PNP), pyridoxal 5\u00b4-phosphate (PLP) and pyridoxamin-5\u00b4-\nphosphate (PMP) are the biological active coenzyme forms (figure 1). \nThey are water-soluble and can be inter-converted in normal human \nmetabolism (B\u00e4ssler 2002). PLP is th e major form that is used by \npyridoxine-dependent enzymes. Thes e enzymes catalyse more than 100 \nessential biochemical reactions in human metabolism.  \nB\n6 vitamers are similarly absorbed  in the upper jejunum and little \nin ileum, but before absorption, phos phate esters must be hydrolysed \nby alkaline phosphatase or other intestinal phosphatases. The non-phosphorylated form enters the mucosal cells by two different processes according to luminal conc entration. At low concentrations, \nvitamers enter the cell by an active  process regulated by requirements. \nAt high concentrations, transport is  by non-saturable passive diffusion \nmechanisms (B\u00e4ssler 2002). Once in the cell, vitamers are \nphosphorylated by ATP dependent pyridoxine kinase in a process \nreferred to as metabolic trapping . The phosphorylated form can not \ntraverse cell membranes and must th erefore be dephosphorylated again \nbefore traversing the basolateral membrane side of the mucosal cell.  \n \n 135Once in the circulation, most of B 6 vitamers are transported to the liver \nwhere they are again phosphorylated  to PNP, PLP or PMP, and then \nreleased to plasma (Board 1998; B\u00e4ssler 2002). Vitamin B 6 in plasma is \nmainly PLP (60%), PN (15%) and PL  (14%). These vitamers circulate \nbound to albumin (B\u00e4ssler 2002). In pe ripheral tissues, in order to cross \ncell membranes, the phosphoryl ated forms need to be \ndephosphorylated by alkaline phosphorylase. Transport into tissue cells is by gradient diffusion. This grad ient is maintained  thanks to the \nimmediate rephosphorylation occurring  inside the cells.  Intracellular \naccumulation of PLP seems to be limited by intracellular protein \nbinding capacity. In circulation, PLP may enter red blood cells where \nPLP bounds to haemoglobin. In red cell mass, PLP is at higher concentration (4 to 5 times) than in plasma. PLP increases the oxygen \naffinity of haemoglobin (Ink 1982). Total body stores of B\n6 have been \nestimated to be as little as 167 mg (Lui, Lumeng et al. 1985). Up to 80% \nof that amount is found in muscle tissue (Board 1998). PLP in \nmetabolism occurs mainly in the li ver where it is oxidised to 4-\npyridoxic-acid (4-PA) which is rele ased and excreted. Almost 50% of \nurinary vitamin B 6 is 4-PA. In total, some 2 mg vitamin B 6 can be \nexcreted every day. In cases of B 6 deficiency, excretion appears to be \nlower. PN is also excreted in faeces but to a limited extent and can \ntherefore be neglected (Lui, Lumeng et al. 1985).   \nGregory has reviewed the bioavailability of vitamin B 6(Gregory \n1997). In a diet typically containing about 15% PN glucoside, which is \nabout 50% as bioavailable as the other vitamers, vitamin B 6 is about 75% \nbioavailable. The bioavailability of non-glucosides of the vitamin is \ngreater than 75%. In the absence of food B 6 compounds are absorbed \nsimilarly, even at high doses. A lo ading dose of 50 mg PL or PLP is \nfound up to 70% in the urine within  24 hours. This demonstrates that \nthe phosphate esters are effectively hydrolysed and absorbed in the gut (Snell 1958; Shane 1978); whereas only 40% PN can be accounted for in the urine under the same conditions , it does raise the plasma PLP \nconcentration and is retained more effectively than is PL (Shane 1978). \nDietary PM and PL are about 10% less effective than PN in raising the plasma PLP concentration, and slig htly more of these vitamins are \nexcreted in the urine as 4-PA (W ozenski, Leklem et al. 1980). Most \ncontrolled B\n6 studies have used PN as the added source, but \nrequirements calculated from these studies would underestimate the B 6  \n \n 136requirement by 5% or less for indi viduals deriving most of their B 6 as \nPLP and PMP from animal source. \n \nFunctions and vitamin B 6-dependent enzymes \nSince vitamin B 6 is a coenzyme in many different metabolic \nreactions, we can consider that vitamin B 6 has a wide variety of \nfunctions in the human body. PLP, as coenzyme, is required for reactions in different metabolic pa thways. To carry out its catalytic \naction, the carbonyl group present in PLP forms a Schiff\u00b4s base with the \n\u03b5-amine of lysine of the apo-enzyme and then the initial catalytic step \nproceeds by the formation of a Schiff\u00b4s base between the \u03b1-amino group \nof an amino-acid and the carbonyl  group of PLP (Board 1998). The \nelectron sink properties of PN enable the holo-enzyme for its catalytic reaction (Jansonius1998). In reacti ons associated with amino acid \nmetabolism, PLP binding enables the amino acid for further reactions. \nSome of the reactions PLP is involved in are: transamination of amino \nacids to keto acids (which can be  then used for gluconeogenesis), \nformation of \u03b1-aminolevuline acid (a precursor of heme group), as \ncoenzyme in serin-palmityl-transfe rase (implicated in sphingomyelin \nsynthesis), decarboxylation of L-am ino acids (to yield amines, which \nfunction as neurotransmitters, hormon es or biogenic amines). In the \nnervous system, PN-dependent enzymes fall into two categories: transaminases and L-amino acid decarboxylases. The crucial PLP-dependent steps of the synthesis of several neurotransmitters are: the enzymatic decarboxylation of 3,4-di hydroxyphenylalanine (DOPA) to \ndopamine, the conversion of tryptophan to both nitric acid and \nserotonine, and the conversion of glutamic acid to \u03b3-aminobutyric-acid \n(GABA) (Kleijnen and Knipschild 1991). Another important metabolic pathway is the metabolism of one-carbon units. One-carbon (methyl) units, usually obtained from serine, are transferred to tetrahydrofolate (THF) yielding 5,10-methylene-tetrahydrofolate (5,10-methylene-THF). This reaction is catalysed by serine-hydroxymethyltransferase (SHMT), \na PLP dependent enzyme (figure  2). 5,10-methylene-THF is \nsubsequently used as a methyl dono r for the synthesis of thymidylate \nand purines (for nucleic acid synthe sis) or methionine (for protein \nsynthesis or biological methylations ). A considerable proportion of \nmethionine is activated by ATP to form S-adenosylmethionine (SAM), \nwhich serves primarily as a univer sal methyl donor in a variety of  \n \n 137reactions. In the brain, for exampl e, SAM-dependent methylations are \nextensive and the products of these reactions include several \nneurotransmitters such as cate cholamines and indoleamines, \nphospholipids and myelin (Selhub, Bagley et al. 2000). \nThe interaction with the ho mocysteine (Hcy) metabolism \nthrough methionine transformation into cysteine (by cystathionine \u03b2-\nsynthase and cystathionine- \u03b3-lyase) (figure 2) is of growing interest \nsince high levels of Hcy have been  related to cardiovascular disease \n(CVD), cognitive impairment or cancer. Hcy is a sulphur-containing \namino acid which is not a constituent of proteins and, in fact, an \nintermediate compound in methionine metabolism. There are two pathways for Hcy disposal in the human body and both are related to methionine status and vitamin B\n6.  \nIn cases of methionine excess, or  when cysteine is required, Hcy \nenters the transsulfuration pathway wh ich consists of condensation of \nHcy with serine to form cystathi onine (catalysed by cystathionine- \u03b2-\nsynthase). Cystathionine is th en degraded to cysteine and \u03b1-\nketobutyrate by cystathionine \u03b3-lyase. Both reactions require PLP as \ncofactor (Mudd, Skovby et al. 1985). In cases of methionine deficiency, Hcy enters the remethylation pathway which is a folate and B\n12 \ndependent process (Selhub and Miller 1992). \nAs a coenzyme for glycogen phosphorylase, PLP is also involved \nin glucose metabolism. In this case , the 5-phosphate group of PLP acts \nas a proton donor or acceptor. In addition to these functions, PLP interacts with different proteins and plays many different roles including regulation of steroid horm one receptors, modulation of the \naffinity of haemoglobin into oxygen or  inhibition of some transcription \nfactors (B\u00e4ssler 2002). \n Measurement of vitamin B\n6  \nOver the last decades several indicators of B 6 status have been \ndeveloped. Indicators of vitamin B 6 status include direct measures, \nplasma or erythrocyte vitamin concentration, or urinary 4-PA; and \nfunctional measures, stimulation or ac tivation of erythrocyte aspartate \naminotransferase ( \u03b1-EAST) and alanine aminotransferase ( \u03b1-EALT) by \nPLP, or determination of tryptophan metabolites, such as urinary xanthurenic acid (XA). The increase  in methionine metabolites (e.g.  \n \n 138Hcy, cystathionine) after a methionine load is also used as an indicator \nof B 6 status (Leklem 1994). All of thes e and their respective reference \nvalues are summarised in table 1 and briefly summed up below. \n \n1. Direct measures in blood and urine.  \n(A) Plasma PLP, other vi tamers and total vitamin B 6 \nThe PLP concentration is a direct  indicator for the activity of \nvitamin B 6 in the organism. Plasma PLP is  used as the primary index of \nwhole-body PL levels. Protein bound PLP in the plasma is in \nequilibrium with free PLP. Binding of  PLP to protein protects it from \nhydrolyses by alkaline phosphatase. The plasma PLP concentration reflects liver PLP (Lumeng and Li 1974), and changes fairly slowly in \nresponse to changes in vitamin intake, taking about 10 days to reach a new steady state (Lui, Lumeng et al. 1985). PLP generally correlates with other indicators of B\n6 status (Lumeng 1978). Leklem has suggested \na plasma PLP concentration of 30 nmol/L as the lower end of normal \nstatus (Leklem 1990), whereas other investigators have proposed a cut-off of 20 nmol/L (Lui, Lumeng et al . 1985). Generally, values lower than \n20 nmol/L indicate B\n6 deficiency.Table 2 shows different physiological \nand other parameters which influence PLP plasma concentration \n(Bitsch 1993; Leklem 1994). Usually, men show higher levels than \nwomen, because of their higher mu scle tissue mass. During gestation \nlower values of this vitamin have  been observed, because of hem \ndilution due to changes in plas ma volume. A release of muscle \nglycogen phosphorylase in prolonged fasting may mask an underlying deficiency, because most PLP in th e body is usually bound to this \nenzyme. Plasma total vitamin B\n6 and plasma PL concentration are \nadditional direct measures that have utility. Since PL is the form that enters the cell, its measurement may be more relevant than that of PLP.  \nA number of methods have been  developed for the assay of B\n6 \nvitamers in plasma for clinical and nutritional purposes. These include microbiological or enzymatic meth ods. Currently, the quantitative \ndetermination of PLP in plasma is commonly performed with \nprocedures that utilise tyrosine apodecarboxylase. Another extensively used method is a chromatographic determination. High-performance \nliquid chromatography (HPLC) proced ures with appropriate detection \nsystems are regarded as the most co nvenient method for the evaluation  \n \n 139of vitamin B 6 nutritional status since it is possible to quantify all \nvitamers and 4-PA in one assay.  \n \n(B) 24-hour urinary excretion of 4-PA and total vitamin B 6  \n4-PA is the major inactive metabolite of PN metabolism. Urinary \n4-PA has been used extensively to evaluate B 6 requirements. \nApproximately 50% of the B 6 intake is excreted as 4-PA, but this \nproportion can vary somewhat. 4-PA excretion responds almost immediately to changes in dietary in take and therefore reflects recent \ndietary B\n6 intake rather than tissue saturation status (Lui, Lumeng et al. \n1985). Thus, 4-PA excretion should not be used for status assessment. Nevertheless, low urinary excretion implies a low intake. Leklem has suggested a value greater than 3 \u00b5mol /day as indicative of adequate \nstatus (Leklem 1990). Urine levels of 4-PA are lower in females than in \nmales and will be reduced in persons with riboflavin deficiency. \nFurther, different pharmaceuticals  (isoniacid, penicillin, and \ncyclosporine) increase urinary excret ion and interfere with the results. \nNeither age nor alcohol intake affects the measured level.  \n 2. Indirect functional measures .  \nActivation coefficient (AC) of \u03b1-EAST and \u03b1-EALT \nThe stimulation of these enzymes by external (added) PLP is a \nfrequently used function al measure of vitamin B\n6 status. These \nindicators are considered long-term measures because of the length of \nthe erythrocyte\u2019s lifespan (120 days). Because there is no protein synthesis in mature erythrocytes, the holo-enzyme:apo-enzyme ratio \nwill reflect the availability of PLP at the time the erythrocytes were \nreleased into the circulation. In vitamin B\n6 deficiency, a greater than \nnormal proportion of aminotransferases is present in form of the catalytically inactive apo-enzyme. This can be converted to the catalytically active holo-enzyme by incubation in vitro  with PLP. Since \nthe seventies, some authors suggest that \u03b1-EALT is a more sensitive \nindex of vitamin B\n6 nutritional status than is \u03b1-EAST (Cinnamon 1970; \nBrown 1975; Hansen, Leklem et al. 1997). In order to overcome some of \nthe differences in methods of measurement and in erythrocyte \ntransaminases activities between norm al healthy individuals, the results \nare generally expressed as an AC  (ratio of activity with added  \n \n 140coenzyme/activity without added coenzyme). Although complete \nsaturation of aminotransferases with  PLP (AC = 1.0) does occur, some \ndegree of unsaturation (AC > 1.0) is co nsidered to be normal. Assuming \nthat erythrocytes must compete with other tissues for the vitamin, and \nhence that erythrocyte aminotransfe rase saturation with PLP reflects \nthe status of other tissues, such inco mplete saturation may be a factor in \nnormal metabolic regulation (Bender 1989). Indicator of deficiency is an \nAC of EAST of greater than 1.6 and of EALT of greater than 1.25 \n(Leklem 1990). As mentioned above,  EAST-AC reduction lags behind \nthe onset of the PN deficiency. Th us, a low aminotransferase AC value \nconfirms a sub acute to chronic de ficiency state. Chronic alcoholism \ncauses these indices to be falsely lo w, and these indices decrease with \nage. \n 3. Metabolites  \n(A) Tryptophan load test (figure 3) \nOne of the earliest markers used to determine B\n6 deficiency was \nthe urinary excretion of XA, which is normally a minor tryptophan \ncatabolite. The major pathway of tryptophan catabolism proceeds via the PLP-dependent kynureninase reaction (Shane 1980). The XA \npathway also involves PLP-depe ndent enzymes, but kynurenine \naminotransferase seems to be less se nsitive to PLP deficiency. Under \nconditions of B\n6 deficiency, this minor pathway is used to a greater \nextent, leading to the increased excretion of abnormal tryptophan metabolites such as XA, and as the deficiency worsens, 3-Hydroxykynurenine (3-HK) and kynuren ine. The tryptophan load test \nhas been widely used as an index of vitamin B\n6 nutritional status. \nVarious challenge doses have been used in different studies such as 2 or 3 grams, as well as 4 grams (Don ald, McBean et al. 1971; Rose 1975; \nLeklem, Linkswiler et al. 1977; Leklem 1990; Leklem 1994). However, as for many of the tests of B\n6 status, it is not clear what level of excretion \nrepresents adverse B 6 status under the conditions of the tryptophan \nchallenge dose. A 24-hour urinary excretion of less than 65 \u00b5mol \nxanthurenate after a 2 g tryptophan  oral dose has been suggested \n(Leklem 1990). The use of  an oral loading dose  of L-tryptophan to \ndetect abnormalities in tryptophan and vitamin B 6 status is an \nunderutilised laboratory procedure. If used only to measure B 6 status, it \nmay be less indicative   \n \n 141than other indices, such as the methionine load test (urinary \ncystathionine), plasma PLP, urinary vitamin B 6, or 4-PA. It may, \nhowever, be more indicative than  erythrocyte aminotransferases. \nMarginal B 6 or magnesium deficiencies cause significant alterations. \nThis test is influenced by protein intake, exercise, lean body mass, and \npregnancy. Hormonal factors and infections enhance tryptophan-to-niacin conversion. Thus, this test is most useful for monitoring an \nindividual \u02b9s response to PN supplementation rather than for \ndiagnosing a deficiency. \n \n(B) Methionine load test (figure 4) \nA methionine loading test has also been studied as a possible \nindicator of vitamin B\n6 status. Three enzymes of the methionine \nmetabolism, cystathionine \u03b2-synthase, cystathionine \u03b3-lyase and \ncysteine sulphinic acid decarboxylases, are PLP-dependent. In vitamin \nB6 deficiency, a test dose of methioni ne (3 g in an adult) results in \nabnormal accumulation and excretio n of Hcy and the mixed disulphide \nof Hcy and cysteine, as well as cystathionine and cysteine sulphinic acid, and reduced excretion of taurine (Park and Linkswiler 1970; Shin and Linkswiler 1974; Linkswiler 1981; Sturman 1981). More recently a \nstandardised methionine load test has been successfully used (Graham, \nDaly et al. 1997). The general procedur e involves the administration of \n100 mg of L-methionine pe r kilogram of body wei ght. The increase in \nHcy concentrations are evaluated in terms of the vitamin B\n6 status. For \nseveral reasons, the methionine load test has been used less often as an \nindex of vitamin B 6 nutritional status than has the tryptophan load test. \n Pathophysiological implications related to vitamin B\n6 deficiency \nSince vitamin B 6 is present in almost all foods, B 6 deficiency due \nto insufficient dietary supply is rare . Additionally, isolated vitamin B 6 \ndeficiency is uncommon and usually  occurs in combination with \ndeficiencies of other B-complex vitami ns. Often PN deficiency is caused \nby absorption disorders, genetic fa ctors, interactions with drugs or \nelevated requirements as shown in table 3. Because of its wide variety \nof functions in the body, clinical vitamin B 6 deficiency results in a broad \nspectrum of impaired features. On  the other hand, borderline vitamin \nB6 deficiency may represent a subtle, undiagnosed and frequent cause   \n \n 142of disease in some population groups.  In fact, a reduced B 6 status close \nto borderline concentrations or even mild deficiency could persist in an individual for months or years wi thout the appearance of any of the \ndiagnostic features or symptoms sugge sting clinical deficiency. In this \nsituation, some PLP related functions may be adequately compensated but others may not (Rosenberg an d Miller 1992). This subclinical \ndeficiency can be attributed to inadeq uate intake and/or to the effect of \nageing on physiological and metabo lic processes, which may act in \nconjunction with many othe r factors. The most common \npathophysiological implicat ions related to vitamin B\n6 deficiency are the \nfollowing: \n 1. Hypochromic, microcytic, iron-refractory anemia  \nB\n6-deficiency anemia is one form of sideroblastic anemia, \ncharacterised by ineffective eryth ropoiesis with hypochromic, \nmicrocytic anemia, splenomegaly, elevated tissue and serum iron, and \nlarge numbers of ringed sideroblasts in the bone marrow (Bottomley 1993). Microcytic anemia reflects decreased haemoglobin synthesis. Vitamin B\n6 deficiency or a genetic defect  of the enzyme aminolevulinate \nsynthase can therefore lead to an iron refractory, microcytic anemia. In \nanimals, it is well established that a deficiency of vitamin B 6 results in a \nsevere microcytic, hypochromic an emia accompanied by strongly \nelevated serum iron levels (Linkswiler 1967). In humans, vitamin B 6 \ndeficiency anemia is very rare. Therefor e, literature is very scarce. In the \nseventies, Ofori-Nkansah et al.  reported that the prevalence is higher in \nmen than in women (Ofori-Nkansah, Weissenfels et al. 1975). Further, \nFishman and colleagues suggest  that a treatment with B 6 may be \neffective in correcting the haematological abnormalities of sideroblastic anemia (Fishman, Christian et al. 2000). \n 2. Immune function \nAnimal studies in the forties demo nstrated that a deficiency of \nvitamin B\n6 results in large effects on ly mphoid tissues. Thymic atrophy \noccurs and lymphocyte depletion in  lymph nodes and spleen has been \nfound in monkeys, dogs, rats, an d chickens (Stoerk 1946; Stoerk 1946). \nMore recently, studies performed in humans confirm that vitamin \naffects immunocompetence (Grimble 1998). Low vitamin B 6 intake and  \n \n 143status have been associated with im paired immune function, especially \nin the elderly (Talbott, Miller et al. 1987; Meydani, Ribaya-Mercado et al. 1991). Decreased lymphocyte and in terleukin (IL)-2 production has \nbeen observed in B\n6-deficient individuals. Restoration of adequate \nvitamin B 6 status resulted in normalisation of lymphocyte proliferation \nand IL-2 production. These results suggest that adequate vitamin B 6 \nintake is important for optimal immune system function, at least in older individuals (Talbott, Miller et al. 1987; Meydani, Ribaya-Mercado et al. 1991).  \nFurther, experimental deficiency in elderly humans has been \nshown to reduce total blood lymp hocyte numbers and decrease the \nproliferative response of lymphocyte s to mitogenic substances. It has \nbeen suggested that the mechanis m for the effect of vitamin B\n6 on \nimmune function relates to the import ance of PLP in the synthesis of \none carbon compounds and hence DNA and RNA synthesis.  \nLow synthesis rates of the compound will thus impair cell \nreplication (Grimble 1998). Further, U937 monocytes which were cultured with PN, PL or PM demo nstrated that these vitamers can \nprevent the oxygen radical generation and lipid peroxidation caused by hydrogen peroxide (Kannan and Jain 2004). Others suggest a \nconnection between inflammation and vitamin B\n6 status (Chiang, \nSelhub et al. 2005; Chiang, Smith et al. 2005). They found significantly \nlower PLP concentrations in patients with rheumatoid arthritis than in \nhealthy subjects. In contrast, no di fference was found between patients \nand controls in erythrocyte PLP or erythrocyte \u03b1-EAST or 4-PA levels. \nTherefore, they suggest that the lower vitamin B 6 concentration \nin patients with rheumatoid arthritis is tissue-specific. Additionally, the \nlower circulating PLP levels observed in rheumatoid arthritis could reflect a decrease in hepatic PLP pools, because plasma PLP is a good indicator of liver B\n6 status during inflammation. Further, the study \nindicates that inflammation directly affects vitamin B 6 metabolism \ndifferently in different tissues (Chian g, Smith et al. 2005). The following \nstudy of the research group analysed the effect of B 6 supplements (50 \nmg PN hydrochloride/day) on B 6 and inflammation status. All markers \nof vitamin B 6 status improved significantly in the B 6 supplementation \ngroup. Although, the authors found no effect of vitamin B 6 \nsupplementation on inflammatory c ytokines, plasma CRP, ESR, or \nrheumatoid factor levels. They suggest that it is likely that  \n \n 144inflammation causes vitamin B 6 deficiency and/or impaired vitamin B 6 \nstatus contributes to more severe  inflammation in patients with \nrheumatoid arthritis. But as improving vitamin B 6 status did not \nalleviate inflammation, it is unlikely that vitamin B 6 inadequacy directly \ncauses or worsens the inflammatory condition (Chiang, Selhub et al. \n2005).  \n 3. Cancer \nSome studies on diet and cancer have disclosed a significant \ninverse correlation between serum PLP (and vitamin B\n6 intake) and \ndifferent types of cancer. There are  several potential mechanisms by \nwhich vitamin B 6 may influence carcinogenesis. First, B 6-deficiency \ncauses a decrease in the enzyme acti vity of SHMT. This results in a lack \nof methylene groups for 5,10-methylene-THF production (Stabler 1997). Consequently, methylation of deoxyu ridylate to deoxythymidylate may \nbe impaired resulting in misinc orporation of uracil instead of \nthymidine into DNA. As a consequence, a greater potential of chromosome strand breaks (Blount, Mack et al. 1997) and/or an impaired DNA excision repair may exist (Choi, Kim et al. 1998). Evidence of this has been reported (Huang, Chen et al. 1998).  In \naddition, disruption of the above mentioned reactions may lead to \nimbalances in the methyl groups re quired for methylation processes, \nresulting in DNA hypomethylation. Altered DNA methylation has been \nobserved in different types of tumors (Jones and Buckley 1990; Jarrard, Bova et al. 1996). The B\n6 connection to the immune system could be a \nmechanism by which low vitamin B 6 status or intake also contributes to \ndevelopment of cancer. The two different PLP-dependent enzymes \nwhich are implicated in the transsulfuration pathway also generate cysteine, an important component of glutathione. Glutathione S-\ntransferases and glutathione peroxi dases are detoxifying agents of \nseveral carcinogenic compounds (Eto 1985; Guilarte 1993). PLP is also involved in steroid hormone ac tion; consequently, PLP can be \nimplicated in some types of steroid related cancer. \nSome experimental studies suggest that borderline-deficient B\n6 \nstatus increases sensitivity to st eroid hormones, and this may have \nimplications for breast, prostate, and uterine carcinogenesis (Bender \n1988). Furthermore, one study found a steroid independent inhibition \nof in vitro  breast cancer cell growth indu ced by PL and this was present  \n \n 145in oestrogen-dependent and oestrogen-independent mammary \ncarcinoma cell lines (Davis and Cowing 2000). Many studies have shown a relation to special types of cancer. Thus, a more detailed \noverview may be helpful. \n 3.1. Colorectal cancer \nKomatsu and coworkers demonstrated that vitamin B\n6 intake \ndecreased both the incidence and th e number of colon tumors in an \nanimal model; it decreased colon cell proliferation and expressions of c-\nmyc and c-fos proteins in a dose-dependent manner (Komatsu, \nWatanabe et al. 2001). More recently , they also showed that the \npreventive effect of vitamin B 6 against colon tumorigenesis in mice is \nmediated by a reduction of oxidativ e stress and nitric oxide production \n(Komatsu, Watanabe et al. 2002). In humans, Wei et al.  found out that in \nwomen plasma concentrations of PLP is inversely associated with risk \nfor colorectal cancer (RR = 0.54 for those in the highest vs lowest \nquartiles, 95% CI = 0.31 to 0.92) (2005; Wei, Giovannucci et al. 2005). Other researchers found an inverse association of vitamin B\n6 intake and \ncolon cancer (Slattery, Curtin et al. 2000). Nevertheless, epidemiologic evidence is still scarce.  \n3.2. Pancreatic cancer \nIn a large nested case-control study (included in the ATBC \nCancer Prevention Study cohort) a statistically significant inverse dose-response relationship was found between plasma PLP levels and pancreatic cancer risk: the risk of su bjects in the highest PLP tertile was \nhalf the risk of the subjects in the lowest tertile (OR = 0.48). \nInterestingly, as much as fifty percent of the study population \npresented lower than adequate PLP plasma levels (< 30 nmol/L) (Stolzenberg-Solomon, Albanes et al. 1999). This is the first study that observed an inverse association be tween plasma PLP concentrations \nand pancreatic cancer risk. Deficiencies in PLP have been shown to impair pancreatic exocrine function in experimental animals. Plasma \nand pancreatic amylase, trypsin and chymotrypsin activities were \nfound to be significantly decreased in B\n6 deficient rats (Dubick, Gretz et \nal. 1995). This situation can theoretically  lead to incomplete digestion of \nfood, greater duodenal cholecystoki nin release, and stimulation of \npancreatic enzyme production, hy pertrophy, and hyperplasia of  \n \n 146exocrine tissue, thereby increasing the susceptibility of the pancreas to \ncarcinogens. In fact, chronic hyperc holecystokininemia has been shown \nto enhance pancreatic carcinogenesis in experimental animals \n(Howatson and Carter 1985; Chu, Rehfeld et al. 1997). Finally, animals \nreceiving inhibitors of cellular me thylation reactions develop acute \nhemorrhagic pancreatitis as a conseq uence of autolytic destruction of \nthe pancreas (Farber and Popper 1950; Goldberg, Chaikoff et al. 1950; Lombardi, Estes et al. 1975) and it is well known that chronic \npancreatitis increases the risk of pancreatic cancer. \n \n3.3. Gastric, oral and pharyngeal cancer  \nSeveral case-control studies have found that high B\n6 intake was \nassociated with a decreased risk of  gastric adenocarcinomas (Harrison, \nZhang et al. 1997; Zhang, Kurtz et al . 1997; Kaaks, Tuyns et al. 1998) and \noral or pharyngeal cancer (Negri, Franceschi et al. 2000). \n \n3.4. Lung cancer \nA nested case-control study with in the ATBC Cancer Prevention \nStudy found a significantly lower risk of lung cancer among men who had higher plasma B\n6 levels. Men presenting high B 6 plasma \nconcentration had about half the risk  of lung cancer compared to men \nwith the lowest vitamin B 6 concentrations (OR = 0.51). This is the first \nreport from a prospectively conducted study to suggest a role for vitamin B\n6 in lung cancer (Hartman, Woodson et al. 2001). \n 3.5. Prostate and breast cancer \nAt present, there are no conclusive data relating vitamin B\n6 levels \nand prostate or breast cancer (Key , Silcocks et al. 1997; Wu, Helzlsouer \net al. 1999). One prospective, nested case-control study showed associations between the average intake of vitamin B\n6 (highest vs lowest \nquintile) and the risk of breast canc er after adjusting for folate intake \n(Zhang, Willett et al. 2003). Thus, the authors suggest that folate and \nvitamin B 6 may have the potential to be chemopreventive against breast \ncancer. \n  \n \n 1474. Cognitive function \nEarly findings supporting the implication of vitamin B 6 status in \nneurocognitive functions are derived from:  \na) animal experiments on B 6 deficiency (Shwartzman 1949; Victor and \nAdams 1956; Schaeffer, Cochary et al. 1990);  \nb) reported cases of neurological abnormalities associated to clinical \nvitamin deficiency (peripheral neurop athy, seizures) (McCormick 1988);  \nc) familial studies on homozygous defects of genes encoding Hcy \nmetabolism enzymes (such as cystathionine- \u03b2-synthase defect) which \nresult in mental retardation, psyc hiatric disturbances and seizures \n(homocystinuria) (Carson, Dent et al. 1965; Valle, Pai et al. 1980).  \n 4.1. Findings in the elderly \nThere are several studies providin g evidence for the importance \nof vitamin B\n6 and brain function in the el derly (Goodwin, Goodwin et \nal. 1983; Deijen, van der Beek et al. 1992; Riggs, Spiro et al. 1996). \nSignificant correlations between vitamin B 6 status and memory were \nfound in the Boston Normative Aging Study. Higher concentrations of \nserum vitamin B 6 were associated with better performance in two \nmemory tests in men (aged 54 - 81 years) and this association was \nindependent of plasma Hcy levels  (Riggs, Spiro et al. 1996). Others \nfound a significantly higher Wechsler  memory score in the top 90% of \nvitamin B 6 intake (Goodwin, Goodwin et al. 1983). Furthermore, Deijen \nand coworkers reported that supplementation with vitamin B 6 could \nsignificantly improve memory in elde rly men (Deijen, van der Beek et \nal. 1992). \nAdditionally, one researcher  sho wed a statistically significant \nimprovement in most of the cognitive function tests in a group of elderly people, supplemented wi th multivitamins (Chandra 2001). \nSubjects with lower blood levels of one or more nutrients showed lower \nresponses on all cognitive-function te sts, but there was no significant \ncorrelation between single nutrients and cognitive function test scores. \nThis evidence favours the hypo thesis that poor vitamin B\n6 status could \nbe, at least in part, responsible fo r the cognitive decline observed in \nsome elderly persons. Further, several studies and meta-analyses have found inverse associations between objective measures of cognitive  \n \n 148function and plasma or serum Hcy co ncentrations (Bell, Edman et al. \n1991; Boushey, Beresford et al. 1995; Ri ggs, Spiro et al. 1996; Jensen \n1998; McCaddon, Davies et al. 1998; Lehmann, Gottfries et al. 1999; \nMiller 1999; Budge, Johnston et al. 2000; Nilsson, Gustafson et al. 2000; \nMorris, Jacques et al. 2001), but others  not (Kalmijn, Launer et al. 1999; \nRavaglia, Forti et al. 2000).  \nThe increased risk for cerebrovas cular disease could be due to a \ntoxic effect of Hcy on vascul ar tissue (Ueland and Refsum 1989). \nRegarding dementia, the interaction between B 6 and Hcy is not clearly \nestablished. Low vitamin B 6 status has been associated with \nAlzheimer\u2019s disease (AD) and vascular dementia. Miller and others have recently reported that low PLP levels were strongly associated with AD, but not with cerebrovascular disease (Miller, Green et al. 2002). On the contrary, Fa\u00dfbender and coworkers reported that \ncompared with patients without cerebrovascular disease, patients with \nsubcortical vessel encephalopathy showed significantly decreased \nplasma concentrations of vitamin B\n6 (Fassbender, Mielke et al. 1999). In \nboth studies, there was an association between Hcy and AD and microangiopathic vascular dementia, respectively, while there was no \ncorrelation between Hcy levels and vitamin B\n6. Others found that \nindividuals with hyperhomocysteinemia had a higher risk of \ndeveloping AD compared with those who had normal Hcy levels (OR = \n4.6) (Clarke, Smith et al. 1998). Another study found a strong relationship between periventricular and subcortical white matter lesions and low vitamin B\n6 l e v e l s  i n  p a t i e n t s  w i t h  A D  ( M u l d e r ,  \nScheltens et al. 2005). \n \n4.2. Convulsive seizures  \nSince the fifties and sixties, PN  deficiency is known to cause \nconvulsive seizures in humans and experimental animals. Hence, a number of investigators reported disorders in central nervous system (CNS) activity in adults and infant s (Coursin 1954; Bessey, Adam et al. \n1957; Canham 1964; Canham, Baker et al. 1969; Coursin 1969). The \nneurological disorders in the infant s manifested itself within 6 weeks \nup to 4 months by convulsive seiz ures, hyperirritability, and abnormal \nacuteness of the sense of hearing . Two reviews from the eighties \nsummarised research on causative fa ctors responsible for convulsions \nduring vitamin B\n6 deficiency (Dakshinamurti 1985; Anonymus 1988).  \n \n 149They propose two hypotheses expl aining the onset of convulsive \nseizures. First, it has been shown that a particular nutritional deficiency leads to the accumulation of a potentially hazardous tryptophan \nmetabolite, 3-HK in the CNS. Kynurenine transaminases and \nkynureninase catalyse are the main routes of 3-HK catabolism and \nrequire PLP. Reductions in their acti vities should lead to a build-up of \n3-HK in the body and brain. Experimentally produced B\n6 deficiency by \nGuilarte and Wagner caused a 200-fold increase in brain regional 3-HK \nlevels. This increase led the authors speculate that such levels of 3-HK \ncould be responsible for the convulsion s that typically occur in infant B 6 \ndeficiency (Guilarte and Wagner 1987). Another possible cause could be changes in the concentration of the neurotransmitter GABA, a major \ninhibitory transmitter in the CNS. GA BA concentrations are reported to \nbe low in the brains of vitamin B\n6 deficient infant animals, and such \nanimals are often seen to convulse (Dakshinamurti and Stephens 1969; \nStephens, Havlicek et al. 1971; Wasynczuk, Kirksey et al. 1983). \nFurthermore, pharmacologic studies indicate that drugs diminishing \nGABA transmission in the CNS prom ote convulsions (Meldrum 1975).  \n 4.3. EEG alterations \nAbnormal EEG-tracing changes were reported in young adult \nmen during experimentally induced vitamin B\n6 deficiency in the sixties \n(Canham 1964; Canham, Baker et al. 1969). The young men were maintained for 21 days on purified diets that provide daily intakes of \u2264 \n0,06 mg vitamin B\n6 and either 30 or 100 g protein. The type of EEG \nabnormalities observed in the yo ung men generally consisted of a \nslowing of activity with either increased or decreased wave amplitude, \nand minimal to marked build-up with hyperventilation, particularly in the frontal and parietal leads (Canham 1964). More recently studies show EEG abnormalities can develop in women with short-term vitamin B\n6-depletion (< 2 weeks) (Kretsch, Sauberlich et al. 1995). \nAbnormal patterns could be revers ed administering 0.5 mg vitamin \nB6/day. EEG changes are probably caused by altered neurotransmitter \nmetabolism in the brain and are thought to occur only in cases of frank B\n6 deficiency. However, before ruling out the possibility of EEG \nabnormalities occurring at marginal levels of vitamin B 6 intake, research \nemploying quantitative analysis of the EEG spectral data should be  \n \n 150conducted (Kretsch, Sauberlich et al. 1995). To our knowledge such \nresearch is still lacking. \n \n4.4. Neuropathies   \nIn the sixties, peripheral neuropathies have been reported in PN \ndeficiency (Linkswiler 1967). Demyelin ation of peripheral nerves has \nbeen observed, which could be caused by a disturbance of \nsphingomyelin synthesis owing to a la ck of PLP as cofactor for serine-\npalmityl-transferase. Recently, pe ripheral neuropathy caused by \nvitamin B 6 deficiency has been report ed in patients on chronic \nperitoneal dialysis. Symptoms in cluded paresthesia, burning and \npainful dysthestias, and thermal sensations (Moriwaki, Kanno et al. 2000). Interestingly, Gorson and Ropper found in diabetic patients with \ndistal sensory polyneuropathies as most common laboratory abnormalities low levels of vitamin B\n6 or B 1. They concluded that the \nfrequency of low vitamin levels suggests that vitamin B 1 and B 6 levels \nshould be assessed in future studies of diabetic patients with distal \nsensory polyneuropathies (Gorson and Ropper 2006). \n 5. CVD and Hcy \nSuboptimal vitamin B\n6 nutriture was first associated with \nvascular disease following development of atherosclerosis in monkeys fed a B\n6 deficient diet (Rinehard 1949). Later, some researchers \n(Verhoef, Stampfer et al. 1996) reported  that estimated dietary intake of \nvitamin B 6 and folate, and plasma concentrations of PLP and folate, \nwere lower in patients who had myocard ial infarction than in controls. \nThey also reported that the freq uency of myocardial infarction was \nnegatively correlated with both folate and vitamin B 6 nutriture. Others \nconfirmed the association of Hcy and vitamin B 6 (Stampfer, Malinow et \nal. 1992; Selhub, Jacques et al. 1993; Robinson, Mayer et al. 1995; Verhoef, Stampfer et al. 1996; Graham , Daly et al. 1997; Folsom, Nieto et \nal. 1998; Rimm, Willett et al. 1998; Jacques, Bostom et al. 2001; Saw, \nYuan et al. 2001). Results of epid emiologic studies suggest that \nmoderately elevated plasma or serum Hcy levels are prevalent in the general population and are associat ed with increased risk for CVD, \nindependent of classical cardiovascul ar risk factors (Boushey, Beresford \net al. 1995; Refsum, Ueland et al. 1998; Welch and Loscalzo 1998;  \n \n 151Eikelboom, Lonn et al. 1999). It is st ill unknown if this is due to the \neffect of vitamin B 6 on platelet function (Chang, Chuang et al. 1999; \nChang, Chang et al. 2002; Kobzar 2002), connective tissue (Myers, \nDubick et al. 1985), blood pressure (Vasdev 2002), thrombogenesis \n(Cattaneo, Lombardi et al. 2001) or, indirectly by causing hyperhomocysteinemia (Mudd 1995). Further, low circulating vitamin \nB\n6 levels have been associated with elevation of the inflammation \nmarker C-reactive protein independen tly of plasma Hcy (Friso, Jacques \net al. 2001).  \n \nHow to handle vitamin B 6 deficiency? \nAlthough overt clinical deficiency of vitamin B 6 occurs only \nrarely, nutrition surveys indicate that vitamin B 6 intakes may be \nmarginal or inadequate in segments of the population. Consequently, the presence of a subclinical defi ciency may be fairly widespread. \nEspecially in the elderly there is a high prevalence of deficient or \nborderline vitamin B\n6 status. Herrmann and Knapp found vitamin B 6 \ndeficiency in 23% of 65 \u2013 75 year old and 40% in > 85 year old persons, respectively (Herrmann and Knapp 2002). According to the SENECA study, 23.3% of the European elderly are B\n6 deficient (PLP < 20 nmol/L) \n(Haller, Lowik et al. 1991). A border line deficient status, which might \npersist in an individual for a long time without developing clinical manifestations, could have pathological consequences. It may contribute to the development of certain diseases, as already stated above.  \nTreatment of B\n6 deficiency \n1.) Treatment of clinical deficiency \nTreatment of vitamin B 6 deficiency implies mega doses of this \nvitamin via oral. Usually around 50 mg/day are administered depending on the cause of the defi ciency; higher doses are given if \nvitamin B\n6 deficiency is related to medica tion use. Some drugs (table 3) \nsuch as isoniacid, penicillamine, hydralazine, L-Dopa and cycloserine \ninterfere with PLP reacting with the carbonyl groups (Baghavan 1985; \nWeir, Keniston et al. 1991). The requirements of vitamin B 6 increase in \neclampsia and preeclamsia (Broph y and Siiteri 1975; Shane 1980) and \nhaemodialysis. B 6-dependent syndromes, which require \npharmacological doses of the vita min, are seldom. These include  \n \n 152cystathionine- \u03b2-synthase deficiency, PN dependent anemias (especially \nsideroblastic anemia), and homocystin uria. Treatment consists of very \nhigh pharmacological doses of PN (Bassler 1988). Supplementation of \nPN hydrochloride in various medica l conditions and their doses are \nshown in table 4. \n  2.) Preventive treatment of bo rderline, subclinical deficiency \nThere are some studies showing th at especially in the elderly \nthere is a high prevalence of deficient or borderline vitamin B\n6 status \n(Haller, Lowik et al. 1991; Herrmann and Knapp 2002). Since a \nsubclinical vitamin B 6 deficiency has been asso ciated to several chronic \ndiseases especially in the elderly,  a supplementation in this group \nseems to be indicated. While vitamin B 6 supplementation is an effective \ntreatment for lowering excessively high  Hcy levels in patients with PN-\nresponsive homocystinuria due to cystathionine \u03b2-synthase deficiency \n(Dudman, Wilcken et al. 1993; Franken, Boers et al. 1994), its role in the \nprevention or treatment of mild hyperhomocysteinemia remains unclear. Results of 11 studies (Wilcken, Gupta et al. 1981; Brattstrom, Israelsson et al. 1988; Brattstrom, Israelsson et al. 1990; Arnadottir, Brattstrom et al. 1993; Ubbink, Vermaak et al. 1994; Bostom, Gohh et al. \n1997; Dierkes, Kroesen et al. 1998; Lakshmi and Ramalakshmi 1998; \nBronstrup, Hages et al. 1999; Mans oor, Kristensen et al. 1999; Bosy-\nWestphal, Holzapfel et al. 2001; McKinley, McNulty et al. 2001) that investigated the effect of vitamin B\n6 on fasting plasma Hcy \nconcentrations are inconclusive. Se ven of the aforementioned studies \n(Wilcken, Gupta et al. 1981; Brattstrom, Israelsson et al. 1988; \nBrattstrom, Israelsson et al. 1990; U bbink, Vermaak et al. 1994; Bostom, \nGohh et al. 1997; Dierkes, Kroesen et al. 1998; Lakshmi and Ramalakshmi 1998; Bosy-Westphal, Holzapfel et al. 2001) found no change in fasting Hcy, and one foun d a significant increase (Arnadottir, \nBrattstrom et al. 1993). Some studies found a significant reduction in fasting Hcy after vitamin B\n6 supplementation (Bronstrup, Hages et al. \n1999; Mansoor, Kristensen et al. 1999; McKinley, McNulty et al. 2001). \nThe first of these studies, carried out in young women who had clinical \nand biochemical vitamin B 6 deficiency, found a significant lowering of \nfasting Hcy of 19.7% after 15 days of treatment with 20 mg PN hydrochloride/day (Mansoor, Kristens en et al. 1999). The trial, however, \nwas not blinded or placebo-controlled and had no washout period. The  \n \n 153second study, a recent placebo-controlled trial, showed a significant \nlowering of fasting Hcy of 17% (p < 0.011) in response to extremely \nlarge doses (120 mg/day) of vitamin B 6 in healthy subjects (Bronstrup, \nHages et al. 1999). McKinley et al.  found that in healthy elderly persons \nwho are folate and riboflavin replete, low-dose vitamin B 6 \nsupplementation (1.6 mg/day) effectiv ely lowers fasting Hcy levels by \n7.5% (p < 0.008) (McKinley, McNulty et al. 2001). Since there is more than one vitamin involved in Hcy me tabolism, most intervention trials \nuse a combination supplement cont aining folic acid, vitamin B\n12, and \nvitamin B 6 (McKay, Perrone et al. 2000; Henning, Tepel et al. 2001; \nSchnyder, Roffi et al. 2002) and theref ore it is somewhat difficult to \nconclude the effect of a single vitamin.  \n \nPrevention of B 6 deficiency \nDietary reference intakes (DRI) \nAccording to data from nationally representative U.S. surveys, \nthe median daily intake of B 6 by men is approximately 2 mg/day and \nthe median intake by women is approximately 1.5 mg/day. German data show the same pattern (Ern\u00e4hru ng 2004). This indicates that the \ngeneral population is not at risk for developing clinical vitamin B\n6 \ndeficiency. \nFurther, the new DRIs set by different international \norganisations, are now taking into account new aspects to estimate requirements. They do not only focu s on the prevention of clinical \ndeficiency, but try to take into a ccount health effects that certain \nnutrients might have. Even though there is evidence that vitamin B\n6 \ncould help to prevent CVD, certain types of cancer, and cognitive \nimpairment, present data are insuffi cient to set EARs based on these \nnew aspects. DRIs and DACH reference values for vitamin B 6 are \nsummarised in table 5. The recommend ed dietary allowance (RDA) for \nadults is 1.3 mg food vitamin B 6/day, which lies in the same range as the \nDACH-settings for men and women, 1.5 and 1.2 mg, respectively (D-A-\nCH 2000). Most studies of B 6 requirements have focused on adults and \nhave been depletion-repletion studie s. Clinical symptoms of vitamin B 6 \ndeficiency have only been observed  during depletion with very low \nlevels of B 6 and have never been seen at intakes of 0.5 mg/day or more, \nsuggesting that an intake of 1 mg/d ay is sufficient for most adults  \n \n 154(Board 1998). The current RDA (1998) for older adults and elderly \npeople (age > 51) are set higher th an for younger adults, based on the \nresults of several repletion-depletion studies. Ribaya-Mercado and \ncoworkers employed a vitamin B 6 depletion-repletion protocol in \nhealthy elderly and showed that higher than RDA (1989: men: 2.0 \nmg/day, women: 1.6 mg/day) intakes were necessary to normalise several parameters of vitamin B\n6 status including enzyme activity, \ntryptophan metabolism, and plasma vitamers. In a related series of \nexperiments, the amount of vitamin B 6 essential to restore several \nimmunologic indices (lymphocyte number and percentages, mitogenic \nresponses, and IL-2 production) to ba seline values was also greater than \nthe current DRI (1998) (Meydani, Ri baya-Mercado et al. 1991). Higher \nlevels of fasting insulin and plasma  glucose were also observed during \nthe periods of low vitamin B 6 status (Ribaya-Mercado 1990). Despite \nevidence that the requirement for vitamin B 6 may be slightly higher in \nolder adults, several surveys have found that over half of individuals \nover age 60 consume less than the current DRI (1.7 mg/day for men and \n1.5 mg/day for women). Several studies have found elderly populations to have plasma PLP concentrations below the cut-off threshold for deficiency (Russell 1992). A high prevalence of marginal vitamin B\n6 \ndeficiency in the elderly is reflected by their reduced activity of \u03b1-EAST \nand \u03b1-EALT, increased excretion of XA , and lowered levels of PLP and \nplasma total vitamin B 6 (Hamfelt 1964; Kant, Moser-Veillon et al. 1988; \nLowik, van den Berg et al. 1989). Wh ile 50 to 90% of older adults are \nreported to have dietary intakes of vitamin B 6 below 1989 RDA levels, \nseveral studies indicate that the physiologic requirement may exceed \nthese recommended values (Hoorn,  Flikweert et al. 1975; Vir 1977). \nConsidering this, it is not unders tandable why the DACH reference \nvalues are not set higher for older ad ults (> 51 years) or even lower for \nmen of the age 71 and older. \n \nFood fortification \nThe possibility to enrich food with vitamins allows it to increase \nthe health status of the populati on. The United States and Canada \nstarted with the first official guide lines concerning the fortification of \nfood with folic acid. Further, Hungary and Chile followed the guidelines and voluntary fortification is present in Switzerland, \nAustralia and Great Britain. Due to the interrelationship of the vitamins  \n \n 155that participate in the Hcy cycle, it has been debated if vitamin B 6 (and \nvitamin B 12) should be added to folate-enriched foods. From the \ndifferent countries that enrich their flour with folate, only in Hungary \nvitamin B 6 is added (880 \u00b5g/100 g flour) beside vitamin B 12 with 0.8 \u00b5g \nand folic acid with 160 \u00b5g (Czeizel and Merhala 1998).  \n  \nToxicity    \nValues of maximum tolerable in takes are summarised in table 5. \nAs a water-soluble vitamin which is  rapidly metabolised and excreted, \nB6 might be expected to have low toxicity. In fact, no adverse effects \nhave been associated with high intake of vitamin B 6 from food sources. \nSchaumburg and others  reported the development of severe sensory \nneuropathy in 7 patients treated with 2 - 6 g of PN hydrochloride/day (Schaumburg, Kaplan et al. 1983). Furt her, reports of peripheral sensory \nneuropathy associated with high-d ose PN therapy (1 to 4 g/day) \nappeared also in the 1980s (Bear 1984; Bredesen 1984; de Zegher, \nPrzyrembel et al. 1985; Friedman, Re snick et al. 1986). However, it is \nnoteworthy that none of the reviews of patients with vitamin B\n6 \ndependency syndromes, who are treated with 500 - 1500 mg/day, mentions the development of periph eral neuropathy (Sturman 1986). \nSome patients developed abnormally low plasma concentrations of PLP \nafter high doses of vitamin B\n6. This rebound avitaminosis presumably \nreflects induction of pyridoxal oxid ase, and hence increased catabolism \nof the vitamin. Within 4 months, plasma concentrations of the vitamin return to normal without supplemen tation (Dalton and Dalton 1987). \nThe limited data involving lower PN doses reveal that the risk of \ndeveloping sensory neuropathy decreases rapidly at doses below 1 \ng/day (Del Tredici 1985; Bernstein 1988). The safe upper limit for vitamin B\n6 has been set at 100 mg/day, ta king into account a security \nfactor of 5, because the lowest dose at which toxicity (sensory neuropathy) has been observed is 500 mg/day (Board 1998). \n \n \n    \n \n 156TABLES: \nTable 1 Parameter for assessment of vitamin B 6 status and reference values \n(modified by Leklem, 1994)    \nParameter Reference value \nDirect \n \n  \nIndirect \n  \n Plasma PLP \nTotal vitamin B\n6  \nUrinary 4-PA excretion Urinary total vitamin B\n6 \n\u03b1-EAST  \n\u03b1-EALT \nXA excretion (2g L-try) \nCystathionine excretion \n(3 g L-Methionine)  > 30 nmol/L/ 20 nmol/L \n > 40 nmol/L \n > 3 \u00b5mol/day  > 0.5 \u00b5mol/day \n < 1.8 (< 80 %) \n < 1.25 (< 25 %)  < 65 \u00b5mol/day \n \n < 350 \u00b5mol/day \n \nTable 2 Parameters by which PLP concentration is influenced (modified \nafter Leklem, 1994)  \n Parameter Plasma-PLP \nNutrition \n  \n \n Physiology \n \n \u2191 vitamin B\n6 \n\u2191 protein \n\u2191 glucose \n\u2193 bioavailability \n \u2191 physical activity, aerobic \n\u2191 age \npregnancy \u2191 activity of alkaline phosphatase \nSmoking \nHypophosphatasia \u2191 \n\u2193 \n\u2193, acute \n \u2193 \n \n\u2191, acute \n\u2193 \n\u2193 \n\u2193 \n\u2193 \n\u2191 \n  \n \n 157Table 3 Conditions that increase risk for PN deficiency  \nAdvanced age \nMedical conditions \n Severe malnutrition  Hospitalization \n Celiac disease \n Hepatitis and extrahepatic biliary obstruction  Hepatocellular carcinoma \n Chronic renal failure \n Kidney transplant  Hyperoxaluria types I and II \n High serum alkaline phosphatase level,  \n                such as in cirrhosis and tissue injury  Catabolic state \nMedical procedures \n Hemodialysis  Peritoneal dialysis \n Phototherapy for hyperbilirubinaemia \nSocial-behavioral conditions  Excessive alcohol ingestion  \n            (except for pyridoxine-supplemented beer) \n Tobacco smoking  Severe malnutrition \nOther risk factors \n Poisoning, such as Gyromitra mushroom poisoning  Perinatal factors, such as pyridoxine-deficient mother \n Inherited conditions,  \n            such as pyridoxine dependent neonatal seizures      Other patient history \n Sideroblastic anemia \nPregnancy \nPhysical exercise \nDrug-interaction Mechanism of interaction \nIsoniazid (hydrazines)  Cycloserine    \nL-3,4-Dihydroxyphenlalanine derivative \nPenicillamine   \nEthinylestradiol, mestranol  \nEthanol  \nTheophylline, caffeine  Reacts with PL and PLP \nReacts with PLP, forms oxime  \nReacts with PLP, forms  tetrahydroquinoline derivative \nReacts with PLP, forms thiazolidine \nIncreased enzyme levels and retention of PLP in tissue  \nIncreased catabolism of PLP \nInhibition of pyridoxal kinase  \n \n 158Table 4 Supplementation of PN hydroc hloride in various medical \nconditions (Frye, 2002).  \nMedical conditions doses \nCirrhosis  50 mg/day  \nHemodialysis  5-50 mg/day \nPeritoneal dialysis  2.5-5 mg/day \nChronic renal failure   2.5-5 mg/day \nSideroblastic anemia   50-600 mg/day \nPN-dependent seizures   100 mg/day \nHomocystinuria   100-500 mg/day \nHomocysteinemia   100-500 mg/day \nGyromitra  poisoning   25 mg/kg \nProphylactic administration should \nbe provided when using: \nisoniacid  \npenicillamine   \n \n30-450 mg/day \n100 mg/day \nEstrogen-induced reduction in tryptophan \nmetabolism may require supplementation   20-25 mg/day \n  \n \n \n  \n \n   \n \n 159Table 5 DRIs and DACH-Reference Values   \n DRI DACH-Reference Values \nVitamin B6 (mg/day) \nEARa RDAb/AI * Vitamin B 6 \n(mg/day)  \nAge \nMen/Women Men/ Women ULc  \nAge \nMen/Women \n0-6 months \n7-12 months \n1-3 years \n4-8 years 9-13 years 14-18  years 19-30  years 31-50  years 51-70  years \n> 70    years \nPregnancy Lactation - \n- 0.4 0.5 0.8 1.1/1.0 1.1/1.3 1.1/1.3 1.4/1.3 \n1.4/1.3 \n-/1.6 -/1.7  0.1 (\u2248 0.014mg/kg) * \n0.3 (\u2248 0.033mg/kg) * \n0.5 0.6 1.0 1.3/1.2 1.3               1.3               1.7/1.5 \n1.7/1.5 \n1.9 2.0 - \n- \n30 40 60 \n \n80 \n \n100 \n100 \n100 100 \n100\n1 \n1001 0-4   months \n4-12 months \n1-4      years \n4-7      years 7-10    years 10-13  years 13-15  years 15-19  years 19-25  years \n25-51  years \n51-65  years > 65    years Pregnancy Lactation 0.1 \n0.3 \n0.4 \n0.5 0.7 1.0 1.4 1.6/1.2 1.5/1.2 \n1.5/1.2 \n1.5/1.2 1.4/1.2 1.9 1.9 \na  Estimated average requirement  \nb  Recommended dietary allowances \nc  Upper level of safe intake; intake of vitamin B 6 as pyridoxine \n*  Adequate Intake \n1   >19 years; < 19 years: 80 mg/day \n   \n \n 160 \n \n \nTable 6 Food sources of PN (vitamin B 6) (modified after Elmadfa et al. , 1998)  \nFood Content (mg/100g)  \nMeat \n Beef liver \n Pork \n Chicken \n Beef \nFish \n Salmon \n Tuna \nEggs and Dairy \n Egg \n Whole milk  Cream cheese (20%)  \nVegetables \n Spinach, raw \n Potatoes, raw \n Peas, green, raw \n Broccoli, raw   Carrots Fruits \n Apple, unpeeled, raw \n Banana, raw \n Grapes, raw \n Walnuts Cereals \n Wheat germ \n Wheat flour, whole grain \n Rye bread \n Bread, white  Rice, white \n Rice, brown \nMiscellaneous \n Spaghetti with tomato sauce          Pizza, all kinds \n Pancakes  Yeast \n Human milk  \n0.90 0.39 \n0.50 \n0.50  \n0.98 \n0.46  \n0.12 \n0.05 0.09 \n \n0.20 0.21 \n0.16 \n0.17 0.30 \n \n0.10 0.37 \n0.13 \n0.87 \n \n4.00 0.46 \n0.20 \n0.04 0.18 \n0.67 \n 0.12 \n0.41 \n0.02 0.81 \n0.01  \n \n 161FIGURES: \n \n \n \n      \n \n               \n \n \n \n      \nFigure 1\n  Metabolic inter-conversion of pyridoxine, pyridoxal, \npyridoxamine and their respective phosphate esters.  \n(modified after B\u00e4ssler, 2002)  \n \n             N   CH 2-OH \n  CH 2-OH HO \n \n H3C        N CH 2-OH \n  CH 2-O-P=O HO \n H3C  OH \n OH \n       N  C \n  CH 2-O-P=O HO \n H3C   O H \n OH \n OH \n       N  C \n  CH 2-OH HO \n \n H3C   O H \n OH \n OH \n       N  CH 2-NH 2 \n  CH 2-O-P=O HO \n H3C        N  CH 2-NH 2 \n  CH 2-OH HO \n \n H3C pyridoxine kinase \n    phosphatase \npyridoxine phosphate oxidase \npyridoxine phosphate oxidase transaminases Pyridoxine P yridoxine 5\u00b4- phosphate \nPyridoxal P yridoxal 5\u00b4- phosphate \nPyridoxamine P yridoxamine 5\u00b4- phosphate pyridoxine kinase \n    phosphatase \npyridoxine kinase     phosphatase  \n \n 162 \n                         \n \n        \nFigure 2   One-carbon unit generation and Hcy metabolism. Vitamin \nB\n6 is involved as coenzyme PLP. PLP: Pyridoxal 5\u00b4-phosphate; SAM: S-\nadenosylmethionine; SAH: S-aden osylhomocysteine; SHMT: Serine-\nhydroxymethyltransferase; THF: tetrahydrofolate; 5-MTHF: 5-methyl tetrahydrofolate; R: methyl group acceptor. \n \n    5 \u2013MTHF THF \n       5,10 \u2013 \n    methylene-THF       Serine \n   Glycine \nPurines (DNA, RNA) \nThymidine (DNA) \n \nFAD SHMT Methionine \n Cysteine Homocysteine SAM \nSAH R \nRC 3H Phosphatidylcholine, Myelin,  \nCatecholamine, DNA, RNA \nCystathionine cystathinonine \u03b2-\nsynthase PLP \nPLP cystathinonine \u03b3-lyase \n  Glutathione B12 PLP  \n \n 163 \n                          \n  \n \nFigure 3 Tryptophan load test. PLP: pyridoxal 5\u2019-phosphate.   \n \n \n \n  Kynurenic acid \u0006\nKynurenine \naminotransferase \n Xanthurenic acid \u0006KynurenineTryptophan \nKynurenine-\nhydroxylase Kynurenine \naminotransferase \n3 - Hydroxyanthranilic acid3 Hydroxykynurenine\nPLP KynureninasePLPPLP\nPLP \n \n 164 \n           \n \nS-adenosylmethionine      S-adenosylhomocyst(e)ine  \n \n   \n \n           \nFigure 4 Methionine load test.  PLP: pyridoxal 5\u2019-phosphate   \n \n  CysteineMethionine  Homocysteine  u \nCystathioninecystathinonine \u03b2-\nsynthasePLP\nPLPcystathinonine \u03b3-\nlyase  B12 + Folate\n\u2550 \n\u2550  \n \n 165REFERENCES:  \n \nSnell, E. E. (1958). Some aspects of the metabolism of vitamin B6. Fourth \ninternational Congress of Bioche mistry-Vitamin Metabolism. New \nYork, Pergamon : 250-265. \nStabler, S. P., Sampson, D.A., Wang, L.P., Allen, R.H. (1997). \u02baElevations \nof serum cystathionine and total homo cysteine in pyridoxine-, folate-, \nand cobalamin-deficient rats. \u02ba J Nutr Biochem 8: 279-289. \nStampfer, M. J., M. R. Malinow, et al. (1992). \u02baA prospective study of \nplasma homocyst(e)ine and risk of myocardial infarction in US \nphysicians. \u02ba Jama 268(7): 877-81. \nStephens, M. C., V. Havlicek, et al. (1971). \u02baPyridoxine deficiency and \ndevelopment of the central nervous system in the rat. \u02ba J Neurochem \n18(12): 2407-16. \nStoerk, H. C. (1946). \u02baEffects of calcium deficiency and pyridoxine \ndeficiency on thumic atro py (accidental involution). \u02ba Proc Soc Exp Biol \nMed 62: 90-96. \nStoerk, H. C., Eisen, H.N. (1946). \u02baSuppression of circulating antibodies \nby pyridoxine deficiency. \u02ba Proc Soc Exp Biol Med 62: 88-89. \nStolzenberg-Solomon, R. Z., D. Albanes, et al. (1999). \u02baPancreatic cancer \nrisk and nutrition-related methyl-gro up availability indicators in male \nsmokers. \u02ba J Natl Cancer Inst 91(6): 535-41. \nSturman, J. A. (1981). Vitamin B6 and sulphur amino acid metabolism. \nMethods in vitamin B6 nutrition, anal ysis and status assessment. J. E. \nLeklem, Reynolds, R.D. New York, Plenum Press : 341-373. \nSturman, J. A. (1986). Vitamin B6 ans sulphur amino acid metabolism, \ninborn errors, brain junction, defi ciency and megavitamin therapy. \nVitamin B6 (pyridoxal phosphate): chemical, biochemical and medical \naspects, Part B. New York, Wiley Interscience : Chapter 16, 507-572. \nTalbott, M. C., L. T. Miller, et al. (1987). \u02baPyridoxine supplementation: \neffect on lymphocyte responses in elderly persons. \u02ba Am J Clin Nutr \n46(4): 659-64. \nUbbink, J. B., W. J. Vermaak, et al. (1994). \u02baVitamin requirements for the \ntreatment of hyperhomocysteinemia in humans. \u02ba J Nutr 124(10): 1927-\n33.  \n \n 166Ueland, P. M. and H. Refsum (1989). \u02baPlasma homocysteine, a risk \nfactor for vascular disease: plasma levels in health, disease, and drug \ntherapy.\u02ba J Lab Clin Med 114(5): 473-501. \nValle, D., G. G. Pai, et al. (1980). \u02baHomocystinuria due to a cystathionine \nbeta-synthase deficiency: clinical manifestations and therapy. \u02ba Johns \nHopkins Med J 146(3): 110-7. \nVasdev, S., Longerich, L., Singal, P. (2002). \u02baNutrition and \nhypertension. \u02ba Nutr Res 22: 111-123. \nVerhoef, P., M. J. Stampfer, et al. (1996). \u02baHomocysteine metabolism and \nrisk of myocardial infarction: relation with vitamins B6, B12, and folate.\u02ba Am J Epidemiol 143(9): 845-59. \nVictor, M. and R. D. Adams (1956). \u02baThe neuropathology of \nexperimental vitamin B6 deficiency in monkeys. \u02ba Am J Clin Nutr 4(4): \n346-53. \nVir, S. C., Love, A.H.G. (1977). \u02baVitamin B6 status of institutionalized \nand non-institutionalized aged. \u02ba Int J Vitam Nutr Res 47: 364-372. \nWasynczuk, A., A. Kirksey, et al. (1983). \u02baEffects of maternal vitamin B-\n6 deficiency on specific region s of developing rat brain: the \nextrapyramidal motor system. \u02ba J Nutr 113(4): 746-54. \nWei, E. K., E. Giovannucci, et al. (2005). \u02baPlasma vitamin B6 and the risk \nof colorectal cancer and adenoma in women. \u02ba J Natl Cancer Inst 97(9): \n684-92. \nWeir, M. R., R. C. Keniston, et al. (1991). \u02baDepression of vitamin B6 \nlevels due to dopamine. \u02ba Vet Hum Toxicol 33(2): 118-21. \nWelch, G. N. and J. Loscalzo (1998). \u02baHomocysteine and \natherothrombosis. \u02ba N \nEngl J Med 338(15): 1042-50. \nWilcken, D. E., V. J. Gupta, et al. (1981). \u02baHomocysteine in the plasma of \nrenal transplant recipients: effe cts of cofactors for methionine \nmetabolism. \u02ba Clin Sci (Lond) 61(6): 743-9. \nWozenski, J. R., J. E.  Leklem, et al. (1980). \u02baThe metabolism of small \ndoses of vitamin B-6 in men. \u02ba J Nutr 110(2): 275-85. \nWu, K., K. J. Helzlsouer, et al. (1999). \u02baA prospective study on folate, \nB12, and pyridoxal 5 \u02b9-phosphate (B6) and breast cancer. \u02ba Cancer \nEpidemiol Biomarkers Prev 8(3): 209-17.  \n \n 167Zhang, S. M., W. C. Willett, et al. (2003). \u02baPlasma folate, vitamin B6, \nvitamin B12, homocysteine, and risk of breast cancer. \u02ba J Natl Cancer Inst \n95(5): 373-80. \nZhang, Z. F., R. C. Kurtz, et al. (1997). \u02baAdenocarcinomas of the \nesophagus and gastric cardia: the role of diet. \u02ba Nutr Cancer 27(3): 298-\n309.  \n \n  \n \n \n    \n \n    \n \n    \n \n    \n \n    \n \n    \n \n \nMATERIAL Y M\u00c9TODOS  \n \n                                                                                               Material y M\u00e9todos  \n \n 169El estudio se ha llevado a cabo siguiendo escrupulosamente las \nnormas deontol\u00f3gicas reconocidas en la Declaraci\u00f3n de Helsinki 1996 (revisi\u00f3n de Edimburgo 2000), Conven io de Oviedo y siguiendo las \nrecomendaciones de Buena Pr\u00e1ctica Cl\u00ednica de la CEE (documento \n111/3976/88 de julio de 1990) y la normativa legal vigente espa\u00f1ola que regula la investigaci\u00f3n cl\u00ednica en  humanos (Real Decreto 561/1993 sobre \nensayos cl\u00ednicos). El protocolo ha si do sometido al comit\u00e9 de ensayos \ncl\u00ednicos de la instituci\u00f3n y se requerir\u00e1 la firma de un documento de consentimiento informado para participar. En los casos que sea \nnecesario, dicho documento ser\u00e1 firmado por familiares o persona m\u00e1s \nallegada. \nEl contenido de los cuadernos de recogida de datos, as\u00ed como los \ndocumentos generados durante todo el estudio, est\u00e1n protegidos de usos no permitidos por personas ajenas  a la investigaci\u00f3n. Por tanto, la \ninformaci\u00f3n generada en este ensa yo ser\u00e1 considerada estrictamente \nconfidencial, permiti\u00e9ndose, sin embargo, su inspecci\u00f3n por las \nAutoridades Sanitarias. \nA titulo informativo se les sumi nistrar\u00e1 la informaci\u00f3n obtenida \nde manera individual a cada interesado .  \n \nTAMA\u00d1O DE LA MUESTRA: \nLa muestra objeto del presente es tudio se compone de un total de \n218 ancianos, 82 hombres y 136 mujeres, con edades comprendidas entre los 58 y 104 a\u00f1os (media 79 \u00b1 8) . El estudio se realiz\u00f3 entre 2002 y \n2004. \nTodos los ancianos estaban institucionalizados en la residencia \n\u201cLa Milagrosa\u201d de Armilla, instituci\u00f3 n perteneciente a la Excelent\u00edsima \nDiputaci\u00f3n de Granada. \nLa valoraci\u00f3n se realiz\u00f3 me diante estudios diet\u00e9ticos, \nbioqu\u00edmicos, y hematol\u00f3gicos. \n \nCRITERIOS DE INCLUSI\u00d3N \nSujetos mayores de 60 a\u00f1os que viv\u00edan en la residencia por lo \nmenos desde hace un a\u00f1o. \n  \n \n                                                                                               Material y M\u00e9todos  \n \n 170CRITERIOS DE EXCLUSI\u00d3N \nSe excluyeron: \n- Todos los sujetos en tratamiento vitam\u00ednico (vitamina B 12, \nvitamina B 6 y folatos). \n- Pacientes con insuficiencia renal cr\u00f3nica. \n- Enfermedades tiroideas. \n \nM\u00c9TODOS: ESTUDIO HEMATOL\u00d3GICO Y BIOQU\u00cdMICO \nEste estudio se realiz\u00f3 en un total de 218 ancianos, 82 hombres y \n136 mujeres que se prestaron voluntari amente a la extracci\u00f3n venosa. \nLas muestras de sangre se recogieron tras ayuno de doce horas, a \nprimera hora de la ma\u00f1ana, por punci\u00f3n de la vena cubital. Parte de la \nsangre se recogi\u00f3 en vacutainers co n EDTA, heparina, citrato y en tubos \nsin anticoagulante para la obtenci\u00f3n de suero. Inmediatamente despu\u00e9s \nde la venopunci\u00f3n los tubos sin anti coagulante, se trasladaron en ba\u00f1o \nde hielo  antes de una hora al laboratorio para su proceso. \nCon la sangre, procedente de los tubos anticoagulados con EDTA, se \nrealizaron las siguientes determinaciones: \na. Hemograma completo. \nb. Recuento de reticulocitos porcen tuales y en valores absolutos \nmediante el analizador Coulter Gen de Isaza. \nc. Se realizaron dos frotis sangu\u00edneos para comprobaci\u00f3n \u00f3ptica de \nla formula leucocitaria y contar la segmentaci\u00f3n de los neutr\u00f3filos con el fin de calcular el \u00edndice de lobularidad (IL) de cada muestra. \nd. Se extrajo ADN mediante la t\u00e9cnica de Qiagen, procedimiento \ndescrito por Higuchi (1989), el ADN obtenido, se congel\u00f3 a menos 80\u00ba C en dos al\u00edcuotas para posteriormente hacer el estudio del polimorfismo de la mutaci\u00f3n C677T de la MTHFR mediante la Reacci\u00f3n en cadena de la polimerasa (PCR) y posterior digesti\u00f3n y amplificaci\u00f3n con la enzima de restricci\u00f3n \nHinf-I (GE Healthcare) como fue descrito por Frosst et al (1995).  \n \n                                                                                               Material y M\u00e9todos  \n \n 171e. 200 microlitros de sangre toral se hemolizaron con hemplysate \nreagent para la determinaci\u00f3n del folato intraeritrocitario, la \nnuestra se proceso inmediatamen te o se congelo a menos 30\u00ba C \npara su an\u00e1lisis posterior, siempre antes de 1 semana. \nf. Se dosific\u00f3 las hemoglobinas A 2 y fetal en las muestras con \nmicrocitosis o anemia microc\u00edtica no ferrop\u00e9nica. \nCon la sangre procedente del tubo anticoagulado con Heparina litio \nse separaron dos al\u00edcuotas de 1 cc de sangre total para la determinaci\u00f3n d e  l a  v i t a m i n a  B\n6. las muestras se congelar on a menos 80\u00ba C hasta su \nan\u00e1lisis. \nLos tubos sin anticoagulante conservados en ba\u00f1o de hielo desde la \nextracci\u00f3n de la sangre, se centri fugaron en centrifuga refrigerada antes \nde una hora de la extracci\u00f3n y se separaron las siguientes al\u00edcuotas: \na.  400 microlitros para la determinaci\u00f3n de Homociste\u00edna, esta se \nanaliz\u00f3 inmediatamente o se congelo a menos 30\u00baC hasta su \nan\u00e1lisis. \nb. 1000 microlitros para la determinaci\u00f3n de la \nHolotranscobalamina II, se congelaron a menos 30\u00ba C hasta su an\u00e1lisis- \nc. 1000 microlitros para las determinaciones bioqu\u00edmicas que se \nanalizaron inmediatamente. \nd. 1000 microlitros para las determinaciones de vitamina B\n12 y folato \ns\u00e9rico, las muestras se analizaron inmediatamente o se congelaron a menos 30\u00ba C hasta su an\u00e1lisis. \ne. 1000 microlitros para las determinaciones del metabolismo \nf\u00e9rrico, transferrina, ferritina, receptores solubles de la \ntransferrina y haptoglobina, estas muestras se analizaron \ninmediatamente. Hitachi 900 (Roche)  \n \n                                                                                               Material y M\u00e9todos  \n \n 172PAR\u00c1METROS HEMATOL\u00d3GICOS \nHemograma completo:  \nLa sangre anticoagulada con EDTA se proceso en el analizador \nADVIA 120 de Bayer. Se determinaron los siguientes par\u00e1metros: \n Leucocitos  \n Hemat\u00edes  Hemoglobina  VCM (volumen corpuscular medio)  HCM (hemoglobina corpuscular media) \n CHCM (concentraci\u00f3n de hemoglobina corpuscular media) \n ADE (\u00edndice de dispersi\u00f3n eritrocitaria)   Plaquetas  VPM (volumen plaquetario medio)  F\u00f3rmula leucocitaria en valores porcentuales y absolutos con \nrecuento de neutr\u00f3filos, linfocitos, monolitos, eosin\u00f3filos, bas\u00f3filos y \nLUC. \nSe realizaron dos frotis sangu\u00edneos con los que comprob\u00f3 \n\u00f3ptimamente la formula leucocitaria y se cont\u00f3 la segmentaci\u00f3n neutr\u00f3fila para hallar el \u00edndice de lobularidad (IL). \n\u00cdndice de lobularidad: \nEn cada uno de los frotis sangu\u00edneos, una vez secados al aire, se \nfijaron con metanol absoluto y se ti\u00f1eron con Giemnsa, se contaron 100 \nneutr\u00f3filos segmentados y se clasific aron en 2, 3, 4, 5, 6 y 7 segmentos, \nla cifra hallada de cada uno de e llos, se multiplic\u00f3 por los segmentos \ncorrespondientes, es decir por 2, 3, 4, 5, 6 y 7 respectivamente, la cifra \nhallada se dividi\u00f3 entre 100 con lo que se obtuvo el \u00edndice de \nlobularidad (IL). \nIL %= (2L x 2 + 3L x 3 + 4L x 4 + 5L x 5 + 6L x 6 + 7 L x 7) / 100 \nTambi\u00e9n se consign\u00f3 la suma de neutr\u00f3filos con 5 l\u00f3bulos \u00f3 m\u00e1s.  \n\u00cdndice de reticulocitos:  \nLa prueba se realiz\u00f3 con sangre anticoagulada con EDTA en el \nCoulter modelo Gen-S, obteni\u00e9ndose  los reticulocitos porcentualmente  \n \n                                                                                               Material y M\u00e9todos  \n \n 173y en valores absolutos. (Valores de  normalidad en nuestro laboratorio \n0.5-1.5 % o 24-85.000 mmcc) \n \nVelocidad de sedimentaci\u00f3n globular: \nSe realiz\u00f3 con el vacutainers anticoagulado con citrato en el \nanalizador autom\u00e1tico SED System de  Becton Dickinson. ( Valores de \nnormalidad en nuestro laboratorio  para la 1\u00aa hora menor de 20 \nmm/hora para hombres e inferior a 30 mm/hora para las mujeres). \n Cromatograf\u00eda de hemoglobinas:  \nUna muestra de 10 microlitros de sangre total anticoagulada con \nEDTA se hemoliz\u00f3 con 1000 microlitros de agua destilada, analiz\u00e1ndose posteriormente en el Hb Gold de los laboratorios Menarini. (Valores de normalidad en nuestro laboratorio para la hemoglobina A\n2 < 3.5 % y \npara la hemoglobina F < 0.5 %) \n \nPAR\u00c1METROS BIOQU\u00cdMICOS-HEMATOL\u00d3GICOS  Par\u00e1metros indicadores del metabolismo f\u00e9rrico: Hierro s\u00e9rico:  \nSe determin\u00f3 por m\u00e9todo colorim\u00e9trico que se realiza en tres \npasos: primero en medio \u00e1cido se se para el hierro de la transferrina, \nreducci\u00f3n del hierro f\u00e9rrico a ferro so mediante el ascorbato y por \n\u00faltimo los iones ferrosos reaccion an con un crom\u00f3geno el FerroZine \npara formar un complejo crom\u00e1tico. La intensidad del color es directamente proporcional a la concentraci\u00f3n f\u00e9rrica y se mide \nfotom\u00e9tricamente en el autoanalizad or Hitachi 911 de Roche. (Webster, \n1960) (CV.= 1.2%) (Valores de normalidad del laboratorio 45-150 \u00b5g/dl), para el control de calidad interno se utilizaron Precinorm universal y Precipath universal de Roche. \n \nTransferrina:  \nSe determin\u00f3 por m\u00e9todo inmunoturbidim\u00e9trico. Los \nanticuerpos anti-transferrina reaccionan con el ant\u00edgeno de la muestra  \n \n                                                                                               Material y M\u00e9todos  \n \n 174formando un complejo ant\u00edgeno-anticuerpo que se mide \nturbidim\u00e9tricamente despu\u00e9s de la ag lutinaci\u00f3n en el autoanalizador \nHitachi 911 de Roche. La adici\u00f3n de PEG posibilita alcanzar un r\u00e1pido \npunto final y aumentar la sensibilidad (1,2) (CV.= 1,1%) (Valores de \nnormalidad del laboratorio 200-360 mg/dl), para el control de calidad interno se utilizaron Precinorm prote\u00ednas y Precipath prote\u00ednas de Roche. \n. \n\u00cdndice de saturaci\u00f3n de la transferrina (IST): \nSe obtiene por c\u00e1lculo matem\u00e1tico con la siguiente formula: \nIST= (Hierro s\u00e9rico x 100)/(1,39 x Transferrina) \n(Valores de normalidad en nuestro laboratorio 20-30%).  \nFerritina: \nSe determino por m\u00e9todo inmunoturbidim\u00e9trico. Los \nanticuerpos anti-ferritina fijados a l\u00e1te x reaccionan con el  ant\u00edgeno de la \nmuestra formando un complejo an t\u00edgeno-anticuerpo que se mide \ndespu\u00e9s de la aglutinaci\u00f3n por turbidimetr\u00eda en el autoanalizador Hitachi 911 de Roche (1,3) (CV.= 5.6%). \n(Valores de normalidad del laborato rio 15-350 \u00b5g/ml), para el control de \ncalidad interno se utilizaron Precinorm prote\u00ednas y Precipath prote\u00ednas \nde Roche. \n \nReceptores solubles de la transferrina (sTfR): \nLos anticuerpos anti-sTfR fijados a l\u00e1tex reaccionan con el \nant\u00edgeno de la muestra formando un  complejo ant\u00edgeno-anticuerpo que \nse mide despu\u00e9s de la aglutina ci\u00f3n por turbidimetr\u00eda en el \nautoanalizador Hitachi 911 de Roche (1,4), (CV.= 2.76%) (Valores de normalidad del laboratorio 2.5-4.5 mg/l), para el control de calidad interno se utilizaron Precinorm prote\u00ednas y Precipath prote\u00ednas de Roche.  \n \n                                                                                               Material y M\u00e9todos  \n \n 175Par\u00e1metros indicadores de hem\u00f3lisis \nHaptoglobina:  \nLos anticuerpos anti-haptoglobina reaccionan con los ant\u00edgenos \nde la muestra formando un complejo  ant\u00edgeno-anticuerpo que se mide \nturbidim\u00e9tricamente en el autoana lizador Hitachi 911 de Roche (1,5) \n(CV.= 1.4%) (Valores de normalidad del laboratorio 30-200 mg/dl), para el control de calidad interno se utilizaron Precinorm prote\u00ednas y Precipath prote\u00ednas de Roche. \n \nLDH: \nM\u00e9todo cin\u00e9tico enzim\u00e1tico que se  realiza en el autoanalizador \nBH/Hitachi 917, utiliz\u00e1ndose controle s y calibradores de Roche. (CV.= \n4.5.0%) (Valores de normalidad del laboratorio 230-460 U/l). \n \nTest directo de la antiglobulina: \nM\u00e9todo manual que utiliza hemat\u00edes procedentes del tubo \nanticoagulado con EDTA y lavados tr es veces con suero salino (ClNa \n9\u2030), se decanta cada vez el sobr enadante, enfrentado una gota de \nhemat\u00edes lavados con una gota de antiglobulina polivalente, la aglutinaci\u00f3n demuestra la presen cia de autoanticuerpos (Coombs, \nMourant y Race 1945). \n \nTest indirecto de la antiglobulina: \nM\u00e9todo manual que utiliza suero. En un tubo de hem\u00f3lisis se \na\u00f1aden tres gotas del suero a estudiar al que se le a\u00f1ade una gota de hemat\u00edes testigo, la mezcla es in cubada durante media hora en ba\u00f1o \nmar\u00eda a 37\u00baC durante 1 hora, los hemat\u00edes ya sensibilizados se lavan tres \nveces con soluci\u00f3n salina (ClNa 9\u2030), decantando cada vez el sobrenadante, al resto se a\u00f1ade anti globulina polivalente, se centr\u00edfuga \na 5000 rpm durante 30 segundos y se ve la presencia o no de aglutinaci\u00f3n. (Coombs, Mourant y Race 1945)  \n \n                                                                                               Material y M\u00e9todos  \n \n 176Par\u00e1metros indicadores del status vitam\u00ednico  \nCianocobalamina (Vitamina B 12): \nT\u00e9cnica de enzimoinmunoensayo que utiliza la tecnolog\u00eda de \nmicroparticulas (MEIA) en el autoanalizador IMx de los laboratorios \nAbbott. Las microparticulas recubiertas de factor intr\u00ednseco se unen a la \nB12 de la muestra tratadas con Na OH y KCN formando un complejo \nfactor intr\u00ednseco-B 12, posteriormente se a\u00f1ade un conjugado B 12 fosfatasa \nalcalina  form\u00e1ndose un complejo entre el conjugado y las microparticulas recubiertas de factor intr\u00ednseco, se a\u00f1ade un sustrato el \n4-metilumbeliferona fosfato y el pr oducto fluorescente resultante se \nmide por un sistema \u00f3ptico MEI A. (6). (CV.=3.9%)(Valores de \nnormalidad en nuestro laboratorio 179-1132 pg/ml) \n \nFolato s\u00e9rico:  \nT\u00e9cnica de enzimoinmunoan\u00e1lisis de fluorescencia, en este \nm\u00e9todo, la matriz de fibra de vidrio de la celdilla de reacci\u00f3n se ha \nrecubierto de un compuesto de am onio cuaternario de elevado peso \nmolecular, que confiere una carga positiva y capacidad de capturar \ncompuestos de carga negativa. Durante  el an\u00e1lisis, se forman complejos \ncargados negativamente, utilizando un reactivo de afinidad soluble \ncompuesto de una prote\u00edna folato-ligante unida a anticuerpos \nmonoclonales y ligados a su vez a carboxi-metil-celulosa. En nuestro \nlaboratorio se utiliz\u00f3 un m\u00e9todo automatizado de inmunoan\u00e1lisis de fluorescencia polarizada comercializado por IMX Abbott. (CV=4 %) (Valores normalidad en nuestro laboratorio > 6 ng/ml) \n \nFolato intraeritrocitario: \n Es la misma t\u00e9cnica del folato s\u00e9rico previa hemolisis de los \nhemat\u00edes por medio de un reactivo hemolizante proporcionado por el laboratorio Abbott (CV=4,6 %) (Valor es de normalidad en nuestro \nlaboratorio >375 ng/ml) \n Piridoxina (Vitamina B\n6): \n T\u00e9cnica cromatogr\u00e1fica liquida de alta resoluci\u00f3n. Previa \nseparaci\u00f3n con \u00e1cido tricloroac\u00e9tico de las vitaminas a las prote\u00ednas a  \n \n                                                                                               Material y M\u00e9todos  \n \n 177las que van unidas, se introduce la muestra en el sistema HPLC, \nmidiendo la concentraci\u00f3n de la vitamina mediante un detector de fluorescencia. Esta t\u00e9cnica se realiz\u00f3 por nuestro grupo de investigaci\u00f3n \nen Bonn (Alemania). (Valores de no rmalidad de nuestro laboratorio > \n20 nmol/l). \n \nHomociste\u00edna: \nT\u00e9cnica de inmunoan\u00e1lisis de polarizaci\u00f3n de la fluorescencia \n(FPIA) que utiliza el autoanalizador  IMx de los laboratorios Abbott la \nHomociste\u00edna en forma oxidada se re duce a Homociste\u00edna libre y esta \nse convierte enzim\u00e1ticamente en S- adenosil-L-Homociste\u00edna (SAH), se \na\u00f1ade un anticuerpo monoclonal, la SAH y el trazador marcado con \nfluoresce\u00edna compiten por los sitios de uni\u00f3n del anticuerpo monoclonal, la intensidad de la luz polarizada se mide con el sistema \n\u00f3ptico FPIA. (CV.=1.9%) (Valores de normalidad en nuestro laboratorio \n5-12 \u00b5mol/l). \n \nHolotranscobalamina II (Holo-TC-II): \nT\u00e9cnica de radioinmunoan\u00e1lisis (RIA), cedida para esta tesis por \nel laboratorio Axis-Shield (Hol oTC RIA. Art 1114208), utiliza suero y \nque mide la vitamina B\n12 ligada a la Transcobalamina II. (CV < 20 \n%)(Valores de normalidad de nuestro laboratorio > 45 pmol/l) \n \n\u00c1cido Metilmal\u00f3nico: \n T\u00e9cnica realizada por nuestro grupo en Bonn (Alemania). \nFue analizado por MS-GC. (Valores de normalidad inferiores a 300 \nnmol/l). \n \nPAR\u00c1METROS BIOQU\u00cdMICOS:  \n Par\u00e1metros lip\u00eddicos Colesterol total: \nTest enzim\u00e1tico colorim\u00e9trico (Kit Chop-PAP) comercializado \npor Roche que utiliza suero y se reali za en el autoanalizador BH/Hitachi  \n \n                                                                                               Material y M\u00e9todos  \n \n 178917, utiliz\u00e1ndose controles y calibrad ores de Roche. (CV.= 1.48%) \n(Valores de normalidad del laboratorio 120-220 mg/dl). \n Triglic\u00e9ridos: \nTest enzim\u00e1tico colorim\u00e9trico (Kit GPO-PAP) comercializado por \nRoche que utiliza suero y se realiza en el autoanalizador BH/Hitachi \n917, utiliz\u00e1ndose controles y calibradores de Roche. (CV.= 4.5%) (Valores de normalidad del laboratorio 50-170 mg/dl). \n \nHDL-Colesterol: \nEl m\u00e9todo directo utiliza dos tipos de reactivos R\n1 y R 2, el \nreactivo R 1 est\u00e1 compuesto por sulfato de  excidodextrina 0.5 mmol/l, \nsulfato de dextran 0.5 g/l y sulfato de magnesio 7mg/ml. El reactivo R 2 \nesta compuesto de PEG-colesteroxidasa, PEG-colesterolesterasa y 4-aminofenazona, estos reactivos est\u00e1n comercializados por los \nlaboratorios Roche. La modificaci\u00f3n de estas enzimas con PEG les \nconfiere actividad catal\u00edtica espec\u00edfica frente al colesterol transportado por las HDL, mientras que la \u03b1-ciclodextrina sulfatada, en presencia de \niones Mg 2\n+, reduce esta actividad frente a las lipoprote\u00ednas con baja \nrelaci\u00f3n prote\u00ednas/l\u00edpidos. \nLa prueba se realiza en el autoanalizador BH/Hitachi 917 \ncomercializado por Roche, utiliz\u00e1ndose controles y calibradores de los laboratorios Roche.(CV = 4.5%) (Valores  de normalidad del laboratorio \n27-67 mg/dl). \n \nVLDL-Colesterol: \nSe obtiene por c\u00e1lculo matem\u00e1tico a partir de los triglic\u00e9ridos, \ndividiendo estos entre 5.(Valores de  normalidad del laboratorio 12-34 \nmg/dl) \n \nLDL-Colesterol: \nSe calcula con la formula de Friedewald (Friedewald y col 1972): \nLDL-Colesterol (mg/dl) = Colesterol total \u2013 (Triglic\u00e9ridos/5 + HDL-\nColesterol).  \n \n                                                                                               Material y M\u00e9todos  \n \n 179Apolipoprote\u00edna  A: \nT\u00e9cnica por inmunoturbidimetria que utiliza anticuerpo APA (5 \nml), anticuerpo de mam\u00edfero para APA humana que utiliza azida \ns\u00f3dica al 0.1% como conservante. La prueba se realiza con suero en el \nautoanalizador Hitachi 911 comercializado por Roche, utiliz\u00e1ndose reactivos, calibradores y controles de la casa Roche. (CV.= 7.5%) (Valores de normalidad del laboratorio 10-216 mg/dl). \n \nApolipoprote\u00edna B: \nT\u00e9cnica por inmunoturbidimetria que utiliza anticuerpo APA (5 \nml), anticuerpo de mam\u00edfero para APA humana que utiliza azida s\u00f3dica al 0.1% como conservante. La prueba se realiza con suero en el autoanalizador Hitachi 911 comercializado por Roche, utiliz\u00e1ndose reactivos, calibradores y controles de la casa Roche. (CV.= 7.5%) (Valores de normalidad del laboratorio 60-133 mg/dl). \n LP(a): \nT\u00e9cnica de inmunoturbidimetria qu e se realiza con suero en el \nautoanalizador Hitachi 911 comercializado por Roche y que utiliza reactivos, calibradores y controles tambi\u00e9n de Roche. (Valores de \nnormalidad del laboratorio 2-200 mg/dl) \n \nPar\u00e1metros proteicos \n Prote\u00ednas s\u00e9ricas totales: \nM\u00e9todo cin\u00e9tico de Biuret que se realiza en el autoanalizador \nBH/Hitachi 917, utiliz\u00e1ndose controle s y calibradores de Roche. (CV.= \n7.5%) (Valores de normalidad del laboratorio 5-7.8 g/dl).  \n \n                                                                                               Material y M\u00e9todos  \n \n 180Par\u00e1metros nitrogenados no proteicos \n Urea: \nM\u00e9todo enzim\u00e1tico colorim\u00e9trico que se realiza en el \nautoanalizador BH/Hitachi 917, utiliz\u00e1n dose controles y calibradores de \nRoche. (CV.= 4.5%) (Valores de normalidad del laboratorio 10-50mg/dl). \n \n\u00c1cido \u00farico: \nM\u00e9todo enzim\u00e1tico colorim\u00e9trico que se realiza en el \nautoanalizador BH/Hitachi 917, utiliz\u00e1n dose controles y calibradores de \nRoche. (CV.= 3.0%) (Valores de normalidad del laboratorio 4.4-7.6 \nmg/dl). \n \nCreatinina: \nM\u00e9todo enzim\u00e1tico colorim\u00e9trico que se realiza en el \nautoanalizador BH/Hitachi 917, utiliz\u00e1n dose controles y calibradores de \nRoche. (CV.= 3.0%) (Valores de normalidad del laboratorio 0.9-1.3 \nmg/dl). \n \n Par\u00e1metros gluc\u00eddicos  \nGlucosa: \nM\u00e9todo enzim\u00e1tico colorim\u00e9trico que se realiza en el \nautoanalizador BH/Hitachi 917, utiliz\u00e1n dose controles y calibradores de \nRoche. (CV.= 3.0%) (Valores de normalidad del laboratorio 65-110 \nmg/dl).  \n \n                                                                                               Material y M\u00e9todos  \n \n 181Enzimas hep\u00e1ticas  \n GOT \nM\u00e9todo cin\u00e9tico enzim\u00e1tico que se  realiza en el autoanalizador \nBH/Hitachi 917, utiliz\u00e1ndose controle s y calibradores de Roche. (CV.= \n5.3.0%) (Valores de normalidad del laboratorio 0-32 U/l). \n \nGPT: \nM\u00e9todo cin\u00e9tico enzim\u00e1tico que se  realiza en el autoanalizador \nBH/Hitachi 917, utiliz\u00e1ndose controle s y calibradores de Roche. (CV.= \n5.3.0%) (Valores de normalidad del laboratorio 0-35 U/l). \n \n\u03b3GT: \nM\u00e9todo cin\u00e9tico enzim\u00e1tico que se  realiza en el autoanalizador \nBH/Hitachi 917, utiliz\u00e1ndose controle s y calibradores de Roche. (CV.= \n5.3.0%) (Valores de normalidad del laboratorio 7-32 U/l). \n \nESTUDIO GEN\u00c9TICO \nCon 500 \u00b5L de sangre total anticoagulada con EDTA se realiz\u00f3 \nextracci\u00f3n de ADN mediante el Kit Qiagen, basado en el procedimiento \ndescrito por Higuchi (1989) y posteriormente se estudio el polimorfismo \nde la C677T de la MTHFR mediante  la Reacci\u00f3n en cadena de la \npolimerasa (PCR) y posterior  digest i\u00f3n y amplificaci\u00f3n con la enzima \nde restricci\u00f3n Hinf-I (GE Healthcare) como fue descrito por Frosst et al (1995). \n ANALISIS ESTAD\u00cdSTICO \nMediante paquete estad\u00edstico SPSS 13.0 para Windows XP se \nrealiz\u00f3 seg\u00fan los casos lo siguiente: \n An\u00e1lisis descriptivo univariante:\n \na) Par\u00e1metros de estad\u00edstica b\u00e1sic a: media, moda, mediana, desviaci\u00f3n \nest\u00e1ndar, percentiles y rango (m\u00e1ximo y m\u00ednimo)  \n \n                                                                                               Material y M\u00e9todos  \n \n 182b) El test de contraste de hip\u00f3tesis entendido como el grado de \nsignificaci\u00f3n de las diferencias entre medias, globales y corregidas (en funci\u00f3n de la edad, sexo, ingesta deficiente, adecuada o excesiva en \nrelaci\u00f3n con cada uno de los par\u00e1metros), se analizar\u00e1 mediante el test \nde la \u02bat\u02ba de Student, test de Newman-Keuls previo an\u00e1lisis de la \nvarianza. En caso de que la distribuci\u00f3n sea no homog\u00e9nea, se aplicar\u00e1n pruebas estad\u00edsticas no param\u00e9tricas como el test de la U de Mann-Whitney o el de Kruskall-Wallis. \nc) El nivel de asociaci\u00f3n entre variables se estudiar\u00e1 mediante \ncoeficiente de correlaci\u00f3n de las relaciones entre datos con \nestablecimiento de la ecuaci\u00f3n de regresi\u00f3n. \n Modelos lineales generales\n: \nSe realizar\u00e1 el an\u00e1lisis de la va rianza (ANOVA) de medidas repetidas \nbasal (a), 5-MTHF (b), PGA (c). En  los casos en que la distribuci\u00f3n \nnormal no pueda ser asegurada, se aplicar\u00e1n pruebas estad\u00edsticas no \nparam\u00e9tricas. Test de Wilcoxon co mparando pares: [(a)-(b)], [(a)-(c)], \n[(b)-(c)]. \n \nM\u00c9TODO BIBLIOGRAFICO \nPara la obtenci\u00f3n del material bibliogr\u00e1fico se utilizaron sistemas \nde b\u00fasquedas directas con el Indice  M\u00e9dico Espa\u00f1ol, Index Medicus y \nExcerpta M\u00e9dica y b\u00fasqueda informatizada con el MEDLINE avanzado, con acceso a las bases de datos Pubmed, Infotrieve, BioMedNet, Medscape, Avicena, Heal thgate, PhyNet y The National \nLibrary of Medecine. \n \n \n    \n \n  \n  \n \n     \n \n     \n \n    \n \n     \nVITAMINAS B Y HOMOCISTE\u00cdNA \n  \n \n 184 \nB-Vitamins and Homocysteine in Spanish institutionalized \nelderly \nRicardo Sola 1,2, Marcela Gonzalez-Gross 2,3, Ulrike Albers3, Laura \nBarrios4, Monika Alder3,5, Manuel J Castillo2, Klaus Pietrzik5 \n1Servicio de Hematolog\u00eda. Hospital Cl\u00ednico San Cecilio de Granada. \nSpain \n2Grupo Effects 262. Facultad de Medicina. Universidad de Granada. \nSpain \n3Facultad de Ciencias de la Actividad F\u00edsica y del Deporte. Universidad \nPolit\u00e9cnica de Madrid. Spain. \n4Centro T\u00e9cnico de Inform\u00e1tica. Cons ejo Superior de Investigaciones \nCient\u00edficas. Spain. \n5Institut f\u00fcr Ern\u00e4hrungs-und Lebensmittelwissenschaften, \nPathophysiologie der Ern\u00e4hrung, Rheinische Friedrichs-Wilhelms \nUniversit\u00e4t Bonn, German \n Address for correspondence: Prof. Dr. Marcela Gonzalez-Gross Facultad de CC de la Actividad F\u00edsica y del DeporteUniversidad \nPolit\u00e9cnica de Madrid \nc/ Mart\u00edn Fierro s/n E-28040 Madrid Tel.: +34 91 336 4006 Fax: +34 91 5497307 e-mail: marcela.gonzalez.gross@upm.es\n \nKey words : Folate - Vitamin B 12 \u2013 Holotranscobalamin II - \nHomocysteine - Elderly \n \n*This study has been supported by the Spanish Ministry of Health \nInstituto de Salud Carlos III (FIS PI021830). Axis-Shield (Oslo, Norway) has kindly provided the Holo-TC RIA reagent kit. We want to thank Ms \nR Arcas, Ms P Carazo, Ms R Perez and Ms Verena Lemmen for their \ncollaboration in this study.  \n \n 185Summary  \nBackground : \nHyperhomocysteinemia is an accepted risk factor for \ncardiovascular disease, and possibly also for cognitive impairment and \ndementia. It has also been proposed as a marker of the status of the B vitamins, which are implicated in the metabolic circle. Therefore, especially in the elderly, it is impo rtant to know the prevalence of high \nhomocysteine (tHcy) levels and the influence that B vitamins have on them.  \n Material and Methods:   \nTwo-hundred and eighteen elderly of both sexes, aged 60-105, \nliving in an elderly home in Gran ada (Spain), were screened for serum \nfolate, red blood cell (RBC) folate, serum cobalamin (B\n12) (Abbott, IMx), \nholotranscobalamin II (Holo-TC II) (HoloTC RIA, Axis-Shield), \nMethylmalonic Acid (MMA) (MS-GC), total pyridoxine (B 6) (HPLC), \nand tHcy (Abbott, IMx). \n \nResults:   \nHyperhomocysteinemia (tHcy >12 \u00b5mol/L) was detected in \n80.7%. Serum folate deficiency was severe ( \u2264 4 ng/mL) in 19.3% and \nmoderate (4 \u20137 ng/mL) in 43.1%. In 14.2%  of the elderly RBC folate was \n\u2264 175 ng/mL, and in 61.0% it was between 175 \u2013 400 ng/mL. Vitamin B 12, \nmeasured in serum ( \u2264 200 pg/mL), was deficient in 15.8%, but if \nmeasured as Holo-TC II ( \u2264 45 pmol/L), deficiency ranges up to 39.1%, \nMMA was high ( \u2265 300 nmol/L) in 45.6%. Vitamin B 6 (< 20 \u00b5g/L) was low \nin 78.9%. In order to identify the fact ors, that could predict tHcy levels, \na multiple regression analysis was performed. Best results corresponded to the combination of lo g serum folate and log Holo-TC II \nwhich gives values of R > 0.5. If an alysed independently, the highest \ncorrelation is with log serum folate  (r = - 0.290), followed by RBC folate \n(r = -0.263), Holo-TC II (r = -0.228), log B\n12 (r = -0.175) and log B 6 (r = -\n0.078).  \n   \n \n 186Conclusion:   \nThere is a high prevalence of vitamin B deficiency and \nhyperhomocysteinemia in the studied population. Our data confirm the \ninfluence of these vitamins, especially folate, on tHcy levels, but \nhyperhomocysteinemia can not be used  as the only diagnostic criterion \nto detect subclinical vitamin deficiency in elderly people, especially to detect vitamin B\n12 and vitamin B 6 deficiency. \n \n Introduction  \nSince the early sixties, several lines of evidence support the \nconcept of elevated homocysteine conc entrations in plasma being a risk \nfactor for atherothrombotic diseases1-5. In the same way, several studies \nand meta-analyses have found inverse associations between objective measures of cognitive function an d plasma or serum homocysteine \nconcentrations\n1,6-14. These observations suggest that homocysteine can \nserve as a predictor of cognitive decline15. More recently, high serum \nhomocysteine levels have been related to increased risk of hip fractures\n16, osteoporosis17, and pseudoexfoliative glaucoma18. \nSerum total homocysteine (tHcy) is determined by a variety of \nhereditary and environmental factor s. Vitamin deficiency of the B \nvitamins implicated in the methylatio n cycle is by far the most frequent \ncause of hyperhomocysteinemia as st ated in a lot of cross-sectional \nstudies15,20. Data published recently ha ve put under question the \nrelevance of reducing tHcy levels in order to prevent cardiovascular \nevents. Two studies found no relati onship between homocysteine and \ncognitive function scores21,22. But in spite of these results, which need \nfurther analysis and are out of scope of the current research, there is \nenough evidence in the literature about the relationship of high \nhomocysteine levels and increased risk of the above-mentioned diseases. In the same sense, several studies support the evidence of considering tHcy in serum as a sens itive marker of folate and vitamin \nB\n12 status in different population groups23, including the elderly6,15,24,25 . \nHyperhomocysteinemia in the elderly is related in most of the \nstudies to the coexistence of deficien cy of one or more of the three B \nvitamins vitamin B 12, folate and vitamin B 6 which might be responsible \nfor the severity and prevalence19,26,27 .  \n \n 187On the other hand, vitamin deficiency by itself has been related \nwith increased risk of several dise ases, which are more prevalent at \nolder ages. Folate deficiency (for review, see28) seems to be involved in \ncardiovascular risk29 and cognitive impairment/dementia30-33 via other \nmechanisms not related to high tHcy  levels. In the same way, vitamin \nB12 deficiency has been related to impaired cognitive function34 among \nothers (for review, see Sola et al, in press35. \nVitamin B 6 deficiency has been related to several diseases (for \nreview, see Spinneker et al, in press36), including loss of neurocognitive \nfunction6. The observation that vitamin B 6 by itself is inversely \nassociated with CVD risk is supported by findings of others37-39. In \nseveral studies, a combination of vi tamin deficiency has been observed, \nwhich aggravates the clinical signs40. \nResearch during the last decade has shown a high prevalence of \nfolate and vitamin B 12 deficiency in elderly people, in most of the \ndeveloped countries in Europe41-43, EEUU19,20, Australia44. Even vitamin \nB6 has been considered a critical vitamin in the elderly45-47. Reasons for \nvitamin deficiency may range from poor food intake, malabsorption \nand drug intake. Some elderly suffe r from disturbed resorption or \nstomach acid production or a deficiency of intrinsic factor which can be \nprevalent in 30%-40%48. Changes in gastric physiology can also be \ninduced by several drugs, whic h consequently impair vitamin \nmetabolism49. Elderly people are at risk because they often take \ndifferent drugs. In Spain, it has been stated, that people aged > 65 take a mean of 3 different medications per day\n50. For example, absorption of \nvitamin B 12 is predominately reduced by pr oton pump inhibitors such \nas omeprazole and lansoprazole51. Specifically at nutritional risk are \ninstitutionalized elderly52. Data on the determinants of homocysteine \nconcentrations in elderly institutionalized Europeans are scarce53. \nTherefore, the objective of the pr esent research was to investigate \nthe prevalence of high tHcy and low vitamin status and the contribution of combined vitamin B deficiency to \nhyperhomocysteinemia in the elderl y. In this report, we describe the \ndistribution of serum total homocyst eine concentrations among elderly \ninstitutionalized Spanish men and women. We examined the association of homocysteine concent ration with serum concentrations of \nfolate, vitamin B\n12, holotranscobalamin II (Holo-TC II), methylmalonic \nacid (MMA), red blood cell (RBC)  folate and total vitamin B 6. To the  \n \n 188best of our knowledge, this is one of  the first studies to include Holo-TC \nII in the complete analysis. \n \nMaterial and Methods \n \nStudy design \nThis study is part of a larger cr oss-sectional study that aims to \nestablish the vitamin B status of Span ish institutionalized elderly, with \nspecial regard to vitamin B 12 and folate in association with \nhomocysteine. It has been supported by a grant from the Fondo de \nInvestigaci\u00f3n Sanitaria, Instituto de Salud Carlos III of the Spanish Ministry of Health. \n Subjects \nTwo-hundred and eighteen elde rly (82 men and 136 women) \naged > 60 years (mean age \u00b1 SD was 76 \u00b1 7 and 81 \u00b1 9 for men and \nwomen, respectively) living in an elderly\u00b4s home in Granada, Spain, \nwere recruited for  \n the study. Anamnesis and blood sampling were included in the \nbiannual medical review that is performed in all the elderly living in \nthe residence. The residents who took  part in the study were all elderly \nliving at the residence. No exclusion criteria were applied. The medication of the elderly was no ex clusion criterion because the reality \nabout drug intake and micronutrien t status should be documented, \nalthough that could affect the resu lts of the study. The mean drug \nintake in Spanish elderly has been estimated recently to be 6 different \nmedications per day. The study was approved by the Human Research Review Committee of the University of Granada, School of Medicine . \nThe study has been performed fo llowing the ethic norms of the \nDeclaration of Helsinki 1961 (revisio n of Edinburgh 2000), Convention \nof Oviedo (1997), the Good Clinical  Practice of the CEE (document \n2001/20/EC April 2001) and the Span ish legislation about clinical \nresearch in humans (Real Decreto 561/1993 sobre ensayos cl\u00ednicos). Informed written consent was obtained from subjects or their relatives.  \n \n 189Blood sampling \nAfter a 10-hours overnight fa st, blood samples were drawn \nbetween 8:00 and 10:00 h in the morning. Following venipuncture, 3 mL \nof EDTA-treated blood was anal ysed within four hours for \nhaematology, for RBC folate and for blood smears Two 8 mL vacutainers with gel for serum were immediately put on ice and \ncentrifuged within one hour at 2000 x g and 4\u00b0C for 10 min. Following \ncentrifugation, they were aliquoted and immediately frozen at -80\u00b0C. \nOne mL heparin-treated blood also was immediately frozen. \n \nAnalytical methods \nHaematological and biochemical data were collected with the \nuse of standard methods. Serum tHcy was analyzed by a totally automated fluorescence polarisation  immunoassay (FPIA; IMx tHcy \nKit, Abbot Diagnostic, Abbot Park, IL, USA). Serum folate, RBC folate, \nand serum cobalamin levels were meas ured by using the fluorometric \nmethod with an Abbot IMx autoanalyser (Abbot Laboratory, Chicago, USA). MMA was measured by gas chromatography and mass spectrometry. Holo-TC II levels wer e measured by a radioimmunoassay \n(HoloTC RIA) provided by Axis-Shield (Oslo, Norway). Axis-Shield has \ndeveloped a simple and reliable assa y method for measuring the active \nvitamin B\n12 in blood, that is HoloTCII, based on the novel finding that \nHoloTCII constitutes the biologically functional vitamin B 12 fraction. \nThus, measurement of this fraction is expected to afford superior \ndiagnostic specificity and allows earl y identification of patients with \nvitamin B 12 deficiency. Vitamin B 6 was analysed by HPLC.  \n \nStatistical analyses \nThe Kolmogorov-Smirnov test indicated that none of the \nparameters was normal distributed. Therefore, parameters were natural log (ln) transformed. Unpaired comparisons were carried out with the two-sided t-test. For comparison of more than two unpaired means, \none-way-ANOVA was applied. A step wise multiple linear regression \nanalysis was used to assess the depe ndency of tHcy on other measured \nvariables. For the descriptive stat istics, mean, standard deviation, \nmedian, and the range between the 5\nth and 95th percentile are shown. P \nvalues < 0.05 were considered to be st atistically significant. Statistical  \n \n 190analyses were performed using the SPSS statistical software (version \n12.0 for Windows XP; SPSS Inc, Chicago). \n \nResults \nTable 1 summarizes median serum concentrations of vitamins \nand related parameters in our study population separated by gender. \nMean Holo-TC II, serum and RB C folate and total vitamin B 6 levels \nwere higher in women, the differences not being significant. Therefore, further data analysis has not been performed by gender.  \n  Figure 1 illustrates the percentage of cases below or above the \nused cut-offs points which indicate abnormal values for all measured parameters\n54-58. Almost half of the study population had serum folate \nconcentrations below the cut-off for moderate deficiency (< 6 ng/mL). \nAccording to RBC folate concentrations, 14% had a deficient folate status (< 175 ng/mL). Seventeen point one percent possessed serum \ncobalamin concentrations lower  than 200 pg/mL. HoloTCII \nconcentrations were suboptimal (<  45 pmol/L) in 37% of our study \npopulation. The percentage of people showing a MMA concentration above 300 nmol/L amounted actua lly 45%. Hyperhomocysteinemia \n(tHcy \u2265 15 \u00b5mol/L) was present in mo re than half of the study \npopulation and the total vitamin B\n6 concentration was deficient in \nnearly 80% of the subjects (< 20 mg/L). \n \nMean homocysteine concentration by vitamin statu s  \nFigure 2 (graphs and tables) show s homocysteine concentrations \nin the quartiles of serum and RBC folate and results of the one way \nANOVA with ln transformed tHcy. Mean serum tHcy concentrations \nfor subjects in the lowest quartile of  serum folate was 19.2 \u00b5mol/L, this \nvalue is significantly higher ( P<0.05) than the mean  for subjects in the \n3rd (P < 0.05) and 4th quartile ( P< 0.001), which were 15.3 and \n13.7 \u00b5mol/L, respectively. Mean serum tHcy concentration for subjects in the first quartile of RBC folate was 18.6 \u00b5mol/L and therefore \nsignificantly different from the mean for subjects in the highest quartile \nwhich was 14.1 \u00b5mol/L ( P=0.001).  \nFigure 3 shows statistics and ANOVA results of tHcy \nconcentrations in the quartiles of vitamin B\n12, Holo-TCII and vitamin B 6.  \n \n 191There were no significant differences between the mean homocysteine \nconcentrations of the four quartiles of both serum cobalamin and HoloTCII and vitamin B\n6.  \nIn Tables 2 and 3, levels of vitamin-related parameter are shown \nusing two different cut-offs of hyperhomocysteinemia (12 and 15 \n\u00b5mol/L, respectively). In Table 2, using the cut-off of \u2264 and > 12 \u00b5mol/L, \nmean levels are statistically different for all parameters exception made for MMA and vitamin B\n6. In Table 3, using the cut-off of \u2264 and > 15 \n\u00b5mol/L, mean levels are statistically different for all parameters \nexception made for SCbl and vitamin B 6.  \nIn the stepwise multiple linear regression analysis, all the \nvitamin-related parameters were included in order to determine the predictors of tHcy. Serum folate was the most powerful independent \npredictor followed by Holo-TC II (Table 4). These factors together explained 26% of the variation of tH cy. If MMA is added to the model, \nthe percentage of the variation of  tHcy explained by them amounts \n27%. If tHcy values > 30 \u00b5mol/L were excluded from the model, MMA also dropped out as a predictor of tHcy levels. \n \nDiscussion \nThe results of the present study indicate that low folate, vitamin \nB\n12 (serum cobalamin and Holo-TC II) and vitamin B 6 status and \nelevated tHcy and MMA concentrat ions are highly prevalent among \nSpanish institutionalized elderly. Our results confirm data published in the literature about the prevalence of low B vitamin levels in older \npopulations\n44,45. \nStudies of homocysteine and vasc ular disease would suggest that \na substantial proportion of our elde rly population may be at elevated \nrisk of vascular disease due to hyperhomocysteinemia1-5. Fifty-five \npercent of our study population had tHcy concentrations above 15 \u00b5mol/L and 82% had tHcy concent rations above 12 \u00b5mol/L, which \nalready is considered a concent ration with elevated risk for \natherothromobotic diseases\n59. Selhub et al19 found that approximately \n29% of their population had tHcy concentrations higher than 14.0 \n\u00b5mol/L and 19% higher than 16.4 \u00b5mol/L. Fifty point twenty-three \npercent  \n  \n \n 192of our study population had homo cysteine levels above 15.8 \u00b5mol/L, \nthe level that Stampfer et al60 related to a more than threefold elevation \nin risk of myocardial infarction.  \nSaw et al61 found that there was a \u2248 1 \u00b5mol/L increase, on \naverage, in homocysteine concent ration per decade increase in age \nbetween 45 and 74 y in Chinese men and women in Singapore. Therefore, it is not surprising th at we found high mean homocysteine \nconcentrations in our population. Nevertheless, a comparison of our \ndata with values measured in differe nt elderly populations\u2019 shows that \nmean tHcy concentrations were higher in our group than in most of the \npreviously reported study groups. Me an concentration in these studies \nranged from 9.1 \u00b5mol/L in a group of Chinese women aged 45\u201374 y\n61 to \n12.4 \u00b5mol/L in a group of 130 independ ently living elderly people over \nthe age of 65 y62. Other authors report tHcy concentrations of 12.0 \n\u00b5mol/L in a population with a mean age of 73.8 y63; in a subset of the \nFramingham offspring cohort aged  67 to 96 years, median tHcy \nconcentration was 11.6 \u00b5mol/L and wa s higher in men than in women, \nwhich disappeared after adjustment for plasma vitamin concentrations\n19. In a subset of the Framin gham offspring cohort with \npeople aged 65 and older who were examined again 7 years later, mean \ntHcy concentration was 10.6 \u00b5mol/L which was 23% higher than in \npersons aged < 45 years and was higher in men than in women64. \nKoehler et al24 studied a population of persons aged 65 and older, and \nfound a mean tHcy concentratio n of 10.29 \u00b5mol/L among non-B-\nvitamin-supplement users (mean age 76.1 y). In Taiwanese elderly, the \noverall prevalence of hyperhomocysteinemia (tHcy > 15 \u00b5mol/L) was \n23.4% for elderly males and 11.2% for elderly females65. \nA possible explanation is the fact, that we studied \ninstitutionalized elderly, which are at greater risk for vitamin \ndeficiencies and thus for high ho mocysteine values than free-living \nelderly. In a subset of participants  of the British National Diet and \nNutrition Survey of people aged 65 and over, Bates et al52 report a much \nhigher mean tHcy concentration in in stitutionalized participants than in \nfree-living subjects, 18.3 \u00b5mol/L and 14.7 \u00b5mol/L, respectively.  \nAs stated before, moderately in creased tHcy and low B vitamin \nconcentrations may cause cardiovascular disease, neuropsychiatric damage, or hematologic abnormalities\n1,66-69. Meta-analyses suggested  \n \n 193that a reduction of 1 \u00b5mol/L tHcy ca n result in a 10 % reduction in risk \nof coronary artery disease. \nThis prognosis was based on tH cy concentrations within the \nrange of 10-15 \u00b5mol/L1. Total Hcy values in our population exceeded \nthis range, and the question remains wh ether this prediction is valid for \nsuch an old population.  \nData are needed on the implication of a 10 % reduction in old \nage. Recent published data from the Veterans Affairs Normative Aging Study suggest that low B vitamin and high homocysteine \nconcentrations predict cognitiv e decline in a 3-year follow-up\n70. \nSince there is still no consensus definition of \nhyperhomocysteinemia, and we did no t have a group of healthy adult \ncontrol subjects to define our own cut-off, for analysing our data we used two cut-offs which have been used in previous studies\n2.71, that is, \n12 and 15 \u00b5mol/L. It has been stated th at plasma tHcy levels between 12 \n\u00b5mol/L and 16 \u00b5mol/L may be referred to as mild \nhyperhomocysteinemia72. The problem with the cu t-offs for tHcy and B \nvitamins has been reported previously by other authors45,73 and is part \nof our current research. In the me anwhile, we have used some of the \nmost frequently used cut-offs in the literature. When comparing the \nresults of the analysed parameter by the two cut-offs trials (Tables 2 and \n3), we observed that for SCbl there is  a change from one situation to the \nother, because the differences are not clearly defined by this parameter. \nFor MMA the situation is the same, because when changing the cut-off \nthe evidence of significance is not clear. This means that both SCbl and \nMMA are not stable in the cut-off borderlines. On the contrary, Holo-\nTC II, serum folate and RBC folate present very clear differences in the \ntwo cut-off trials. These differences are clearer when using 12 \u00b5mol/L as \ncut-off. Vitamin B 6 does not change in the two processes. It is also \ninteresting to point out that in th e interval between 12 and 15 \u00b5mol/L \nthere are a lot of individuals. The \u201cn \u201d changes from 42 subjects to 99 in \nthe \u2264 12 and \u2264 15 \u00b5mol/L groups, respectively . If the data are analysed \nthe inverse way, measuring tHcy levels in the quartiles of the \nparameters instead of cut-offs (Fig. 2 and 3), the previously established \nrelationships are confirmed for both  RBC and serum folate. For Holo-\nTC II it is not so clear. It seems that  this variable behaves better with an \nestablished cut-off. All in all, there is no doubt about the high  \n \n 194prevalence of abnormal levels of vitamin-related parameters and the \nvariation with other reference values would be very small.  \nIn a stepwise linear regression model, only serum folate, Holo-\nTC II, and MMA remained in the model as significant predictors of \ntHcy. Serum levels of these three parameters account for 27% of the variation in tHcy. Strongest predicto r was serum folate. This is in line \nwith previous findings that folate plays the most important role in homocysteine metabolism\n24,74,75 . In a study of the Framingham offspring \ncohort64, concentrations of folate were identified as primary \ndeterminants of homocysteine. Studies performed in Europe confirm \nthese findings62,76. We found no significant correlation between vitamin \nB6 and tHcy levels, confirming data from other studies45. Our results \nconfirm the importance of the influe nce of serum folate and introduces \nHolo-TC II on the changes produced on  tHcy levels, in this case, with \nno previous hypothesis of cut-off. Although the levels obtained for R2 \nare not enough to justify a predictive model (Table 4).  \n \nPrevalence of B vitamin deficiency \nThe vitamin B 12 status in our study population is comparable to \nfindings of different studies. Mean serum B 12 concentrations scatter \naround 250 pmol/L in most studies an d are higher in women than in \nmen, though not always significant19,24,56,63,77 . Very low vitamin B 12 \nvalues are reported by Bates et al52 in both free-living and \ninstitutionalized elderly.  \nIn Europe, folate deficiency is the most common vitamin \ndeficiency. A population especially at risk are institutionalized elderly. \nWe found a very high prevalence of marginal folate deficiency 48% (< 6 \nng/mL) and 7% with serum folate le vels below 3 ng/mL. According to \nthe long-term parameter RBC folate, 14% of our population are at risk for folate deficiency. Considering tH cy a more sensitive indicator of \nfolate deficiency, there could be an  even higher prevalence of tissue \ndeficiency of folate. We found elevat ed tHcy concentrations in 82% of \nour population, indicating an ove rall inadequate B-vitamin status. \nMeasurement of the metabolite, which\n accumulates when \nvitamin  B12-, folate-, and  vitamin B 6-dependent enzymatic reactions are \nimpaired, should provide a better indication of intracellular deficiency \nof these vitamins. Joosten et al78 measured serum concentrations of  \n \n 195these vitamins and four metabolites , including tHcy, in 99 healthy \nyoung people, 64 healthy elderly su bjects, and 286 elderly hospitalized \npatients. A low serum vitamin B 12 concentration was found in 6% and \n5%, low folate in 5% and 19%, and low vitamin B 6 in 9% and 51%, and \none or more metabolites were elevated in 63% and 83% of healthy \nelderly subjects and elderly hospitalized patients, respectively. These \nresults strongly suggest that the prevalence of tissue deficiencies of \nvitamin B 12, folate, and vitamin B 6 as demonstrated by the elevated \nmetabolite concentrations is substantially higher than that estimated by \nmeasuring concentrations of the vitamins. This may be true in our \npopulation as well. Clarke et al56 reported that amon g persons aged 65-\n74 and \u2265 75 years, \u2248 10% and 20%, respectively, were at high risk of \nfolate deficiency. Overall, \u2248 10% of the younger age group with low \nfolate also had low B 12 concentrations (< 150 pmol/L). Mean serum \nfolate levels in our study population are comparable to those observed \nin other studies among elderly. Repo rted values for folate range around \n14-25 nmol/L24,56,64 . Very low mean serum folate levels are reported by \nHenning et al63 who investigated a group of German elderly (mean 5.5 \nnmol/L).  \nDiscrepancies between the percentages of inadequate vitamin \nstatus in function of which paramete r is used are shown in Figure 1. \nVitamin B 12 deficiency ranges from 17.13% if serum cobalamin is \nmeasured, 37.4% if Holo-TC II is measured, and up to 44.9% if MMA is considered. Several authors have stated that the clinical severity of vitamin B\n12 deficiency is unrelated to vitamin B 12 concentrations, \nreflecting the limitations of standard vitamin B 12 assays79,80. \nFunctional deficiency may occu r even in people whose serum \nvitamin B 12 concentrations are in the normal (i.e. reference) range78. \nFolate deficiency also causes macrocytic anemia but may have \nneurologic features that differ from those of vitamin B 12 deficiency. \nAccurate identification of vitamin B 12 deficiency is important because \ninappropriate treatment with folic acid will correct the haematological \nsigns of vitamin B 12 deficiency but leave the neurological symptoms \nunaltered81. Several studies indicate that serum vitamin B 12 is not a \nreliable indicator of vitamin B 12 deficiency. Therefore, we measured not \nonly serum cobalamin but also a more  sensitive parameter to detect B 12 \ndeficiency: Holo-TC II58,82-84 . We found a significant correlation (r=0.656; \np \u2264 0.01) between Holo-TC II and serum B 12. Serum cobalamin as a \nclassical marker for vitamin B 12 deficiency may lead to an  \n \n 196underestimation of the problem. Fu nctional markers like Holo-TC II \nmight be more useful for early detection of vitamin B 12 deficiency. The \nobservations of the present study, when combined with those of van \nAsselt85, Bjorkegren and Svardsudd76, and Bates52 suggest that older \npeople living in Europe may be at risk for functional vitamin B 12 \ndeficiency.  \nIn summary, there is a high prev alence of vitamin B deficiency \nand hyperhomocysteinemia in th e studied population. Routine \nscreening of older persons for vitamin B 12, folate and vitamin B 6 \ndeficiency may be indicated. Our da ta confirm the influence of these \nvitamins, especially folate, on tHcy levels, but elevated tHcy can not be \nused as the only diagnostic criterion to detect subclinical vitamin deficiency in elderly people. Folates and Holo TC II are the best predictors of tHcy levels. But da ta analysis suggests that these \nparameters taken separately are not completely predictive of tHcy \nlevels.  \n \n 197References:  \n \n1.- Boushey, C.J., Beresford, S.A.A ., Omenn, G.S. and Motulsky, A.G. \n(1995) A quantitative assessment of plasma homocysteine as a risk \nfactor for vascular disease: Probable benefits of increasing folic acid intakes. JAMA. 274, 1049-1057. \n2.- Graham, I.M., Daly, L.E., Refsum, H.M., Robinson, K., Brattstrom, \nL.E., Ueland, P.M., Palma-Reis, R.J., Boers, G.H., Sheahan, R.G., Israelsson, B., Uiterwaal, C.S., Me leady, R., McMaster, D., Verhoef, \nP., Witteman, J., Rubba, P., Bellet, H., Wautrecht, J.C., de Valk, H.W., \nSales Luis, A.C., Parrot-Rouland, F.M ., Tan, K.S., Higgins, I., Garcon, \nD., Andria, G. and et al. (1997) Plas ma homocysteine as a risk factor \nfor vascular disease. European Concerted Action Project. JAMA. 277, 1775-1781. \n3.- Nygard, O., Nordrehaug, J.E., Refsum, H., Ueland, P.M., Farstad, M. \nand Vollset, S.E. (1997) Plasma homocysteine levels and mortality in \npatients with coronary artery disease. N. Engl. J. Med 337, 230-236. \n4.- Refsum, M., H., Ueland, M., P. M ., Nygard, M., O. and Vollset, S. E. \n(1998) Homocysteine and cardiovascular disease. Annu. Rev. Med. 49, 31-62. \n5.- Wald, N.J., Watt, H.C., Law, M. R., Weir, D.G., McPartlin, J. and \nScott, J.M. (1998) Homocysteine an d ischemic heart disease: Results \nof a prospective study with implic ations regarding prevention Arch. \nIntern. Med. 158, 862-867. \n6.- Riggs, K., Spiro, A., 3\nrd, Tucker, K. and Rush, D. (1996) Relations of \nvitamin B-12, vitamin B-6, folate, and homocysteine to cognitive \nperformance in the Normative Aging Study. Am. J. Clin. Nutr. 63, \n306-314. \n7.- Miller, J.W. (1999) Homocysteine and Alzheimer\u2019s disease. Nutr. \nRev. 57,126-129. \n8.- Lehmann, M., Gottfries, C.G. and Regland, B. (1999) Identification of \ncognitive impairment in the elderly: homocysteine is an early \nmarker. Dement. Geriatr. Cogn. Disord. 10, 12-20. \n9.- McCaddon, A., Davies, G., Hudson , P., Tandy, S. and Cattell, H. \n(1998) Total serum homocysteine in  senile dementia of Alzheimer \ntype. Int. J. Geriatr. Psychiatry. 13, 235-239.  \n \n 19810.-Bell, I.R., Edman, J.S., Morrow, F.D., Marby, D.W., Mirages, S., \nPerrone, G., Kayne, H.L. and Cole, J.O. (1991) B complex vitamin patterns in geriatric and young adult inpatients with major \ndepression. J. Am. Geriatr. Soc. 39, 252-257. \n11.-Budge, M., Johnston, C., Hogervorst, E., de Jager, C., Milwain, E., \nIversen, S.D., Barnetson, L., King, E. and Smith, A.D. (2000) Plasma \ntotal homocysteine and cognitive performance in a volunteer elderly  population. Ann. N. Y. Acad. Sci. 903, 407-410. \n12.-Nilsson, K., Gustafson, L. and Hultberg, B. (2000) The plasma \nhomocysteine concentration is better than that of serum \nmethylmalonic acid as a marker fo r sociopsychological performance \nin a psychogeriatric population. Clin. Chem. 46, 691-696. \n13.-Morris, M.S., Jacques, P.F., Rose nberg, I.H. and Selhub, J. (2001) \nHyperhomocysteinemia associated with poor recall in the third \nNational Health and Nutrition Ex amination Survey. Am. J. Clin. \nNutr. 73, 927-933. \n14.-Jensen, E., Dehlin, O., Erfurth, E. -M., Hagberg, B., Samuelsson, G., \nSvensson, T. and Hultberg, B. ( 1998) Plasma homocysteine in 80-\nyear-olds: Relationships to medical, psychological and social variables. Arch. Gerontol. Geriat. 26, 215-226. \n15.-Gonzalez-Gross, M., Marcos, A. and Pietrzik, K. (2001) Nutrition \nand cognitive impairment in the elderly. Br. J. Nutr. 86, 313-321. \n16.-McLean, R.R., Jacques, P.F., Selhub , J., Tucker, K.L., Samelson, E.J., \nBroe, K.E., Hannan, M.T., Cupples, L.A. and Kiel, D.P. (2004) Homocysteine as a predictive factor for hip fracture in older persons. N. Engl. J. Med. 350, 2042-2049. \n17.-Herrmann, M., Widmann, T.  and Herrmann, W. (2005) \nHomocysteine \u2014 a newly recognised  risk factor for osteoporosis. \nClin. Chem. Lab. Med. 43, 1111-1117. \n18.-Cumurcu, T., Sahin, S. and Aydin, E. (2006) Serum homocysteine, \nvitamin B 12 and folic acid levels in different types of glaucoma. B.M.C. Ophthalmol. 6, 6. \n19.-Selhub, J., Jacques, P.F., Wilson , P.W.F., Rush, D. and Rosenberg, \nI.H. (1993) Vitamin status and intake as primary determinants of homocysteinemia in an elderl y population. JAMA. 270, 2693-2698.  \n \n 19920.-Selhub, J., Jacques, P.F., Rosenber g, I.H., Rogers, G., Bowman, B.A., \nGunter, E.W., Wright, J.D. and Johnson, C.L. (1999) Serum total homocysteine concentrations in the third National Health and \nNutrition Examination Survey (1991-1994): population reference \nranges and contribution of vitamin status to high serum concentrations. Ann. Intern. Med. 131, 331-339. \n21.-Kalmijn, S., Launer, L.J., Lindeman s, J., Bots, M.L., Hofman, A. and \nBreteler, M.M. (1999) Total homocyst eine and cognitive decline in a \ncommunity-based sample of elderly subjects: the Rotterdam Study. \nAm. J. Epidemiol. 150, 283-289. \n22.-Ravaglia, G., Forti, P., Maioli, F ., Zanardi, V., Dalmonte, E., Grossi, \nG., Cucinotta, D., Macini, P. And Caldarera, M. (2000) Blood \nhomocysteine and vitamin B levels are not associated with cognitive skills in healthy normally ageing su bjects. J. Nutr. Health. Aging. 4, \n218-222. \n23.-Vrentzos, G.E., Papadakis, J.A., Malliaraki, N., Bampalis, D.E., Repa, \nA., Lemonomichelaki, V., Petinellis, E.G. and Ganotakis, E.S. (2006) \nSerum homocysteine concentration as a marker of nutritional status of healthy subjects in Crete, Gr eece. J. Hum. Nutr. Diet. 19, 117-123. \n24.-Koehler, K.M., Baumgartner, R.N., G arry, P.J., Allen, R.H., Stabler, \nS.P. and Rimm, E.B. (2001) Associat ion of folate intake and serum \nhomocysteine in elderly pe rsons according to vitamin \nsupplementation and alcohol use. Am. J. Clin. Nutr. 73, 628-637. \n25.-Carmel, R., Green, R., Rosenblatt, D.S. and Watkins, D. (2003) \nUpdate on cobalamin, folate, and homocysteine. Hematol. (Am. Soc. \nHematol. Educ. Program), 62-81. \n26.-Jacques, P.F., Selhub, J., Bostom, A.G., Wilson, P.W.F. and \nRosenberg, I.H. (1999) The effect of folic acid fortification on plasma \nfolate and total homocysteine concentrations N. Engl. J. Med. 340, 1449-1454. \n27.-Selhub, J. (2006) The many facets  of hyperhomocysteinemia: studies \nfrom the Framingham cohorts. J. Nutr. 136, 1726S-1730S. \n28.-Gonzalez-Gross, M., Prinz-Langen ohl, R. and Pietrzik, K. (2002) \nFolate status in Germany 1997-2000. In t. J. Vitam. Nutr. Res. 72, 351-\n359.  \n \n 20029.-Morrison, H.I., Schaubel, D., Desm eules, M. and Wigle, D.T. (1996) \nSerum folate and risk of fatal co ronary heart disease. JAMA. 275, \n1893-1896. \n30.-Snowdon, D.A., Tully, C.L., Smith, C.D., Riley, K.P. and \nMarkesbery, W.R. (2000) Serum folate and the severity of atrophy of the neocortex in Alzheimer disease: findings from the Nun study. Am. J. Clin. Nutr. 71, 993-998. \n31.-Seshadri, S., Beiser, A., Selhub, J ., Jacques, P.F., Rosenberg, I.H., \nD\u2019Agostino, R.B., Wilson, P.W.F. and Wolf, P.A. (2002) Plasma \nhomocysteine as a risk factor for dementia and Alzheimer\u2019s disease \nN. Engl. J. Med. 346, 476-483. \n32.-Ramos, M.I., Allen, L.H., Mung as, D.M., Jagust, W.J., Haan, M.N., \nGreen, R. and Miller, J.W. (2005) Low fo late status is associated with \nimpaired cognitive function and dementia in the Sacramento Area Latino Study on Aging. Am. J. Clin. Nutr. 82, 1346-1352. \n33.-Ravaglia, G., Forti, P., Maioli, F., Martelli, M., Servadei, L., Brunetti, \nN.,Porcellini, E. And Licastro, F. (2005) Homocysteine and folate as risk factors for dementia and Alzh eimer disease. Am. J. Clin. Nutr. \n82,636-643. \n34.-McCaddon, A. and Kelly, C.L. (1994) Familial Alzheimer\u2019s disease \nand vitamin B12 deficiency. Age Ageing. 23, 334-337. \n35.-Sola, R., Gonzalez-Gross, M., Pietrzik, K. and Castillo, M.J. (In press) \n\u00bfExiste la necesidad de una detecci\u00f3n precoz del d\u00e9ficit de vitamina B12? Nutr. Hosp. \n36.-Spinneker, A., Sola, R., Lemmen, V., Gonzalez-Gross, M., Castillo, \nM.J. and Pietrzik, K. (In press) Vi tamin B6 status, deficiency and its \nconsequences \u2014 an overview.  \n37.-Folsom, A.R., Nieto, F.J., McGo vern, P.G., Tsai, M.Y., Malinow, \nM.R., Eckfeldt, J.H., Hess, D.L. and Davis, C.E. (1998) Prospective study of coronary heart disease inci dence in relation to fasting total \nhomocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities  (ARIC) study. Circulation. 98, \n204-210.  \n \n 20138.-Robinson, K., Mayer, E.L., Miller, D.P., Green, R., van Lente, F., \nGupta, A., Kottke-Marchant, K., Savon, S.R., Selhub, J., Nissen, S.E. and et al. (1995) Hyperhomocys teinemia and low pyridoxal \nphosphate. Common and independen t reversible risk factors for \ncoronary artery disease. Circulation. 92, 2825-2830. \n39.-Friso, S., Jacques, P.F., Wilson, P.W., Rosenberg, I.H. and Selhub, J. \n(2001) Low circulating vitamin B(6) is associated with elevation of the inflammation marker C-reac tive protein independently of \nplasma homocysteine levels. Circulation. 103, 2788-2791. \n40.-Paulionis, L., Kane, S.L. and Meckling, K.A. (2005) Vitamin status \nand cognitive function in a long-term care population. B.M.C. Geriatr. 5, 16. \n41.-Serra-Majem, L., Ribas Barba, L., Armas Navarro, A., Alvarez Leon, \nE. and Sierra, A. (2000) Ingesta de energ\u00eda y nutrientes y riesgo de \ningesta inadecuada en las Islas Canarias (1997-98). Arch. Latinoam. \nNutr. 50, 7-22. \n42.-Christodoulakos, G., Panoulis, C., Rizos, D., Moustakarias, T., \nPhocas, I. and Creatsas, G. (2001) Homocysteine and folate levels in postmenopausal women. Maturitas 39, 161-167. \n43.-van Wayenburg, C.A., van de Laar, F.A., de Waal, M.W., Okkes, \nI.M., van den Akker, M., van der Veen, W.J., Schellevis, F.G., van \nStaveren, W.A., van Binsbergen, J.J. and van Weel, C. (2005) Nutritional deficiency in Dutch primary care: Data from general \npractice research and registration networks. Eur. J. Clin. Nutr. 59 \nSuppl. 1, 187-194. \n44.-Flood, V.M., Smith, W.T., Webb, K.L., Rochtchina, E., Anderson, \nV.E. and Mitchell, P. (2006) Prevalence of low serum folate and \nvitamin B12 in an older Australian population. Aust. N. Z. J. Public Health. 30, 38-41. \n45.-Wolters, M., Hermann, S. and Hahn, A. (2003) B vitamin status and \nconcentrations of homocysteine and methylmalonic acid in elderly German women. Am. J. Clin. Nutr. 78, 765-772.  \n \n 20246.-Bates, C.J., Pentieva, K.D., Prentice , A., Mansoor, M.A. and Finch, S. \n(1999) Plasma pyridoxal phosphat e and pyridoxic acid and their \nrelationship to plasma homocysteine in a representative sample of \nBritish men and women aged 65 years  and over. Brit. J. Nutr. 81, \n191-201. \n47.-van den Berg, H. (1999) Vitamin B6 status and requirements in older \nadults. Brit. J. Nutr. 81, 175-176. \n48.-Herbert, V. (1998) The elderly n eed oral vitamin B-12. Am. J. Clin. \nNutr. 67, 739-740. \n49.-Schumann, K. (1999) In teractions between drugs and vitamins at \nadvanced age. Int. J. \u001fital. Nutr. Res. 69, 173-178. \n50.-Arjona Mateos, C.R., Criado Vela sco, J. and S\u00e1nchez Sol\u00eds, L. (2002). \nEnfermedades cr\u00f3nicas y consumo de f\u00e1rmacos en mayores de 65 anos. Med. Gen. 47, 684-695. \n51.-Bradford, G.S. and Taylor, C.T.  (1999) Omeprazole and vitamin B12 \ndeficiency. Ann. Pharmacother. 33, 641-643. \n52.-Bates, C.J., Schneede, J., Mishra, G., Prentice, A. and Mansoor, M.A. \n(2003). Relationship between meth ylmalonic acid, homocysteine, \nvitamin B12 intake and status an d socio-economic indices, in a \nsubset of participants in the Br itish National Diet and Nutrition \nSurvey of people aged 65 y and over. Eur. J. Clin. Nutr. 57, 349-357. \n53.-Refsum, H., Smith, A.D., Ueland, P.M., Nexo, E., Clarke, R., \nMcPartlin, J., Johnston, C., Engbaek,  F., Schneede, J., McPartlin, C. \nand Scott, J.M. (2004) Facts and recommendations about total homocysteine determinations: An expert opinion. Clin. Chem. 50, 3-\n32. \n54.-Roe, D.A. (1986) Nutritional assess ment of the elderly. World. Rev. \nNutr. Diet. 48, 85-113. \n55.-Keller, H.E. and Salkeld, R.M. (1988) Bereichswerte von \nAnalysenparametern fuer den Vitaminstatus. G.C.R. B. 106, 334. \n56.-Clarke, R., Refsum, H., Birks, J., Ev ans, J.G., Johnston, C., Sherliker, \nP., Ueland, P.M., Schneede, J., McPartlin, J., Nexo, E. and Scott, J.M. \n(2003) Screening for vitamin B-12 an d folate deficiency in older \npersons. Am. J. Clin. Nutr. 77, 1241-1247.  \n \n 20357.-Herbert, V. (1994) Staging vitamin B-12 (cobalamin) status in \nvegetarians. Am. J. Clin. Nutr. 59, 1213S-1222. \n58.-Wickramasinghe, S.N. and Fida, S. (1993) Correlations between \nholo-transcobalamin II, holo-hapto corrin, and total B12 in serum \nsamples from healthy subjects and patients. J. Clin. Pathol. 46, 537-539. \n59.-Stanger, O., Herrmann, W., Pietrzi k, K., Fowler, B., Geisel, J., \nDierkes, J. and Weger, M. (2003) DACH-LIGA homocystein \n(german, \u001fital\u001fan and swiss homocy steine society): consensus paper \non the rational clinical use of homocysteine, folic acid and B-\nvitamins in cardiovascular and thro mbotic diseases: guidelines and \nrecommendations. Clin. Chem. Lab. Med. 41, 1392-1403. \n60.-Stampfer, M.J., Malinow, M.R., Willett, W.C., Newcomer, L.M., \nUpson, B., Ullmann, D., Tishler, P.V. and Hennekens, C.H. (1992) A prospective study of plasma homocy st(e)ine and risk of myocardial \ninfarction in US physicians. JAMA. 268, 877-881. \n61.-Saw, S.M., Yuan, J.M., Ong, C.N., Arakawa, K., Lee, H.P., Coetzee, \nG.A. and Yu, M.C. (2001) Geneti c, dietary, and other lifestyle \ndeterminants of plasma homocysteine concentrations in middle-aged and older Chinese men and women in Singapore. Am. J. Clin. \nNutr. 73, 232-239. \n62.-Ortega, R.M., Jimenez, A., Andres, P., Faci, M., Lolo, J.M., Lozano, \nM.C., Bermejo, L.M., Lopez-Sobaler, A.M. and Requejo, A.M. (2002) Homocysteine levels in elderly Spanish people: influence of pyridoxine, vitamin B12 and folic acid intakes. J. Nutr. Health. Aging. 6, 69-71. \n63.-Henning, B.F., Tepel, M., Riezler, R. and Naurath, H.J. (2001) Long-\nterm effects of vitamin B(12), fola te, and vitamin B(6) supplements \nin elderly people with normal se rum vitamin B(12) concentrations. \nGeront. 47, 30-35. \n64.-Jacques, P.F., Bostom, A.G., Wilson, P.W., Rich, S., Rosenberg, I.H. \nand Selhub, J. (2001) Determinants  of plasma total homocysteine \nconcentration in the Framingham Offspring cohort. Am. J. Clin. \nNutr. 73, 613-621.  \n \n 20465.-Chen, K.J., Pan, W.H., Yang, F.L., Wei, I.L., Shaw, N.S. and Lin, B.F. \n(2005) Association of B vitamins status and homocysteine levels in elderly Taiwanese. Asia. Pac. J. Clin. Nutr. 14, 250-255. \n66.-Lindenbaum, J., Rosenberg, I., Wils on, P., Stabler, S. and Allen, R. \n(1994) Prevalence of cobalamin deficiency in the Framingham elderly population. Am. J. Clin. Nutr. 60, 2-11. \n67.-Clarke, R. and Collins, R. (1998) Can dietary supplements with folic \nacid or vitamin B6 reduce cardio vascular risk? Design of clinical \ntrials to test the homocysteine hypothesis of vascular disease. J. \nCardio. Risk. 5, 249-255. \n68.-Arnesen, E., Refsum, H., Bonaa, K. H., Ueland, P.M., Forde, O.H. and \nNordrehaug, J.E. (1995) Serum to tal homocysteine and coronary \nheart disease. Int. J. Epidemiol. 24, 704-709. \n69.-Homocysteine Studies Collaboration (2002) Homocysteine and risk \nof ischemic heart disease and stroke: A meta-analysis JAMA. 288, \n2015-2022. \n70.-Tucker, K.L., Qiao, N., Scott, T., Rosenberg, I. and Spiro, A., 3\nrd \n(2005) High homocysteine and lo w B vitamins predict cognitive \ndecline in aging men: the Veterans  Affairs Normative Aging Study. \nAm. J. Clin. Nutr. 82, 627-635. \n71.-Guttormsen, A.B., Schneede, J., Ueland, P.M. and Refsum, H. (1996) \nKinetics of total plasma homocysteine in subjects with hyperhomocysteinemia due to folate or cobalamin deficiency. Am. J. Clin. Nutr. 63, 194-202. \n72.-Pietrzik, K. and Bronstrup, A. (1997) Causes and consequences of \nhyperhomocyst(e)inemia. Int. J. Vitam. Nutr. Res. 67, 389-395. \n73.-Baik, H.W. and Russell, R.M. (1999) Vitamin B12 deficiency in the \nelderly. Ann. Rev. Nutr. 19, 357-377. \n74.-Tawakol, A., Omland, T., Gerhard, M., Wu, J.T. and Creager, M.A. \n(1997) Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation  in humans. Circulation. 95, \n1119-1121. \n75.-Selhub, J., Bagley, L.C., Miller, J. and Rosenberg, I.H. (2000) B \nvitamins, homocysteine, and neurocog nitive function in the elderly. \nAm. J. Clin. Nutr. 71, 614S-620S.  \n \n 20576.-Bjorkegren, K. and Svardsudd, K. (2001) Serum cobalamin, folate, \nmethylmalonic acid and total ho mocysteine as vitamin B12 and \nfolate tissue deficiency markers amongst elderly Swedes \u2014 a \npopulation-based study. J. Intern. Med. 249, 423-432. \n77.-Bronstrup, A., Hages, M. and Pietrzik, K. (1999) Lowering of \nhomocysteine concentrations in elderly men and women. Int. J. \nVitam. Nutr. Res. 69, 187-193. \n78.-Joosten, E., van den Berg, A., Ri ezler, R., Naurath, H., Lindenbaum, \nJ., Stabler, S. and Allen, R. (1993) Metabolic evidence that \ndeficiencies of vitamin B-12 (cob alamin), folate, and vitamin B-6 \noccur commonly in elderly peop le. Am. J. Clin. Nutr. 58, 468-476. \n79.-Stabler, S.P. (2000) B12 and nutrition. In: Biochemistry and \nbiochemistry of B12 (Banerjee, R., ed.) pp. 343-365, John Wiley and Sons, New York. \n80.-Carmel, R. (2000) Current concepts in cobalamin deficiency. Annu. \nRev. Med. 51, 357-375. \n81.-Lindenbaum, J. and Allen, R.H.  (1995) Clinical spectrum and \ndiagnosis of folate deficiency. In : Folate in health and disease \n(Bailey, L.B., ed.) pp. 43-73, Marcel Dekker, New York. \n82.-Nexo, E., Christensen, A.-L., Hvas, A.-M., Petersen, T.E. and \nFedosov, S.N. (2002) Quantification of holo-transcobalamin, a \nmarker of vitamin B12 defi ciency. Clin. Chem. 48, 561-562. \n83.-Herzlich, B. and Herbert, V. (1988) Depletion of Serum \nHolotranscobalamin-Ii \u2014 an early sign of negative vitamin-B12 balance. Lab. Invest. 58, 332-337. \n84.-Lindenbaum, J., Savage, D.G., Stabler, S.P. and Allen, R.H. (1990) \nDiagnosis of cobalamin deficiency: II. Relative sensitivities of serum \ncobalamin, methylmalonic acid, and total homocysteine concentrations. Am. J. Hematol. 34, 99-107. \n85.-van Asselt, D.Z., de Groot, L.C., van Staveren, W.A., Blom, H.J., \nWevers, R.A., Biemond, I. and Hoefnagels, W.H. (1998) Role of \ncobalamin intake and atrophic gastri tis in mild cobalamin deficiency \nin older Dutch subjects. Am. J. Clin. Nutr. 68, 328-334. \n  \n \n   \n  \n \n     \n \n     \n \n    \n \n     \n \n     \n \n  \n \n \nDIAGN\u00d3STICO PRECOZ DE LA DEFICIENCIA DE B\n12 \n  \n \n 207Diagnostic scheme for the e arly diagnosis of vitamin B 12 deficiency in \nelderly people. \nSola R(1,2) Gonz\u00e1lez-Gross M(1,3,4), B arrios L(5), Pietrzik K(4), Castillo \nMJ(1). \n(1) Grupo EFFECTS 262. Dpto. Fisiolog\u00eda , Facultad de Medicina, Universidad \nde Granada, Spain. \n(2) Servicio de Hematolog\u00eda. Hospit al Cl\u00ednico Universitario San Cecilio, \nGranada. Spain. \n(3)Facultad de Ciencias de la Activi dad F\u00edsica y del Deporte. Universidad \nPolit\u00e9cnica de Madrid. Spain. \n(4) Institut f\u00fcr Ern\u00e4hrungs-und Lebens mittelwissenschaften. Pathophysiologie. \nRheinische Friedrich-Wilhelms -Universit\u00e4t. Bonn. Germany. \n(5) Centro T\u00e9cnico de Inform\u00e1tica. CSIC. Spain. \n  \n \n \u001fital for correspondence: Prof. Dr. Marcela Gonzalez-Gross Facultad de CC de la Actividad F\u00edsica y del Deporte. Universidad \nPolit\u00e9cnica de Madrid. c/ Mart\u00edn Fierro s/nE-28040 Madrid \nTel.: +34 91 336 4006Fax: +34 91 5497307 e-mail: marcela.gonzalez.gross@upm.es\n \n  *Project granted by the Spanish Mini stry of Health, Instituto de Salud \nCarlos III (FIS PI021830). Axis-Shield (Oslo, Norway) has kindly \nprovided the Holo-TC RIA reagent kit.  We want to thank Ms R Arcas, \nMs P Carazo, Ms R Perez and Dr Edward Valente for their collaboration in this study. \n  \n \n 208Summary:  \nBackground:  The elderly population is particularly at risk for \ndeveloping vitamin B 12-deficiency. Sensitive methods for early detection \nof vitamin B 12-deficiency are not common in the routine laboratory. \nNormal serum cobalamin (SCbl) does not necessarily reflect a normal B 12 \nstatus. The determination of meth yl malonic acid (MMA) is very \nexpensive and not routinely possible. Holotranscobalamin II (Holo-TC), the fraction of functional vitamin B\n12, has been proposed as a more \nsensitive B 12 status indicator. The aim of the present study is to establish \na diagnostic scheme (DiagS) which incl udes these variables taking into \naccount both clinical and economical criteria.  \nMaterial and Methods : Two-hundred and eighteen elderly of both \nsexes, aged 60-105, living in an Elde rly Home in Granada (Spain), were \nscreened for SCbl (Abbott, Imx), Holo-TC (HoloTC RIA, Axis-Shield, MMA (MS-GC),serum folate, red blood cell (RBC) folate, and tHcy \n(Abbott, Imx), which were the variables chosen based on clinical criteria. \nSeveral segmentation algorithms wer e drawn and analysed using SPSS \n13.0 for Windows. \nResults : From the initially four decision trees, two were analysed \nfurther after comparing the diagnosis with the clinical diagnosis made \nby the physician (haematologist). SCbl and tHcy were completely \nexcluded from the model. DiagS 3 identified 19.05% isolated B\n12 \ndeficiency, 39.5% combined B 12/folate deficiency, 27.14% isolated folate \ndeficiency and 14.3% as being normal. In DiagS 4 the respective values \nwere 19.9%, 24.17%, 42.38% and 22.75%. \nIn both DiagS, mean levels of all parameter are statistically different \nbetween the 4 outcome groups. SCbl and Holo TC levels were lowest \nand MMA levels highest in the combined deficiency group in both DiagSs. Serum folate was lowest in the isolated folate deficiency group, \nwhereas RBC folate was lowest in the combined deficiency group. Thcy \nwas highest in the combined deficiency group. \nConclusion : The proposed DiagSs which eliminate SCbl and start the \nscreening with Holo-TC after establishing  folate status seem to be more \nprecise in detecting functional vitamin B\n12 deficiency and the combined \nfolate/B 12 deficiency in institutionalized elderly. Which of both proposed \nDiagSs is more precise must be  stated in further analysis.  \n  \n \n 209Introduction  \n \nIn developed countries, clinical vitamin deficiency has mostly \ndisappeared and only affects marginal  population groups. May be the \nonly exception in this si tuation is for vitamin B 12, which clinical \ndeficiency, the megaloblastic anemia, affects about 5% of the elderly people (Baessler et al. 2002) in Europe, USA (SEVERAL REF). Also at risk for clinical vitamin B\n12 deficiency are vegetarians, the more strict \nvegetarians the more the risk (K rajcovicova-Kudlackova et al. 2000), \npeople suffering from gastritis and chronic consumers of  medication for \nthis pathology, like H2 pump inhibitors (Bradford and Taylor, 1999; Schumann, 1999; Arjona et al. 2002). Subclinical deficiency is quite more prevalent, especially in the elderly (Asselt et al. 1998; Bjorkegren & Svardsudd, 2001; Bates, 2003; Allen, 2004). In the literature there are data ranging from 6 to 40%, but as there is no accepted method for a \nvalid diagnosis of subclinical vitamin B\n12 deficiency, these data have to \nbe taken with caution. In the gene ral population, the most prevalent \nvitamin deficiency is for folate that affects both sexes and all age groups \n(Baessler et al, 2002; Koletzko & Piet rzik, 2004). This means that in the \nelderly people, folate and vitamin B 12 deficiency come together. In fact, \nthe combined folate/vitamin B 12 deficiency was supposed to be present \nin up to 63% of the healthy elderly subjects and up to 83% in elderly \nhospitalized patients in the study do ne by Joosten et al. (1993). As both \nvitamin deficiencies lead to the de velopment of megaloblastic anemia \nand the clinical diagnosis based on the identification of the hypersegmentation of the nucleus of neutrophiles is common to both \ndeficiencies, it is not possible to diffe rentiate by this method if there is \nan isolated vitamin B\n12 or isolated folate deficiency or a combined \ndeficiency (Herbert & Das, 1994), beside s that it appears at a later stage. \nBut early diagnosis is decisive, as neurologic symptoms due to vitamin \nB12 deficiency at an advanced stat e are irreversible. Therefore, the \nscientific community is searching for a better diagnostic method, which \ncould be used in the routine clin ical laboratory, considering also \neconomical aspects. Normal se rum cobalamin (SCbl) does not \nnecessarily reflect a normal B 12 status. In several articles, methylmalonic \nacid (MMA) has been proposed as an  alternative diagnostic method for \nvitamin B 12 deficiency. More recently, Holotranscobalamin (Holo TC) \nhas been presented to afford superior diagnostic specificity because it \nconstitutes the biologically functional vitamin B 12 fraction. Total  \n \n 210homocysteine (tHcy) has been cite d as a marker for blood B vitamin \nlevels. Arguments will be discussed further in this article, but all in all, analysing the available literature, it seems that no single parameter will \nallow early identification of vitamin B\n12 deficiency. Therefore, the main \nobjective of our study was to estab lish a diagnostic scheme in order to \ntry to facilitate early diagnosis and to differentiate between isolated folate, isolated B\n12 and combined B 12/folate deficiency. For this aim, we \nhave used several B 12-related parameters measured in Spanish \ninstitutionalized elderly among who there was a high prevalence of \nvitamin B deficiency (Sola et al. 2006, in press). \n \nMaterial and methods : \n \nStudy design This study is part of a cross-sectio nal study that aims to establish the \nvitamin B status of Spanish institutio nalized elderly, with special regard \nto vitamin B\n12 and folate in association wi th homocysteine. It has been \nsupported by a grant from the Fondo de Investigaci\u00f3n Sanitaria of the Instituto de Salud Carlos III (Spanish Ministry of Health, FIS PI021830). Briefly, this study includes nutritional assessment by means of the Mini \nNutritional Assessment (Guigoz and He llas, 1996), cognitive analysis by \nmeans of the Mini Mental State (Fol stein, 1975) and haematological and \nbiochemical data. For this work, from all the analysed variables in the blood, those which are related directly to B\n12 and folate metabolism were \nselected, based on clinical criteria an d correlation coefficients (Sola et al, \n2006, in press). These are: SCbl, Holo-T C, tHcy, serum folate, red blood \ncell (RBC) folate, and MMA. Morphologic data (lobe average, rule of \nfives, mean corpuscular volume) wer e excluded from the diagnostic \nschemes, because they are not includ ed in the routine praxis of the \nlaboratories, but were analysed afterwards for the several outcomes.  \n Subjects \nTwo-hundred and eighteen elderly of both sexes (82 males, 136 \nfemales) aged 60-105 (mean age 79.23\u00b18.43 years), living in an Elderly\u00b4s Home in Granada, Spain, were recrui ted for the study. The residents \nwho took part in the study were all el derly living at the residence. They  \n \n 211were not taking any vitamin supplement. Anamnesis and blood \nsampling were included in the biannual medical review that is performed in all the elderly living  in the residence. There were no \nexclusion criteria. None of the vo lunteers presented any problem that \nwould have justified their exclusio n from the study. The study was \napproved by the Human Research Re view Committee of the University \nof Granada, School of Medicine.  The study has been performed \nfollowing the ethic norms of the Declaration of Helsinki (revision of Edinburgh 2000), Convention of Oviedo, the Good Clinical Practice of \nthe CEE (document 111/3976/88 July 1990)  and the Spanish legislation \nabout clinical research in humans (Real Decreto 561/1993 sobre ensayos cl\u00ednicos). \n \nBlood sampling \nAfter an overnight fast, blood samples were drawn between 8:00 \nand 10:00 h in the morning. Followi ng venipuncture, 3ml of EDTA-\ntreated blood was analysed within an hour. Two 8 ml vacutainers with gel for serum were put on ice immediately and centrifuged within one hour at 2000 x g and 4\u00b0C for 10 min. Following centrifugation they were aliquoted and immediately frozen at -80\u00baC.  \n \nAnalytical methods \nHematologic and biochemical data were collected with the use of \nstandard methods. Hypersegmentatio n of the neutrophylic granulozytes \nwas analysed as lobe average and according to the rule of five (Herbert and Colman, 1988). Serum tHcy was me asured by a totally automated \nfluorescence polarisation immunoa ssay (FPIA; Imx tHcy Kit, Abbot \nDiagnostic, Abbot Park, IL, USA). Se rum folate, RBC folate, and serum \ncobalamin levels were measured by us ing the flourometric method with \nan Abbot Imx autoanalyser (Abbot Laboratory, Chicago, USA). Holo-TC levels were measured by a radioimmunoassay (HoloTC RIA) provided by Axis-Shield (Oslo, Norway). AMM was analysed by MS-GC. \n \nStatistical analyses \nNo statistical significant differences (p>0.05) were found between \nsexes; therefore, all data for both men and women were analysed  \n \n 212together. As not all the variables fo llowed a normal distribution after \nusing the Kolmogorov-Smirnov test, natural log-transformed data were used for calculating Pearson\u2019s correla tions coefficients. These are shown \nin Table 1 for the variables incl uded in the further analyses.  \nThe complete set of data was available for 210 subjects. Several \nsegmentation algorithms were drawn and analysed based on the before-\nmentioned variables. The diagnost ic outcome was divided into 4 \npossible groups: 1) Isolated B\n12 deficiency. 2) Combined B 12-folate \ndeficiency. 3) Isolated folate deficiency. 4) Normal.  \n  For all the variables, categories were established using current \nreference values for vitamin status (Roe, 1986; Keller and Salkeld, 1988) and professional experience of the authors. That is: for SCbl \u2264 200 pg/ml \ninadequate and > 200 pg/ml adequate; for Holo-TC \u2264 45 pmol/L \ninadequate and > 45 pmol/L adequate; for tHcy > 12 \u00b5mol/L inadequate and \u2264 12 \u00b5mol/l adequate; for serum folate ( \u2264 7 ng/ml inadequate and > 7 \nng/ml adequate; for RBC folate \u2264 175 ng/ml inadequate and >175 ng/ml \nadequate; for AMM \u2265300 nmol/l inadequate and < 300 nmol/l adequate.  \nFour hierarchical step-by-step classification proposals were \ndeveloped (Figures 1-4). Variable s were chosen following clinical \ncriteria, and the cut-off points used to determine normality or deficiency \nwere those mentioned before.  \nAs both serum folate and RBC fo late were confounders in these \nprocesses, it was decided that the si tuation related to folate had to be \nidentified first. Therefore, in all four  alternative decision trees the folate \nstatus was first identified. The four proposals were formulated \norganizing the before-mentioned parameters in different order. \nDiagnostic Scheme (DiagS) 1 (Figure 1) started with SCbl and included \n14 possible outcomes of diagnosis. From these outcomes, 10 diagnose a \nvitamin B\n12 deficiency (from these, five an isolated B 12 deficiency (in \nyellow) and five combined with fola te deficiency (in orange)). DiagS 2 \n(Figure 2) started with analysis of  tHcy and than with Holo-TC and \nincluded 12 possible outcomes of diagnosis. From these outcomes, 8 \ndiagnose a vitamin B 12 deficiency (four an isolated B 12 deficiency (in \nyellow) and four a combined deficiency (in orange).  \nDiagS 3 (Figure 3) started with  the analysis of Holo-TC and \nincluded 6 possible outcomes. From these outcomes, two diagnose an  \n \n 213isolated B 12 deficiency, two a combined de ficiency and one an isolated \nfolate deficiency (in green). \nDiagS 4 (Figure 4) included a change in the classification \nmethodology, because at the second level of the decision tree, cut-off \npoints for Holo-TC were redefined us ing intervals (< 40, between 40 and \n50, and \u226550), considering the interval bet ween 40 and 50 pmol/l as a grey \nzone.  \nAlthough they are different classification proposals, \nDiagS1,DiagS2 and DiagS3 give the same results in 98% of the cases \nafter performing cross tabulation. Therefore, and taking into account \nthat DiagS3 is the most simple one because it includes only 3 variables, it is proposed as the optimal one within this group and compared to DiagS4. \nIn order to decide which of the decision trees is the most \nadequate one, results were studied statistically by means of: a) \nDescriptive analysis. Means, disp ersion measurements, maximum and \nminimum and confidence intervals, in order to establish if each of the \nproposed groups behaves separately in each variable as expected due to \nit\u2019s diagnostic classification. B) Box-Jenkins graphs. By means of box \nplots, behaviour patterns can be observed for each variable in all the \ngroups and within a group. For the within-a-group analysis, variables \nhave been standardized dividing them  by the maximum. C) Analysis of \nthe variance in order to assign statistical significance to the analysis performed in A and B. Test for the ho mogeneity of variance, robust tests \nfor differences of means and multiple comparisons.  \nAll these analysis have been performed for DiagS 3 and 4. The \nbest classifying process will be th at one where the groups are best \ndefined in all its variables and also present higher statistical differences. As an additional criterion, DiagS3  and 4 have been compared to the \nclinical diagnosis made by the phys ician (haematologist) after studying \nall the subjects one by one.  \nStatistical analyses were performed using the SPSS statistical \nsoftware (version 13.0 for Windows XP; SPSS Inc, Chicago).   \n \n 214Results \nFollowing DiagS 3 (Figure 3), 24 subj ects were identified with an \nisolated B 12 deficiency (outcome 1) and 55 with a combined B 12 \ndeficiency (outcome 4). With the posterior MMA analysis, 15 (outcome \n2) and 28 (outcome 5) subjects, resp ectively, could be identified. This \nmeans that if the only diagnostic cr iterion would have been the analysis \nof Holo-TC levels, 43 subjects would not have been identified as being \ndeficient.  \nFollowing DiagS 4 (Figure 4), Ho lo-TC analysis identified 21 \nsubjects with an isolated B 12 deficiency (outcome 1) . In the grey zone, the \nMMA analysis identified 3 more cases (outcome 2). In the combined folate- B\n12 deficiency (outcome 5), the an alysis of Holo-TC identified 42 \nsubjects. In the grey zone, the MMA analysis identified 9 more cases \n(outcome 6). This means that if th e MMA analysis would have not been \nperformed, 12 subjects would not have been identified as being \ndeficient.  \nTaken together, DiagS 3 identified 19.05% isolated B 12 deficiency, \n39.5% combined B 12/folate deficiency, 27.14% isolated folate deficiency \nand 14.3% as being normal. In DiagS 4 the respective values were 19.9%, \n24.17%, 42.38% and 22.75%. \nIn both DiagSs, mean levels of all parameter are statistically \ndifferent between the 4 outcome groups  (Tables 2 and 3). SCbl and Holo \nTC levels were lowest and MMA levels highest in the combined deficiency group in both DiagSs. Seru m folate was lowest in the isolated \nfolate deficiency group, whereas RB C folate was lowest in the combined \ndeficiency group. Thcy was highest in the combined deficiency group. \nIn order to be able to discuss wh ich of the DiagSs could be more \nfeasible, data are analysed in several ways. All the parameters have been standardized in order to be comparab le and are shown in Figures 5 and \n6. Median RBC folate levels are higher in isolated B\n12 deficiency in DiagS \n3 (Figure 3a) than in DiagS 4 (Figur e 4a). In the rest of the outcomes, \nlevels and patterns are very similar.  \nIn Tables 7 and 8, descriptive variables for selected \nhaematological data are presented. Statistically significant differences \nbetween outcome groups were only for the lobe average in both DiagSs. \nThe mean values for lobe averag e are shown in Figures 7 and 8. \nComparing both DiagS, mean valu es of combined deficiency and  \n \n 215isolated folate deficiency are closer in DiagS 3 than in DiagS4. In DiagS \n3, mean lobe average value in the normal group is higher than that in the isolated B\n12 deficiency group. For the rest of the variables, mean \nvalues are similar in the outcomes of both DiagSs. \n \nDiscussion \nAs has been stated before, especially  in the elderly, there is a need \nto detect at the initial phase vitamin B 12 deficiency, because they are at a \ngreater risk for functional B 12 deficiency. The clinical presentation of \nvitamin B 12 deficiency varies considerably and rarely includes all the \nclassic features, such as macrocytic  anemia, peripheral neuropathy and \nsub-acute combined degeneration of  the spinal cord (Carmel, 2000). \nMore typically, vitamin B 12 deficiency presents as non-specific \nsymptoms fatigue, lassitude, malaise,  vertigo, and cognitive impairment \nthat could be attributed to old age and should be avoided by means of \nearly detection. Moreover, the clinical severity of vitamin B 12 deficiency \nis often unrelated to SCbl concentrat ions. This has been demonstrated in \nDiagS1, as 92 subjects from our samp le would not have been diagnosed \nif the only diagnostic criterion would have been SCbl levels. This is also \nconfirmed in DiagS 3 and 4, as mean SCbl levels in all 4 outcomes of \nboth diagnostic schemes are above 200 pg/ml, the cut-off used in several \npublications in the literature (C hanarin, 1979). This means, that \nfunctional deficiency occurs even in people whose SCbl levels are in the \nnormal (ie reference) range. In the isolated vitamin B 12 deficiency group \nof DiagS 3, mean SCbl levels are ev en above 300 pg/ml, the cut-off used \nby Pennypacker et al. (1992) studying geriatric patients in Denver. \nConcerns about the limitations of standard vitamin B 12 assays \nhave been stated before (Carmel, 2000; Stabler, 2000). Holo-TC has been proposed in the literature as a more sensitive parameter (Wickramasinghe et al, 1993; Nexo et al, 2002; Herzlich et al, 1988; \nLindenbaum et al, 1990; Hvas & Nexo, 2005). Mean Holo TC levels are below 35 pmol/l in the isolated B\n12 and in the combined deficiency group \nin DiagS4 (Table 3). The cut-off of  35 pmol/l has been proposed by \nseveral authors (Hermann et al, 2003). In fact, we found a strong \ncorrelation (r= 0.656; p<0.01) between Holo-TC and SCbl.  \n  \n \n 216DiagS3 is more related to the diagnosis made by the \nhaematologist when comparing the resu lts by crosstabulation (Table 5). \nThe haematologist included SCbl levels and tHcy levels for his \ndiagnosis. This could explain some of the differences found with the \nclassifying processes. But analysing haematological data, DiagS4 gives \nbetter results than DiagS3, especially  for the lobe average, which could \nbe an indicator for the initial phase of megaloblastic anaemia. In several \npublications in the literature, no relationship has been found between \nhaematological and biochemical data in elderly when analysing vitamin \nB12 status. So, this fact needs further analysis. \nThe clinical-economical advantage of DiagS 4 is that less MMA \nanalysis have to be performed. MMA analysis is very expensive and the \nMS-GC method is complicated and not possible in the routine laboratory. There are several other physiological/pathological conditions where MMA is elevated, not only in B\n12 deficiency. Furthermore, in the \n93 subjects with MMA \u2265300 pmol/l, mean SCbl levels were 317.24\u00b1228 \npg/ml and mean Holo TC levels were 54.63\u00b146.3 pmol/l. The advantage of Holo TC is that is specific for cobalamin metabolism and that the \nanalysis can be performed in the routine laboratory. Mean tHcy levels were 17.9\u00b16.66 \u00b5mol/l. MMA and Holo TC  have a highly significant \ncorrelation (r=0.500; p<0.01) (Table 1). \nThe advantage of the diagnostic schemes proposed in this paper \nis that they permit not only to iden tify subclinical deficiencies, but also \nto distinguish between isolated B\n12, isolated folate or combined B 12/folate \ndeficiency. This diagnosis is import ant for the therapeutic treatment. \nThe serum concentrations of the vitamins taken by their own can not \ngive such specific information. On the other hand, as adequate cut-off \npoints for blood parameters are still controversial, the decision tree seems to be a more adequate  identification method.  \nWhich of the decision trees is the most adequate one must to be \nanalysed further with more data. Perha ps it would be necessary to study \na group of elderly in which B12 defici ency is not so highly prevalent. \nBut in the meantime, using one of th e DiagS seems to be more adequate \nthan analysing data separately.   \n \n 217 \nReferences  \nArjona Mateos, C.R., Criado Velasco, J. and S\u00e1nchez Sol\u00eds, L. (2002) \nEnfermedades cr\u00f3nicas y consumo de f\u00e1rmacos en mayores de 65 anos. \nMed. Gen. 47, 684-695. \nAllen LH. Folate and vitamin B12 status in the Americas. Nutr Rev \n2004;62(6 Pt 2):S29-33. \nB\u00e4ssler KH, Golly I, Loew K, Pietrzik K. Vitamin-Lexikon. Govi Verlag, \nFrankfurt-Main. 2002. \nBates, C.J., Schneede, J., Mishra, G ., Prentice, A., Mansoor, M.A. (2003) \nRelationship between methylmaloni c acid, homocysteine, vitamin B12 \nintake and status and socio-economic in dices, in a subset of participants \nin the British National Diet and Nutr ition Survey of people aged 65 and \nolder. Eur J Clin Nutr 57, 349-357. \nBjorkegren, K., Svardsudd, K. (2001) Serum cobalamin, folate, \nmethylmalonic acid and totoal homocysteine as vitamin B\n12 and folate \ndeficiency markers amongst elderl y Swedes \u2013 a population-based \nintervention study. J. Intern. Med. 246, 317- 324. \nBradford, G.S. and Taylor, C.T. (1999) Omeprazole and vitamin B12 \ndeficiency. Ann. Pharmacother. 33, 641-643. \nCarmel, R. (2000) Current concepts in cobalamin deficiency. Annu Rev \nMed 51, 357-375. \nChanarin I. The Megaloblastic Anaemias . 2nd ed. Oxford, England. \nBlackwell Scientific Publishers:1979. \nFolstein MF, Folstein SE, McHugh PR . \u201cMini-mental state\u201d. A practical \nmethod for grading the cognitive stat e of patients for the clinician. J \nPsychiatr Res 1975;12(3):189-98. \nGuigoz Y, Vellas B, Garry PJ. Assess ing the nutritional status of the \nelderly: The Mini Nutritional Asse ssment as part of the geriatric \nevaluation. Nutr Rev 1996;54(1 Pt 2):S59-65. \nHerbert VD, Colman N. Folic acid and vitamin B12. In: ME Shils, JA \nOlson, M Shike, eds. Modern Nutrition in Health and Disease. 7th \nedition. Malvern, PA: Lea & Febiger, 1988, pp 388-416.  \n \n 218 Herbert V, Das KC. Folic acid and vitamin B12. En: ME Shils, JA Olson, \nM Shike, eds. Modern Nutrition in Health and Disease. 8th edition. \nMalvern, PA: Lea & Febiger, 1994, pp 402-425. \nHermann W, Obeid R, Schorr H, Geisel J. Functional vitamin B12 \ndeficiency and determination of holo transcobalamin in populations at \nrisk. Clin Chem Lab Med 2003; 41:1478-88. \nHerzlich B, Herbert V. Depletion of serum holotranscobalamin II. An \nearly sign of negative vitamin B 12 balance. Lab Investig 1988;58:332-337. \nHvas AM, Nexo E. Holotranscobalamin\u2014a  first choice assay for diagnosing \nearly vitamin B deficiency? J Intern Med. 2005;257(3):289-98.  \nKeller HE, Salkeld RM. Bereichswerte von Analysenparametern fuer \nden Vitaminstatus. GCR 1988; 106:334. \nKoletzko B, Pietrzik K: Gesundheitliche Bedeutung der Fols\u00e4urezufuhr. \nDeutsches \u00c4rzteblatt 2004; 101:A1670-1681.  \nKrajcovicova-Kudlackova M, Blazicek P, Kopcova J, Bederova A, \nBabinska K. Homocysteine levels in  vegetarians versus omnivores. Ann \nNutr Metab 2000;44(3):135-8. \nJoosten, E., van den Berg, A., Riezle r, R., Naurath, H.J., Lindenbaum, J., \nStabler, S.P., Allen, R.H. (1993) Metabolic evidence that deficiencies of vitamin B\n12 (cobalamin), folate and vitamin B 6 occur commonly in \nelderly people. Am J. Clin. Nutr. 58, 468-476. \nLindenbaum J, Savage DG, Stabler SP, et al. Diagnosis of cobalamin \ndeficiency. II: relative sensitivities of serum cobalamin, methylmalonic \nacid, and total homocysteine concentrations. Am J Hematol 1990;34:99-107.  \nNexo E, Christensen AL, Hvas AM, Petersen TE, Fedosov SN. \nQuantification of holo-transcobalamin, a marker of vitamin B\n12 \ndeficiency. Clin Chem 2002;48:561-562. Pennypacker LC, Allen RH, \nKelly JP, Mathews LM, Grigsby J, Kaye K, Lindenbaum J, Stabler SP. \nHigh prevalence of cobalamin defici ency in elderly outpatients. J Am \nGeriatr Soc 1992; 40(12): 1197-204. \nRoe DA. Nutritional assessment of the elderly. World Rev Nutr Diet \n1986;48:85-113. \nSchumann, K. (1999) Interactions between drugs and vitamins at \nadvanced age. Int. J. \u001fital. Nutr. Res. 69, 173-178.  \n \n 219Sola R, Gonzalez-Gross M, Albers U,  Barrios L, Alder M, Pietrzik K, \nCastillo MJ. B-Vitamins and Homocysteine in Spanish institutionalized elderly. Int J Vit Nutr Res (in press) \nStabler, S.P. (2000) B\n12 and nutrition. In:  Banerjee R, ed. Chemistry and \nbiochemistry of B 12. New York: john Wiley and Sons, 2000, pp 343-65. \nVan Asselt, D.Z., de Groot, L.C., van Staveren, W.A., Blom, H.J., Wevers, \nR.A., Biemond, I., Hoefnagels, W.H. ( 1998) Role of cobalamin intake and \natrophic gastritis in mild cobalamin deficiency in older Dutch subjects. \nAm J Clin Nutr 68, 328-334. \nWickramasinghe SN, Fida S. Correla tions between holotranscobalamin \nII, holo-haptocorrin, and total B 12 in serum samples from healthy \nsubjects and patients. J Clin Pathol 1993;46:537-539. \n \n  \n \n  \n  \n \n     \n \n     \n \n    \n \n     \n \n     \n \n    \n \nMTHFR \n  \n 221EFECTO DEL POLIMORFISMO DE LA MTHFR EN EL DEFICIT DE \nFOLATOS E HIPERHOMOCISTEINEMIA EN ANCIANOS \nINSTITUCIONALIZADOS. \nRicardo Sola\n1.3, Marcela Gonzalez-Gross2.3.4, Jonatan R Ruiz3, Miguel \nGarc\u00eda-Fuentes, Laura Barrios, Klaus Pietrzik4, Manuel J Castillo3 \n1Servicio de Hematolog\u00eda. Hospital Cl\u00ednico San Cecilio. Granada. Spain \n2Facultad de Ciencias de la Actividad F\u00edsica y del Deporte, Universidad \nPolit\u00e9cnica de Madrid. Spain. \n3Grupo Effects 262. Facultad de Medicina. Universidad de Granada. Spain \n4Institut f\u00fcr Ern\u00e4hrungs- und Lebensmittelwissenschaften - \nErn\u00e4hrungsphysiologie. Rheinische Friedrich-Wilhelms Universit\u00e4t. \nGermany. \n \nIntroducci\u00f3n: \n \nEl folato es un cofactor esencial  en la s\u00edntesis de ADN y en las \nreacciones de metilaci\u00f3n dando lugar en caso de d\u00e9ficit a hiperhomocisteinemia. Los niveles inadecuados de folato, se asocian con un amplio espectro de entidades c l\u00ednicas que comprenden alteraciones \nhematol\u00f3gicas, anemia megalobl\u00e1stica, asociada o no a leucopenia y/o \ntrombopenia e hipersegmentaci\u00f3n neut r\u00f3fila, estomatitis o glositis y \nmanifestaciones neurol\u00f3gicas y deterioro cognitivo\n 1. \nEn los \u00faltimos a\u00f1os, su deficiencia debido a la \nhiperhomocisteinemia que provoca pare ce estar asociada con el desarrollo \nde enfermedades cardiovasculares2,3,4, defectos del tubo neural5, \ncomplicaciones en el embarazo6, enfermedad de Alzheimer 7, fracturas 8 y \nde ciertas neoplasias 9.  \nEl folato s\u00e9rico (FS) y el folato in traeritrocitario (FE), son indicadores \nde los niveles de esta vitamina. El  \u00faltimo refleja la concentraci\u00f3n y \nsuministro a largo plazo, mientras que el FS est\u00e1 directamente relacionado \ncon la ingesta reciente. El FE es capt ado por los eritrocitos en desarrollo de \nla m\u00e9dula \u00f3sea y circula en la sangre durante los ciento veinte d\u00edas de vida \nde la c\u00e9lula madura. El FE no permite la detecci\u00f3n de cambios recientes o \ntransitorios en la ingesta de folato. Por tato en el ser humano, niveles de  \n  \n 222folato bajos se pueden detectar despu\u00e9 s de 120 d\u00edas de deficiencia en la \ningesta o defecto de absorci\u00f3n. En contraposici\u00f3n el FS es un buen \nindicador de la ingesta de esta vitamina a corto plazo y valores bajos se \npueden detectar en las dos primeras se manas de iniciada la deficiencia ya \nsea por falta de ingesta, defectos en la absorci\u00f3n del mismo, ingesta de alcohol y ciertos medicamentos.  \nRecientemente se han descubierto factores gen\u00e9ticos que podr\u00edan \nafectar los niveles de FS y FE, como la sustituci\u00f3n C \u2192 T en la posici\u00f3n 677 \nque codifica la Metiltetrahidrofo lato reductasa (MTHFR), enzima \nencargada de reducir el 5,10 Metilentetrahidrofolato a 5-\nMetiltetrahidrofolato, principal forma en que el folato circula en el \norganismo. La C677T, es la mutaci\u00f3n m\u00e1s frecuente de las que afectan a la \nMTHFR\n10. Entre el 5 y el 15% de las pe rsonas normales son homocigotos \npara la mutaci\u00f3n C677T en el gen de la MTHFR, que se relaciona con el aumento de homociste\u00edna en plasma y una redistribuci\u00f3n de folatos en el \norganismo, con un FS disminuido\n11, mientras que con el FE no hay \nconsenso, para unos autores estar\u00e1 disminuido12, mientras que para otros \nestar\u00e1 aumentado13. \nAdem\u00e1s se han descubierto po limorfismos en los genes que \ncodifican las prote\u00ednas involucradas en la absorci\u00f3n y transporte del folato \ny que comprenden un intercambio de ba se en el gen del transportador de \nfolato reducido G80A y un interc ambio de base menos frecuente que \ncodifica la glutamato carboxipeptidasa C1561T. \n \nObjetivos: \nEl objetivo del presente trabajo ha sido establecer la posible relaci\u00f3n \nentre las concentraciones plasm\u00e1ticas de homociste\u00edna, FS y FE en un \ngrupo de ancianos institucionalizados y el genotipo C677T del gen de la \nMTHFR. \n \nM\u00e9todos: \nSe estudiaron 218 ancianos, 82 hombres y 136 mujeres con edades \ncomprendidas entre los 60 y 102 a\u00f1os. Tras un ayuno de doce horas y por \npunci\u00f3n en la vena cubital, se extrae la sangre, distribuy\u00e9ndola en un tubo \ncon EDTA para hematimetr\u00eda completa en el ADVIA-120 de Bayer, morfolog\u00eda eritrocitaria, hipersegmentaci\u00f3n neutr\u00f3fila y folato  \n  \n 223intraeritrocitario (IMX Abbott). 8 cc de sangre se depositaron en tubos con \ngel para la obtenci\u00f3n de suero que se depositaron en ba\u00f1o con hielo y se \ncentrifugaron antes de 1 hora para la determinaci\u00f3n de bioqu\u00edmica \ncompleta (Hitachi 911 Roche), vitamina B\n12, folato s\u00e9rico, homociste\u00edna \ntotal (tHcy) en el IMX de Abbott, holotranscobalamina II (Holo-TC-II) (RIA, Axis-Shiel) y \u00e1cido metilmal\u00f3nico (AMM), 4 cc en un tubo de sangre \ntotal heparinazada para la determinaci\u00f3n de la vitamina B\n6. Las muestras \nde suero que no se procesaron inmediatamente se congelaron a \u2013 80\u00ba C hasta su posterior an\u00e1lisis. \nCon 500 \u00b5L de sangre total anticoagulada con EDTA se realiz\u00f3 \nextracci\u00f3n de ADN mediante el Qiagen, procedimiento descrito por Higuchi (1989) y posteriormente se estu dio el polimorfismo de la C677T de \nla MTHFR mediante la Reacci\u00f3n en cadena de la polimerasa (PCR) y posterior digesti\u00f3n y amplificaci\u00f3n con la enzima de rest ricci\u00f3n Hinf-I (GE \nHealthcare) como fue descrito por Frosst et al (1995). \nLos participantes completaron un cuestionario que permiti\u00f3 \ndeterminar sus h\u00e1bitos alimenticios en  el \u00faltimo a\u00f1o (Mini Nutricional \nAssessment MNA). Por \u00faltimo la entrevista puso de manifiesto sus h\u00e1bitos tab\u00e1quicos, actividad f\u00edsica e ingesta de medicamentos de las 4 \u00faltimas semanas. Los autores analizaron la relaci\u00f3n entre FS y FE, as\u00ed como la \nasociaci\u00f3n entre ellos y los factores que podr\u00edan modificar sus \nconcentraciones. Tambi\u00e9n se realiz\u00f3 un estudio del deterioro cognitivo \nmediante el Mini Mental Test (MMT). \n \nAn\u00e1lisis estad\u00edstico: \nDebido a la asimetr\u00eda en la distribu ci\u00f3n de las variables bioqu\u00edmicas, \nse procedi\u00f3 a su transformaci\u00f3n  logar\u00edtmica consigui\u00e9ndose una \ndistribuci\u00f3n normal de estas. El an\u00e1lis is estad\u00edstico se hizo con las formas \nlogar\u00edtmicas de las variables aunque en las tablas se representar\u00e1n los \nvalores de la concentraci\u00f3n de las variables en su forma antilogar\u00edtmica.  \nSe aplic\u00f3 la prueba de la t de Student para estudiar el efecto de la \nmutaci\u00f3n de la MTHFR en las concentraciones de tHcy, FS y FE. Por otra \nparte, se realiz\u00f3 an\u00e1lisis de la vari anza (ANOVA) para estimar el efecto de \nlos polimorfismo estudiados. Los c\u00e1lculos estad\u00edsticos se realizaron con la versi\u00f3n 12 del programa SPSS para Windows. \n  \n  \n 224Resultados: \nDe los 218 sujetos, se diagnostic aron 175 ancianos con tHcy > 12 \n\u00b5mol/l. 106 (43.11%) con folato s\u00e9rico \u2264 6 ng/ml y con folato \nintraeritrocitario \u2264 175 ng/ml 13 (7.33%), de estos 16 tienen ambos bajos, lo \nque representa 119 ancianos deficientes que representan el 54.84 % de prevalencia de d\u00e9ficit de folato. 38 ancianos (7.33%) tienen una B\n12 s\u00e9rica \u2264 \n200 pg/ml, 52 ancianos (23,85 %) tienen una Holo-TC \u2264 45 y 29 un AMM \u2265 \n300, lo que representa una prevalencia para el d\u00e9ficit de vitamina B 12 de 119 \nancianos que representan el 54,84% de la poblaci\u00f3n estudiada. D\u00e9ficit \nmixto B 12-folato, 76 ancianos (34,86 %). \nEn un an\u00e1lisis de regresi\u00f3n lineal m\u00faltiple el log del FS (r = - 0.285 p \n< 0.01) es el m\u00e1s fuerte predictor independiente de hiperhomocisteinemia (log tHcy), seguido del log del FE (r = - 0.269 p < 0.01), log AMM (r = 0.315 p < 0.01), log Holo-TC ( r = - 0.239 p < 0.01), log B\n6 ( r = - 0.083 p < 0.05) y \npor ultimo log B 12 ( r = - 0.171 p < 0.05). \nEl an\u00e1lisis no revel\u00f3 diferencias significativas entre hombres y \nmujeres, por lo que el estudio se rea liz\u00f3 sin tener en cuenta el sexo. El \ndiagrama de dispersi\u00f3n demostr\u00f3 la relaci\u00f3n lineal entre FS y FE. El an\u00e1lisis demostr\u00f3 correlaciones positivas importantes entre FS y FE ( p < 0.01). Similares hallazgos se observ aron con el FE, aunque de menor \nmagnitud. \nEl an\u00e1lisis de varianza (ANOVA) del FS, FE y tHcy seg\u00fan el \npolimorfismo de la MTHFR, mostr\u00f3 con el test de Scheff\u00e9 una diferencia en las medias significativas (p < 0.05) en tre el FE del polimorfismo normal y \ndel homocigoto exclusivamente. \nEn nuestro estudio 31 sujetos presentaron el genotipo homocigoto \nde la MTHFR (677TT), lo que representa  el 14 %, 16 hombres y 15 mujeres, \npresentaron unos niveles m\u00e1s elevados de FE comparados con el polimorfismo heterocigoto (677CT) y normal (677CC). El polimorfismo de \nla MTHFR 677CT tuvo un efecto pronunci ado en la correlaci\u00f3n entre FS, FE \ny tHcy; en los sujetos normales (677CC), el FS, se correlaciono \nexclusivamente y de forma invers a con la tHcy ( r = - 0.416 p < 0.05), \nmientras que en los heterocigotos (677C T), el FS se correlaciono de forma \ndirecta con el FE ( r = 0.535 p < 0.01) y de forma inversa con la tHcy ( r = - \n0.308 p < 0.01) y por \u00faltimo en la forma homocigoto (677TT) se correlaciono \nel FS y FE de forma directa ( r = 0.529 p < 0.01) pero no con la tHcy. \n  \n  \n 225Conclusiones: \nConcentraciones medias de tHcy, est\u00e1n influenciadas por la edad, \nestado nutricional, estilo de vida y factores gen\u00e9ticos. En el presente \nestudio utilizando el test no param\u00e9trico de  Kruskal Wallis y el an\u00e1lisis \npost hoc de Bonferoni para las variables transformadas (tabla) y coincidiendo con otros autores \n14, no se han podido establecer diferencias \nsignificativas en las concentraciones me dias de tHcy (p = 0.600) y de FS (p = \n0.631). Sin embargo, se han encontrado dife rencias significativas en el FE (p \n= 0.021) entre los grupos con distinto polimorfismo en la MTHFR, estas \ndiferencias significativas son m\u00e1s fue rtes entre individuos normales y \nhomocigotos (p = 0.025) que entre heterocigotos y homocigotos (p = 0.071). se deduce de este estudio que las co ncentraciones de FS y tHcy no est\u00e1n \ninfluenciadas por el polimorfismo de la MTHFR y si el FE. Por tanto en individuos homocigotos puede haber un FE elevado, parece ser que por acumulo intracelular de folato, bajo una forma que no es el \nmetiltetrahidrofolato, los folatos acumulad os no participan en el ciclo de la \nmetilaci\u00f3n ni en la s\u00edntesis de DNA\n13. Ser\u00eda importante en individuos \nhomocigotos analizar las distintas formas  de folatos intraeritrocitarios para \ndiagnosticar el estado deficitario. \n  \n  \n 226Bibliografia: \n \n1. Stabler, S.P., Allen, R.H., Savage, D.G., & Lindenbaum, J. Clinical \nspectrum and diagnosis of cobalamin deficiency. Blood 1990; 76: 871\u2013881. \n2. Boushey, C. J., Beresford, S. A., Omenn, G. S. & Motulsky, A. G. A \nquantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increased folic acid intakes. J. Am. \nMed. Assoc. 1995; 274: 1049\u20131057. \n3. The Homocysteine Studies Collabo ration Homocysteine and risk of \nischemic heart disease. A meta analysis. J. Am. Med. Assoc. 2002; 288: \n2015\u20132023. \n4. Wald, D. S., Law, M. & Morris, J.  K. Homocysteine and cardiovascular \ndisease: evidence on causality from a meta-analysis. Br. Med. J. 2002; 325: \n1202\u20131208. \n5. Steegers-Theunissen RPM, Boers GHJ,  Trijbels JMF, et al. Maternal \nhyperhomocysteinemia: a risk factor for neural-tube defects? Metabolism. \n1994; 43: 1475-1480 6. Hague WM. Homocysteine and pregnanc y. Best Practice Res Clin Obstet \nGynaecol 2003; 17: 459\u2013469. \n7. Clarke R, Smith AD, Jobst KA, Refsum  H, Sutton L, Ueland PM. Folate, \nvitamin B\n12, and serum total homocysteine levels in confirmed Alzheimer \ndisease. Arch Neurol. 1998; 55: 1449-1455. 8. McLean RR, Jacques PF, Selhub J et  al. Homocysteine as a predictive \nfactor for hip fracture in older persons. N Engl J Med 2004; 350: 2042\u20139. \n9. Pietrzik K, Br\u00f6nstrup A. Folate in preventive medicine: a new role in \ncardiovascular disease, neural tube defects, and cancer. Ann Nutr Metab \n1997; 41: 331-343. \n10. De Bree A, Verschuren WMM, Bjorke-Monsen AL, Van der Put NMJ, \nHeil SG, Trijbels FJM, et al. Effect of methyenetetrahydrofolate reductasa \n677C-T mutation on the relation among folate intake and plasma folate and \nhomocysteine concentration in a general population sample. Am J Clin Nutr 2003; 77: 667-93.  \n  \n 22711. Frosst P, Blom HJ, Milos R, et al . A candidate genetic risk factor for \nvascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995; 10: 111-113. \n12. Leo A. J Kluijtmans, Ian S. Young, Colin A. Boreham, Liam Murray, \nDorothy McMaster, Helene McNulty, J.J. Strain, Joseph McPartlin, John M. Scott, and Alexander S. Whitehead.  Genetic and nutritional factors \ncontributintg to hyperhomocysteinem ia in young adults. Blood. 2003; 101: \n2483-88. \n13. Bagley, P. J. & Selhub, J. A common mutation in the \nmethylenetetrahydrofolate reductas e gene is associated with an \naccumulation of formylated tetrahydrofolates in red blood cells. Proc. Natl. Acad. Sci. U.S.A. 1998; 95:13217\u201313220. \n14. Delvin EE, Rozen R, Merouani A, Genest J, Lamber M. Influence of \nmethilenetetrahidropholate reductase genotype, age, vitamin B\n12 and folate \nstatus on plasma homocysteine in children. Am J Clin Nutr 2000; 72: 469-\n73. \n  \n  \n 228Tablas y gr\u00e1ficos:  \n \n \n                                    Concentraciones de FS, FE y tHcy seg\u00fan el polimorfismo de la \nMTHFR \n                            Normal                         Heterocigoto                    Homocigoto           P \n                                 (N = 54)                        (N = 104)                             (N = 31  \n \nFS (ng/ml)         6.08 (2.68-18.29)\n1       6.10 (2.66-16.20)               5.30 (2.63-16.34)        NS 1  \n \nLog FS                       1.82 \u00b1 0.582                1.81 \u00b1 0.49                        1.79 \u00b1 0.52             NS2       \n FE (ng/ml)        252.5 (66.8-652.05)     270 (88.15-754.6)              359 (122.6-1138)        0.05     Log FE                       5.53 \u00b1 0.55\na                 5.61 \u00b1 0.57                         5.84 \u00b1 0.6           < 0.05   \n \ntHcy (\u00b5mol/l)     16.15 (7.15-26.81)       15.6 (9.78-27.59)               16.64 (4.65-50.0)       NS   Log tHcy                 2.71 \u00b1 0.35                   2.77 \u00b1 0.40                          2.72 \u00b1 0.61             NS   \n1 Kruskal Wallis- test (no par\u00e1metrico)  \n2 ANOVA con post hoc Bonferoni \na significativo con el grupo homocigoto \n \n   \n \n  \n  \n 229 \n  \n \n   \nComparaciones m\u00faltiples \nVariable dependiente: logfoler  \nBonferroni  \nIntervalo de confianza al \n95% \n(I) \nMTHFR (J) \nMTHFR Diferencia \nde medias \n(I-J) Error \nt\u00edpico Sig. L\u00edmite \ninferior L\u00edmite \nsuperior \nNormal   \nHeterocig\noto -,07741 ,09631 1,000 -,3101 ,1553Normal \nHomocigo\nto -,32683(*) ,12960 ,038 -,6399 -,0138\nNormal ,07741 ,09631 1,000 -,1553 ,3101\nHeterocig\noto   Heterocig\noto \nHomocigo\nto -,24942 ,11756 ,106 -,5334 ,0346\nNormal ,32683(*) ,12960 ,038 ,0138 ,6399\nHeterocig\noto ,24942 ,11756 ,106 -,0346 ,5334Homocigo\nto \nHomocigo\nto   \n*  La diferencia entre las medias es significativa al nivel .05.  \n  \n 230 \nNormal Heterocigoto Homocigoto\nMTHFR051015202530Folato s\u00e9rico ng/ml\nNormal Heterocigoto Homocigoto\nMTHFR0,00250,00500,00750,001000,001250,00Folato Intraeritrocitario ng/ml\nNormal Heterocigoto Homocigoto\nMTHFR6,807,007,207,407,607,80Media de folato s\u00e9rico\nNormal Heterocigoto Homocigoto\nMTHFR280,00300,00320,00340,00360,00380,00400,00420,00Media de folato intraeritrocitario\n \n \n  \n \n     \n \n \nTabla 1.Plasma total homocysteine (tHcy), serum folate and red blood \ncell  \n  \n 231 \n(RBC) folate  concentration acco rding to MTHFR (677C>T) genotype. \nValues are mean \u00b1 SD.  \n1P-value is based on one-way analysis of variance for differences between \nmeans. \n*Significantly different from CC (P < 0.05) by Tukey\u2019s test. \n \n  \n \n \n \n                                                          MTHR 677C>T genotype \n CC            \n(n=54, 28%) CT          \n(n=105, 55%) TT             \n(n=31, 16%) P-value1 \ntHcy (\u00b5mol/L) 16\u00b15.5 18.5\u00b119.2 17.6\u00b110.0 0.941 \nSerum Folate (ng/mL) 7.7\u00b17.5 7.0\u00b13.7 6.9\u00b14.0 0.497 \nRBC Folate (nmol/L) 291.7\u00b1164.7 321.2\u00b1200.9 417.1\u00b1260.7* 0.039  \n  \n 232Table 2 . Plasma total homocysteine (tHcy) concentration according to \nMTHFR (677C>T) genotype, and serum folate status. \n                                                  MTHR 677C>T genotype \n CC CT TT P-value1 \nSerum Folate <6.10 (ng/mL)     \n      tHcy (\u00b5mol/L) 19.0\u00b15.4 18.3\u00b16.3 16.2\u00b16.0 0.34 \nSerum Folate >6.10 (ng/mL)     \n      tHcy (\u00b5mol/L) 13.0\u00b13.8 15.4\u00b14.6 14.3\u00b14.1 0.08 P-value\n1 >0.001 0.008 0.34  \n \nValues are mean \u00b1 SD.  \n1P-value is based on two-way analysis of variance for differences between \nmeans. \n*Borderline different from CC (P = 0.069) by Tukey\u2019s test.  \n  \n 233Table 3 . Plasma total homocysteine (tHcy) concentration according to \nMTHFR (677C>T) genotype, and serum folate status. \n  MTHR 677C>T genotype \n  CC CT TT P-value1 \nSerum Folate <4 (ng/mL)     \n      tHcy  (\u00b5mol/L) 18.4\u00b15.7 26.6\u00b15.8 17.9\u00b19.3 0.54 \nSerum Folate 4-6 (ng/mL)     \n      tHcy (\u00b5mol/L) 18.2\u00b15.6 16.6\u00b15.8** 15.2\u00b13.1 0.33 \nSerum Folate >6 (ng/mL)     \n      tHcy (\u00b5mol/L) 12.9\u00b13.7* 15.2\u00b14.5\u2020 14.3\u00b14.1 0.13 \nP-value1 0.001 0.002 0.39  \n \n \nValues are mean \u00b1 SD. \n1P-value is based on two-way analysis of variance for differences between \nmeans. \n*Significantly different from serum folate <4 ng/mL (P = 0.010), and serum \nfolate 4-6 ng/mL (P = 0.002) by Tukey\u2019s test. \n**Significantly different from serum folate <4 ng/mL (P = 0.022) by Tukey\u2019s \ntest. \n\u2020Significantly different from serum fo late <4 ng/mL (P = 0.002)  by Tukey\u2019s \ntest. \n \n    \n  \n 234 \n \n \n Table 4 . Plasma total homocysteine (tHcy) concentration according to \nMTHFR (677C>T) genotype, and red blood  cell (RBC) folate concentration. \n                                                  MTHR 677C>T genotype \n CC CT TT P-value1 \nRBC Folate <270 (nmol/L)     \n      tHcy (\u00b5mol/L) 17.4\u00b15.3 17.9\u00b15.9 14.4\u00b15.6 0.24 \nRBC Folate >270 (nmol/L)     \n      tHcy (\u00b5mol/L) 14.2\u00b15.4 15.4\u00b15.1 15.8\u00b15.2 0.55 P-value\n1 0.037 0.022 0.34  \n \nValues are mean \u00b1 SD. tHcy means total plasma homocysteine. \n1P-value is based on two-way analysis of variance for differences between \nmeans.  \n  \n 235Table 5 . Plasma total homocysteine (tHcy) concentration according to \nMTHFR (677C>T) genotype, and serum folate status. \n  MTHR 677C>T genotype \n  CC CT TT P-value1 \nRBC Folate <150 (nmol/L)     \n      tHcy  (\u00b5mol/L) 15.3\u00b15.2 17.1\u00b15.4 11.4\u00b14.0 0.54 \nRBC Folate 150-250 (nmol/L)     \n      tHcy (\u00b5mol/L) 20.6\u00b14.6 16.9\u00b15.8** 13.7\u00b13.8\u00a7 0.33 \nRBC Folate >250 (nmol/L)     \n      tHcy (\u00b5mol/L) 7.0\u00b18.1* 17.2\u00b14.6\u2020 14.7\u00b14.5 0.13 \nP-value1 0.023 <0.001 0.025  \n \n \nValues are mean \u00b1 SD. \n1P-value is based on two-way analysis of variance for differences between \nmeans. \n*Significantly different from RBC folate 150-250 nmol/L (P = 0.018) by \nTukey\u2019s test. \n**Significantly different from RBC fola te <150 nmol/L (P = 0.032) by Tukey\u2019s \ntest. \n\u2020Significantly different from RBC folate <150 nmol/L (P < 0.001), and from \nRBC folate 150-250 nmol/L (P = 0.039)   by Tukey\u2019s test. \n\u00a7Significantly different from RBC fola te <150 nmol/L (P = 0.023) by Tukey\u2019s \ntest. \n  \n  \n 236Table 6 . Plasma total homocysteine (tHcy) concentration according to \nMTHFR (677C>T) genotype, and tHcy cutoff points. \n                                                  MTHR 677C>T genotype \n CC CT TT P-value1 \ntHcy <15.76 (\u00b5mol/L)      \n      tHcy (\u00b5mol/L) 11.8\u00b12.6 12.4\u00b12.1 11.3\u00b13.6 0.26 \ntHcy <15.76 (\u00b5mol/L)      \n      tHcy (\u00b5mol/L) 20.2\u00b14.2 21.2\u00b14.6 19.1\u00b13.4 0.24 P-value\n1 >0.001 >0.001 >0.001  \n \nValues are mean \u00b1 SD. tHcy means total plasma homocysteine. \n1P-value is based on two-way analysis of variance for differences between \nmeans. \n \n  \n  \n 237Correlaciones MTHFR HETEROCIGOTO\n1 ,695** -,122 ,955** ,583** -,285**\n,000 ,213 ,000 ,000 ,003\n105 105 105 105 105 105\n,695** 1 -,169 ,604** ,912** -,281**\n,000 ,084 ,000 ,000 ,004\n105 105 105 105 105 105\n-,122 -,169 1 -,119 -,227* ,809**\n,213 ,084 ,227 ,020 ,000\n105 105 105 105 105 105\n,955** ,604** -,119 1 ,535** -,308**\n,000 ,000 ,227 ,000 ,001\n105 105 105 105 105 105\n,583** ,912** -,227* ,535** 1 -,367**\n,000 ,000 ,020 ,000 ,000\n105 105 105 105 105 105\n-,285** -,281** ,809** -,308** -,367** 1\n,003 ,004 ,000 ,001 ,000\n105 105 105 105 105 105Correlaci\u00f3n de Pearson\nSig. (bilateral)\nN \nCorrelaci\u00f3n de Pearson\nSig. (bilateral)\nN \nCorrelaci\u00f3n de Pearson\nSig. (bilateral)\nN \nCorrelaci\u00f3n de Pearson\nSig. (bilateral)\nN \nCorrelaci\u00f3n de Pearson\nSig. (bilateral)\nN \nCorrelaci\u00f3n de Pearson\nSig. (bilateral)\nN Folato_ser_ng/ml\nFolato_intra_ng/ml  \nHomocisteina_mcmol/L\nlogfolse\nlogfole r\nloghomo  Folato_ser _\nng/mlFolato_intra _\nng/mlHomocistein\na_mcmol/L logfolse logfole rloghomo\nLa correlaci\u00f3n es significativa al nivel 0,01 (bilateral).**. \nLa correlaci\u00f3n es significante al nivel 0,05 (bilateral).*. \n \n Correlaciones MTHFR HOMOCIGOTA\n1 ,628 ** -,355 ,962 ** ,541 ** -,154\n,000 ,058 ,000 ,002 ,408\n31 31 29 31 31 31\n,628 ** 1 -,041 ,570 ** ,937 ** -,089\n,000 ,833 ,001 ,000 ,633\n31 31 29 31 31 31\n-,355 -,041 1 -,370 * ,043 ,883 **\n,058 ,833 ,048 ,825 ,000\n29 29 29 29 29 29\n,962 ** ,570 ** -,370 * 1 ,529 ** -,127\n,000 ,001 ,048 ,002 ,496\n31 31 29 31 31 31\n,541 ** ,937 ** ,043 ,529 ** 1 -,082\n,002 ,000 ,825 ,002 ,662\n31 31 29 31 31 31\n-,154 -,089 ,883 ** -,127 -,082 1\n,408 ,633 ,000 ,496 ,662\n31 31 29 31 31 31Correlaci\u00f3n de Pearson\nSig. (bilateral)\nN \nCorrelaci\u00f3n de Pearson\nSig. (bilateral)\nN \nCorrelaci\u00f3n de Pearson\nSig. (bilateral)\nN \nCorrelaci\u00f3n de Pearson\nSig. (bilateral)\nN \nCorrelaci\u00f3n de Pearson\nSig. (bilateral)\nN \nCorrelaci\u00f3n de Pearson\nSig. (bilateral)\nN Folato_ser_ng/ml\nFolato_intra_ng/ml  \nHomocisteina_mcmol/L\nlogfolse\nlogfole r\nloghomoFolato_ser _\nng/mlFolato_intra _\nng/mlHomocistein\na_mcmol/L logfolse logfole rloghomo\nLa correlaci\u00f3n es significativa al nivel 0,01 (bilateral).**. \nLa correlaci\u00f3n es significante al nivel 0,05 (bilateral).*.  \n  \n 238Comparaciones m\u00faltiples  \nScheff\u00e9  \n,77797 ,85283  ,660 -1,3264 2,8823\n,81512 1,14759  ,777 -2,0165 3,6468\n-,77797 ,85283  ,660 -2,8823 1,3264\n,03715 1,04099  ,999 -2,5315 2,6058\n-,81512 1,14759  ,777 -3,6468 2,0165\n-,03715 1,04099  ,999 -2,6058 2,5315\n-29,58291 33,91834  ,684 -113,2759 54,1101\n-125,40202 * 45,64143  ,025 -238,0215 -12,7825\n29,58291 33,91834  ,684 -54,1101 113,2759\n-95,81911 41,40201  ,071 -197,9779 6,3397\n125,40202 * 45,64143  ,025 12,7825 238,0215\n95,81911 41,40201  ,071 -6,3397 197,9779\n-2,56798 2,53879  ,600 -8,8324 3,6964\n-1,62152 3,41626  ,894 -10,0511 6,8081\n2,56798 2,53879  ,600 -3,6964 8,8324\n,94646 3,09894  ,954 -6,7001 8,5931\n1,62152 3,41626  ,894 -6,8081 10,0511\n-,94646 3,09894  ,954 -8,5931 6,7001(J) R_MTHFR\nHeterocigoto\nHomocigoto\nNormal\nHomocigoto\nNormal\nHeterocigoto\nHeterocigoto\nHomocigoto\nNormal\nHomocigoto\nNormal\nHeterocigoto\nHeterocigoto\nHomocigoto\nNormal\nHomocigoto\nNormal\nHeterocigoto(I) R_MTHFR\nNormal\nHeterocigoto\nHomocigoto\nNormal\nHeterocigoto\nHomocigoto\nNormal\nHeterocigoto\nHomocigotoVariable dependiente  \nFolato_ser_ng/ml  \nFolato_intra_ng/ml\nHomocisteina_mcmol/LDiferencia de\nmedias (I-J) Error t\u00edpico Sig. L\u00edmite inferio rL\u00edmite\nsuperiorIntervalo de confianza al\n95%\nLa diferencia entre las medias es significativa al nivel .05. *.  \nCorrelaciones del FS y FE con la tHcy, seg\u00fan el polimorfismo de la MTHFR \n \n     CC                         CT                            TT \n \nFS     r = - 0.269 ( p < 0.05)                r = - 0.122                         \nr = - 0.355 \n FE     r = - 0.304 ( p < 0.05)                r = - 0.169                         \nr = - 0.041 \n \n \n \n  \n  \n 239Normal Homocigoto Heterocigoto\ndna_nu6,906,916,926,936,946,956,966,97Mean Folato_ser_ng/ml\n  \n  \n 240Normal Homocigoto Heterocigoto\ndna_nu280,00300,00320,00340,00360,00380,00400,00420,00Mean Folato_intra_ng/ml\n \n  \n  \n  \n  \n \n     \n \n     \n \n \n \n  \n \n     \n \n    \nHOMOCISTE\u00cdNA EN ADOLESCENTES  \n  \n 242B-Vitamins and Homocysteine in Spanish adolescents \nAl-Tahan J\n1, Sola R2, Gonz\u00e1lez-Gross M 2,3, Ruiz JR2, Garc\u00eda-Fuentes M4, \nMoreno L5, Breidenassel C1, Castillo MJ2, Pietrzik K1. \n1Institut f\u00fcr Ern\u00e4hrungs- und Lebensmittelwissenschaften - \nErn\u00e4hrungsphysiologie. Rheinische Friedrich-Wilhelms Universit\u00e4t. \nGermany. \n2Grupo Effects 262. Facultad de Medicina. Universidad de Granada. \nSpain \n3 Facultad de Ciencias de la Actividad F\u00edsica y del Deporte, Universidad \nPolit\u00e9cnica de Madrid. Spain. \n4 Dpto. Pediatr\u00eda. Facultad de Medicina. Universidad de Cantabria. \n5 Dpto de Fisiatria. EU Ciencias de la Salud. Universidad de Zaragoza. \n Correspondence address : \nProf. Dr. Marcela Gonzalez-Gross.Facultad de CC de la Actividad F\u00edsica \ny del Deporte. Universidad Polit\u00e9cnica de Madridc/ Mart\u00edn Fierro s/nE-28040 Madrid \n \nTel.: +34 91 336 4039  \nFax: +34 91 5497307  e-mail: marcela.gonzalez.gross@upm.es   \nAcknowledgements : This study has been supported by the Spanish \nMinistry of Health Instituto de Salud Carlos III (FIS PI021830). The AVENA study was supported by th e Spanish Ministry of Health, \nInstituto de Salud Carlos III (FIS 00/0015), CSD grants 05/UPB32/01 and 09/UPB31/03, 13/UPB/20/04the Spanish Ministry of Education (AP2003-2128; AP-2004-2745), and grants from Panrico S.A., Madaus S.A. and Procter and Gamble S.A. We want to thank Ms P Carazo, Ms R Perez \nand Ms Teresa Amigo for their collaboration in this study.  \n  \n  \n 243Abstract  \nBackground : Adolescence is characterized by a very intense growth and \npersonal development during a re latively short period of time. \nTherefore, nutritional needs are high er than during other life stages. \nDue to their important role in cell formation B-Vitamins, in particular \nfolate and cobalamine, are responsible for human beings\u00b4 healthy \ngrowth. Additionally, they are strongly connected with the emergence \nof homocysteine, an independent risk  factor for cardiovascular diseases. \nHowever, the B-Vitamin and homocysteine status of Spanish adolescents is not well known.  \nObjectives : The aim of this study is to assess the status of B-Vitamins \nand homocysteine in healthy Spanish adolescents for the subsequent \nestablishment of new adolescent reference values.  \nMaterial and Methods : Serum cobalamine, serum folate, homocysteine \nand methylenetetrahydrofolate redu ctase 677C>T variant, BMI, self-\nreported Tanner stage were determined in a sample of 165 Spanish adolescents (84 females, 81 males;  13-18.5 years) and analysed by \ngender with the Student\u2019s T-test. Interactions between socioeconomic \nstatus, age-group, methylenetetrahy drofolate reductase polymorphism, \nBMI, Tanner stage and vitamin status , respectively was examined by \nANOVA (level of significance P < 0.05).  \nResults : Boys had markedly higher homocysteine mean values (males: \n9.79 \u00b1 4.03 \u00b5mol/L; females: 8.30 \u00b1 2.13\u00b5mol/L) whereas girls showed \nhigher serum cobalamine values co mpared to the boys (males: 559.66 \u00b1 \n141.80 pmol/L; females: 672.15 \u00b1 250.85 pmol/L). Serum folate significantly increased with a better socioeconomic status (low: 5.76 \u00b1 2.23 ng/mL; high: 6.48 \u00b1 2.48 ng/mL). Ad olescents with the homozygous \nvariant of methylenetetrahydrofolate  reductase displayed significantly \nhigher values for homocysteine and lower values for serum folate \n(normal: 5.60 \u00b1 1.53 ng/mL serum folate, 8.60 \u00b1 1.57 \u00b5mol/L \nhomocysteine; homozygous: 4.45 \u00b1 1.39 ng/mL serum folate, 11.28 \u00b1 3.81 \u00b5mol/L homocysteine). Between BMI, Tanner stage, age group and vitamin status no correlations were found.  \nConclusions : These data reinforce findings concerning higher \nhomocysteine and lower serum folate  levels in homozygous persons. \nRegarding reference values for adul ts results remain within normal \nranges. However, adolescents might be subject to other ranges than adults. Hence, to assure a better asse ssment of health in adolescence a \nrevision of adolescent refere nces would be reasonable.   \n  \n 244Introduction  \nAdolescence is a crucial period of a human life and implies \nmanifold changes in physiology and psychology. Both factors influence \nthe adolescent\u2019s behaviour, nutritio nal needs, and habits. Adolescence \nis characterized by a very intense growth and personal development \nduring a relatively short period of  time. Therefore, nutritional needs \nand energy requirements are higher th an during other life stages [1, 2]. \nIncreasing evidence demonstrates th at risk factors start to implement \nduring childhood and adolescence and increase the probability of developing several diseases e. g.  atherosclerosis, dyslipidaemia, \nnegative dietary habits, obesity, diab etes, osteoporosis and certain types \nof cancer [3-5] during adulthood.  \nB-Vitamins are involved in almost all metabolic reactions e. g. \nprotein, carbohydrate, fat, and nucleic acid metabolism. Special attention should be paid to folate and cobalamine (Cbl) because of their \nimportant role in cell formation. Both vitamins are responsible for \nhuman beings\u00b4 healthy growth. Cbl deficiency may lead to severe neurological disorders, which have b een described in strict vegetarians \n[6, 7]. Furthermore in the state of Cbl deficiency the metabolic active \nparts of folate accumulate in the irreversible form of 5-methyltetrahydrofolate due to several feedback mechanisms. The regeneration to tetrahydrofolate is vitamin B\n12 dependant. \nSubsequently, Cbl deficiency causes a functional deficiency of folate. \nHomocysteine (tHcy) is a sulphur-containing amino acid formed \nduring metabolism of methionine. This pathway uses folate as a \nsubstrate and vitamin B 12 as a co-factor. The other pathway is the trans-\nsulphuration pathway, which results in the production of cysteine and uses vitamin B\n6 as a co-factor. Therefore, a lack of these vitamins leads \nto an increase of the tHcy level whic h is a risk factor for cardiovascular \ndiseases [8].  \nThe problem of inadequate consumption of foodstuffs in \nconjunction with negative nutritional habits and physical inactivity etc. increasingly affects the young po pulation. In order to give any \nrecommendations, an evaluation of th e present day situation is required \naccording to Kersting et al. [9]. Good and evidence-based information \non nutritional requirements as well as tHcy and B-Vitamin status of \nhealthy adolescents in Europe is sparse [10, 11]. Hence, it is necessary to \ngain representative and comparable data of the adolescent population. Therefore, we have assessed the folate , Cbl, and tHcy status of healthy \nSpanish adolescents.   \n  \n 245Methods  \nStudy design  \nThis research was conducted in a sub-sample of the AVENA-\nStudy ( Alimentaci\u00f3n y Valoraci\u00f3n del Estado Nutricional en \nAdolescentes: Feeding and Assessment of Nutritional Status of Spanish \nAdolescents). The cross-sectiona l AVENA-Study was designed to \nevaluate the following parameters in a representative sample of \nSpanish adolescents from Granada, Madrid, Murcia, Santander, and Zaragoza (Spain) in order to identify risk factors for chronic diseases in adulthood: 1) the dietary intake, food habits and nutrition knowledge; 2) the daily physical activity and pe rsonal approach; 3) the physical \ncondition; 4) the anthropometry and body composition; 5) the \nhematobiochemical study: plasma lipid phenotypic and metabolic \nprofile, blood cell counts; 6) the gene tic markers of cardiovascular risk \nlipid factors; 7) the immunocomp etence and 8) the psychological \nprofile. The complete and detailed me thodology of the project has been \ndescribed elsewhere [12]. \nSubjects  \nAs it was not included in the main protocol, serum cobalamine \n(sCbl), serum folate, tHcy, MTHF R polymorphism and Creatinine \n(Crea) were available in a sub-sample  of 165 adolescents aged 13 to 18.5 \nyears. Before blood sampling, each subject was evaluated and all anamnesis data were registered and reviewed to judge the adolescent\u2019s \nmedical status. After finishing the fi eld study, the subjects who did not \nfulfil the inclusion criteria were ex cluded. Exclusion criteria were the \nfollowing: diabetes, pregnancy, abuse of alcohol or drugs and in general, pathologies that are not directly related to nutrition. \nThe socioeconomic status was assessed by means of the \neducational level and the type of occupation of the father [Sociedad \nEspa\u00f1ola de Epidemiolog\u00eda. La medici\u00f3n de la clase social en ciencias \nde la salud. Informe de un grupo de trabajo de la Sociedad Espa\u00f1ola de \nEpidemiolog\u00eda. Barcelona: SG Editores, 1995.]. According to this information, adolescents were classified into five categories: low, medium-low, medium, medium-high, and high socioeconomic status.  \nAfter receiving complete information about the aims and \nmethods of the study, all subjects an d their parents or guardians signed \nfully informed written consent. The protocol was approved by the Review Committee for Research Invo lving Human Subjects of the \nHospital Universitario Marqu\u00e9s de Valdecilla (Santander, Spain).   \n  \n 246Anthropometric methods  \nSubjects were barefoot and in their underwear for \nanthropometric measurements. Weight  was measured with a Seca scale \n(with a precision of \u00b1 100g), height wi th incorporated stadiometer to the \nscale. Harmonization and stand ardization of anthropometric \nmeasurements used to assess body  composition within the AVENA-\nStudy was strictly controlled and has been previously published by \nMoreno et al. [13] and the AVENA group. The International Obesity \nTask Force (IOTF) has proposed the use of international cut-off points \nin children and adolescents to be used as reference standards for body mass index (BMI) and the subjects  were divided into normal, \noverweight, and obesity, according to  the IOTF criteria published by \nCole et al. [14]. To achieve groups with higher numbers of subjects, the \noverweight and obesity groups were studied as one group. Body fat percentage was calculated by the form ulas described by Slaughter et al. \n[15]. During anthropometrical measurements, trained interviewers asked the adolescents to classify themse lves in one of the five stages of \npubertal maturity defined by Tanner and Whitehouse [16]. The \nstandard staging of pubertal maturity describes breast and pubic hair \ndevelopment in girls and genital and pubic hair development in boys.  \nBlood sampling and analytical methods  \nStandardized in all cities, blood samples were collected by \nvenipuncture by a trained phlebotomist between 8:00 and 9:30 a.m. \nBlood for serum samples were collected  in vacumtainers and allowed to \nclot. The serum was separated by cent rifugation, divided into aliquots, \nfrozen, and stored at -80\u00b0C un til withdrawn for analysis.  \nBiochemical data were collected by  using the standard methods. \nCrea was detected by using the colo rimetric Jaff\u00e9 method with Hitachi \n917 Systems. tHcy was measured by a totally automated fluorescence \npolarisation immunoassay (FPIA; IMx tHcy Kit, Abbot Diagnostic, \nAbbot Park, IL, USA). Serum FOLATE and sCbl levels were measured by using the flourometric method with an Abbot IMx auto analyser \n(Abbot Laboratory, Chicago, USA). Total blood DNA was extracted and purified from 500 \u00b5L of whole blood  with anticoagulant EDTA, using \nthe procedure described by Higuchi [17]. Genotyping of the 677C>T \nvariant in the human methylenetet rahydrofolate reductase (MTHFR) \ngene was performed by means of po lymerase chain reaction and allele-\nspecific restriction digestion of the amplified products with the \nrestriction enzyme Hinf I (GE Health care), as previously described by \nFrosst et al. [18].   \n  \n 247Statistical analysis  \nThe sample was adjusted by a weight factor in order to \nequilibrate the sample in accordance to the distribution of the Spanish \npopulation (Source: The Spanish Nation al Institute for Statistics) and to \nwarrant that age and gender were representative. Median values, 2.5\nth \nand 97.5th percentile if possible, 5th and 95th percentile ranges were \ncalculated for these variables as well as mean values and standard \ndeviations (SD). Prior to further analysis, the data were checked for \nnormal distribution with the use of  the Kolmogorov-Smirnov-Test. The \ndata for tHcy and sCbl were not norm ally distributed and therefore log \ntransformed in order to normalize distribution for analyses. The Student\u00b4s T-test was used to compare  both gender with respect to the \nblood values of serum folate, sCbl, tHcy, MTHFR polymorphism, BMI \nCrea, and the Tanner stage. Interacti ons between socioeconomic status, \nage-group, MTHFR polymorphism, BMI, Tanner stage and vitamin status, respectively was examined by  ANOVA. The level of significance \nwas set at P < 0.05. Statistics were performed using SPSS 13.0 for \nWindows XP (SPSS Inc, Chicago, Illinois, USA). \nResults  \nThe mean age \u00b1 SD of the studied sub-group was 14.7 \u00b1 1.4 for \nmales and 14.5 \u00b1 1.4 for females (not sign ificant; n.s.). According to the \npubertal maturity, the studied boys  and girls (n.s.) were mainly at \nTanner stage IV (39.7 %) and V (44.0 %), with smaller percentage at \nlower stages: I (0 %), II (3.0 %)  and III (13.3 %). BMI was not \nsignificantly different between genders; however, bodyfat differed (F = 4.25, P < 0.001). Girls had an average bodyfat content of 24.2 \u00b1 6.8 % \nwhereas boys had 18.6 \u00b1 8.0 %. The MTHFR polymorphism appeared \nequally in both genders. Table 1  shows sCbl, serum folate, tHcy and \nCrea values for males and females. sCbl (F = 1.57,  P = 0.001), tHcy (F = \n0.12,  P = 0.002), and Crea (F = 2.23,  P < 0.001) values revealed significant \ndifferences between the gender  groups. As depicted in Figure 1-3,  boys \nhad markedly higher tHcy and Crea values and girls had higher sCbl \nvalues compared to the boys.  \nTable 2  presents sCbl, serum folate , tHcy, and Crea values by \nsocioeconomic status. In this table the 5\nth and 95th percentile was chosen, \nas the 2.5th and 97.5th percentiles were equivalent with minimum and \nmaximum due to the small number of  persons of each group. Serum \nfolate significantly increased with a better socioeconomic status (F = \n3.393, P = 0.011) as depicted in Figure 4 . Other correlations could not be \nfound.   \n  \n 248In Table 3  results of sCbl, serum folate , and tHcy are shown by MTHFR \npolymorphism. Adolescents with th e homozygous variant of MTHFR \ndisplayed significantly higher va lues for homocysteine (F = 7.19, P = \n0.001) and lower values for serum folate (F = 4.57, P = 0.012) compared \nwith the normal group. These findings are also depicted in Figure 5 and \n6.  \nTable 4  illustrates sCbl, serum folate, tHcy, and Crea by age group and \ngender, and complementing  Table 5  shows these results except for Crea \nas percentiles. Looking at the wh ole examined population by age \ngroup, the 15-year-olds showed the hi ghest values for sCbl in mean and \nmedian. The lowest mean was presen ted by the 16-year-old age group \nand the 14-year-old age group presented the lowest median. For serum \nfolate, the youngest age group revealed the highest values in mean and \nmedian, whereas the oldest age grou p showed the lowest results. In \ncontrast to that, the youngest age group demonstrated the lowest values for tHcy with 8.49 \u00b1 2.23 \u00b5mol/L. The 16-year-old had the highest mean with 9.95 \u00b1 3.74 \u00b5mol/L and the 17-year-old had the highest median for tHcy. Crea rose in either gender with increasing age \n(F = 13.933, P<0.05).  \nThe male subgroup showed sim ilar results for serum folate, \ntHcy, and Crea, but not for sCbl. Resu lts for this vitamin did not follow \na trend. The 16- and 17-year-olds revealed higher values for tHcy and Crea, whereas the results for serum folate were low. The younger age \ngroups presented high serum folate and low tHcy, and Crea values \n(n.s.).  \nThe female subgroup did not de monstrate clear trends; however, \nsome results especially for Crea were similar to the boys. 15-year-old adolescents had the highest values for sCbl, and 14-year-old the lowest \nvalues. Lowest results for serum folate were found in the 14-year-old \nage group. The highest mean for serum folate was found in the \nyoungest age group with 5.92 \u00b1 1.99 ng /mL and the highest median in \nthe oldest age group with 5.90 ng/mL. The maximal values for tHcy were found at age 16 whereas the ag e group of 15-year-old showed the \nlowest mean for tHcy.  \nNeither there were significant di fferences of vitamin status \namong the obesity stages, and bodyfat, nor among the Tanner stages \nexcept for Crea. For Crea, values rose  with increasing Tanner stage (F = \n4.210, P = 0.007).   \n  \n 249Discussion  \nThe aim of the present study was to  analyze folate, Cbl, and tHcy \nstatus in a Spanish adolescent popu lation. Few studies investigated the \ntHcy and B-Vitamin status in ad olescents (10). However, there were \nsome aspects which made the comp arability of these studies difficult. \nThe investigated data were either de monstrated by different statistical \nmeans and age groups or the unit of measure varied. The majority of \nthe studies observed a rather unrepresentative group and this might also have restricted the present study.  \nIn Nigeria, VanderJagt et al. [19]  investigated the folate and Cbl \nstatus of a female representative gr oup (12-16 years) in a region with a \nhigh incidence of neural tube defect s. Mean serum folate concentrations \nfor the 162 girls was 6.8 \u00b1 2.3 ng/m L (range: 2.3-13.3 ng/mL) and were \nhigher than the found results in  the AVENA-Study. Mean sCbl \nconcentration in this population  was 224 \u00b1 81.6 pmol/L (range: 94-519 \npmol/L). According to the prevailing vegetarian diet, as described in the same paper, Nigerian girls ha d much lower sCbl values than \nSpanish girls. The concentration of tHcy could be determined only for \n56 of the 162 subjects. The mean tHcy concentration was 15.9 \u00b1 5.0 \n\u00b5mol/L and ranged from 8.3 to 35.6 \u00b5mol/L. These concentrations were \ncomparable to the results measured  in Spanish boys; however, tHcy \nlevels for girls in the AV ENA-Study were much lower.  \nOsganian et al. [20] aimed to point out the role of tHcy as a risk \nfactor for cardiovascular diseas e (CVD) in children. The 3524 US \nschoolchildren (13 and 14 years) of this cross-sectionally designed analysis were part of a larger study, the Child and Adolescent Trial for Cardiovascular Health (CATCH). Complete laboratory data, including values for tHcy, folate, Cbl, and vitamin B\n6 were available for 3321 \nchildren. The mean tHcy concent ration was 5.3 \u00b1 1.9 \u00b5mol/L (range: 0.1-\n25.7 \u00b5mol/L) thus, lower than those found in the AVENA-Study. The \nmean level of folate was 18.5 \u00b1 9.1 ng/mL (range: 3.8-143.0 ng/mL) and \nthe mean Cbl concentration was leve lled at 396.1 \u00b1 164.6 pmol/L (range: \n21-1747 pmol/L). Mean concentrations for folate and Cbl were similar to the data found in the present stud y though the ranges measured by \nOsganian et al. were much higher which might be explained by the \nhigh consumption of fortified food.  \nThe Third National Health and Nutrition Examination Survey \n(NHANES) (1991 \u2013 1994) had the objective to identify reference ranges for tHcy in US residents and to  measure the dimensions of the \ncontribution of circulating vitamin concentrations to high tHcy  \n  \n 250concentrations. In this cross-sectio nally designed prevalence study 3563 \nmales and 4523 females took part. Selhub et al. [21] presented the \nresults as percentiles by gender and age group. Ten percent of the male participants (12-19 years) had folate concentrations of 2.5 ng/mL or less \nand 90 % had 10.1 ng/mL folate or less. Females of the same age group showed similar values. In  the present study the 10\nth percentile was \nlevelled a bit higher but the 90th percentile was levelled lower than \npercentiles in the Third NHANES . For Cbl the authors found 246 \npmol/L and 591 pmol/L as 10th and 90th percentile for males and 235 \npmol/L and 639 pmol/L for fema les. In the AVENA-Study 10th and 90th \npercentiles for vitamin B 12 were both higher. Additionally, some age \ngroups revealed Cbl values double as high as measured in the \nNHANES. tHcy concentrations wer e available from 167 boys and 183 \ngirls. In males Selhub et al. meas ured 4.7 \u00b5mol/L and 8.9 \u00b5mol/L tHcy, \nin females 3.4 \u00b5mol/L and 6.9 \u00b5mol/L tHcy. Results of the present study \nwere higher, especially the upper percentiles. In males, the percentile values for tHcy were consistently high er than in females, though both \ngender showed similar ranges between  the upper and lower percentile. \nFurthermore the ranges seemed to incr ease slightly with age regardless \nof sex. The authors discovered a nega tive correlation between tHcy and \nfolate and a weaker correlation  between tHcy and Cbl.  \nIn Taiwan, Chang et al. [22] in vestigated the determinants and \ndistributions of plasma tHcy levels  and the relationship between tHcy, \nfolate, and Cbl among randomly select ed school children (609 boys and \n625 girls; 12-15 years). Boys revealed  significantly higher tHcy levels \nthan girls ( P<0.05) with concentrations of 10.50 \u00b1 4.13 \u00b5mol/L and 8.95 \u00b1 \n2.61 \u00b5mol/L, respectively. Measured tHcy concentrations of both gender were higher than those es tablished in the AVENA-Study. \nAdditionally, boys had lower plasma folate levels (2.67 \u00b1 1.26 ng/mL \nversus 2.82 \u00b1 1.14 ng/mL) and Cbl concentrations (444.8 \u00b1 158.4 pmol/L \nversus 495.0 \u00b1 181.5 pmol/L) than girls ( P<0.05). Found data for folate \nand cobalamine were lower than the discovered concentrations in the \npresent study. Particularly, folate concentrations were half the concentration of the Spanish adolescents.  \nTonstad et al. [23] examined the relationship between tHcy, lipid, \nand apolipoprotein B concentrations  in 678 Norwegian children (8-12 \nyears) and premature cardiovascular disease in family members. The children showed a mean tHcy concen tration of 5.25 \u00b5mol /L. In Italy, \nMinniti et al. [24] measured tHcy concentrations of 96 healthy children \n(7.5-12.5 years) to determine new paediatric reference ranges. In boys, \ntHcy levelled at 7.4 \u00b1 2.15 \u00b5mol/L, while  the value for girls levelled at  \n  \n 2516.1 \u00b1 1.18 \u00b5mol/L thus was significantly different from the boys\u2019 \n(P<0.05). An age dependent distribution was also discovered in this \nstudy. Studies working on tHcy and several risk factors for coronary \nheart disease (CHD) with similar re sults and an even wider range of \nage groups were carried out by Gallistl et al. [25] and Glowinska et al. [26]. The data found in the above mentioned studies were lower than \nthe concentrations measured in the youngest age group of the present \nstudy. These results reinforce the observation that tHcy concentrations rise with increasing age.  \nAnother study investigated the nutritional status of socially \ndisadvantaged schoolchildren (12-13 years ) in London. Doyle et al. [27] \nfound mean Cbl concentrations of 481 \u00b1 210 pmol/L and 478 \u00b1 174 \npmol/L for the 34 participating boys and the 32 girls, respectively. Mean \nfolate concentrations were 8.0 \u00b1 3.0 ng/mL for boys and 6.2 \u00b1 2.3 ng/mL \nfor girls. Boys had markedly higher values for folate than girls ( P<0.02). \nThe measured concentrations for Cbl did not vary in great dimensions \nbetween genders (n.s.). Values for folate were higher and values for Cbl were lower than results of the present study.  \nRaslova et al. [28] investigated the effect of diet and \nmethyltetrahydrofolate reductase (MTHFR) polymorphism on plasma \ntHcy in Slovakian adolescents (113 boys and 202 girls; 14 years). Mean \nplasma tHcy concentrations levelled at 9.4 \u00b1 3.5 \u00b5mol/L for boys and at \n8.9 \u00b1 3.1 \u00b5mol/L for girls (range boys: 2.0-19.0; range girls: 4.0-31.0 \n\u00b5mol/L). Results were similar to the data measured in the AVENA-\nStudy. It is remarkable that fema les showed a higher maximum than \nmales in the study of Raslova et al., whereas in the present study it was \nthe opposite. The boys\u00b4 maximal tHcy concentration was higher than the girls\u00b4. According to previous statements, the authors did not find any sex differences, though a positive correlation of tHcy \nconcentrations with age.  \nIn the work done by Reddy [29], 120 healthy children up to an \nage of 18 years from New Orleans (US)  were studied in order to set up \nnew paediatric reference ranges for tHcy. The age group 14 to 18 years \nshowed mean tHcy concentrations of  9.8 \u00b1 3.8 \u00b5mol/L for boys and 9.4 \u00b1 \n3.6 \u00b5mol/L for girls which are similar to the data found in the AVENA-\nStudy. Although there appeared to be  a slight trend of higher values \nwith age, neither the differences  among the four age groups were \nstatistically significant, nor ther e was found a significant difference \nbetween the genders.   \n  \n 252The National Diet and Nutritio n Survey (NDNS): Young People \nat the age four to 18 years was cond ucted in mainland Britain during \n1997. Bates et al. [30] described the di stribution of tHcy, cysteine, and \ncysteinyl-glycine and compared them with values observed in British \nelderly from a previous NDNS. The data for tHcy were shown as geometric mean (GM) as well as 2.5\nth and 97.5th percentile. A value of \n6.18 (2.9/11.5) \u00b5mol/L and 6.40 (3.9/14.3) \u00b5mol/L was found in boys and \ngirls (11-14 years), respectively. In  the age group 15 to 18 years the GM \nwas 8.54 (4.1/20.1) \u00b5mol/L for male s and 7.80 (3.9-14.3) \u00b5mol/L for \nfemales. Values were lower than meas ured in the present study, though \ncomparing GM with arithmetic means is not a good comparinson. tHcy rose with increasing age and was in dependent from sex.  In winter \ntHcy was lower than in other seasons. In adolescents older than 15 \nyears, tHcy was higher in smokers and in the younger age groups it \nwas higher when the mother was a smoker.  \nIn Spain, Vilaseca et al. [31] examined 195 children and \nadolescents (two months - 18 years) in order to establish new reference values for tHcy. The median and the 2.5\nth and 97.5th percentile for the \nwhole sample was 6.3 (3.7/10.3) \u00b5mol/L. Results were independent of \nsex, but correlated positively with age ( P<0.001). Comparing the age \ngroups of eleven- to 15-year-old ( 6.6 \u00b5mol/L) and 16 to 18-year-old (8.1 \n\u00b5mol/L) the tHcy concentration of th e older age group was significantly \nhigher ( P<0.001). Bjorke Monsen et al. [32] investigated cobalamine \nconcentrations and the association to folate and the metabolic markers \nin 700 healthy children in Norway. Th e age group of ten- to 19-year-old \nconsisted of 213 adolescents. Differences in gender were not observed. The age group ten to 15 years showed  a median and interquartile range \nof 436 (295-529) pmol/L sCbl, 5.2 ( 4.0-6.6) ng/mL serum folate, and 6.52 \n(5.7-7.7) \u00b5mol/L plasma tHcy. In the age group of 15 to 19 years the \nfollowing values were found, 369 ( 294-452) pmol/L sCbl, 4.3 (3.4-5.5) \nng/mL serum folate, and 7.75 (6.6-9.1) \u00b5mol/L tHcy. From age seven to \n15 years, tHcy increased while serum folate and sCbl decreased. The results of the AVENA-Study consistent ly showed higher concentrations \nfor serum cobalamine and tHcy. This might be explained by the higher \nnumber of younger children that ha d been included in the studies \ncarried through by Vilaseca et al. and Bjorke Monsen et al. However, in \nthe similar age groups of 16 to 18 years, Cbl and tHcy concentrations remained high. Values found for fola te were in accordance with results \nof the present study.  \nThe Family Intervention Trial (FIT) study evaluated nutritional \nstatus, health, and cardiovascular risk factors in a large cohort of first  \n  \n 253grade pupils, their older siblings and parents. The work, done by Rauh \net al. [33], is part of this prospect ive intervention study. Plasma tHcy, \nsCbl, serum folate, Crea and seru m cystatin C were measured in 257 \nGerman children from Erlangen (6-17 years). The data were shown separately for boys and girls as mean \u00b1 SD, range, 2.5\nth and 97.5th \npercentile. The author found 5.7 \u00b1 1.7 \u00b5mol/L tHcy in males (range: 1.9-\n11.0; P: 3.1/10.5), and 5.5 \u00b1 1.6 \u00b5mol/L for girls, (range: 0.6-11.4; P: \n2.7/9.2). Cbl concentrations for boys  were 529.0 \u00b1 180.6 pmol/L (range: \n232.9-1083.1; P: 259.9/993.1), and for girls 551.5 \u00b1 180.7 pmol/L, (range: 193.0-1219.1; P: 304.5/993.7). Folate concentrations were levelled at 11.0 \u00b1 3.7 ng/mL, (range: 3.0-18.0; P: 3 .8/17.8) for boys, and 10.5 \u00b1 3.7 ng/mL \n(range: 4.3-23.8; P: 4.4/17.8) for girls. Comparing the results despite the \ndifferent age groups, folate concentrations were consistently lower and \nsCbl values of the AVENA-Study wer e somewhat higher than found in \nthe study done by Rauh et al., thou gh the Cbl ranges were similar. tHcy \nconcentrations also showed higher values in the AVENA-Study due to \nthe older age of the sample. Results fo r tHcy in the study of Rauh et al. \nwere independent of gender and cyst atin C, but correlated positively \nwith Crea and lean body mass ( P<0.0001). There was an inverse \ncorrelation ( P<0.0001) between tHcy and serum cobalamine as well as \nfolate.  \nConclusion  \nThe results of the above mentioned studies varied strongly. Most \nvalues for Cbl and tHcy were leve lled below those measured in the \nAVENA-Study, whereas most values for folate were situated above. The majority of the cited studies omitted Tanner stages, socioeconomic status and MTHFR polymorphism. Of ten age groups were not divided \nexactly into years of age which co mplicates comparing different age \ngroups. Gender differences were discovered only by a few works, in \ncontrast to the results of the present study. Also the ob servation that the \nvitamin status deteriorates and tHcy rises with increasing age could not \nbe established. A possible reason might be the rather small sample size in each age group in comparison wi th other studies, although most \nstudies examined the same sample si ze with an even wider age range. \nTo exclude this restriction, a study with a higher number of adolescents \nwould improve the representativeness.  \n   \n  \n 254R\nEFERENCES  \n1. Duyer, J., Nutritional requireme nts of adolescence.  Nutr Rev, 1981. \n39(2): p. 56-72. \n2. Deheeger, M., F. Bellisle, and M.F. Rolland-Cachera, The french \nlongitudinal study of growth and nutrition: data in adolescent males \nand females.  J Hum Nutr Dietet, 2002. 15: p. 429-438. \n3. Block, G., B. Patterson, and A. Subar, Fruits, vegetables and cancer \nprevention. A review of epidemiological evidence.  Nutr Cancer, 1992. \n18: p. 1-29. \n4. Bouchard, C. and J.P. Despres, Physical activity and health: \natherosclerotic, metaboli c, and hypertensive diseases.  Res Q Exerc \nSport, 1995. 66: p. 268-275. \n5. Diplock, A.T., Antioxidants and disease prevention.  Mol Asp Med, \n1993. 15: p. 293-376. \n6. Bar-Stella, P., Y. Rakover, and D. Ratner, Vitamin B12 and folate \nlevels in long-term vegans.  Isr J Med Sci, 1990. 26: p. 309-312. \n7. Ashkenazi, S., et al., Vitamin B12 deficiency due to a strictly \nvegetarian diet in adolescence.  Clin Pediatr (Phila), 1987. 26: p. 662-\n3. \n8. B\u00e4ssler, K.-H., et al., Vitamin-Lexikon . 3. ed. 2002, M\u00fcnchen Jena: \nUrban & Fischer. \n9. Kersting, M., U. Alexy, and W. Sichert-Hellert, Vitamin Intake of \n1- to 18-Year-Old German Children and Adolescents in the Light of \nVarious Recommendations.  Int J Vitam Nutr Res, 2000. 70(2): p. 48-\n53. \n10. Al-Tahan, J., M. Gonz\u00e1lez -Gross, and K. Pietrzik, B-Vitamin status \nin European adolescents. A review of the literature.  Nutr. Hosp., \n2006. 21(4): p. 452-65. \n11. Lambert, J., et al., Dietary intake and nutritional status of children \nand adolescents in Europe.  Br J Nutr, 2004. 92 Suppl. 2 : p. S147-211. \n12. Gonzalez-Gross, M., et al., Alimentacion y valoracion del estado \nnutricional de los adolescent es espanoles (Estudio AVENA). \nEvaluacion de riesgos y propuesta de intervencion. I. Descripcion \nmetodologica del proyecto.  Nutr Hosp, 2003. 18(1): p. 15-28. \n13. Moreno, L., et al., Harmonization of anthropometric measurements \nfor a multicenter nutrition survey in Spanish adolescents.  Nutrition, \n2003. 19: p. 481-386.  \n  \n 25514. Cole, T., et al., Establishing a standard defi nition for child overweight \nand obesity worldwide: international survey.  BMJ, 2002. 320: p. 1-6. \n15. Slaughter, M.H., et al., Skinfold equations for estimation of body \nfatness in children and youth.  Hum Biol, 1988. 60(5): p. 709-23. \n16. Tanner, J.M. and R.H. Whitehouse, Clinical longitudinal standards \nfor height, weight, height ve locity and stages of puberty.  Arch Dis \nChild, 1976. 51: p. 170-179. \n17. Higuchi, R., Simple and rapid preparation of samples for PCR.  Erlich \nH editors. PCR Technology. Stockton Press., 1989: p. 31-37. \n18. Frosst, P., et al., A candidate genetic risk factor for vascular disease: a \ncommon mutation in methyl enetetrahydrofolate reductase.  Nat Genet, \n1995. 10(1): p. 111-3. \n19. VanderJagt, D.J., et al., Folate and Vitamin B12 Status of Adolescent \nGirls in Northern Nigeria.  J Natl Med Assoc, 2000. 92: p. 334-340. \n20. Osganian, S.K., et al., Distribution of and Factors Associated With \nSerum Homocysteine Levels in Chil dren; Child and Adolescent Trial \nfor Cardiovascular Health.  JAMA, 1999. 281(13): p. 1189-1196. \n21. Selhub, J., et al., Serum Total Homocysteine Concentrations in the \nThird National Health and Nutrition Examination Survey (1991-\n1994): Population Reference Ranges and Contribution of Vitamin \nStatus to High Serum Concentrations.  Ann Intern Med, 1999. 131: p. \n331-339. \n22. Chang, J.-B., et al., Determinants and distributions of plasma total \nhomocysteine concentrations am ong school children in Taiwan.  \nEuropean Journal of Epidemiology, 2002. 18: p. 33-38. \n23. Tonstad, S., et al., Relation of total homocysteine and lipid levels in \nchildren to premature cardiovasc ular death in male relatives.  Pediatr \nRes, 1996. 40(1): p. 47-52. \n24. Minniti, G., et al., Plasma and serum total homocysteine \nconcentrations in paediatric pati ents, evaluated by  high-performance \nliquid chromatography with fluorescence.  Clin Chem Lab Med, 2000. \n38(7): p. 675-6. \n25. Gallistl, S., et al., Insulin is an independent correlate of plasma \nhomocysteine levels in ob ese children and adolescents.  Diabetes Care, \n2000. 23(9): p. 1348-52.  \n  \n 25626. Glowinska, B., et al., New atherosclerosis ri sk factors in obese, \nhypertensive and diabetic children and adolescents.  Atherosclerosis, \n2003. 167(2): p. 275-86. \n27. Doyle, W., et al., Nutritional status of school children in an inner city \narea.  Arch Dis Child, 1994. 70: p. 376-381. \n28. Raslova, K., et al., Effect of diet and 677 C-->T 5, 10-\nmethylenetetrahydrofolate reductase genotypes on plasma \nhomocyst(e)ine concentrations in slovak adolescent population.  Physiol \nRes, 2000. 49(6): p. 651-8. \n29. Reddy, M.N., Reference ranges for total homocysteine in children.  \nClinica Chimica Acta, 1997. 262: p. 153-155. \n30. Bates, C.J., et al., Correlates of plasma homocysteine, cysteine and \ncysteinyl-glycine in respondents in the British National Diet and \nNutrition Survey of young people aged 4-18 years, and a comparison with the survey of people aged 65 years and over.  Br J Nutr, 2002. \n87(1): p. 71-9. \n31. Vilaseca, M.A., et al., Total homocysteine in pediatric patients.  Clin \nChem, 1997. 43(4): p. 690-2. \n32. Bjorke Monsen, A.L., et al., Cobalamin Status and Its Biochemical \nMarkers Methylmalonic Acid and Homocysteine in Different Age Groups from 4 Days to 19 Years.  Clin Chem, 2003. \n33. Rauh, M., et al., Homocysteine concentrations in a German cohort of \n500 individuals: reference ranges and de terminants of plasma levels in \nhealthy children and their parents.  Amino Acids, 2001. 20(4): p. 409-\n18. \n  \n  \n 257 \nTable 1: Serum Cobalamine, serum folic acid, homocysteine and creatinin values by \ngender \nParameters are shown as mean values \u00b1 SD, median, (2.5th and 97.5th percentile), \nminimum, and maximum.  \nGender (n) Serum Cobalamine in \npmol/L Serum folic acid \nin ng/mL * Homocysteine in \n\u00b5mol/L * Creatinin a in \nmg/dL * \nm (82) 559.66 \u00b1 141.80 5.40 \u00b1 1.82 9.79 \u00b1 4.03 0.99 \u00b1 0.11 \n 540.00 (268.00/946.47) 5.26 (2.10/10.94) 8.92 (5.51/22.94) 1.00 (0.79/1.25) \n 247.00 - 984.00 2.00 - 11.30 5.50 - 33.47 0.77 - 1.30 \nf (79) 672.15 \u00b1 250.85 5.41 \u00b1 1.60 8.30 \u00b1 2.13 0.91 \u00b1 0.10 \n 594.82 (280.63/1559.64) 5.40 (2.90/8.69) 7.91 (5.09/13.86) 0.90 (0.71/1.16) \n 230.00 - 1636.00 2.70 - 12.80 4.81 - 14.39 0.70 - 1.20 \na males: n = 81  \n* significant difference ( P<0.05)  \nTable 2: Serum Cobalamine, serum folic acid, homocysteine, and creatinin values \nby socioeconomic status \nParameters are shown as mean values \u00b1 SD, median, (5th and 95th percentile), \nminimum, and maximum.  \nStatus (n) Serum Cobalamine in \npmol/L  Serum folic acid \nin ng/mL * Homocysteine in \n\u00b5mol/L  Creatinin in \nmg/dL  \nLow (3) 564.91 \u00b1 151.09 5.76 \u00b1 2.23 8.07 \u00b1 2.01 1.00 \u00b1 0.07 \n  514.89 (448.00/777.00) 5.21 (3.90/9.00) 8.04(5.65/10.46) 1.00(0.92/1.09) \n  448.00 - 777.00 3.90 - 9.00 5.65 - 10.46 0.92 - 1.09 \nMedium-low  632.33 \u00b1 230.93 4.80 \u00b1 1.30 9.79 \u00b1 3.65 0.95 \u00b1 0.11 \n(35) 597.01 (362.21/1040.85) 4.83 (2.85/6.72) 8.83 (5.96/20.62) 0.94 (0.77/1.16) \n  255.00 - 1636.00 2.10 - 8.10 4.81 - 23.73 0.71 - 1.20 \nMedium- 612.03 \u00b1 226.50 5.46 \u00b1 1.58 9.03 \u00b1 3.81 0.95 \u00b1 0.13 \n medium (62) 576.00 (351.22/1082.72) 5.60 (2.90/8.50) 8.46 (5.54/14.04) 0.94 (0.75/1.19) \n  268.00 - 1563.00 2.10 - 8.80 5.03 - 33.47 0.70 - 1.30 \nMedium-\nhigh  632.57 \u00b1 195.49 6.16 \u00b1 1.99 8.90 \u00b1 2.28 0.96 \u00b1 0.11 \n(30) 587.83 (417.21/1139.44) 5.72 (3.34/11.17) 8.51 (5.91/14.44) 0.95 (0.76/1.13) \n  374.00 - 1311.00 2.70 - 11.30 5.87 - 14.44 0.75 - 1.15 \nHigh (8) 576.38 \u00b1 66.00 6.48 \u00b1 2.48 8.08 \u00b1 1.12 0.93 \u00b1 0.07 \n  586.00 (462.00/668.00) 5.94 (4.10/12.80) 8.35 (6.39/9.51) 0.91 (0.84/1.03) \n  462.00 - 668.00 4.10 - 12.80 6.39 - 9.51 0.84 - 1.03 \n* significant difference ( P<0.05)  \n \n  \n  \n 258 \n \n \n \n \n \n \n \n \nTable 3: Serum Cobalamine, serum folic ac id, and homocysteine values by MTHFR \npolymorphism  \nParameters are shown as mean values \u00b1 SD, median, (2.5th and 97.5th) percentile, \nminimum, and maximum.  \nMTHFR \nPolymorphism \n(n) Serum Cobalamine in \npmol/L Serum folic acid in \nng/mL * Homocysteine in \u00b5mol/L \n* \nnormal (45) 597.24 \u00b1 201.05 5.60 \u00b1 1.53 8.60 \u00b1 1.57 \n  587.51 (252.94/1430.27) 5.50 (2.85/12.10) 8.54 (6.44/13.92) \n  247.00 \u2013 1528.00 2.60 - 12.80 6.39 - 14.39 \nheterozygous (64) 601.78 \u00b1 156.49 5.02 \u00b1 1.56  9.82 \u00b1 3.82 \n  585.97 (296.99/1003.39) 5.04 (2.07/9.12) 9.04 (6.41/24.38) \n  230.00 \u2013 1036.00 2.00 - 11.10  6.40 - 33.47 \nhomozygous (23) \n\u00b0 576.97 \u00b1 198.86 4.45 \u00b1 1.39 11.28 \u00b1 3.81 \n  532.00 (382.77/1220.01) 4.10 (2.75/7.88) 10.83 (7.00/22.82) \n  360.00 \u2013 1311.00 2.70 - 8.10 6.85 - 23.73 \n* significant difference ( P<0.05)  \n\u00b0 5th and 95th percentile   \n  \n 259Table 4: Serum Cobalamine, serum folic acid, homocysteine, and creatinin by age group and gender  \nParameters are shown as mean values \u00b1 SD, median (5th and 95th percentile), minimum, and maximum.  \nAge Gender (n) Serum Cobalamine in \npmol/L  Serum folic acid in \nng/mL  Homocysteine in \n\u00b5mol/L  Creatinin* in mg/dL \n13 All (45) 613.81 \u00b1 209.78 5.78 \u00b1 1.66 8.49 \u00b1 2.23 0.89 \u00b1 0.10 \n  581.55 (269.65/1043.88) 5.62 (3.60/8.61) 7.96 (5.57/13.45) 0.88 (0.72/1.07) \n  255.00 - 1528.00 3.30 - 12.80 5.53 - 14.39 0.70 - 1.10 \n m (18)  533.00 \u00b1 151.72 5.57 \u00b1 1.01 8.63 \u00b1 1.67 0.95 \u00b1 0.09 \n  535.00 (268.00/851.00) 5.20 (4.00/7.60) 8.07 (6.21/11.07) 0.94 (0.85/1.10) \n  268.00 - 851.00 4.00 - 7.60 6.21 - 11.07 0.85 - 1.10 \n f (27)  668.03 \u00b1 227.85 5.92 \u00b1 1.99 8.39 \u00b1 2.57 0.86 \u00b1 0.10 \n  604.12 (376.68/1362.59) 5.80 (3.45/10.98) 7.63 (5.55/14.21) 0.86 (0.71/1.06) \n  255.00 - 1528.00 3.30 - 12.80 5.53 - 14.39 0.70 - 1.07 \n14 All (40)  594.80 \u00b1 226.46 5.42 \u00b1 1.76 9.43 \u00b1 4.61 0.93 \u00b1 0.09 \n  541.07 (316.72/920.72) 5.40 (2.13/8.58) 8.51 (5.50/19.89) 0.92 (0.79/1.13) \n  230.00 - 1636.00 2.10 - 11.10 4.81 - 33.47 0.77 - 1.16 \n m (25) 564.00 \u00b1 141.07 5.71 \u00b1 1.88 9.95 \u00b1 5.50 0.94 \u00b1 0.10 \n  587.81 (326.86/829.05) 5.69 (2.10/10.16) 8.71 (5.51/28.84) 0.92 (0.78/1.12) \n  302.00 - 846.00 2.10 - 11.10 5.50 - 33.47 0.77 - 1.13 \n f (14) 648.75 \u00b1 326.97 4.89 \u00b1 1.45 8.51 \u00b1 2.24 0.91 \u00b1 0.08 \n  536.43 (230.00/1636.00) 4.61 (2.90/8.60) 8.42 (4.81/12.79) 0.91 (0.79/1.16) \n  230.00 - 1636.00 2.90 - 8.60 4.81 - 12.79 0.79 - 1.16 \n15 All (34) 645.28 \u00b1 234.59 5.31 \u00b1 1.87 8.52 \u00b1 2.71 0.94 \u00b1 0.10 \n  615.55 (313.26/1157.52) 5.11 (2.63/10.51) 8.03 (5.47/14.81) 0.92 (0.81/1.13) \n  247.00 - 1563.00 2.00 - 11.30 5.03 - 19.85 0.81 - 1.15 \n m (17) 571.71 \u00b1 139.66 5.50 \u00b1 2.28 9.32 \u00b1 3.31 0.99 \u00b1 0.11 \n  604.59 (247.45/776.69) 5.14 (2.01/11.29) 8.76 (5.53/19.78) 1.01 (0.81/1.15) \n  247.00 - 777.00 2.00 - 11.30 5.52 - 19.85 0.81 - 1.15 \n f (18) 714.28 \u00b1 284.76 5.14 \u00b1 1.43 7.78 \u00b1 1.80 0.89 \u00b1 0.06 \n  637.08 (384.00/1563.00) 5.15 (2.70/7.70) 7.36 (5.03/12.15) 0.90 (0.81/1.06) \n  384.00 - 1563.00 2.70 - 7.70 5.03 - 12.15 0.81 - 1.06 \n16 All (23) 592.91 \u00b1 183.58 5.44 \u00b1 1.68 9.95 \u00b1 3.74 1.03 \u00b1 0.11 \n  553.30 (437.16/1236.92) 5.49 (2.39/8.95) 8.83 (6.20/22.90) 1.02 (0.83/1.29) \n  427.00 - 1311.00 2.20 - 9.00 5.65 - 23.73 0.82 - 1.30 \n m (11) 528.29 \u00b1 89.38 5.53 \u00b1 2.24 11.00 \u00b1 5.09 1.05 \u00b1 0.12 \n  498.00 (427.00/728.00) 5.75 (2.20/9.00) 9.13 (5.65/23.73) 1.03 (0.87/1.30) \n  427.00 - 728.00 2.20 - 9.00 5.65 - 23.73 0.87 - 1.30 \n f (12) 655.62 \u00b1 230.26 5.35 \u00b1 0.98 8.93 \u00b1 1.22 1.00 \u00b1 0.11 \n  587.06 (493.00/1311.00) 5.45 (4.00/7.30) 8.82 (6.91/11.72) 1.02 (0.82/1.20) \n  493.00 - 1311.00 4.00 - 7.30 6.91 - 11.72 0.82 - 1.20 \n17- All (19) 630.42 \u00b1 163.62 4.60 \u00b1 1.29 9.52 \u00b1 2.50 1.07 \u00b1 0.08 \n18.5  565.14 (475.00/984.00) 4.64 (2.90/6.50) 9.29 (6.08/14.44) 1.08 (0.94/1.24) \n  475.00 - 984.00 2.90 - 6.50 6.08 - 14.44 0.94 - 1.24 \n m (11) 608.50 \u00b1 179.11 4.08 \u00b1 1.04 10.80 \u00b1 1.97 1.11 \u00b1 0.07 \n  542.00 (475.00/984.00) 4.15 (2.90/5.60) 10.18 (9.04/14.44) 1.10 (1.03/1.24) \n  475.00 - 984.00 2.90 - 5.60 9.04 - 14.44 1.03 - 1.24 \n f (8) 659.29 \u00b1 146.99 5.27 \u00b1 1.32 7.83 \u00b1 2.14 1.02 \u00b1 0.06 \n  593.00 (536.00/954.00) 5.90 (2.90/6.50) 7.02 (6.08/12.15) 1.01 (0.94/1.13) \n  536.00 - 954.00 2.90 - 6.50 6.08 - 12.15 0.94 - 1.13  \n  \n 260*age 15: creatinin all (n = 33). male (n = 16) \n \n \nTable 5: Serum cobalamine, serum folic acid, and homocysteine in percentiles \n  Percentiles \nsex age 5 10 15 25 50 75 85 90 95 \nSerum Cobalamine in \npmol/L         \nm 13 268.0 337.4 404.7 446.2 535.0 590.2 763.1 812.7 851.0 \n 14 326.9 360.2 372.6 474.2 587.8 653.8 718.1 759.9 829.1 \n 15 247.5 313.9 447.1 476.0 604.6 661.6 721.6 738.7 776.7  16 427.0 438.0 448.3 453.9 498.0 600.7 654.7 708.1 728.0  17 475.0 475.0 475.0 532.0 542.0 576.0 984.0 984.0 984.0 \nf 13 376.7 492.1 510.3 554.1 604.1 725.4 824.3 908.2 1362.6 \n 14 230.0 360.8 421.4 465.9 536.4 843.5 905.5 1209.1 1636.0 \n 15 384.0 445.3 452.9 532.3 637.1 868.3 1037.0 1101.9 1563.0  16 493.0 505.0 523.2 533.0 587.1 621.2 968.9 1211.1 1311.0  17 536.0 536.0 540.2 556.0 593.0 757.0 913.0 954.0 954.0 \nSerum Folic acid in \nng/mL         \nm 13 4.0 4.4 4.8 4.9 5.2 6.2 7.1 7.4 7.6 \n 14 2.1 2.2 4.2 4.9 5.7 6.7 7.4 8.2 10.2 \n 15 2.0 3.4 3.8 3.9 5.1 5.9 7.9 10.5 11.3 \n 16 2.2 2.4 2.7 3.8 5.7 7.5 8.8 8.9 9.0 \n 17 2.9 2.9 2.9 2.9 4.2 4.8 5.6 5.6 5.6 \nf 13 3.5 3.6 3.8 4.3 5.8 7.1 7.6 8.5 11.0 \n 14 2.9 3.2 3.5 3.9 4.6 5.8 6.4 7.3 8.6  15 2.7 3.2 3.6 3.9 5.2 6.3 6.8 7.4 7.7  16 4.0 4.0 4.1 4.5 5.4 6.0 6.5 7.1 7.3  17 2.9 2.9 3.1 4.0 5.9 6.3 6.5 6.5 6.5 \nHomocysteine in \u00b5mol/L         \nm 13 6.2 6.6 6.9 7.5 8.1 10.7 10.9 11.0 11.1 \n 14 5.5 6.3 6.9 7.5 8.7 9.6 12.1 17.3 28.8 \n 15 5.5 6.2 6.3 6.9 8.8 10.5 11.6 14.8 19.8  16 5.7 6.4 7.4 8.4 9.1 12.1 20.0 22.8 23.7  17 9.0 9.0 9.0 9.3 10.2 11.6 14.4 14.4 14.4 \nf 13 5.5 5.6 5.9 6.3 7.6 10.0 11.3 12.8 14.2 \n 14 4.8 5.7 6.2 6.9 8.4 9.8 11.7 12.4 12.8  15 5.0 6.0 6.4 6.4 7.4 8.9 10.0 10.9 12.2 \n 16 6.9 7.2 7.7 8.2 8.8 9.8 10.0 11.2 11.7 \n 17 6.1 6.1 6.1 6.3 7.0 9.2 11.5 12.2 12.2 \n  \n  \n 261Male Female\nGender0,0010,0020,0030,00Homocysteine in \u00b5mol/L76\n164778081\n \nFigure 1: Distribution of homocysteine by gender \nThe lower and upper lines of the box correspond to the 25th and 75th percentiles, \nrespectively. The line in the middle of the box represents the median. The error bars \nare situated at minimum and maximum. \u00b0 outliners; * extreme values.  \n \nMale Female\nGender50010001500Serum Cobalamin in pmol/L51\n1471058512210182\n \nFigure 2: Distribution of serum cobalamin by gender  \nThe lower and upper lines of the box correspond to the 25th and 75th percentiles, \nrespectively. The line in the middle of the box represents the median. The error bars \nare situated at mi nimum and maximum. \u00b0 outliners; * extreme values.   \n  \n 262Male Female\nGender0,600,700,800,901,001,101,201,30Creatinine in mg/dL82150\n \nFigure 3: Distribution of creatinin by gender \nThe lower and upper lines of the box correspond to the 25th and 75th percentiles, \nrespectively. The line in the middle of the box represents the median. The error bars \nare situated at minimum and maximum. \u00b0 outliners; * extreme values.  \nlow medium-low medium medium-high high\nSocioeconomic status2,04,06,08,010,012,014,0Serum folic acid in ng/mL60\n4107\n \nFigure 4: Distribution of serum folic  acid by socioeconomic status \nThe lower and upper lines of the box correspond to the 25th and 75th percentiles, respectively. \nThe line in the middle of the box represents the median. The error bars are situated at minimum \nand maximum. \u00b0 outliners; * extreme values.   \n  \n 263normal heterozygous homozygous\nMTHFR Polymorphism5,0010,0015,0020,0025,0030,0035,00Homocysteine in \u00b5mol/L1657678777981\n80\n \nFigure 5: Distribution of homocy steine by MTHFR Polymorphism \nThe lower and upper lines of the box correspond to the 25th and 75th percentiles, respectively. \nThe line in the middle of the box represents the median. The error bars are situated at minimum \nand maximum. \u00b0 outliners; * extreme values. \nnormal heterozygous homozygous\nMTHFR Polymorphism2,04,06,08,010,012,014,0Serum folic acid in ng/mL\n694660\n6334107\n \nFigure 6: Distribution of serum folic acid by MTHFR Polymorphism  \nThe lower and upper lines of the box correspond to the 25th and 75th percentiles, respectively. \nThe line in the middle of the box represents the median. The error bars are situated at minimum \nand maximum. \u00b0 outliners; * extreme values.  \n  \n  \n \n \n     \n \n     \n \n    \n \n     \n \n   \nTHE AVENA STUDY  \n  \n 265Cardiovascular fitness is negatively associated with homocysteine \nlevels in female adolescents    Jonatan R. Ruiz, BSc; Ricardo Sola, MD, Marcela Gonzalez-Gross, PhD; \nFrancisco B. Ortega, BSc; Vicente-Rodriguez G, PhD; Miguel Garcia-Fuentes, MD, PhD; Angel Gutierrez, MD, PhD; Michael Sj\u00f6str\u00f6m, MD, PhD; Klaus Pietrzik, PhD; Manuel J. Castillo MD, PhD.  Department of Medical Physiology, School of Medicine, University of \nGranada, 18071 Granada, Spain (Jonatan R Ruiz, Ricardo Sola, Marcela \nGonzalez-Gross, Francisco B Orteg a, Angel Gutierrez, and Manuel J \nCastillo); Unit for Preventive Nutrition, Department of Biosciences and Nutrition at NOVUM, Karolinska Institutet, Huddinge, Sweden (Jonatan R Ruiz, Francisco B Ortega, and Michael Sj\u00f6str\u00f6m); Unit of Hematology, University Hospital San Cecilio (Ricardo Sola); E. U. \nCiencias de la Salud, University of Zaragoza, Spain (German Vicente-\nRodriguez); School of Sport Sciences, Universidad Polit\u00e9cnica de Madrid. Spain (Marcela Gonz\u00e1lez-Gro ss); Department of Pediatrics, \nUniversity of Cantabria, Santander, Sp ain (Miguel Garcia-Fuentes); and \nInstitut fuer Ernaehrungswissensch aft, Abt. Pathophysiologie der \nErn\u00e4hrung, Rheinische Friedrich-Wilhelms Universit\u00e4t, Bonn, Germany \n(Klaus Pietrzik).    \nWord Count:  2625 \n  \n  \n 266ABSTRACT \n Background: Homocysteine has been suggested to be an independent \nrisk factor for several multi-system  diseases. Low cardiovascular fitness \nis another important health pr oblem. The association between \ncardiovascular fitness and homocystei ne levels in adolescents is not \nknown.  \nObjectives: To examine the association between cardiovascular fitness \nand homocysteine levels in adolescents. \nDesign:  Cross-sectional study. A tota l of 156 Spanish adolescents (76 \nmales, and 80 females), aged 14.8 \u00b1 1.4 years old were studied. Cardiovascular fitness was measured by the 20 m shuttle run test. Genotyping for the methylenetetrahydrofolate reductase (MTHFR) 677C>T polymorphism was done by DNA sequencing. Fasting homocysteine levels was the outcom e variable. Multiple regressions \nwere used to determine the degr ee to which the variance in \nhomocysteine was explained by cardiovascular fitness after controlling \nfor age, puberty, birth weight, smoking, socioeconomic status, sum of six skinfolds, serum folate and vitamin B\n12, and MTHFR 677C>T \ngenotype.  \nResults: Cardiovascular fitness was sign ificantly associated with \nhomocysteine levels in female adolescents after controlling for potential confounders.  Mean values of homocy steine were significantly higher in \nthe MTHFR 677CT and TT subgroups co mpared to the CC subgroup in \nmales, while in females, mean values  of homocysteine were significantly \nhigher in the TT subgroup comp ared to CC and CT subgroup.  \nConclusions: The results suggest that cardiovascular fitness is \nnegatively associated with homocystei ne levels in female adolescents, \neven after controlling for MTHFR 677C>T genotype, which show an \ninfluence on homocysteine levels in both male and female adolescents.   \n  \n 267INTRODUCTION \n \nHomocysteine has been suggested  to be an independent risk \nfactor for several multi-system diseases,\n1 including coronary heart \ndisease,2,3 stroke,4 dementia and Alzheimer \u02b9s disease,5 risk of hip \nfracture,6 and pregnancy complications.7 Moreover, elevated \nhomocysteine levels have been a ssociated with increased oxidative \nstress and endothelial damage,8,9 although the mechanisms are yet \nclarified.  In children, it has been  shown that elevated homocysteine \nlevels are positively associated wi th cardiovascular disease in their \nparents,10,11 grandparents,2,13 and relatives.14 \nHomocysteine levels are influenced by modifiable and non-\nmodifiable factors. Among the latte r, age and gender seem to play a \nspecific role. Levels of homocysteine are  higher in boys than in girls, and \nthis gender effect seems to be enhanced during and after puberty.15 \nGenetic factors also seem to affect homocysteine levels.16 The most \ncommon mutation in the European population is the \nmethylenetetrahydrofolate reductase (MTHFR) polymorphism 677C>T.\n17 \nDeficient serum levels of both folate and vitamin B 12 have been \nassociated with elevated homocysteine levels in children,18 adults,19 and \nin the elderly.20 Lifestyles factors such as smoking, lack of physical \nactivity, excessive alcohol intake and obesity have been associated with elevated levels of homocysteine in adults.\n19,21,22 \nPoor cardiovascular fitness (CVF) is another important risk factor \nfor cardiovascular disease and it has also been shown to be a predictor \nof morbidity and all cause mortality.23-25 Kuo and colleagues26 have \nrecently described a significant ne gative association between CVF and \nhomocysteine levels in adult wome n. Cardiovascular fitness has been \nnegatively associated with features of the metabolic syndrome in children and adolescents,\n27,28 and with plasma lipid profile in both \noverweight and non-overweight adolescents.29 However, studies \nexamining the association between CVF and homocysteine levels in \nadolescents are lacking. For public health strategies and preventive \np u r p o s e s  i t  i s  o f  i n t e r e s t  t o  u n derstand the relative influence of \nmodifiable factors on homocysteine levels from an early age. Therefore, the aim of this study was to examine, in a dataset of Spanish adolescents, the associations of homo cysteine with CVF after controlling \nfor potential confounders.  \n  \n 268METHODS \nParticipants \nThe studied adolescents were a subsample of the AVENA study \n(Alimentaci\u00f3n y Valoraci\u00f3n del Estado Nutricional de los Adolescentes \nEspa\u00f1oles: Food and Assessment of the Nutritional Status of Spanish \nAdolescents). The AVENA Study was de signed to assess the health and \nnutritional status of adolescents. Da ta collection took place from 2000 to \n2002 in five Spanish cities (Madrid, Murcia, Granada, Santander and Zaragoza). The present report is base d on the adolescents in which both \nhomocysteine and MTHFR genotypes were measured (n = 156, 76 males, \nand 80 females). The AVENA study desi gn has been reported in detail \nelsewhere.\n30-32  \nA comprehensive verbal description of the nature and purpose of \nthe study was given to both the adolescents and their teachers. Written consent to participate was requested from both parents and adolescents. \nExclusion criteria were: no personal history of cardiovascular or \nmetabolic disease; free of disease an d medication at the time of the \nstudy; and pregnancy. The study prot ocol was performed in accordance \nwith the ethical standards laid down  in the 1961 Declaration of Helsinki \n(as revised in Hong-Kong in 1989, and in Edinburgh in 2000), and approved by the Review Committ ee for Research Involving Human \nSubjects of the Hospital Universitari o Marqu\u00e9s de Valdec illa (Santander, \nSpain). \nBefore any testing was performed, the parents completed a \nquestionnaire part of which addressed the child\u2019s previous and current health status. Socioeconomic st atus was also assessed via the \nquestionnaire, and was defined by the educational level and occupation of \nthe father. According to this information, and following the \nrecommendation of the Spanish Society for Epidemiology,\n33 the \nadolescents were classified into five categories: low, medium-low, medium, medium-high and high  socioeconomic status.  \nSmoking habits at the time of  the study were reported via \nquestionnaire by the adolescents, and categorized as smoking, non-\nsmoking, and partial smoker.  \nPhysical examination \nHeight and weight were measured by standardized procedures. \nBody mass index (BMI) was calculated as weight/height squared (kg/m\n2). Skinfold thicknesses were me asured with a Holtain skinfold  \n  \n 269caliper at the biceps, triceps, subsca pular, suprailiac, thigh and calf on \nthe left side of the body to the nearest 0.2 mm.\n34-36 The complete set of \nanthropometric measurements was performed three times, but not \nconsecutively. The anthropometric variables were measured in order \nand then the same measurements wer e repeated two more times. For \ncalculations, mean values were obta ined from the three measurements. \nIntra-observer reliability for skinfold  thickness was higher than 95% for \nalmost all the cases; inter-observer reliability for skinfold thickness ranged from 83.05 for biceps skinfold to 96.38 for calf skinfolds.\n36 The \nsum of the six skinfold thicknesses was used as an indicator of body fat. \nThese measures have been shown to correlate highly with dual-energy \nX-ray absorptiometry-measured body fat percentage in adolescents of \nsimilar ages.37  \nIdentification of pubertal development was assessed according to \nTanner & Whitehouse.38 Self-reported breast development in girls, and \ngenital development in boys, was used for pubertal stage classification.  \nMeasurement of cardiovascular fitness \nCardiovascular fitness was assesse d by the 20 m shuttle run test \nas previously described.39 Briefly, participants were required to run \nbetween two lines 20 m apart, while keeping pace. Running pace was \ndetermined by audio signals emitted from a pre-recorded cassette tape. \nThe initial speed was 8.5 km \u22c5h-1, which was increased by 0.5 km \u22c5h-1 per \nminute (one minute equal to one stage). The tape used was calibrated over one minute. Subjects were instru cted to run in a straight line, to \npivot upon completing a shuttle, and to pace themselves in accordance \nwith the audio signals. The test was finished when the subject failed to \nreach the end lines concurrent with the audio signals on two \nconsecutive occasions. Otherwise, the test ended when the subject \nstopped because of fatigue. All me asurements were carried out under \nstandardized conditions on an indoor rubber floored gymnasium. \nConstant vocal encouragement was given to participants throughout the test. All participants were very well familiarized with the test, since the \n20 m shuttle run test is one of the fi tness tests included  in the physical \neducation curriculum in our country. Adolescents were instructed to \nabstain from strenuous exercise in the 48 hours preceding the test. \nCardiovascular fitness was considered as the number of stages \ncompleted (precision of 0.5 steps), wh ere this number was converted to \npredict maximal oxygen consumption (VO\n2max, mL\u22c5kg-1\u22c5min-1) by the \nLeger\u2019s equation:39 VO 2max = 31.025+3.238S-3.248A+0.1536SA, where A is \nthe age, and S the final speed (S = 8+0.5 x number of stages completed).  \n  \n 270Homocysteine, serum folate and vitamin B\n12 assays \nWith the subject in the supine position, blood samples were taken \nby venipuncture after an overnight fast, using vacuum tubes (Vacutainer) and placed on ice i mmediately. The fasting state was \nverbally confirmed by the subject before blood sampling. All samples \nwere processed within 1 h by centrifugation, divided aliquots, and portions were stored at -80\u00b0C until withdrawn for analysis.  \nHomocysteine in acidified citrated plasma\n40 was assayed using a \nfluorescence polarization immunoassay on a IMx\u00ae unit (Abbott \nLaboratories, IL, USA). Serum folate and vitamin B 12 levels were \nmeasured using the flourometric  method with an Abbot IMx\u00ae \nautoanalyser (Abbot Laboratory, Chicago, USA).  \nMTHFR genotyping  \nTotal blood DNA was extracted and purified from 500 \u00b5L of \nwhole blood anticoagulated with EDTA, using the Quiagen procedure described by Higuchi.\n41 Genotyping of the 677C>T variant in the human \nMTHFR gene was performed by means of polimerase chain reaction and \nallele-specific restriction digestion of the amplified products with the \nrestriction enzyme Hinf I (GE Health care), as previously described by \nFrosst et al.17 \nStatistical analysis \nThe data are presented as means \u00b1 SDs, unless otherwise stated. \nAfter serum folate and vitamin B 12 were normalized by natural \nlogarithm transformation, all the residuals showed a satisfactory \npattern. \nThe impact on homocysteine of gender and MTHFR 677C>T were \nanalyzed by one-way analysis of variance (ANOVA) since there was a \nsignificant interaction between gender and MTHFR 677C>T, and the \nsubgroup means were comp ared by Tukey\u2019s test.  \nFollowing a bivariate correlation analysis, multiple regressions \nwere used to study the relation be tween homocysteine and CVF after \ncontrolling for potential confounders. We used an extended-model approach: Model 1 examined the influence of CVF on homocysteine \nlevels after controlling for age, puberty, birth weight, smoking, \nsocioeconomic status, and sum of si x skinfolds; Model 2 examined the \ninfluence of CVF on homocysteine levels after controlling for the \nconfounders included in the Model 1 plus serum folate and vitamin B\n12; \nModel 3 examined the influence of CVF on homocysteine levels after  \n  \n 271controlling for the cofounders includ ed in the Model 1 and Model 2 plus \nthe MTHFR 677C>T genotype. Semipartial correlation ( sr) was used as a \nmeasure of the relationship bet ween CVF and homocysteine after \ncontrolling for the effect that on e or more additional variables ( e.g. age, \nbirth weigth, etc.) had on one of those variables. The analyses were \nperformed using the Statistical Package for Social Sciences (SPSS, v. 14.0 \nfor WINDOWS; SPSS Inc, Chicago), and the level of significance was set to = .05. \n  \n  \n 272RESULTS \nData completeness and ba seline characteristics \nBoth homocysteine and MTHF R genotype were measured in156 \nadolescents (76 males, and 80 female s). Of these, 77% had valid CVF \ndata as determined by the criter ia explained in the material and \nmethods section. Pubertal development were obtained from 96%, and 94% had skinfolds thickness data. Bi rth weight, socioeconomic status, \nand smoking habit information were available for 93, 87 and 71% of the subjects, respectively. \nThe descriptive characteristics of the study sample are shown in \nTable 1. Males were significantly heavier and taller than females, and \nfemales had significantly higher skinfolds thicknesses. Males had \nsignificantly higher levels of ho mocysteine, lower levels of serum \nvitamin B\n12, and significantly higher CVF (Table 1).     \nMeans values of homocysteine wer e significantly higher in the \nCT and TT subgroups compared to th e CC subgroup in males, while in \nfemales, mean values of homocystei ne were significantly higher in the \nTT subgroup compared to the CC and CT subgroups (Table 2).  \nBivariate associations separated by gender \nIn females, homocysteine was ne gatively associated with CVF ( r = \n-0.38; P = .022) and with serum folate and vitamin B 12 (r = -0.68; P < .001, \nand r = -0.40; P = .017, respectively).  Smoking was negatively correlated \nwith CVF ( r = -0.32; P = .047). In males, homocysteine was negatively \nassociated with serum folate ( r = -0.62; P < .001), and sum of six skinfolds \nnegatively associated with CVF ( r = -0.64; P < .001).  \nRelations, between homocysteine  and cardiovascular fitness controlling for \ndifferent confounders and separated by gender \nThe results of the regression mo dels using homocysteine as the \noutcome variable are shown in Table 3. Variation in homocysteine levels \nwas significantly explained by CVF in female adolescents after controlling for age, puberty, birt h weight, smoking, socioeconomic \nstatus, and sum of six skinfolds (Mod el 1).  Additional adjustments for \nserum folate and B\n12 (Model 2), and MTFHR 677C>T (Model 3) further \nstrengthened the association be tween homocysteine and CVF in \nfemales. No significant association was found between homocysteine and CVF in male adolescents.  \n  \n 273DISCUSSION \nThe results of this study suggest th at CVF is negatively associated \nwith homocysteine levels in female adolescents, but not associated with \nhomocysteine levels in male adolescents. The results also suggest that \nhomocysteine levels are higher in males than in females, that serum \nfolate and vitamin B\n12 are negatively associated with homocysteine \nlevels, and that MTHFR 677C>T plays and important role in homocysteine levels. There exist no other available data on the association of homocysteine leve ls with CVF in adolescents.  \nCardiovascular fitness is a direct marker of physiological status \nand reflects the overall capacity of the cardiovascular and respiratory \nsystems and the ability to carry out prolonged strenuous exercise.\n42 \nTheoretically, low CVF may be the consequence of pathological changes peripherally affecting the tissues and the associated vasculature or centrally perturbing coronary arter ies and the heart. High CVF during \nchildhood and adolescence has been  associated with a healthier \nmetabolic profile during these years.\n28,29 Moreover, CVF has recently \nbeen associated with arterial comp liance in children aged 9-11 years, \nwhich supports the concept that CVF may exert a protective effect on the cardiovascular system from an early age.\n43 It is biologically plausible \nthat high CVF provides more health protection than low CVF, even in \nhealthy adolescents as has been found in adults.23-25  \nHomocysteine is metabolized to homocysteine-thiolactone by \nmethionyl-tRNA synthetase. Homocyst eine-thiolactone acylates lysine \nresidues of proteins, a process called protein homocysteinylation.44 \nProtein homocysteinylation is a po ssible mechanism of homocysteine-\nrelated protein damage, which in conjunction with the increased \noxidative stress and endothelial damage  seen in subjects with elevated \nhomocysteine levels may result in impaired CVF.9 However, this can not \nexplain why the association between homocysteine and CVF exists only in female adolescents. Our findings  support a previous study examining \nthe relationship between homo cysteine and CVF in adults.\n26 Kuo et al.26 \nwhich showed that high homocysteine levels were negatively associated \nwith estimated CVF in adult women.  However, they did not find any \nassociation in men, which is in concordance with our results. These results suggest sex hormones may pl ay a role in mediating the CVF- \nhomocysteine association, exerting di fferent effects in females than in \nmales; however further studies to determine whether this is the case are \nneeded. One longitudinal study followed 499 independent community-\ndwelling elderly for 3 years and found that people with elevated  \n  \n 274homocysteine levels were at an incr eased risk of decline in physical \nfunction.\n45 However, CVF data were not provided and a gender \ncomparison was not performed. \nIn the present study, CVF was ob jectively measured by the 20 m \nshuttle run test. The reliability and vali dity of this test  has been widely \ndocumented in adolescents.46-48 We did not have a direct measure of \nmaximal oxygen uptake, the most valid method of measuring CVF. However, from a practical point of view, field tests may be a better option than laboratory testing (espec ially in epidemiological studies) \nbecause a large number of subjects ca n be tested at the same time, which \nenhances the motivation of the part icipants, and the tests are simple, \nsafer, and often the only feasible ch oice, especially in schools settings. \nThe 20 m shuttle run test has been shown to meet these criteria. Cardiovascular fitness was consider ed as the number of stages \ncompleted in the 20 m shuttle run test  (precision 0.5 step) for being the \nmost direct measure obtained. Ho wever, CVF estimated from Leger\u2019s \nequation (VO\n2max, ml/kg/min) was also provided for the purpose of \nmaking comparisons with other stud ies possible. When the analyses \nwere performed using VO 2max, or speed (km/hr) instead of the number of \nstages as the measurement of CVF, similar results were obtained (data \nnot shown). \nThe results from the present stud y should be interpreted with \ncaution due to the limitations of the cross-sectional design, i.e., direction of causality can not be determined. Elevated homocysteine levels may be simply a marker of an unhealthy lif estyle that is associated with poor \nexercise capacity. The relationship between levels of homocysteine and \nCVF should be studied prospectively. It must be borne in mind is that \nthe subjects involved in this stud y were healthy adolescents with no \npreviously diagnose cardiovascular pathologies. Also, our study included a moderate number of part icipants. However, we believe that \ncovariates that may confound the me asures of association in our study \nwere appropriately considered and controlled.  \nIn conclusion, the results of this study suggest that CVF is \nnegatively associated with homocystei ne levels in female adolescents, \neven after controlling the MTHFR 677C>T genotype, which shows an \ninfluence on homocysteine levels in both male and female adolescents.  These results should stimulate a deba te on whether the metabolism of \nhomocysteine could be one way in wh ich the benefits of high CVF are \nexerted, at least in females.  \n  \n 275Correspondence:  Jonatan R. Ruiz, BSc, Department of Medical \nPhysiology, School of Medicine, University of Granada, 18071 Granada, \nSpain. Tel:  +34 958 243 540, Fax:  +34 958 249 015. E-mail: ruizj@ugr.es\n  \n Funding/support : This study was supported by the Spanish Ministry of \nHealth Instituto de Salud Carlos III (FIS PI021830). The AVENA study \nwas funded by the Spanish Ministry of Health, FEDER-FSE funds FIS n\u00ba 00/0015, CSD grants 05/UPB32/0, 109/UPB31/03 and 13/UPB20/04, the Spanish Ministry of Education  (AP2003-2128; AP-2004-2745), and \nscholarships from Panrico S.A., Madaus S.A. and Procter and Gamble \nS.A.  \n \nAcknowledgement : The authors thank Prof. Olle Carlsson from the \nUnit for Preventive Nutrition, Dep artment of Biosciences and Nutrition \nat NOVUM, Karolinska Institutet, for statistical assistance. \n \nFurther information: MCG, MGG, AGS, MGF,  contributed to the \nconcept and study design. JRR, RS, MGG, FOP, AGS, MCG performed \nthe data collection. JRR, RS, MGG, MCG conceived the hypothesis, and \nJRR conducted the statistical analyses and drafted the manuscript. All \nauthors contributed to the interpretation and discussion of the results, and critically revised the drafted manuscript.  \n \nConflict of interest : None of the authors had any conflict of interest. No \nbenefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this \narticle.   \n  \n 276REFERENCES \n \n1. Virtanen JK, Voutilainen S, Alfthan G, Korhonen MJ, Rissanen \nTH, Mursu J, et al. Homocystei ne as a risk factor for CVD \nmortality in men with other CVD risk factors: the Kuopio \nIschaemic Heart Disease Risk Factor (KIHD) Study. J Int Med.  \n2005; 257: 255-262. \n2. Homocysteine Studies Collaboration. Homocysteine and risk of \nischemic heart disease and stroke: a meta-analysis. JAMA.  2002; \n288: 2015-2022.  \n3. Vrentzos GE, Papadakis JA, Malliaraki N, et al. Diet, serum \nhomocysteine levels and ischaemic heart disease in a Mediterranean population. Br J Nutr.  2004; 91: 1013-1019.  \n4. Ford ES, Smith SJ, Stroup DF, Steinberg KK, Mueller PW, Thacker \nSB. Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case\u2013control \nstudies and nested case\u2013control studies. Int J Epidemiol. 2002; 31: \n59-70. \n5. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a \nrisk factor for dementia and Alzheimer \u02b9s disease. N Engl J Med.  \n2002; 346: 476-483. \n6. McLean RR, Jacques PF, Selhub J et al. Homocysteine as a \npredictive factor for hip fracture in older persons. N Engl J Med.  \n2004; 350: 2042-2049. \n7. Hague WM. Homocysteine and pregnancy. Best Practice. Res Clin \nObstet Gynaecol.. 2003; 17: 459-469. \n8. Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin \nInvest.  1996; 98: 5-7. \n9. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N \nEngl J Med.  1998; 338: 1042-1050.  \n10. Greenlund KJ, Srinivasan SR, Xu JH, et al. Plasma homocysteine \ndistribution and its association wi th parental history of coronary \nartery   disease in black and white children: the Bogalusa Heart \nStudy. Circulation.  1999; 99: 2144-2149. \n11. Kark JD, Sinnreich R, Rosenberg IH, Jacques PF, Selhub J. Plasma \nhomocysteine and parental myocardial infarction in young adults in Jerusalem. Circulation.  2002; 105: 2725-2729.   \n  \n 27712. Hyanek J, Stribrny J, Sebesta P, et al. Diagnostic significance of \nmild hyperhomocysteinemia in a population of children with \nparents or grandparents who have peripheral or coronary artery disease. Cas Lek Cesk.  1999; 138: 333-336. \n13. Morrison JA, Jacobsen DW, Sprecher DL, Robinson K, Khoury P, \nDaniels SR. Serum glutathione in adolescent males predicts parental coronary heart disease. Circulation.  1999; 100: 2244-2247.  \n14. Tonstad S, Refsum H, Sivertsen M, Christophersen B, Ose L, \nUeland PM. Relation of total homocysteine and lipid levels in children to premature cardiovascu lar death in male relatives. \nPediatr Res.  1996; 40: 47-52.  \n15. De Laet C, Wautrecht JC, Brasseur D, et al. Plasma homocysteine \nconcentration in a Belgian school-age population. Am J Clin Nutr.  \n1999; 69: 968-672. \n16. Gonzalez-Gross M, Marcos A, Piet rzik K. Nutrition and cognitive \nimpairment in the elderly. Br J Nutr.  2001; 86: 313-321.  \n17. Frosst P, Blom HJ, Milos R, et al . A candidate genetic risk factor \nfor vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet.  1995; 10: 111-\n113.  \n18. Papoutsakis C, Yiannakouris N, Manios Y, et al. Plasma \nhomocysteine levels in Greek children are influenced by an \ninteraction between the methyl enetetrahydrofolate reductase \nC677T genotype and folate status. J Nutr.  2005; 135: 383-388. \n19. Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, \nSelhub J. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. Am J Clin \nNutr.  2001; 73: 613-621. \n20. Selhub J, Jacques PF, Wilson PW, Rush D, Rosenberg IH. Vitamin \nstatus and intake as primary determinants of homocysteinemia in an elderly population. JAMA.  1993; 270: 2693-2698.  \n21. Nygard O, Refsum H, Ueland PM, Vollset SE. Major lifestyle \ndeterminants of plasma total homocysteine distribution: the \nHordaland Homocysteine Study. Am J Clin Nutr.  1998; 67: 263-\n270.  \n  \n 27822. Silaste ML, Rantala M, Alfthan G, Aro A & Kesaniemi YA. \nPlasma homocysteine concentration is decreased by dietary intervention. Br J Nutr.  2003 89: 295-301.  \n23. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. \nExercise capacity and mortality among men referred for exercise \ntesting. N Engl J Med.  2002; 346: 793-801.  \n24. Carnethon MR, Gidding SS, Nehgme R, Sidney S, Jacobs DR, Liu \nK. Cardiorespiratory fitness in young adulthood and the \ndevelopment of cardiovascular disease risk factors. JAMA.  2003; \n290: 3092-3100. \n25. LaMonte MJ, Barlow CE, Jurca R,  Kampert JB, Church TS, Blair \nSN. Cardiorespiratory fitness is inversely associated with the incidence of metabolic syndrome: a prospective study of men and women. Circulation.  2005; 26: 505-512.  \n26. Kuo HK, Yen CJ, Bean JF. Levels of homocysteine are inversely \nassociated with cardiovascular fitness in women, but not in men: \ndata from the National Health and Nutrition Examination Survey \n1999-2002. J Intern Med.  2005; 258: 328-335. \n27. Mesa JL, Ortega FB, Ruiz JR, Castillo MJ, Hurtig Wennl\u00f6f A, \nGuti\u00e9rrez A. The importance of  cardiorespiratory fitness for \nhealthy metabolic traits in children and adolescents. The AVENA \nStudy. J Public Health.  2006; 14: 178-180. \n28. Ruiz JR, Ortega FB, Meusel D, Harro M, Oja P, Sj\u00f6str\u00f6m M. \nCardiorespiratory fitness is associated with features of metabolic risk factors in children. Should cardiorespiratory fitness be assessed in a European health mo nitoring system? The European \nYouth Heart Study. J Public Health.  2006; 14: 94-102. \n29. Mesa JL, Ruiz JR, Ortega FB, Warnberg J, Gonzalez-Lamuno D, \nMoreno LA, Gutierrez A, Castillo MJ. Aerobic physical fitness in \nrelation to blood lipids and fasting glycaemia in adolescents: Influence of weight status. Nutr Metab Cardiovasc Dis.  2006; 16: \n285-293.  \n30. Gonzalez-Gross M, Castillo MJ, Moreno L, et al. [Feeding and \nassessment of nutritional status  of spanish adolescents (AVENA \nstudy). Evaluation of risks an d interventional proposal. I. \nMethodology]. Nutr Hosp.  2003; 18: 15-28.   \n  \n 27931. Moreno LA, MI Mesana, Fleta J, et al. Overweight, obesity and \nbody fat composition in Spanish adolescents. The AVENA Study. \nAnn Nut Metab.  2005; 49: 71-76 . \n32. Ruiz JR, FB Ortega, LA Moreno, et al. Serum lipid and lipoprotein \nreference values of Spanish adolescents; The AVENA study. Soz \nPraventivMed.  2006; 51: 99-109. \n33. Sociedad Espa\u00f1ola de Epidemiolog\u00eda. La medici\u00f3n de la clase \nsocial en Ciencias de la Salud. Informe de un grupo de trabajo de la Sociedad Espa\u00f1ola de Epidemiolog\u00eda. Barcelona: SG Editores, 1995. \n34. Moreno LA, Rodr\u00edguez G, Guill\u00e9 n J, Rabanaque MJ, Le\u00f3n JF, \nAri\u00f1o A. Anthropometric measur ements in both sides of the \nbody in the assessment of nutr itional status in prepubertal \nchildren. Eur J Clin Nutr.  2002; 56: 1208-1215. \n35. Moreno LA, Mesana MI, Gonz\u00e1lez-Gross M, et al. \nAnthropometric body fat composition reference values in \nSpanish adolescents. The AVENA Study. Eur J Clinical Nutr.  2006; \n60: 191-196. \n36. Moreno LA, Joyanes M, Mesana MI, et al. Harmonization of \nanthropometric measurements for a multicenter nutrition survey \nin Spanish adolescents. Nutrition.  2003; 19: 481-486. \n37. Rodriguez G, Moreno LA, Blay MG, et al. Body fat measurement \nin adolescents: comparison of sk infold thickness equations with \ndual-energy X-ray absorptiometry. Eur J Clin Nutr. 2005; 27: 1-9. \n38. Tanner JM, Whitehouse RH. Clinic al longitudinal standards for \nheight, weight, height velocity and stages of puberty. Arch Dis \nChild.  1976; 51: 170-179.  \n39. L\u00e9ger LA, Lambert A, Goulet A, Rowan C, Dinelle Y. Capacity \naerobic des Quebecois de 6 a 17 an s \u2013 test Navette de 20 metres \navec paliers de 1 minute. Can J Appl Sport Sci. 1984; 9: 64-69.  \n40. Willems HP, Bos GM, Gerrits WB, den Heijer M, Vloet S, Blom \nHJ. Acidic citrate stabilizes blood samples for assay of total homocysteine. Clin Chem.  1998; 44: 342-345. \n41. Higuchi R. \u02baSimple and rapid preparation of samples for PCR. \nEn: Erlich H editores. PCR Technology. Stockton Press 1989: 31-37.  \n  \n 28042. Taylor HL, Buskirk E, Henschel A. Maximal oxygen uptake as an \nobjective measure of cardiorespiratory performance. J Appl \nPhysiol.  1995; 8: 73-80.  \n43. Reed KE, Warburton DE, Lewanczuk RZ, et al. Arterial \ncompliance in young children: the role of aerobic fitness. Eur J \nCardiovasc Prev Rehabil.  2005; 12: 492-497. \n44. Jakubowski H. Homocysteine thiolactone: metabolic origin and \nprotein homocysteinylation in humans. J Nutr.  2000; 130: 377S-\n381S. \n45. Kado DM, Bucur A, Selhub J, Rowe JW, Seeman T. Homocysteine \nlevels and decline in physical function: MacArthur. Studies of \nSuccessful Aging. Am J Med. 2002; 113: 537-542.  \n46. van Mechelen W, Hlobil H, Ke mper HC. Validation of two \nrunning tests as estimates of maximal aerobic power in children. Eur J Appl Physiol. 1986; 55: 503-506.  \n47. L\u00e9ger LA, Mercier D, Gadoury C, Lambert J. The multistage 20 \nmetre shuttle run test for aerobic fitness. J Sports Sci. 1988; 6: 93-\n101. \n48. Liu NYS, Plowman SA, Looney MA. The reliability and validity \nof the 20-meter shuttle test in American students 12 to 15 years old. Res Q Exerc Sport. 1992; 63: 360-365.  \n  \n 281Table 1. Descriptive characteristics of the subjectsa \n All (n = 156) Males (n = 76) Females (n = 8 0\nAge (y) 14.8 \u00b1 1.4 15.1 \u00b1 1.4 14.6 \u00b1 1.4 \nTanner (1/2/3/4/5) (%) 0/2/14/42/42 0/2/22/27/49 0/3/6/56/35 \nWeight (kg) 58.6 \u00b1 12.8 61.8 \u00b1 14.0 55.3 \u00b1 10.5b\nHeight (cm) 165.4 \u00b1 8.5 170.1 \u00b1 7.5 160.8 \u00b1 6.6c \nBody mass index (kg/m2) 21.3 \u00b1 3.6 21.2 \u00b1 3.7 21.3 \u00b1 3.5 \nSum of six skinfolds (mm) 82.1 \u00b1 32.8 71.8 \u00b1 29.5 92.9 \u00b1 32.8c\nBirth weight (kg) 3.3 \u00b1 0.5 3.3 \u00b1 0.6 3.3 \u00b1 0.5 Homocysteine (\u00b5mol \u22c5L\n-1)d 9.2 \u00b1 3.4 10.0 \u00b1 4.1 8.4 \u00b1 2.22 \nSerum vitamine B 12 (pmol\u22c5L-1)d 612.9 \u00b1 208.8 558.0 \u00b1 143.1 667.7 \u00b1 247. 2\nSerum folate (ng \u22c5mL-1) 5.4 \u00b1 1.7 5.3 \u00b1 1.7 5.4 \u00b1 1.6 \nCardiovascular fitness (steps) 5.8 \u00b1 2.8 7.5 \u00b1 2.3 3.8 \u00b1 1.8b \nCardiovascular fitness (km \u22c5hr-1) 10.9 \u00b1 1.4 11.8 \u00b1 1.2 9.9 \u00b1 0.9b \nCardiovascular fitness (mL \u22c5kg-1\u22c5min-1)e 42.6 \u00b1 7.9 47.5 \u00b1 6.5 37.1 \u00b1 5.4b \nSmoking (%)       \nNo 83 80 87 \nYes 10 12 7 \nPartial smoker 7 8 6 Socioeconomic status (%)         \nLow 3 5 0 \nMedium-low 26 28 25 Medium 46 49 44 \nMedium-high 18 16 21 \nHigh 7 2 10 \n  \na  Unless otherwise indicated, data are expressed as mean \u00b1 SD. \nb,c Sex differences were conducted by one way analyses of variance. bP < .01 , cP < .001.  \nd Natural log-transformed values were used in  the analysis, but nontransformed values \nare presented in the table. \ne Estimated from Leger\u2019s equation.3  \n  \n 282 Table 2.  Homocysteine levels according to methylenetetrahydrofolate reductase (MTHFR) 677C>T genotype and gender group\na. \n \n \n    \n \n    \n \n    \na Unless otherwise indicated, data are expressed as mean \u00b1 SD. \nb P-values for the MTHFR 677C>T genotype factor. \n*Significantly different from CC (CT vs CC, P = .01; TT vs CC, P = .003) by Tukey\u2019s test. \n**Significantly different from CC ( P < .001), and CT ( P = .022) by Tukey\u2019s test. \n   MTHFR 677C>T genotype P  valueb \n CC CT TT  \nMales (n=76)     \n Homocysteine (\u00b5mol \u22c5L-\n1) 8.3\u00b11.4 11.1\u00b15.4* 12.8\u00b15.5* .003 \nn (%) 35 (46) 31 (41) 10 (13)  \nFemales (n=80)     \n Homocysteine (\u00b5mol \u22c5L-\n1) 7.5\u00b12.3 8.3\u00b11.7 10.2\u00b12.2** .001 \nn (%) 26 (33) 41 (51) 13 (16)   \n  \n 283Table 3. Standardized multiple regression coefficients (\n\u03b2), confidence interval (95% CI), \nstandardized coefficient of determination ( R2), and semipartia l correlation ( sr) examining the \nassociation of CVF with homocysteinea.   \n \nHomocysteineb \nModel \u03b2 95% CI P value  R2 sr \nMales       \nModel 1 0.127 -0.055 0.088 .638 0.100 0.086 \nModel 2 0.135 -0.035 0.070 .498 0.406 0.091 Model 3 0.119 -0.032 0.063 .511 0.507 0.080 \n \nFemales       \nModel 1 -0.404 -0.131 0.001 .050 0.160 -0.360 \nModel 2 -0.402 -0.108 -0.021 .006 0.637 -0.358 \nModel 3 -0.395 -0.107 -0.020 .007 0.651 -0.351 \n \na Controlled confounders: Model 1 = age, pube rty, birth weight, smoking, socioeconomic \nstatus, and sum of six skinfolds; Model 2 = model 1 plus serum folate, serum vitamin B 12; \nModel 3 = model 2 plus MTHFR 677C>T genotype. \nb Homocysteine values were natural log-transformed.  \n \n   \n \n \n   \n \n \n  \n  \n  \n              \n \n                  \n \n           \nDISCUSI\u00d3N GENERAL \n  \n \n 285DISCUSION: \n \nLa hiperhomocisteinemia que se produce ante el d\u00e9ficit de \ncualquiera de las vitaminas B estudiadas en esta tesis, est\u00e1 relacionada con \nel del aumento de riesgo de enferm edad cardiovascular, aumento de la \naterosclerosis y otras enfermedades relacionadas con la hiperhomocisteinemia. Pero hay otras enfermedades propias de cada estado deficitario, no debemos olvid ar la patolog\u00eda del tubo neural que \nacaece en ni\u00f1os nacidos de madres con d\u00e9ficit cl\u00ednico o subcl\u00ednico de folato. \nLa enfermedad cardiovascular (ECV ), representa, la primera causa \nde muerte en los pa\u00edses des arrollados originando en Espa\u00f1a \naproximadamente el 40% de todas las muertes. El descubrimiento de que la ECV va precedida de los llamados factores de riesgo cardiovasculares (FRCV) y haciendo de su presencia en  los individuos portadores de estos \nuna mayor probabilidad de desarrollar patolog\u00edas cardiovasculares, hace \nde su detecci\u00f3n y prevenci\u00f3n la principa l estrategia a seguir en este tipo de \npacientes. Los FRCV se clasifican en diferentes grupos: principales o causales \n(hipertensi\u00f3n arterial, diabetes mellitas, aumento del colesterol total, aumento del LDL-c, disminuci\u00f3n de l HDL-c, tabaquismo y edad) que \nconstituyen la base de la valoraci\u00f3 n global del riesgo cardiovascular; \npredisponentes (obesidad, inactividad f\u00edsica, hi storia familiar de cardiopat\u00eda \ncoronaria prematura, sexo masculino, resistencia a la insulina, factores \n\u00e9tnicos y psicosociales) que contribuye n al desarrollo de los causales y de \nlos condicionales (aumento de los triglic\u00e9ridos s\u00e9ricos, aumento de las \nparticulas LDL peque\u00f1as y densas, lipoprote\u00edna (a), homociste\u00edna, fibrin\u00f3geno, inhibidor del activador de l plasmin\u00f3geno 1 o PAI-I, factor de \nvon Willebrand, factor V Leiden, activador tisular del plasmin\u00f3geno, \nantitrombina III, proteina C reactiva e infecci\u00f3n por chlamydia pneumonial). \nAdem\u00e1s de estos FRCV est\u00e1 la enfermedad ateroscler\u00f3tica que \nradica en la acumulaci\u00f3n progresiva de placas ateroscler\u00f3ticas coronarias que aumentan con la edad y cuyo n\u00famero varia ampliamente en los \nindividuos. Aunque la edad es una po derosa predoctora de coronariopat\u00eda \ncr\u00f3nica (CPC) en la poblaci\u00f3n, hay un creciente inter\u00e9s en la valoraci\u00f3n de \nla carga individual de estas placas mediante m\u00e9todos no invasivos para \nestimar el riesgo. El RCV expresa la probabilidad de padecer una enfermedad cardiovascular en un determinado periodo de tiempo,  \n \n 286generalmente 5 o 10 a\u00f1os, incluy\u00e9ndose en  \u00e9ste concepto la posibilidad de \ndesarrollar las enfermedades ateroscler \u00f3ticas m\u00e1s importantes: cardiopat\u00eda \nisqu\u00e9mica, enfermedad cardiovascu lar y arteriopat\u00eda perif\u00e9rica. La \nvaloraci\u00f3n global del riesgo cardiova scular es la estimaci\u00f3n del riesgo \nabsoluto basada en la sumaci\u00f3n de los riesgos proporcionados por cada \nuno de los factores. El c\u00e1lculo del ries go absoluto permite la identificaci\u00f3n \nde individuos de alto riesgo para su precoz intervenci\u00f3n.  \nDe todo esto deducimos la importancia que puede tener la \nprevenci\u00f3n de los estados deficitarios , diagn\u00f3stico del d\u00e9ficit y tratamiento \noportuno tanto del d\u00e9ficit cl\u00ednico como del subcl\u00ednico. \nEn cuanto al diagn\u00f3stico , hemos comprobado que el d\u00e9ficit de \nfolato es f\u00e1cilmente diagn\u00f3sticable, con los par\u00e1metros utilizados en la \npr\u00e1ctica cl\u00ednica (folato s\u00e9rico e int raeritroctario), y que la homociste\u00edna \nayuda en el diagn\u00f3stico, recordemos la estrecha correlaci\u00f3n folatos-homociste\u00edna. Ahora bien, como en los niveles de folato influyen causas \ngen\u00e9ticas como la mutaci\u00f3n C677T de  la MTHFR, esta ser\u00e1 determinada \ncuando no encontremos otra causa que justifique el estado deficitaio. \nNo ocurre igual con la vitamina B\n12, la cobalamina s\u00e9rica se ha \nmostrado tanto en la literatura como en esta tesis, un par\u00e1metro poco eficaz y la homociste\u00edna influye poco en la vitamina B\n12, solo aumenta \ncuando el d\u00e9ficit est\u00e1 plenamente esta blecido. Es la introducci\u00f3n de la \nHolo-TC II la que nos ayudar\u00e1 precozmente al diagn\u00f3stico incluso del d\u00e9ficit subcl\u00ednico, d\u00e9ficit que m\u00e1s nos interesa desde el punto de vista preventivo.  \nEn cuanto a la prevenci\u00f3n, en primer lugar recomendar al paciente \nel cambio en los habitos de vida que influyen en el d\u00e9 ficit vitam\u00ednico e \nhiperhomocisteinemia (alimentaci\u00f3n, alcohol, tabaquismo, etc),  ser\u00eda \noportuno recomendar en grupos de riesgo la suplementaci\u00f3n vitam\u00ednica, teniendo en cuenta que la suplementa ci\u00f3n aislada con folato, como est\u00e1  \nestablecida en algunos pa\u00edses de nuestro entorno, puede provocar un efecto negativo sobre el d\u00e9ficit de B\n12 al enmascarar las alteraciones \nmorfol\u00f3gicas hematol\u00f3gicas de los he mat\u00edes (macrocitosis), mientras el \nd\u00e9ficit  prosigue y tarde o temprano llegan las alteraciones neurol\u00f3gicas \nque llegan a ser irreversibles. Por tanto es recomendable  en poblaciones de \nriesgo la suplementaci\u00f3n mixta Folato-B 12. \nComo hemos visto el tratamiento oral es igual de eficaz que el \nparenteral, dejando este \u00faltimo cuando los problemas g\u00e1stricos o  \n \n 287intestinales impidan el primero o cuando el tratamiento sea urgente como \nocurre cuando hay establecidas manife staciones neurol\u00f3gicas en los d\u00e9ficts \nde B 12. \n  \n \n  \n \n     \n \n     \n \n     \n \n    \n \n     \n \n    \n \n \n  \nRESUMEN \n  \n \n 220Resumen del proyecto \n \nLa deficiencia de B 12 representa un importante problema de Salud P\u00fablica \nobjeto de creciente atenci\u00f3n. Afecta especialmente al colectivo de personas \nancianas y se ha relacionado con patolog\u00ed as de gran incidencia y gravedad que, \nadem\u00e1s, tienen gran coste socio-econ\u00f3mic o como son enfermedad ateroscler\u00f3tica \n(cardiopat\u00eda isqu\u00e9mica, enfermedad cere brovascular), trastornos cognitivos, \ndemencias, entre ellas, la enfermedad de Alzheimer, e incluso ciertos tipos de \nc\u00e1ncer.  \nTambi\u00e9n se han identificado meca nismos que implican una menor \nabsorci\u00f3n de B 12 y que est\u00e1n ligados a la ingesta de ciertos f\u00e1rmacos y al \nenvejecimiento. El diagn\u00f3stico precoz del d\u00e9ficit de B 12 resulta muy complejo como \nlo es tambi\u00e9n realizar el estadiaje evolutivo de la carencia. Esto es especialmente importante porque una carencia instaurad a produce lesiones irreversibles, en \nparticular a nivel del Sistema Nervioso. En contraste con la dificultad del \ndiagn\u00f3stico precoz, el tratamiento es senc illo y altamente coste-efectivo, pudiendo \nincluso ser de car\u00e1cter preventivo y dirigido  tanto a la poblaci\u00f3n general como a la \npoblaci\u00f3n de riesgo. El objeto del presente  proyecto es, precisamente, establecer la \nsecuencia espec\u00edfica de manifestacio nes que acompa\u00f1an al d\u00e9ficit de B\n12 y \ncomprobar la eficiencia de un prot ocolo diagn\u00f3stico fiable para detectar \nprecozmente el d\u00e9ficit de B 12. El estudio se ha realizado en poblaci\u00f3n de riesgo \n(ancianos institucionalizados). Se ha incluido la medida de holotranscobalamina, lo que resulta de absoluta novedad. \nAsimismo, se ha contado con la colaboraci\u00f3n de la Universidad de Bonn y \nla empresa I+D AXIS que ha desarrolla do el RIA de holotranscobalamina. \nHemos podido confirmar la elevada prevalencia de deficiencia de folato, \nvitamina B6 y vitamina B\n12 en ancianos institucionalizados. Esta elevada \nprevalencia debe ser confirmada en estudios  posteriores y en otras poblaciones, ya \nque de confirmarse, exige la toma de medidas de salud p\u00fablica urgentes. Los \nniveles deficitarios de vitaminas del grup o B est\u00e1n asociados con niveles elevados \nde homociste\u00edna, en especial la deficienci a de folato, con el consiguiente riesgo \nmencionado en el p\u00e1rrafo anterior.  \nAsimismo, hemos observado que tanto los niveles s\u00e9ricos de cobalamina \ncomo de homociste\u00edna no sirven para de tectar deficiencias subcl\u00ednicas de las \nvitaminas analizadas. Por tanto, la medida  de la holo-transcobalamina se presenta \ncomo un m\u00e9todo alternativo interesante. Aunque en vista de los datos analizados, \ntodo parece indicar que ning\u00fan par\u00e1met ro por si mismo puede diagnosticar el  \n \n 221d\u00e9ficit de vitamina B 12. Mediante el m\u00e9todo diagn\u00f3stico propuesto se pretende \nfacilitar el trabajo en el laboratorio de an\u00e1lisis cl\u00ednico de rutina, analizando \naquellos par\u00e1metros (holo-transcobalamin a y \u00e1cido metil-mal\u00f3nico) que mejor \nparecen identificar a los sujetos de riesgo. No obstante, cuando la medida del  \n\u00e1cido metil-mal\u00f3nico no sea posible, el esquema diagn\u00f3stico 4 identifica a un porcentaje muy elevado de la poblaci\u00f3n deficitaria.  \n   \n \n     \n \n    \n \n     \n \n  \n \n  \n  \n \n     \n \n     \n \n    \n \n  \n   \nCOMUNICACIONES A CONGRESOS  \n \n  \n \nHOLO-TRANSCOBALAMIN AS AN EARLY INDICATOR OF VITAMIN B12\nDEFICIENCY IN A GROUP OF INSTITUTIONALIZED                      \nELDERLY SPANISH PEOPLE*.\nM Gonzalez-Gross (1,2), R Sola (1,3), V Lemmen (1,2), D Janke (2), MJ Castillo (1), K Pietrzik (2).\n(1)  Dpt. Physiology. School of Medicine. University of Granada. Spain. (2) Dpt. Pathophysiology of Human Nutrition. Institute o f \nNutrition. University of Bonn. Germany. (3) Haematology Service, Clinical University Hospital, Granada, Spain.\nmggross@canal21.com\nBACKGROUND\nVitamin B12deficiency represents an important public health problem. It \nespecially affects the elderly and has been related to chronic degenerative \ndiseases like coronary heart disease, cognitive impairment and dementia. \nData about the real vitamin B12status of the Spanish elderly population are \nscarce. Early diagnosis of vitamin B12deficiency is essential, because \ndespite of these sub clinical manifestations, neuropathy can be irreversible. \nIn this setting the use of markers like Holo-transcobalamin (Holo-TC) and \nmethylmalonic acid (MMA) for functional vitamin B12deficiency can be \nmore adequate than serum B12, as has been published in several studies in \nthe literature. \nOBJECTIVE\nThe aim of the study was to establish the B12status of the Spanish elderly \npopulation, and to assess the frequency and severity of vitamin B12 \ndeficiency by different biochemical, functional and morphological markers in a representative elderly population living in an elderly home institution \nin the south of Spain.\nMATERIAL AND METHODS\nThis study is part of a lager cross-sectional study that aims to establish the \nvitamin B status of Spanish elderly, specifically B6, B12and folate, and that \nhas been supported by a grant from the Fondo de Investigacion Sanitaria of \nthe Spanish Ministry of Health. One-hundred and nineteen elderly aged 60 \u2013 90 years, living in the Elderly\u00b4s Home \u201cLa Milagrosa\u201d, in Armilla\n(Granada), Spain, were recruited for the study. After presentation of the \nstudy protocol, written informed consent was obtained from interested \nsubjects. All residents took part in the study, the data shown are for 66% of \nall elderly living at the Residence. The study was approved by the Human \nResearch Review Committee of the Universidad of Granada, School of \nMedicine. The study has been performed following the ethic norms of the Declaration of Helsinki 1996 (revision of Edinburgh 2000), Convention of \nOviedo, the Good Clinical Practice of the CEE (document 111/3976/88 \nJuly 1990) and the Spanish legislation about clinical research in humans \n(Real Decreto 561/1993 sobre ensayos cl\u00ednicos). After an overnight fast, \nblood samples were drawn between 8:00 and 10:00 h in the morning\nwithout stasis via venipuncture of the antecubital vein. Blood was \ndistributed as follows: 4 ml in a vacutainer with EDTA for hematology, hypersegmentation of P\nolymorph N uclear N eutrophils (PNN), and red \nblood cell (RBC) folate (Abbott, IMX). Eight ml in a vacutainer with gel \nand centrifuged within one hour. Serum was collected in 2 eppendorfs and \nimmediately analyzed for serum B12, folate, total homocysteine (tHcy) \n(IMX, Abbott) and Holotranscobalamin (Holo-TC) (Axis-Shield). \nMethylmalonic acid (MMA) was sent to the laboratory at the University of \nBonn always frozen by specialised Courier and analysed by GC-MS.\nREFERENCES\nHerzlich B, Herbert V. Depletion of serum holotranscobalamin II. An early sign of negative vitamin B12balance. Lab Investig 1988;58:332-337.\nNexo E, Christensen AL, Hvas AM, Petersen TE, Fedosov SN. Quantification of holo-transcobalamin, a marker of vitamin B12deficiency. Clin Chem 2002;48:561-562.\nWickramasinghe SN, Fida S. Correlations between holo-transcobalamin II, holo-haptocorrin, and total B12in serum samples from healthy subjects and patients. J Clin Pathol 1993;46:537-539.\nCONCLUSIONS\nPrevalency of B vitamin (folate and B12) in Spanish elderly is high. Serum \ncobalamin as a classical marker for vitamin B12deficiency may lead to \nunderestimation of the problem. Functional markers like Holo-TC and \nMMA might be more useful for early detection of vitamin B12deficiency. \nDiscrepancies between the different markers might be related to \nimpairment of renal function and indicate the need for further \ninvestigation. Figure 1. Prevalence of vitamin B12-deficiency in institutionalized\nelderly measured by different pa rameters\n%\n3,0%5,0%11,0%15,3%22,0%38,1%49,2%57,60%70%\n0,0%10,0%20,0%30,0%40,0%50,0%60,0%70,0%80,0%\nMegaloblastic anemia\nMacrocytosis\nHypersegmentation ( index > 3.2)\nSerum B12 (< 147 pmol/L)\nHolo-TC (< 40 pmol/L)\nRBC folate (< 250 ng/ml)\nMMA (> 350 nmol/L)\nSerum folate (< 7 ng/ml)\nHomocystein (> 12 \u00b5mol/L)\n* Project granted by the Spanish Ministry of Health (FIS PI021830) and Axis-Shield (Oslo, Norway).\n272\n 343. 8\u00b1190.8\n RBC folate (ng/ml)\n1.02\n 1.1\u00b10.38\n Creatinin (mg/dl)\n6.40\n 7.17\u00b13. 58\n Serum folate (ng/ml)\n14.95\n 17.3\u00b110.06\n tHcy (\u00b5mol/L)\n312\n 612. 5\u00b11290. 6\n MMA (nmol/L)\n51.60\n 74.82\u00b183. 6\n Holo-TC (pmol/L)\n353. 2\n 430. 6\u00b1339.01\n Serum B12 (p g/ml)\nMe dia n\n Me an+/-S D\n ParameterTable 1. Vitamin status in institutionalized elderlyRESULTS                                                         \nBiochemical parameters (like Holo-TC and MMA) are much more \nsensitive and specific as morphological alterations (megaloblastic anemia, \nmacrocytosis, PNN), which additionally are influenced by folate status. In all cases with low serum B12 levels, the functional parameters (Holo-TC, \nMMA) indicated deficiency as well but to a greater extend.\n \nEuromedlab 2003. Barcelona  \n \n  \nPATTERN OF MORPHOLOGICAL AND BIOCHEMICAL MARKERS IN VITAMIN B12 \nDEFICIENCY *\nR Sola (1,2), M Gonzalez-Gross (1,3), V Lemmen (1,3), D Janke (3), MJ Castillo (1), K Pietrzik (3).\n(1)  Dpt. Physiology. School of Medicine. University of Granada. Spain. (2) Haematology Service, Clinical University Hospital, \nGranada, Spain. (3) Dpt. Pathophysiology of Human Nutrition.  Institute of Nutrition. University of Bonn. Germany. \nmggross@canal21.com\nBACKGROUND\nMegaloblastic anaemia is a classical manifestation of vitamin B12deficiency. \nNevertheless, other markers might be more sensitive and/or specific. In this \nsetting the use of functional markers for vitamin B12deficiency like Holo-\ntranscobalamin (Holo-TC), and methylmalonic acid (MMA) can be more \nadequate than serum B12, as has been published in several studies in the \nliterature. B12deficiency especially affects the elderly and has been related to \nchronic degenerative diseases like coronary heart disease, cognitive impairment \nand dementia. Data about the real vitamin B12status of the Spanish elderly \npopulation are scarce. Early diagnosis of vitamin B12deficiency is essential, \nbecause despite of these sub clinical manifestations, neuropathy can be \nirreversible. \nOBJECTIVE\nThe aim of the study was to assess the pattern of morphological and biochemical markers of vitamin B12 deficiency in order to find early and reliable indicators of \nvitamin B12 deficiency in a group considered at risk, that is institutionalized \nelderly. \nREFERENCES\nHerzlich B, Herbert V. Depletion of serum holotranscobalamin II. An early sign of negative vitamin B12 balance. Lab Investig 1988; 58:332-337.\nLindenbaun J, Savage DG, Stabler SP, et al. Diagnosis of cobalamin deficiency. II: relative sensitivities of serum cobalamin, meth ylmalonic acid, and total homocysteine concentrations. Am J \nHematol 1990;34:99-107. \nNexo E, Christensen AL, Hvas AM, Petersen TE, Fedosov SN. Quantification of holo-transcobalamin, a marker of vitamin B12 deficienc y. Clin Chem 2002;48:561-562.\nWickramasinghe SN, Fida S. Correlations between holo-transcobalamin II, holo-haptocorrin, and total B12 in serum samples from heal thy subjects and patients. J Clin Pathol 1993;46:537-539.\nCONCLUSIONS\nAbnormalities in serum levels of B12, folate and/or Holo-TC precede the \nhaematological signs (lobularity, macrocytosis or megaloblastic anaemia) at \nleast in institutionalized elderly subjects. Functional markers like Holo-TC and \nMMA might be more efficient in the detection of early vitamin B12 deficiency \ncompared to serum B12analysis. B vitamin (folate and B12) deficiency is \nprevalent in Spanish elderly. Serum cobalamin as a classical marker for vitamin \nB12 deficiency may lead to underestimation of the problem. Discrepancies \nbetween the different markers indicate the need for further investigation. Figure 2. Prevalence of vitamin B12-deficiency in institutionalized\nelde rly measure d by diffe re nt pa ramete rs\n%\n* Project granted by the Spanish Ministry of Health (FIS PI021830) and Axis-Shield (Oslo, Norway). Reagents for HoloTC assay were kind ly provided by Axis... Acknowledgements: Participants in this research work are Dr F. \nMorales and Dr G. Orihuela, physicians in charge of the patients under study at the Residencia de Ancianos La Milagrosa, Armilla, Granada . The skillful technical assitance of Ms R. Arcas is gratefully acknowledged.  \n272\n 343.8\u00b1190.8\n RBC folate (ng/ml)\n1.02\n 1.1\u00b10.38\n Creatinin (mg/dl)\n6.40\n 7.17\u00b13.58\n Serum fol ate (ng/ml )\n14.95\n 17.3\u00b110.06\n tH cy (\u00b5mol/L)\n312\n 612.5\u00b11290.6\n MMA (nmol/L)\n51.60\n 74.82\u00b183.6\n Holo-TC (pmol/ L)\n353.2\n 430.6\u00b1339.01\n Serum B12 (p g/ml)\nMed ian\n Mean+/-SD\n ParameterTable 1. Vitamin status in institutionalized elderlyRESULTS       \nMegaloblastic anaemia was observed in 3%, macrocytosis in 5% of the subjects, \nhypersegmentation was present in 11.0%. Hypersegmentation was related to \nisolated serum B12 deficiency in 4 cases, isolated folate deficiency in 10% and \ncombined vitamin deficiency in 3 cases. There was a significant positive \ncorrelation between Holo-TC and serum B12 (r=0.822; p<0.01), serum folate\n(r=0.268; p<0.05), RBC folate (r=0.292; p<0.05) and a significant inverse \ncorrelation between Holo-TC and AMM (r=-0.531; p<0.01) and HPNN (r=-\n0.352; p<0.01). No single case of hypersegmentation was observed without the \ncoexistence of either abnormal B12 respectively Holo-TC or folate values. \nFigure 1. Megaloblastic anemia\n3,0%5,0%11,0%15,3%22,0%38,1%49,2%57,60%70%\n0,0%10,0%20,0%30,0%40,0%50,0%60,0%70,0%80,0%\nMegaloblastic anemia\nMacrocytosis\nLobe average > 3.2\nSerum B12 (< 147 pmol/L)\nHolo-TC (< 40 pmol/L)\nRBC folate (< 250 ng/ml)\nMMA (> 350 nmol/L)\nSerum folate (< 7 ng/ml)\nHomocystein (> 12 \u00b5mol/L)MATERIAL AND METHODS\nThis study is part of a larger cross-sectional study that aims to establish the \nvitamin B status of Spanish elderly, specifically B6, B12and folate and to \nfacilitate early diagnosis of vitamin deficiency. It has been supported by a grant \nfrom the Fondo de Investigacion Sanitaria of the Spanish Ministry of Health. \nOne-hundred and nineteen elderly aged 60 \u2013 90 years, living in the Elderly\u00b4s\nHome \u201cLa Milagrosa\u201d, in Armilla (Granada), Spain, were recruited for the study. After presentation of the study protocol, written informed consent was obtained \nfrom interested subjects. All residents took part in the study, the data shown are \nfor 66% of all elderly living at the Residence. The study was approved by the \nHuman Research Review Committee of the Universidad of Granada, School of \nMedicine. The study has been performed following the ethic norms of the \nDeclaration of Helsinki 1996 (revision of Edinburgh 2000), Convention of \nOviedo, the Good Clinical Practice of the CEE (document 111/3976/88 July \n1990) and the Spanish legislation about clinical research in humans (Real \nDecreto 561/1993 sobre ensayos cl\u00ednicos). After an overnight fast, blood \nsamples were drawn between 8:00 and 10:00 h in the morning via venipuncture\nof the antecubital vein. Blood was distributed as follows: 4 ml in a vacutainer\nwith EDTA for hematology, hypersegmentation of P\nolymorph N uclear \nNeutrophils (PNN), and red blood cell (RBC) folate (Abbott, IMX). Eight ml in \na vacutainer with gel and centrifuged within one hour. Serum was collected in 2 \neppendorfs and immediately analyzed for serum B12, folate, total homocysteine\n(tHcy) (IMX, Abbott) and Holotranscobalamin (Holo-TC) (RIA, Axis-Shield). \nMethylmalonic acid (MMA) was sent to the laboratory at the University of Bonn\nalways frozen by specialised Courier and analysed by GC-MS.\n \nEuropeo de Hematolog\u00eda 2003. Lyon  \n \n \nMARCADORES BIOQU\u00cdMICOS Y MORFOL\u00d3GICOS DE LA DEFICIENCIA \nDE VITAMINA B12\n\u00bfExiste la detecci\u00f3n prec\u00f3z de una deficiencia funcional de B12?\nR Sola (1,2), M Gonz\u00e1lez-Gross (2,3), V Lemmen (2,3), D Janke (3), MJ Castillo (3), K Pietrzik (3).\n(1) Servicio de Hematolog\u00eda. Hospital Cl\u00ednico Universitario San Cecilio, Granada, Espa\u00f1a.\n(2) Dpto. Fisiolog\u00eda, Facultad de Medicina, Universidad de Granada, Espa\u00f1a.\n(3) Dpto. Fisiopatolog\u00eda de la Nutrici\u00f3n Humana. Instituto de Nutrici\u00f3n, Universidad de Bonn. Alemania.\nmggross@canal21.com\nFUNDAMENTOS\nLa anemia megalobl\u00e1stica es una manifestaci\u00f3n cl\u00e1sica \nde la deficiencia de vitamina B12. Sin embargo, puede \nhaber otros marcadores m\u00e1s sensibles y/o espec\u00edficos para la detecci\u00f3n de esta deficiencia en estadios tempranos. La holo-transcobalamin (holo-TC), la forma \nfuncional de la vitamina B\n12puede ser uno de esos \nmarcadores. \nOBJETIVO\nEvaluar el patr\u00f3n de los marcadores morfol\u00f3gicos y bioqu\u00edmicos de la deficiencia de vitamina B\n12con el fin \nde encontrar uno o varios indicadores precoces de dicha deficiencia. \nBIBLIOGRAF\u00cdA\nHerzlich B, Herbert V. Depletion of serum holotranscobalamin II. An early sign of negative vitamin B12 balance. Lab Investig 1988 ;58:332-337.\nLindenbaun J, Savage DG, Stabler SP, et al. Diagnosis of cobalamin deficiency. II: relative sensitivities of serum cobalamin, m ethylmalonic acid, and total homocysteine \nconcentrations. Am J Hematol 1990;34:99-107. \nNexo E, Christensen AL, Hvas AM, Petersen TE, Fedosov SN. Quantification of holo-transcobalamin, a marker of vitamin B12 deficien cy. Clin Chem 2002;48:561-562.\nWickramasinghe SN, Fida S. Correlations between holo-transcobalamin II, holo-haptocorrin, and total B12 in serum samples from hea lthy subjects and patients. J Clin Pathol \n1993;46:537-539.\nCONCLUSIONES\nLas anormalidades en los niveles s\u00e9ricos de B12, \nfolato y/o holo-TC preceden a los signos \nhematol\u00f3gicos (lobularidad aumentada), al menos en \nancianos institucionalizados. La holo-TC puede representar un par\u00e1metro m\u00e1s eficiente de detecci\u00f3n precoz de la deficiencia de vitamina B\n12comparado \ncon el an\u00e1lisis s\u00e9rico de la vitamina B12, aunque dada \nla escasez de datos en la bibliograf\u00eda se debe profundizar en este aspecto. Figura 1. La prevalencia de la deficiencia de B12en ancianos \ninstitucionalizados establecido mediante distintos par\u00e1metros.\n%\n*Proyecto financiado por el Fondo de Investigaci\u00f3n Sanitaria (FIS PI021830). Los reactivos para la determinaci\u00f3n de la holo TC II fueron suministrados por \nAxis-Shield (Oslo, Norway). Agradecimientos a Dr. F Morales, Dr. G Orihuela,  D\u00aa. R Arcas y D\u00aa P.Carazo por su colaboraci\u00f3n en est e estudio.Tabla 1. Estado vitam\u00ednico y par\u00e1metros\nrelacionados en ancianos institucionalizados\nRESULTADOS \nSeg\u00fan los par\u00e1metros analizados, la prevalencia de la \ndeficiencia sub-cl\u00ednica de vitaminas fue la siguiente: 56,5% folato s\u00e9rico (< 7 ng/ml), 36% folato \neritrocitario (< 250 ng/ml). La prevalencia de \ndeficiencia de vitamina B\n12fue del 26,9% seg\u00fan la \ndeterminaci\u00f3n de holo-TC (< 40 pmol/L), mientras que \u00fanicamente fue del 13,75% seg\u00fan los valores s\u00e9ricos de B\n12(< 179 pg/ml). Valores elevados de \nMMA (> 350 nmol/L) se observaron en el 49,2% de \nlos casos, valores elevados de tHcy en el 81,8%. Hipersegmentaci\u00f3n neutr\u00f3fila se apreci\u00f3 en el 13% de los casos.\n3,0%5,0%13,0%15,3%26,9%36,0%49,2%56,50%82%\n0%10%20%30%40%50%60%70%80%90%\nMegaloblastic anemia\nMacrocytosis\nLobe average > 3.2\nSerum B12 (< 147 pmol/L)\nHolo-TC (< 40 pmol/L)\nRBC folate (< 250 ng/ml)\nMMA (> 350 nmol/L)\nSerum folate (< 7 ng/ml)\nHomocystein (> 12 \u00b5mol/L)M\u00c9TODOS\nEn 170 ancianos institucionalizados de ambos sexos con \nedades comprendidas entre los 60 y 95 a\u00f1os se \ndeterminaron los siguientes par\u00e1metros: cobalaminas\u00e9rica (Abbott IMX), holo-TC (Axis-Shield), \u00e1cido metilmal\u00f3nico (MMA, GC-MS), folato s\u00e9rico, folato eritrocitario, homociste\u00edna total (tHcy) (Abbott, IMX), e \nhipersegmentaci\u00f3n neutr\u00f3fila.1,02 1,1\u00b10,38 creatinina (mg/dl)299 358,01\u00b1199,13 folato eritrocitario (ng/ml)6,35 7,16\u00b13,6 folato s\u00e9rico (ng/ml)15,07 17,16\u00b19,20 tHcy (\u00b5mol/L)312 603,21\u00b11306,14 MMA (nmol/L)57,13 80,18\u00b188,78 holo-TC (pmol/L)348 415,09\u00b131,42 B12 s\u00e9rico (pg/ml)Mediana Me dia +/-DSParametr o\n \nNacional de Hematolog\u00eda 2003.  Santiago de Compostela  \n \n \nFolate deficiency is the strongest determinant of the frequency and \nseverity of hyperhomocysteinemia in a group of institutionalized\nSpanish elderly people. \nV Lemmen 1,2, M Gonz\u00e1lez-Gross 1,2, R Sola 1,3, D Janke2, F Morales 1, K Pietrzik 2\n1Dpt. Physiology, School of Medicine, University of Granada, Spain.\n2Dpt. Pathophysiology of Human Nutrition, Institute of Nutritional Science, Rheinische Friedrich-Wilhelms Universit\u00e4t Bonn, \nGermany.\n3Haematology Service, Clinical University Hospital San Cecilio, Granada, Spain.\nBackground\nHyperhomocysteinemia is associated with chronic diseases such as cerebrovascular and coronary artery disease. B-\nvitamin deficiency seems to be the main cause for high homocysteine levels. The coexistence of folate and B12\ndeficiency might be responsible for the severity and prevalence of hyperhomocysteinemia in the elderly, but reliable data on the occurrence of folate and vitamin B\n12 deficiency in the elderly are scarce.\nObjective\nThe objective of this study was to investigate the contribution of combined folate and B12-deficiency to \nhyperhomocysteinemia in the elderly. \nMaterial and Methods\nOne-hundred and seventy elderly of both gender and a mean age of 78.1 \u00b18.6 years, living in the Elderly Home \u201cLa \nMilagrosa\u201d in Armilla, Granada (Spain), were screened for serum folate, red blood cell (RBC) folate, serum cobalamin (Abbott, IMx), holotranscobalamin II (holo-TC II) (HoloTC RIA, Axis-Shield), and total Homocysteine \n(tHcy) (Abbott, IMx).\nThe prevalence of folate deficiency was 51 %. Forty-seven \npercent had low serum folate (< 6 ng/ml) and 35 % had \nlow RBC folate (< 250 ng/ml). The prevalence of vitamin \nB\n12deficiency was 30 %. Sixteen percent had low serum \nB12 (< 200 pg/ml) levels and 27 % had low holo-TC II (< 40 \npmol/L). More than half of our study population (51 %) \npresented high tHcy levels (>= 15 \u00b5mol/L). In a multiple \nlinear regression analysis log serum folate was the most powerful independent predictor of log total \nhomocysteine, followed by log holo-TC II. Mean \nhomocysteine levels were significantly higher in the \nhighest two quartiles of serum folate compared to the \nlowest.\nConclusion\nThere is a very high prevalence of B-Vitamin deficiency in Spanish institutionalized elderly. Our data confirm an \nimportant role for blood levels of B-Vitamins in homocysteine metabolism. We found folate deficiency to be the \nstrongest determinant of high homocysteine levels. However, isolated B12deficiency or combined B12and folate \ndeficiency aggravate the frequency and severity of hyperhomocysteinemia. Twenty-one percent were neither \ncorrelated to vitamin B12 nor to folate deficiency, which may be due to vitamin B2or B6deficiencies that have not \nbeen determined in our study. This will be part of further research.\nReferences\n[1]C.J. Boushey, S.A.A. Beresford, G.S. Omenn and A.G. Motulsky (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Journal \nof the American Medical Association, 274, 1049-1057.\n[2]I.M. Graham, L.E. Daly, H.M. Refsum et al. (1997) Plasma homocysteine as a risk factor for vascular disease: The European Conce rted Action Project. Journal of the \nAmerican Medical Association, 277, 1775-1781. \n[3]J. Selhub, P. Jacques, P.W.F. Wilson, D. Rush and I.H. Rosenberg (1993) Vitamin status and intake as primary determinants of ho mocysteinemia in an elderly \npopulation. Journal of the American Medical Association, 270, 2693-2698.\nThe project has been granted by the Spanish Ministry of Health (FIS PI021830). Prof. Manuel J. Castillo is the project leader. Axis-Shield \n(Oslo, Norway) has kindly provided the holo-TC RIA reagent kit. We want to thank Mr. G Orihuela, Mrs. R Arcas and Mrs. P Carazo for \ntheir collaboration in this study.\nDeterminants of high homocysteine levels\nisolated folate \ndeficiency\n38%\nisolated B12 deficiency\n12%Combined deficiency\n29%no association with \nB12/folate deficiency\n21%lowest quartile 2.quartile 3.quartile highest quartile\nserum folate10,020,030,040,0tH\ncy (m\ncm\nol/L)\nlowest quartile 2.quartile 3.quartile highest quartile\nRBC folate10,020,030,040,0tH\ncy (m\ncm\nol/L)Mean homocysteine concentrations in quartiles of serum and RBC folate\n* significantly different ( P< 0.05) to the mean of the highest \nquartile (one-way ANOVA with post-hoc Scheff\u00e9 test).***log homocysteine\nlog serum folate3, 0 2,5 2,0 1,5 1,0 ,55,0\n4,5\n4,0\n3,5\n3,0\n2,5\n2,0\n1,5Regression line: y = 3.34 \u2013 0.32 x. \nS curve fit. (r= 0.41, P< 0.001).\nThe horizontal line shows the cut-off of tHcy \n=15 \u00b5mol/L which cuts the regression line at \nlog serum folate = 2.67(= 14.5 ng/mL).\nThe second horizontal line shows the cut-off \nof tHcy = 12 \u00b5 mol/L which cuts the \nregression line at log serum folate = 1.97 (= \n7.2 ng/mL). Relation between log serum total homocysteine and log serum folateResults\n \nFirst Internacional Conference  of Folates. Varsovia. 2004  \n \n \n11%16%27%49% 51%\n3%\n0,0%10,0%20,0%30,0%40,0%50,0%60,0%\nMegaloblastose\n\u00dcbersegmentierung > 3.2\nSerum B12 (< 200 pg/mL)\nholo-TC II (< 40 pmol/L)\nMMA (>300 nmol/L)\nHomocystein (> 15 \u00b5mol/L)Vitamin B12-Mangel Pr\u00e4valenz bei institutionalisierten spanischen Senioren\nV. Lemmen (1), M. Gonz\u00e1lez-Gross (1), R. Sola (2), D. Janke (1), G. Orihuela (3), K. Pietrzik (1)\n(1)Institut f\u00fcr Ern\u00e4hrungswissenschaft, Abteilung Pathophysiologie der Ern\u00e4hrung, Rheinische Friedrich-Wilhelms-\nUniversit\u00e4t Bonn\n(2)Facultad de Medicina, Dpt. de Fisiolog\u00eda, Universidad de Granada (Spanien)\n(3)Residencia de Ancianos \u201cLa Milagrosa\u201d Armilla (Granada, Spanien)\nProblemstellung\nDie Gefahr einen Vitamin B12-Mangel zu entwickeln ist aufgrund h\u00e4ufiger Gastritiden speziell bei \u00e4lteren \nMenschen erh\u00f6ht. Eine biochemische Fr\u00fcherkennung ist aufgrund mangelnder Methodik bis heute \nroutinem\u00e4\u00dfig nicht m\u00f6glich. Die Messung des Serumcobalamins (SCbl) f\u00fchrt h\u00e4ufig zu falsch positiven \noder falsch negativen Ergebnissen, weshalb seit einigen Jahren neben der Methylmalons\u00e4ure (MMA)-\nMessung die Erfassung des funktionellen Vitamin B12-Anteils in Form von Holotranscobalamin II (Holo-TC) \nin Forschungseinrichtungen eingesetzt wird. Die Studie verfolgt das Ziel, verschiedene morphologische \nund biochemische Parameter der B12\u2013Versorgunssituation vergleichend zu betrachten. \nMethoden\nBlutproben von 170 institutionalisierten spanischen Senioren (mittleres Alter 78.1 Jahre) wurden auf \nSCbl (Abbott, IMx) , Holo-TC (HoloTC-RIA, Axis-Shield), MMA (GC-MS), Gesamtserumhomocystein(tHcy), Erythrozytenfolat und Serumfolat (Abbott, IMx) analysiert.\nDie Pr\u00e4valenz einer Megaloblastose lag \nlediglich bei 3%, die \u00dcbersegmentierung der neutrophilen Granulozyten bei 11%. \nBiochemisch zeigten 16 % niedrige SCbl-\nSpiegel (< 200 pg/ml), w\u00e4hrend bei 27 % \nerniedrigte Holo-TC Werte (< 40 pmol/L) \ngemessen wurden. Das Serumfolat war niedrig (<6 ng/ml) bei 47 % und das Erythrozytenfolat\n(< 250 ng/ml) bei 35 %. Die Korrelation \nzwischen SCbl und Holo-TC war hoch (r= 0, 77, \np< 0,001). \nEine multiple lineare Regressionsanalyse \nzeigte, dass die erh\u00f6hten tHcy-Werte (51% > \n15 \u00b5mol/L) in den \u00fcberwiegenden F\u00e4llen durch \nFolat- oder B\n12-Mangel erkl\u00e4rt werden k\u00f6nnen.\nSchlussfolgerung\nDie Daten best\u00e4tigen eine h\u00f6here Sensitivit\u00e4t des Holo-TC gegen\u00fcber SCbl. Da die hohen Hcy-Wertejedoch haupts\u00e4chlich durch die niedrigeen Folatspiegel zu erkl\u00e4ren sind, scheint es nicht sinnvoll Hcy als \nParamter f\u00fcr den B12-Mangel heranzuziehen. Die hohe Pr\u00e4valenz eines B\n12-Mangels bei spanischen \ninstitutionalisierten Senioren erfordert eine intensivere Erforschung dieses Problems auch in anderen \nL\u00e4ndern.\n*Mit finanzieller Unterst\u00fctzung des Spanischen Gesundheitsministeriums (FIS PI021830). Prof. Manuel J. Castillo ist Projektleite r. Axis-Shield (Oslo, Norway) \nhat die holo-TC RIA Reagenzienkits zur Verf\u00fcgung gestellt. Dr. F. Morales, Frau R Arcas und Frau P Carazo danken wir f\u00fcr ihre Hilfe .DieMultiple lineare Regressionsanalyse zeigt, welcher Anteil der \nVariation des Serum-Homocysteins (tHcy) durch die verschiedenen\nVitaminkonzentrationen erkl\u00e4rt werden kann1\n< 0.001 28 0.53 Log holo-TC II< 0.001 17 0.41 Log serum folate%P R2 R\n1R, multipler Korrelationskoeffizient, nach schrittweiser Regressonsanalyse\nR2, Prozent der Variation des tHcy, dass durch die biochemischen Paramter erkl\u00e4rte werden\nkann\n100 200 300 400 500\nVitamin B12(pg/mL)0,040, 080, 0120,0holo-TC\nII (pmol/L)\n**\n***\n*\n*\n**\n****\n*\n*\n**\n***\n*\n***\n****\n*\n**\n***\n**\n****\n*\n**\n*\n**\n*\n***\n*\n***\n***\n****\n*\n***\n**\n***\n*\n**\n*\n***\n*\n**\n*\n** *\n***\n****\n**\n*\n*\n**\n*\n**\n*\n***\n* *\n*\n*\n*\n**\n*\n**\n*\n**\n***\n***\n*Streudiagramm der einzelnen Individuen anhand der Vitamin \nB12und Holo-TC KonzentrationenPr\u00e4valenz von Vitamin B12-Mangel in dieser Studienpopulation \ngemessen anhand von verschiedenen Parametern\nErgebnisse\nLiteratur\n[1]C.J. Boushey, S.A.A. Beresford, G.S. Omenn and A.G. Motulsky (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Journal of the American Medical Association, \n274, 1049-1057.\n[2]I.M. Graham, L.E. Daly, H.M. Refsum et al. (1997) Plasma homocysteine as a risk factor for vascular disease: The European Conce rted Action Project. Journal of the American Medical Association, 277, 1775-\n1781. \n[3]J. Selhub, P. Jacques, P.W.F. Wilson, D. Rush and I.H. Rosenberg (1993) Vitamin status and intake as primary determinants of ho mocysteinemia in an elderly population. Journal of the American Medical \nAssociation, 270, 2693-2698.\n \nCongreso de la DGE (Deutsche Ge sellschaft f\u00fcr Ern\u00e4hrung) Munich 2006  \n \n Validity of serum cobalamin, holotranscobalamin or methyl maloniValidity of serum cobalamin, holotranscobalamin or methyl maloni c c \nacid for determination of vitamin Bacid for determination of vitamin B1212statusstatus\nV Lemmen 1,2, M Gonzalez-Gross 1,2, R Sola 1,3, D Janke2, S Seher1,2,  MJ Castillo1, K Pietrzik 2\n1Dpt. Physiology, School of Medicine, University of Granada, Spain.\n2Dpt. Pathophysiology of Human Nutrition, Institute of Nutritional Science, University of Bonn, Germany.\n3Haematology Service, Clinical University Hospital San Cecilio, Granada, Spain.\nAimsAims The elderly population is particularly at risk for \ndeveloping vitamin B12-deficiency. Inadequate diets, \ndiseases like atrophic gastritis or intestinal malabsorption \nare the main reasons for vitamin B12-deficiency in this age \ngroup. Sensitive methods for early detection of vitamin B12-\ndeficiency are not common in the routine laboratory. \nNormal serum cobalamin (SCbl) does not necessarily reflect \na normal B12status. Therefore, besides determining methyl \nmalonic acid (MMA), holotranscobalamin (Holo-TC), the fraction of functional vitamin B\n12, has been proposed as a \nmore sensitive B12 status indicator. The objective of this \nstudy is to establish B12status by different methods and to \ncompare their validity.MethodsMethods One-hundred and eighty elderly of both \ngender and a mean age of 78.1 \u00b18.6 years, living in the \nElderly Home \u201cLa Milagrosa\u201d in Armilla, Granada (Spain). \nAfter an overnight fast, blood samples were drawn between 8:00 and 10:00 h in the morning without stasis via venipuncture of the antecubital vein. Blood was screened for \nSCbl (Abbott, IMx), Holo-TC (HoloTC-RIA, Axis-Shield), \ntotal homocysteine (tHcy), red blood cell (RBC) folate and serum folate (Abbott, IMx). Methylmalonic acid (MMA, GC-MS) was analysed for only half of our study population (n= 90). Serum for this analysis was sent to the laboratory at \nthe University of Bonn always frozen by specialised Courier \nand analysed by HPLC. \nResultsResults Twenty-seven subjects \npresented SCbl values lower than 200 pg/ml (15.0 %). Forty-nine showed Holo-TC values lower than 37 pmol/L (27.2 %) \nand 46 of 90 had MMA values over 300 \nnmol/L (51.1 %). Of those subjects with low SCbl 22 (81.5 %) also showed low Holo-TC. Thirteen subjects of this group had MMA determined and this was \nabnormal in all cases. In the Holo-TC \nnormal group the SCbl results agreed in 96 %, whereas only 44.9 % in the low Holo-TC group presented low SCbl. MMA values showed no clear pattern. If \nMMA was used to screen for B12 status \nin this elderly group then just over 50% of them would be identified as deficient. This is likely less than double the number \nthat are deficient based on Holo-TC. \nUsing only SCbl to assess B12 status would reveal only half those identified based on Holo-TC. Total homocysteine was higher than 15\u00b5mol/L (53.3 %) in \nmore than fifty percent (96 out of 180) of \nour study population.\nConclusionConclusion These results support the complexity of determining B12 status. The discrepancy of data showed that HoloTC had \na higher sensitivity for detection of B12 compared to SCbl. It has been proposed in the past that MMA could be an earlier marke ro f  \nfunctional deficiency and that this explanations the differences between MMA and SCbl. If we consider that Holo-TC is an early marker of B12 deficiency this explanation does not hold. Our data suggest that there is a high incidence of abnormal MMA not explained by B12 status. Total hcy was not looked at because of the complication of folate status. Further investigation, especia lly a \nlongitudinal study aimed at addressing this question, would be of interest. \nThe project has been granted by the Spanish Ministry of Health (FIS PI021830). Axis-Shield (Oslo, Norway) has kindly provided t he holo-TC RIA reagent kit. We want to \nthank Mr. G Orihuela, Mr. F Morales, Mrs. R Arcas and Mrs. P Carazo for their collaboration in this study.\nContact e-mail: marcela.gonzalez-gross@uni-bonn.de\n15,0%27,0%38,3%51,1%48,5%53,3%\n0,0%10,0%20,0%30,0%40,0%50,0%60,0%\nSerum B12\nHolo-TC\nRBC folate\nSerum folate\nMMA\ntHcyFigure 1Figure 1\nPrevalence of vitamin B12-deficiency in institutionalized\nelderly measured by different parametersFigure 2Figure 2\nDistribution of Individuals according to their\nvitamin B12and HoloTC concentrations\n020406080100120140160180200\n0 100 200 300 400 500 600 700 800 900SCbl (pg/ml)HoloTC (pm ol/L)\nSCblHoloTC<37 pmol/L>37 pmol/LSCbl\n> 200 pg/ml  \n< 200 pg/ml < 200 pg/ml > 200 pg/ml MMA\nMMA\nMMA\nMMA> 300 nmol/L\n< 300 nmol/L\n> 300 nmol/L\n< 300 nmol/L\n> 300 nmol/L\n< 300 nmol/L\n> 300 nmol/L\n< 300 nmol/L25\n41\n0\n7\n4\n11\n02Figure 3Figure 3\nDistribution of individuals in different categories defined by HoloTC, \nSCbl and MMA concentrations (n=90)\nReferencesReferences : : 1)Herzlich B, Herbert V. Depletion of serum holotranscobalamin II. An early sign of negative vitamin B12 balance. Lab Investig 1988; 58:332-337.\n2)Lindenbaum J, Savage DG, Stabler SP, et al. Diagnosis of cobalamin deficiency. II: relative sensitivities of serum cobalamin, met hylmalonic acid, and total homocysteine \nconcentrations. Am J Hematol 1990;34:99-107.  3)Nexo E, Christensen AL, Hvas AM, Petersen TE, Fedosov SN. Quantification of holo-transcobalamin, a marker of vitamin \nB12 deficiency. Clin Chem 2002;48:561-562. 4)Wickramasinghe SN, Fida S. Correlations between ho lo-transcobalamin II, ho lo-haptocorrin, and total B12 in serum samples \nfrom healthy subjects and patients. J Clin Pathol 1993;46:537-539.\n \n8th Nordic Nutrition Conference. Tonsberg 2004.  \n \n \nConclusion\nExiste una elevada prevalencia de deficiencia de vitaminas del grupo B en el grupo de poblaci\u00f3n estudiada. La deficiencia\ncombinada de B6, B12 y folato es la m\u00e1s frecuente, seguida de la aislada de folato. Nuestros datos confirman la influenciade los niveles de vitaminas del grupo B, en especial folato, sobre los de homociste\u00edna, aunque la hiperhomocisteinemia no \nse puede emplear como \u00fanico criterio diagn\u00f3stico para detectar el d\u00e9ficit subcl\u00ednico de vitaminas en ancianos, en especial \npara detectar el d\u00e9ficit de B12. \nBibliograf\u00eda\nHerzlich B, Herbert V. Depletion of serum holotranscobalamin II. An early sign of negative vitamin B12 balance. Lab Investig 1988; 58:332-337.\nLindenbaun J, Savage DG, Stabler SP, et al. Diagnosis of cobalamin deficiency. II: relative sensitivities of serum cobalamin, meth ylmalonic acid, and total homocysteine concentrations. Am J \nHematol 1990;34:99-107. \nNexo E, Christensen AL, Hvas AM, Petersen TE, Fedosov SN. Quantification of holo-transcobalamin, a marker of vitamin B12 deficienc y. Clin Chem 2002;48:561-562.\nSelhub, P. Jacques, P.W.F. Wilson, D. Rush and I.H. Rosenberg (1993) Vitamin status and intake as primary determinants of homoc ysteinemia in an elderly population. Journal of the American \nMedical Association, 270, 2693-2698.\nProyecto financiado por el Ministerio de Sanidad y Consumo, Instituto de Salud Carlos III (FIS PI021830). Axis-Shield (Oslo, Norway) facilit\u00f3 los kits \npara la determinaci\u00f3n de holo-TC RIA . Nuestro agradecimiento a R Arcas, P Carazo y R.P\u00e9rez por su colaboraci\u00f3n en este estudio.***\nINFLUENCIA DE LAS VITAMINAS DEL GRUPO B SOBRE LA \nHIPERHOMOCISTEINEMIA EN ANCIANOS INSTITUCIONALIZADOS\nSola R(1,2) Gonz\u00e1lez-Gross M(2,3), Seher S(2,3), Lemmen V(2,3), Pietrzik K(3), Castillo MJ(2).\n(1) Servicio de Hematolog\u00eda. Hospital Cl\u00ednico Universitario San Cecilio, Granada. Espa\u00f1a.\n(2) Dpto. Fisiolog\u00eda, Facultad de Medicina, Universidad de Granada, Espa\u00f1a.\n(3) Dpto. Fisiopatolog\u00eda de la Nutrici\u00f3n Humana. Instituto de Nutrici\u00f3n, Universidad de Bonn. Alemania. marcela.gonzalez-gross@u ni-bonn.de\nINTRODUCCI\u00d3N\nLa hiperhomocisteinemia es un factor de riesgo independiente de enfermedad cardiovascular y manifestaci\u00f3n del estado deficitari od e  \nvitaminas del grupo B, folato, vitaminas B6 y B12. Todas ellas intervienen en el ciclo de la Metionina aunque no  influyen en l a\nhiperhomocisteinemia  con igual intensidad.\nOBJETIVOS\nEl objetivo es investigar la contribuci\u00f3n de los d\u00e9ficits de vitaminas del grupo B, folato, B6 y B12 a la hiperhomocisteinemia en \nancianos institucionalizados.\nMATERIAL Y METODOS\nSe estudian 218 ancianos, 82 hombres y 136 mujeres con edad entre 60-105 a\u00f1os. Tras ayuno de doce horas y por punci\u00f3n de la ven a \nc u b i t a l ,  s e  e x t r a e  l a  s a ng r e  e n  1  t u b o  c o n  E D T A  p a r a  h e m a ti m e t r \u00ed a  c o m p l e t a  ( A D V I A - 1 2 0  B A Y E R ) ,  e s t u d i o  d e  hi p e r s eg m e n t a c i \u00f3 n neutr\u00f3fila y folato intraeritrocitario (IMX Abbott). Ocho cc en tubos con gel para la obtenci\u00f3n de suero que se depositan en ba \u00f1o de \nhielo y se centrifugan antes de 1 hora para determinaci\u00f3n de bioqu\u00edmica completa (Hitachi-911 ROCHE) B12 s\u00e9rica, folato, \nhomociste\u00edna total (tHcy) (IMX, Abbott) Holotranscobalamina (Holo-TC) (RIA, Axis-Shield) y AMM (GC-). 4 cc de sangre total \nheparinizada para determinaci\u00f3n de vitamina B6. Las muestras que no se procesaron antes de 1 hora,  se congelaron a \u2013 80\u00baC. \nRESULTADOS\nSe diagnostican 176 ancianos con tHcy \u2265 12 \u00b5mol/L. 106 (43.11%) con el folato s\u00e9rico \u2264 6 ng/ml (tHcy X 21.54)y con folato \nintraeritrocitario \u2264 175 ng/ml 13 (7.33 %), de estos 16 tienen ambos bajos. lo que representa 119 ancianos deficientes que representan \nun 54.84 % de prevalencia de d\u00e9ficit de folato. 38 sujetos (7.33%) tienen una B12 s\u00e9rica \u2264 200, 52 ancianos (23.85%) Holo-TC \u2264 45 y 29 \nel AMM \u2265 300, lo que representa una prevalencia para el d\u00e9ficit de vitamina B12 de 119 ancianos que representan el 54.84 %. D\u00e9ficit\nmixto B12-folato, 76 ancianos que representan el 34.86%. En un \u00e1nalisis de regresi\u00f3n lineal multiple el log del folato s\u00e9rico (r= -0.5 36) \nes el m\u00e1s fuerte factor predictor independiente de hiperhomocisteinemia ( log tHcy), seguido de log folato intraeritrocitario (r= -\n0.342), Log AMM (r=0.342), log Holo-TC (r= -0.200), log B6 (r= - 0.109) y por \u00faltimo log B12 (r= -0.095).\nlowest quartile 2.quartile 3.quartile highest quartile\nserum folate10,020,030,040,0tH\ncy (m\ncm\nol/L)\nlowest quartile 2.quartile 3.quartile highest quartile\nRBC folate10,020,030,040,0tH\ncy (m\ncm\nol/L)Mean homocysteine concentrations in quartiles of serum and RBC folate\n* significantly different ( P< 0.05) to the mean of the highest \nquartile (one-way ANOVA with post-hoc Scheff\u00e9 test).Prevalencia general de d\u00e9ficit de vitaminas del grupo B\nDI AGNOSTI CO\nRec uent o\n6 6 12\n2 6 8\n3 10 13\n5 31 36\n10 51 61\n3 9 12\n7 24 31\n6 39 45\n42 176 218Nor mal\nD\u00e9ficit de B6\nD\u00e9ficit de B12\nD\u00e9ficit de Folato\nD \u00e9ficit B6 -B 12-f ola to\nD\u00e9ficit de B6-B12\nD\u00e9ficit de B6-Folato\nd\u00e9ficit de B12-FolatoDI AG\nTotal<=12 >12R_THCY\nTotal\nDIAGNOSTICOD\u00e9ficit de\n B12-F\nolatD\u00e9ficit de\n B6-FolatoD\u00e9ficit de\n B6-B12D\u00e9ficit B6-B12-folatD\u00e9ficit de\n FolatoD\u00e9ficit d\ne B12D\u00e9ficit de\n B6NormalRecuento60\n50\n40\n3020\n10\n0tHcy <=12 mcmol/L\ntHcy >12 mcmol/LDiagn\u00f3stico del d\u00e9ficit en funci\u00f3n de los niveles de homociste\u00edna\nD\u00e9ficit B6\n4%\nD\u00e9ficit B6-folato\n14%Normal\n6%\nD\u00e9ficit B12-folato\n20%\nD\u00e9ficit B12\n6%\nD\u00e9ficit folato\n17%D\u00e9ficit B6-B12-folato\n27%D\u00e9ficit B6-B12\n6%\n \nCongreso Nacional de Hematolog\u00eda. Valencia. 2004  \n \n \nDiagnostic scheme for the early diagnosis of vitamin B12deficiency in \nelderly people.\nSola R 1,2Gonz\u00e1lez-Gross M 2,3,4, Barrios L5, Janke D 4, Pietrzik K4, Castillo MJ2\n1Grupo EFFECTS 262. Dpt. Physiology, School of Medicine, University of Granada, Spain. \n2Haematology Service, Clinical University Hospital San Cecilio, Granada, Spain.\n3Facultad de Ciencias de la Actividad F\u00edsica y del Deporte. Universidad Polit\u00e9cnica de Madrid. Spain.\n4Institut f\u00fcr Ern\u00e4hrungs-und Lebensmittelwissenschaften. Pathophysiologie. Rheinische Friedrich-Wilhelms-Universit\u00e4t. Bonn. Germ any.\n5Centro T\u00e9cnico de Inform\u00e1tica. CSIC. Spain.\nBackground\nThe elderly population is particularly at risk for developing vitamin B12-deficiency. Inadequate diets, diseases like \ngastritis or intestinal malabsorption are the main reasons for vitamin B12-deficiency in this age group. Sensitive methods \nfor early detection of vitamin B12-deficiency are not common in the routine laboratory. Normal serum cobalamin (SCbl) \ndoes not necessarily reflect a normal B12 status. The determination of methyl malonic acid (MMA) is very expensive and \nnot routinely possible. Holotranscobalamin II (Holo-TC II), the fraction of functional vitamin B12, has been proposed as a \nmore sensitive B12 status indicator. \nObjective\nThe aim of the present study is to establish a diagnostic scheme (DiagS) taking into account both clinical and economical \ncriteria.\nMaterial and Methods\nTwo-hundred and eighteen elderly of both sexes, aged 60-105, living in an Elderly Home in Granada (Spain), were \nscreened for SCbl (Abbott, IMx), (Holo-TC II) (HoloTC RIA, Axis-Shield, MMA (MS-GC),serum folate, red blood cell (RBC) \nfolate, and tHcy (Abbott, IMx), which were the variables chosen based on clinical criteria.\nConclusion\nThe proposed diagnostic scheme which eliminates SCbl and starts the screening with Holo-TC II seems to be more \nprecise in detecting functional vitamin B12 deficiency and the combined folate/B12 deficiency in institutionalized \nelderly. The reason for the di fferent num ber i n each of the deficiency  groups in both Di ag S has to be analy sed m ore i n \ndepth. \nReferences\n[1]C.J. Boushey, S.A.A. Beresford, G.S. Omenn and A.G. Motulsky (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Journal \nof the American Medical Association, 274, 1049-1057.\n[2]I.M. Graham, L.E. Daly, H.M. Refsum et al. (1997) Plasma homocysteine as a risk factor for vascular disease: The European Conce rted Action Project. Journal of the \nAmerican Medical Association, 277, 1775-1781. \n[3]J. Selhub, P. Jacques, P.W.F. Wilson, D. Rush and I.H. Rosenberg (1993) Vitamin status and intake as primary determinants of ho mocysteinemia in an elderly \npopulation. Journal of the American Medical Association, 270, 2693-2698.\nThe project has been granted by the Spanish Ministry of Health (FIS PI021830). Prof. Manuel J. Castillo is the project leader. Axis-Shield \n(Oslo, Norway) has kindly provided the holo-TC RIA reagent kit. We want to thank Mr. G Orihuela, Mrs. R Arcas and Mrs. P Carazo for \ntheir collaboration in this study.Results\nWorkout B12 \ndeficiency\nSerum folate \u22647 or RB C folate \u2264175 Serum folate >7 + RB C folate >175\nHomocy stein <12 Homocystein \u226512 Homocystein <12 Homocystein \u226512\nHolo TC Holo TC Holo TC Holo TC\nHolo TC \u226445\nOutc ome 7Holo TC >45Holo TC \u226445\nOutc ome 10Holo TC >45Holo TC \u226445\nOutc ome 1Holo TC >45Holo TC \u226445\nOutcome 4Holo TC >45\nAMM AMM AMM AMM\nAMM  \u2265300\nOutcome 8AMM <300\nOutc ome 9AMM  \u2265300\nOutc ome 11AMM <300\nOutcome 12AMM  \u2265300\nOutcome 2AMM <300\nOutc ome 3AMM  \u2265300\nOutc ome 5AMM <300\nOutcome 6\nDiagnostic scheme 1 . Start with serum cobalamin and include 14 \npossible outcomes for diagnosing B12 deficiency. Yellow squares express pure B12 deficiency; orange squares express \ncombined B12/folate deciciency; green square express pure folate\ndeficiency; dark blue squares express normal subjects.Workout B12 \ndeficiency\nSerum folate \u22647 or\nRBC olate \u2264175Serum folate > 7 + RB C folate\n>175\nB12\nB12 \u2264200\nOutc ome 1B12>200B12\nB12 \u2264200\nOutcome 8B12>200\nHOMOCYSTEIN HOMOCYSTEIN\ntHcy <12 tHcy\u226512 tHcy <12 tHcy\u226512\nHOL O-TC HOL O-TC HOL O-TC HOL O-TC\nHolo-tc\u226445\nOutc ome 2Holo-TC >45Holo-tc\u226445\nOutc ome 5Holo-TC >45Holo-tc\u226445\nOutcome 9Holo-TC >45Holo-tc\u226445\nOutcome 12Holo-TC >45\nAMM AMM AMM AMM\nAMM  \u2265300\nOutc ome 3AMM  <300Outcome 4AMM  \u2265300\nOutoc me 6AMM  <300Outcome 7AMM  \u2265300\nOutcome 10AMM  <300\nOutc ome 11AMM  \u2265300\nOutc ome 13AMM  <300\nOutcome14\nDiagnostic scheme 2. started with Holo-TC II and included 12 possible \noutcomes for diagnosing B12 deficiency. Yellow squares express pure B12 deficiency; orange squares express combined B12/folate deciciency; green square express pure folatedeficiency; dark blue squares express normal subjects.\nDiagnostic scheme 1 identified 8.7% pure B12 deficiency, 50.9% combined B12/folate deficiency, 31.2% pure folate\ndeficiency and 6.0% as being normal. \nDiagnostic scheme 2 identified 9.6% pure B12 deficiency, 67.0 % combined B12/folate deficiency, 14.7% pure folate\ndeficiency and 5.0% as being normal.\n \n5th internacional Conference Homocysteine metabolism. Milan 2005  \n \n \nHyperhomocysteinemia as diagnostic criterion for vitamin B deficiency \nin institutionalized elderly\nSola R 1,2Gonz\u00e1lez-Gross M 2,3,4, Barrios L5, Janke D 4, Pietrzik K4, Castillo MJ2\n1Grupo EFFECTS 262. Dpt. Physiology, School of Medicine, University of Granada, Spain. \n2Haematology Service, Clinical University Hospital San Cecilio, Granada, Spain.\n3Facultad de Ciencias de la Actividad F\u00edsica y del Deporte. Universidad Polit\u00e9cnica de Madrid. Spain.\n4Institut f\u00fcr Ern\u00e4hrungs-und Lebensmittelwissenschaften. Pathophysiologie. Rheinische Friedrich-Wilhelms-Universit\u00e4t. Bonn. Germ any.\n5Centro T\u00e9cnico de Inform\u00e1tica. CSIC. Spain.\nBackground\nHyperhomocysteinemia is an accepted risk factor for cardiovascular disease, and possibly also for cognitive impairment \nand dementia. It has also been proposed as a marker of the status of the B vitamins which are implicated in the metabolic \ncircle. \nObjective\nTo know the prevalence of high homocysteine (tHcy) levels and the influence that B vitamins have on them. \nMaterial and Methods\nTwo-hundred and eighteen elderly of both sexes, aged 60-105, living in an Elderly Home in Granada (Spain), were \nscreened for serum folate, red blood cell (RBC) folate, serum cobalamin (Abbott, IMx), holotranscobalamin II (holo-TC II) \n(HoloTC RIA, Axis-Shield), Methylmalonic Acid (AMM) (MS-GC), total pyridoxine (B6)(HPLC) and tHcy (Abbott, IMx).\nConclusion\nThere is a high prevalence of vitamin B deficiency and hyperhomocysteinemia in the studied population. Our data \nconfirm the influence of these vitamins, especially folate, on tHcy leves, but hyperhomocysteinemia can not be used as \nthe only diagnostic criteria to detect subclinical vitamin deficiency in elderly people, especially to detect vitamin B12 and \nvitamin B6 deficiency. \nReferences\n[1]C.J. Boushey, S.A.A. Beresford, G.S. Omenn and A.G. Motulsky (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Journal \nof the American Medical Association, 274, 1049-1057.\n[2]I.M. Graham, L.E. Daly, H.M. Refsum et al. (1997) Plasma homocysteine as a risk factor for vascular disease: The European Conce rted Action Project. Journal of the \nAmerican Medical Association, 277, 1775-1781. \n[3]J. Selhub, P. Jacques, P.W.F. Wilson, D. Rush and I.H. Rosenberg (1993) Vitamin status and intake as primary determinants of ho mocysteinemia in an elderly \npopulation. Journal of the American Medical Association, 270, 2693-2698.\nThe project has been granted by the Spanish Ministry of Health (FIS PI021830). Prof. Manuel J. Castillo is the project leader. Axis-Shield \n(Oslo, Norway) has kindly provided the holo-TC RIA reagent kit. We want to thank Mr. G Orihuela, Mrs. R Arcas and Mrs. P Carazo for \ntheir collaboration in this study.Results\n16 22 38\n19,5% 16,2% 17,4%\n66 114 180\n80,5% 83,8% 82,6%\n82 136 218\n100,0% 100,0% 100,0%Recuento\n% de sexo\nRecuento\n% de sexo\nRecuento\n% de sexo<=200\n>200B12\nTotalHombre Mujersexo\nTotal\n17 36 53\n25,8% 31,6% 29,4%\n49 78 127\n74,2% 68,4% 70,6%\n66 114 180\n100,0% 100,0% 100,0%Recuento\n% de sexo\nRecuento\n% de sexo\nRecuento\n% de sexo<13\n>=13Homociste\u00edna\nTotalHombre Mujersexo\nTotal\n14 37 51\n27,5% 72,5% 100,0%\n38 87 125\n30,4% 69,6% 100,0%\n52 124 176\n29,5% 70,5% 100,0%Recuento\nRecuento\nRecuento<13\n>=13Homociste\u00edna\nTotal<=45 >45Holo-TC\nTotal\n8 5 13\n61,5% 38,5% 100,0%\n22 7 29\n75,9% 24,1% 100,0%\n30 12 42\n71,4% 28,6% 100,0%Recuento\n% de R_HOLOT C\nRecuento\n% de R_HOLOT C\nRecuento\n% de R_HOLOT C<=45\n>45Holo-TC\nTotal<300 >=300AMM\nTotalTable 1 . Contingency table of B12 by sex. Table 2 . Contingency table of homocysteine by sex.\nTable 3 . Contingency table of homysteine Holo-TC. Table 4 . Contingency table of HOLO-TC AMM B12 >200 and \nhomocysteine <13SEX\nMale FemaleSEX\nMale Female\n \n5th internacional Conference Homo cysteine metabolism. Milan 2005  \n \n \nANEMIA PERNICIOSA FAMILIAR Y DEFICIT SELECTIVO DE IgA\nR Sola (1,2), M Gonzalez-Gross (1,3),  MJ Castillo (1), K Pietrzik (3).\n(1)  Dpt. Fisiolog\u00eda. Facultad de Medicina. Universidad de Granada. (2) Servicio de Hematolog\u00eda. Hospital Cl\u00ednico Universitario de San \nCecilio. Granada.  (3) Dpt. Pathophysiology of Human Nutrition. Institute of Nutrition. University of Bonn. Germany. \nmggross@canal21.com\nIntroducci\u00f3n: \nPropia de la presenilidad y vejez, fue descrita por Addison en 1855. El estomago de estos enfermos, deja de segregar Factor Intr\u00ed nseco. \nEn la actualidad, se conoce el mecanismo inmunol\u00f3gico autoinmune responsable de las alteraciones g\u00e1stricas y la malabsorci\u00f3n de \nvitamina B12. Las c\u00e9lulas parietales del estomago, van desapareciendo progresivamente y se va configurando la gastritis atr\u00f3fica.\nCaso cl\u00ednico:\nMujer de 43 a\u00f1os que acude a nuestra consulta procedente de su m\u00e9dico de cabecera para estudio de anemia no filiada. \nLa paciente refer\u00eda astenia y disnea al menor esfuerzo. En el Hemograma: leucocitos 3.900/mm3,, Hb 7,2 g/dl, Hct\u00ba 20,7%, VCM 118 fl. \nPlaquetas 144.000 mm3. la formula leucocitaria era normal con una morfolog\u00eda patol\u00f3gica que mostraba anisopoiquilocitosis acusada de \npredominio macroc\u00edtico, anisocrom\u00eda y cuerpos de Howell-Jolly, as\u00ed como los neutr\u00f3filos mostraban una acusada polisegmentaci\u00f3n.\nBioqu\u00edmica hematol\u00f3gica: patr\u00f3n ferrocin\u00e9tico normal, vitamina B12 < 60 pg/ml, folato s\u00e9rico e intraeritrocitario normales y homociste\u00edna \nde 150 mcg/L. Bioqu\u00edmica: LDH 1111 U/l, resto sin inter\u00e9s.\nSe le realizaron las siguientes pruebas complementarias:\nPunci\u00f3n de medula \u00f3sea, medula hipercelular compatible con anemia megalobl\u00e1stica.\nECO abdominal discreta esplenomegalia. La gastroscopia, compatible con gastritis atr\u00f3fica.\nProteinograma normal con una IgG < 6,1 mg/dl, IgG e IgM normales.\nAnticuerpos antinucleares (-), anti c\u00e9lulas parietales (+),  anti factor intr\u00ednseco (+), antitiroglobulina, antiperoxidasa y an tiendomisio \nnegativos. Debido a la edad de la paciente hacemos estudio familiar (tabla inferior)\nConclusiones.\nSe diagnostican dos hermanas de anemia perniciosa, remitiendo los s\u00edntomas cl\u00ednicos y datos anal\u00edticos tras tratamiento con \ncianocobalamina intramuscular. El propositus tenia asociado d\u00e9ficit selectivo y asintom\u00e1tico de IgA, que no se modifico con trat amiento \nel hijo var\u00f3n mostraba hiperhomocisteinemia probablemente por d\u00e9ficit funcional de vitamina B12 y la hija ANA (+) de patr\u00f3n mot eado \nque est\u00e1 en evaluaci\u00f3n.\nEst\u00e1 demostrada la predisposici\u00f3n gen\u00e9tica de esta  enfermedad y su asociaci\u00f3n a otras  enfermedades autoinmunes, desarroll\u00e1ndo se con \nm\u00e1s frecuencia en individuos con familiares afectos por la enfermedad. La asociaci\u00f3n anemia perniciosa y d\u00e9ficit de IgA, no es \ninfrecuente y cuando ocurre es necesario extremar los cuidados transfusionales, la posible presencia de anticuerpos anti IgA pu ede dar \nlugar a accidentes transfusionales graves e incluso  muerte. Es recomendable el uso de hemat\u00edes lavados.\nBibliograf\u00eda:\n1.- Gueant JL, Candito M, Andres E, Van Obberghen E, Nicolas JP. Familial pernicious anaemia with hyperhomocisteinemia in \nrecurrent early pregnancy loss. Thromb Haemost. 2004;92:1147-9.\n2.- Heisel MA, Siegel SE, Falk RE, et al. Congenital pernicious anemia: report of seven patiens, with studies of extended family. J pediat.  \n1984;105:564-8.\n3.- Spector JL. Juvenile achlorhydric pernicious anemia with IgA Deficiency. A family study. JAMA 1974;228:334-6.                                                 \n Caso Cl\u00ednico Hermana Hijo Hija \nHb (gr/dl) 7.6 10.3 16.9 14.9 \nVCM (fl) 118 103 95.4 94.6 \nB12 < 60 100 227 229 \nFolatos N N N N \nHomociste\u00edna 150 48 29 8 \nCreatinina N N N N \nIgA < 6 108 116 190 \nAc C. Parietales + + \u001f \u001f \nGastroscopia + +  \nInmunocomplejos +   \nANA \u001f \u001f \u001f + \n \nCongreso Nacional de Hematolog\u00eda. 2005. Madrid  \n \n \nHintergrund\nFolat- und Vitamin B12-Unterversorgungszust\u00e4nde stellen aufgrund \nverschiedener Faktoren besonders bei Senioren ein h\u00e4ufiges Problem dar. Dieses \u00e4u\u00dfert sich zun\u00e4chst in einem Anstieg des \nHomocysteins (tHcy)-Spiegels und kann sich in einer \nmegaloblastischen An\u00e4mie manifestieren. Da h\u00e4ufig nur eine \nMonotherapie mit Fols\u00e4ure erfolgt, ist nicht auszuschlie\u00dfen, dass aufgrund der engen Verkn\u00fcpfung zum Vitamin B\n12-Stoffwechsel \nletzteres st\u00e4rker verbraucht wird und sich der Vitamin B12-Mangel \nzus\u00e4tzlich verst\u00e4rkt. \nZielsetzung\nZiel der Studie war es, die Auswirkungen der Fols\u00e4urederivate \nPteroylmonoglutamins\u00e4ure (PGA)  und L-5-Methyltetrahydrofolat \n(L-5-MTHF) auf Parameter des Vitamin B12- und tHcy-Status\nspanischer Heimbewohnern zu untersuchen.Methoden\nRandomisierte, doppelblinde Interventionsstudie bei spanischen \nHeimbewohnern (n = 94, mittleres Alter 81,2 \u00b1 7,9 Jahre, 37 \nM\u00e4nner, 57 Frauen) mit subklinischem Vitamin B12-Mangel. Zu \nBeginn, nach 14-t\u00e4giger Gabe von L-5-MTHF (10,4 mg/d) und nach 14-t\u00e4giger PGA-Gabe (10 mg/d) erfolgte eine Untersuchung der folgenden Blutparameter: Erythrozyten-Folat, Serumfolat, Holo-Transcobalamin II (Holo-TC II), Serum-B\n12und tHcy. Ergebnisse\nSowohl die Gabe von L-5-MTHF als auch von PGA bewirkte eine \nhochsignifikante Verbesserung der tHcy- und Folatwerte bei den Heimbewohnern (p \u2264 0,001). Das Serumfolat erh\u00f6hte sich \u00fcber die \nInterventionsdauer um 849% auf 57,2 ng/mL und das Erythrozyten-\nFolat stieg um 399% auf 1103,6 ng/mL. Die tHcy-Werte hingegen \nsanken durch die Supplemente um 75% auf 13,0 \u00b5mol/L (Abb. 1.) Nach Supplementation mit L-5-MTHF und PGA blieben sowohl die Holo-TC II-Werte als auch die Serum-B\n12-Spiegel (Abb. 2) \nunbeeinflusst. \nSchlussfolgerungen\nDie Daten zeigen, dass die Fols\u00e4urederivate (L-5-MTHF und PGA) \nsichtbare Effekte auf den tHcy-Spiegel haben und sich dabei nicht \nin der Supplementform unterscheiden. Auswirkungen der \nSupplemente auf Serum-B12-Werte und Holo-TC II-Spiegel konnten \nnicht gezeigt werden. Ob eine langfristige Gabe von Fols\u00e4ure denVitamin-B\n12-Status beeinflusst, muss zuk\u00fcnftig gezeigt werden.\n*Mit finanzieller Unterst\u00fctzung des Spanischen Gesundheitsministeriums (FIS PI021830). Axis-Shield (Oslo, Norway) hat die Holo-T C RIA Reagenzienkits\nzur Verf\u00fcgung gestellt. Merck Eprova AG die L-5-MTHF Supplemente. Frau R Arcas, Frau P. Carazo und Frau R. P\u00e9rez danken wir f\u00fcr i hre Hilfe.13,0 \u00b13,9 13,0 \u00b13,8 17,3 \u00b15,5Gesamt-Homocystein\n(\u00b5mol/L)1103,6 \u00b1732,6 710,4 \u00b1516,7 276,7 \u00b1197,1Erythrozyten-Folat\n(ng/mL)57,2 \u00b162,0 34,0 \u00b127,8 6,7 \u00b16,4 Serumfolat (ng/mL)74,5 \u00b158,4 68,0 \u00b141,8 73,0 \u00b171,0 Holo-TC II (pmol/L)234,7 \u00b1114,4 246,8 \u00b1127,9 232,0 \u00b1112,8 Vitamin B12 (pmol/L)Nach \nPGA-GabeNach L-5-\nMTHF-GabeBaseline Parameter\nTabelle 1: Blutparameter zu den verschiedenen Zeitpunkten (MW \u00b1 SD)Vitamin B12 (pmol/L)\nAbbildung 2: Vergleich der Vitamin B12-Werte nach verschiedenen \nSupplementgaben\nGesamt-Homocystein (\u00b5mol/L)\nAbbildung 1: Vergleich der tHcy-Werte anhand der verschiedenen \nSupplementgaben. Signifikante Senkung der Werte nach L-5-MTHF-\nGabe (p \u22640,001). \nEinfluss von L-5-MTHF- und PGA-Supplementen\nauf Parameter des Vitamin B12-Status\nvon spanischen Heimbewohnern\nSpinneker A1, Gonz\u00e1lez-Gross M1,2,3, Sola R3, Castillo MJ3, Pietrzik K1\n1Institut f\u00fcr Ern\u00e4hrungs- und Lebensmittelwissenschaften - Humanern\u00e4hrung.\nRheinische Friedrich-Wilhelms Universit\u00e4t Bonn. \n2 Facultad de CC de la Actividad F\u00edsica y del Deporte, Universidad Polit\u00e9cnica de Madrid. Spanien.\n3 Grupo Effects 262.Dpto. Fisiolog\u00eda. Facultad de Medicina. Universidad de Granada. Spanien.\na.spinneker@uni-bonn.de\nIEL\nIEL\n \nCongreso de la DGE (Deutsche Gesell schatt f\u00fcr Ern\u00e4hrung). Stuttgart 2006. \n ", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}